Annual Report 2012-2013

ANNUAL REPORT 2012-2013 Copies of this annual report are available on QIMR’s website at www.qimr.edu.au/annualreport and by contacting QIMR on (07) 3362 0222, freecall 1800 993 000 or by emailing [email protected].

Queensland Institute of Medical Research 300 Herston Road, Herston, Queensland Australia 4006 T: +61 7 3362 0222 F: +61 7 3362 0102 W: www.qimr.edu.au

QIMR is committed to providing accessible services to people from culturally and linguistically diverse backgrounds. If you have difﬁculty in understanding the annual report, you can contact us on (07) 3362 0222 and the Institute will arrange an interpreter to communicate the report to you.

ISSN 1839 – 1877

CONTENTS

Letter of compliance ...... 3 Our performance ...... 28

Highlights ...... 4 Our research achievements .... 43

Awards and achievements ...... 5 Supporting our research ...... 64

QIMR at a glance ...... 6 Financial statements ...... 66

Message from Patron ...... 9 Supporting information ...... 102 Awards ...... 102 ...... Chairman’s report 10 Lectures ...... 104 Patents ...... 112 Director’s report ...... 11 Grants and funding ...... 114 Our organisation ...... 12 QIMR Fellows ...... 116 Publications ...... 117 Our governance ...... 18 Compliance checklist ...... 148 Our management ...... 25 Glossary/Acronyms ...... 150 Page 2 QIMR Annual Report 2012–2013 LETTER OF COMPLIANCE

30 August 2013

The Honourable Lawrence Springborg MP Minister of Health Parliament House BRISBANE QLD 4000

Dear Minister

I am pleased to present the Annual Report 2012–2013 and ﬁnancial statements for the Council of the Queensland Institute of Medical Research.

I certify that this Annual Report complies with: • the prescribed requirements of the Financial Accountability Act 2009 and the Financial and Performance Management Standard 2009, and

• the detailed requirements set out in the Annual report requirements for Queensland Government agencies.

A checklist outlining annual reporting requirements can be found on the ﬁnal pages of this Annual Report or accessed at our website:

http://www.qimr.edu.au/annualreport

Yours sincerely

THE HON PAUL de JERSEY AC Chair QIMR Council

300 Herston Road, Herston Q 4006 Australia | QIMR Locked Bag 2000, Royal Brisbane Hospital Q 4029 T (617) 3362 0222 F (617) 3362 0111 W www.qimr.edu.au

Page 3 RESEARCH HIGHLIGHTS

CANCER

Developed EphA3-targeted therapeutics for clinical Published for the first time an association between trials in leukaemia. human papilloma viral load and risk of cutaneous squamous cell carcinoma. Showed that the prevalence of weekend sunburn is still high in Queensland especially in young male adults. Identified 49 genetic polymorphisms associated with risk of breast cancer. Published evidence from a randomised trial that sunscreen can slow the prevention of skin photoaging Identified nine new ovarian cancer risk loci. changes. Developed novel tissue-based biomarkers for Developed models to predict the incidence of lymphoma. oesophageal adenocarcinoma in the Australian Completed the largest and most comprehensive population. genetic analysis of melanomas of unknown primary (MUP), revealing insights into the origin of this rare subset of tumours.

INFECTIOUS DISEASES

Developed new diagnostics for parasitic diseases, Completed preclinical studies on the prophylactic including malaria, scabies and helminths. vaccine for human cytomegalovirus to prevent birth defects. Used experimental human blood stage malaria challenge system for developing new drugs and Successfully completed clinical testing of a new vaccines for malaria. diagnostic test to predict cytomegalovirus-associated complications in transplant patients. Developed a novel protein inhibitor of HIV called nullbasic which provides excellent protection from infection in human cells in vitro. Completed a ﬁve-year longitudinal study of schistosomiasis transmission in an endemic area in Schuan Province, China. Carried out the ﬁrst release of Wolbachia for dengue control in Vietnam.

Page 4 QIMR Annual Report 2012–2013 MENTAL HEALTH / COMPLEX DISORDERS

Created an imaging test for major depression. Led advances in understanding genes contributing to risk for endometriosis by finding novel genomic regions Detected biomarker for risk of bipolar disorder. associated with risk, demonstrating that the genetic Identified 10 loci influencing allergic sensitisation. factors underlying disease are similar in European and Japanese populations. Identified an additional regulatory variant in the IL6R gene that associates with asthma risk. Reported five novel risk loci for migraine. Demonstrated a role for diabetes as a risk Identified a genetic variant in the obesity gene FTO factor for severe hepatic fibrosis in patients with which confers risk of melanoma. haemochromatosis. Developed a new diagnostic test for cerebral palsy.

AWARDS AND ACHIEVEMENTS

QIMR Senior Scientist and head of the Institute’s Cancer and Population Studies Group, Professor Adele Green AC was awarded Queensland Australian of the Year.

Awarded $2.4 million for a NHMRC Centre of Research Excellence for Oesophageal Cancer.

Dr Motoko Koyama was awarded the Research Australia Discovery Award for her work into the role of dendritic cells in Graft-versus-host disease.

Ofﬁcially opening QIMR’s new research facility after two years of construction, in December 2012.

QIMR was ranked the highest medical research institute in Australia, according to the Nature Publishing Index 2012 Asia-Paciﬁc.

Page 5 AT A GLANCE

RESEARCH AGREEMENTS Research service agreements Clinical trial agreements Intellectual property agreements Others

PATENT PORTFOLIO

New treatment patents

Vaccine patents

Delivery platforms patents

Diagnostic patents

Drug target patents

Medical device patents

Page 6 QIMR Annual Report 2010–20112012–2013 20

NHMRC GRANTS 15 AWARDED ($ MILLIONS) 10 $MILLIONS

* NHMRC grants and fellowships were announced 5 in late 2012 for funding commencing in 2013

0 2009 2010 2011 2012 2013 YEAR Grants

700 SCIENTIFIC 600 PUBLICATIONS 500 400

300 PUBLICATIONS 200

100

0 2009 2010 2011 2012 2013 YEAR Articles High Impact (publications in journals with impact factors of 10 or more)

700 STAFF NUMBERS 600 500

400

STAFF 300

200

100

0 2009 2010 2011 2012 2013 YEAR Staff Students

Page 7 MESSAGE FROM OUR PATRON

QIMR Director and CEO Professor Frank Gannon, Governor of Queensland, Her Excellency Ms Penelope Wensley AC, water memory artist Judy Watson and Queensland Minister for Health The Honourable Lawrence Springborg MP.

Page 8 QIMR Annual Report 2010–20112012–2013 QIMR 2012-2013 Annual Report; Patron’s Message

Every day, thousands of people drive or walk past QIMR’s buildings in Herston, near the centre of Brisbane, unaware that they are passing a distinguised and internationally - acclaimed research institution that is a major part of Queensland’s ever-growing knowledge infrastructure.

Within QIMR’s walls and behind its anonymous windows, there is research and translational activity underway that has the potential to change lives and communities for the better through discoveries that improve the prevention, diagnosis and treatment of a wide range of diseases. The following pages report with quiet pride on the crucial work that QIMR has been pursuing in the past twelve months in pursuit of that admirable goal.

This Annual Report, of necessity, uses highly technical language to describe in detail the many and varied research sectors in which QIMR is active, and the organisation’s achievements in these areas. However, any lay person perusing its pages will quickly understand the relevance of QIMR’s work because many of the diseases it targets are regularly subjects of discussion with family, friends and colleagues, and in the media. Ovarian, breast and oesophageal cancers, HIV, asthma, anorexia and dementia constitute but a few of the conditions that were the focus of QIMR’s endeavours in 2012- 2013.

This work is carried out with the support of QIMR’s partnerships, connections and networks with hospitals and other medical institutions in Queensland, and with health research professionals from all over Australia and internationally. This network is an invisible and invaluable asset for QIMR and for Queensland. It is the key to QIMR’s inﬂuence on the national and global level and also an important source of knowledge and ideas that, ultimately, will beneﬁt our State.

QIMR is now supported in its work by new, state-of-the-art facilities at Herston, opened in December 2012 by the philanthropist Mr Chuck Feeney, whose generosity played a major role in making the new building possible. I take this opportunity to thank Mr Feeney and all those who supported the construction of this wonderful new asset for QIMR. I was pleased, in April this year, to unveil yet another kind of asset for QIMR – Judy Watson’s striking art work water memory in the foyer of the new building, which provides a powerful reminder to passers-by of the power and legacy of knowledge, both traditional and new, in that place.

I thank the Council and the CEO of QIMR, Professor Frank Gannon, other members of the senior executive, scientists, support staff and research students for their untiring efforts in 2012-2013, on behalf of the Queensland community. Their endeavours have kept QIMR at the forefront of efforts to unlock the stubborn secrets of illnesses that pose enormous challenges to health professionals and health infrastructure in Queensland, more broadly in Australia, and more broadly still in developed and developing countries.

It is cause for pride among Queenslanders that we have an institution of the status and national and international reach of QIMR in our State, and cause also for continuing government, corporate and philanthropic support of QIMR’s vital work. I congratulate QIMR on its achievements in 2012-2013 and wish the institution continuing success in years to come.

Penelope Wensley AC Governor of Queensland and Patron, QIMR

Page 9 CHAIR’S REPORT

It has been another extraordinary year of advances for QIMR, by the Queensland Health Minister, the Honourable Lawrence in terms of research produced, collaborations formed, and Springborg MP. The alliance between QIMR, The University facilities available for our world-class scientists. of Queensland (UQ), Metro North Hospital and Health Service through Royal Brisbane and Women’s Hospital, and Many of our scientists are now established in the new Queensland University of Technology (QUT) will drive vital 15 floor building linking the Bancroft Centre and the Clive imaging research reform. Berghofer Cancer Research Centre. It was made possible by the generous support of Mr Chuck Feeney and The Atlantic In December, QIMR and UQ also signed an historic strategic Philanthropies and funding from the Commonwealth and alliance with Emory University (Georgia, USA) to collaborate State governments. The official opening by Mr Feeney in on new drugs and vaccines for cancer and infectious December was a day of great celebration for QIMR and an diseases. The Queensland Emory Development (QED) opportunity to say thank you to a man who has made such Alliance will build on existing, smaller-scale collaborative an enormous difference to medical research, not only in relationships between the three institutions to generate Queensland, but around the world. exciting new commercial opportunities from drug and biological research. Meanwhile, the refitting of the Bancroft Centre continues apace, as laboratories are upgraded and refitted. Scientists QIMR’s signature fundraising event, the Rio Tinto Ride to will begin moving into those updated facilities in the Conquer Cancer, goes from strength to strength. The second months ahead. annual event in August last year saw more than 1500 riders and almost 300 crew members raise an extraordinary $5.2 In April we also unveiled the extraordinary art installation in million for the Institute’s cancer program. Preparations are the foyer of our new building. Acclaimed indigenous artist well underway for the third Ride in August 2013. Judy Watson’s water memory recognises and embraces the links between traditional knowledge and modern QIMR also launched a sister event in 2013: the Weekend medical research. It is both a striking feature and a reference to End Women’s Cancers. Proceeds from the two-day 60 to the many histories of the QIMR site, and the water kilometre walk in October will be shared with the Royal connecting them all. We thank QIMR Patron and Queensland Brisbane and Women’s Hospital. The enormous community Governor, Her Excellency Ms Penelope Wensley AC and support for this event in its inaugural year is yet another the Queensland Health Minister, the Honourable Lawrence reassuring sign of QIMR’s reputation for research excellence, Springborg MP and our supporters for attending the and its importance to the broader community. official opening. Christopher Coyne It was an important year for new scientific collaborations. The ACTING CHAIR OF THE COUNCIL OF THE $22 million Herston Imaging Research Facility (HIRF) took a QUEENSLAND INSTITUTE OF MEDICAL RESEARCH major step forward in May with a signing ceremony witnessed (to 20 June 2013)

While still very new to QIMR, I consider it an enormous I take this opportunity to thank Mr Christopher Coyne and privilege to chair the distinguished Council of this highly Professor Bryan Campbell who were respectively Chairman respected medical research institute. Its reputation for and Deputy Chairman in the interim period. scientiﬁc excellence is of a global dimension. I look forward to working with them and other members of As all Queenslanders are proud of their internationally Council in the years ahead. renowned Queensland Institute, as a Queenslander I am very proud now to lead it. Chief Justice Paul de Jersey CHAIR OF THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (from 20 June 2013)

Page 10 QIMR Annual Report 2012–2013 DIRECTOR’S REPORT

I am pleased to report that QIMR’s world-class research around the world, and it was both an honour and a pleasure continues to grow and make a real difference to Queensland, to have him lead the official proceedings at the opening Australia and the world. ceremony. Mr Feeney is notorious for his desire to avoid the limelight and media attention. It is a measure of the For the second year running, we have been named the special place QIMR holds for Mr Feeney that he agreed to highest ranked medical research institute in Australia. attend the opening ceremony: a first in a very long career That independent ranking is based on the numbers of of philanthropy. studies we have had published in the prestigious Nature scientific journals. This is testament to the quality of QIMR also celebrated the completion of the QIMR research research underway at QIMR. We have more than 500 faculty reorganisation and the recruitment of a number of scientists working on cancer, infectious diseases and new research groups, including those of Professor Mark mental health and complex disorders. They are making their Smyth, Dr Michelle Teng, Dr Stacey Edwards, Dr Juliet mark and making a difference by producing research with French, Dr Nicole Cloonan, Dr Jason Mulvenna and Dr consequences. A striking indication of their abilities, is that Andreas Moller. on average, QIMR researchers published over two articles per work day and attended over three international speaking Finally, I’d like to take a moment to remember a man who invitations per week over the course of 2012-13. played such a big role in establishing the foundations for QIMR’s strengths today. In 2013, I’m sad to report, Bob Much of this work quite rightly garners headlines: the MacLennan passed away. Emeritus Professor MacLennan advances in cancer and mental health, or work on tropical founded our Epidemiology Unit in 1986, making QIMR the diseases that affect Queenslanders will always attract much first Australian medical research institute to recognise the of the public interest. powerful insights to be gained from this field. Even today, the commitment of QIMR to epidemiology studies are a special I would like to take a moment to also recognise our global aspect of our research approaches to foster prevention as responsibilities. QIMR is carrying out important work into well as cures for disease. The selection of Adele Green from malaria, and parasitic infections that may not be a major this area of studies as the Queensland Australian of the problem in Australia as yet, but which kill millions of people Year shows the importance and quality of the work that is around the world. Not only is this the right thing to do, it is performed by these groups. also a wise strategy in a world where the increasing ease of international travel also means disease can spread more Ultimately, the community should take pride and comfort easily. It also is in keeping with our awareness, exemplified in the knowledge that there is world-quality research by an Asian strategy for the Institute, of the fact that we are happening so close to home. In the decades since QIMR’s adjacent to the high potential countries in Asia inception in 1945, our scientists have had an enormous impact on our collective wellbeing. Together, we will Of course, we can now pursue our research in state-of- continue to work towards our common goal: better health the-art facilities, which were officially opened in December through medical research. by American philanthropist Mr Chuck Feeney, whose generous donations helped fund the new 15-storey building. Professor Frank Gannon Mr Feeney’s foundation, The Atlantic Philanthropies, has Director and CEO now given away $US6 billion to non-profit organisations

PagePa 11 OUR ORGANISATION

ROLE AND MAIN Our vision FUNCTION To be a world renowned medical research institution QIMR was established under the Queensland Institute of Medical Research Act 1945 for the purpose of research into any branch or branches of medical science.

QIMR is a world leading medical research institute. Our research focuses on three areas: cancer; infectious diseases; and mental health and a range of complex disorders. Working in close collaboration with clinicians and other Our mission research institutes, our aim is to improve health by developing prevention strategies, new diagnostics and better treatments. Better health through medical research

GOVERNMENT OBJECTIVES FOR Our philosophy THE COMMUNITY QIMR supports scientists who perform world-class

QIMR research aligns with the Queensland Government’s medical research aimed at objective of growing a four pillar economy, by actively improving the health and providing economic beneﬁts to Queensland through: well-being of all people • Leveraging Queensland Health’s $18.864 million investment more than four-fold from other sources, including salaries for researchers, up to $80 million (approx) per annum; • Providing over 600 high quality jobs. This will grow to approximately 1,000 by 2017; • Providing 360 building and services related jobs and an • Providing the research that resulted in a new skin cancer investment of $200 million into the construction sector; drug that is manufactured in Queensland and now • Actively working to deliver international conferences to available for sale; and Queensland, assisting the tourism industry; • Maintaining eight active licensing agreements for • Working on topics such as depression, skin cancer its technology. and tropical health that are of direct relevance to the Queensland resources and agribusiness sectors;

Page 12 QIMR Annual Report 2012–2013 STRATEGIC PLAN

QIMR is entering the last year of its strategic plan, or All operations underpin the Institute’s vision, which is to be roadmap for the 2011-14 period. The roadmap guides a world leader in medically relevant research and to transfer the operations of the Institute in a competitive and this knowledge and understanding to the clinic. changing environment. The Institute’s strategic priorities for 2011-14 are to: The strategic focus of the roadmap is driven by the following: • Strengthen research activities; • QIMR will become a world leader in medically relevant • Introduce a career development structure; research and the transfer of this knowledge and • Support researchers to promote retention; understanding to the clinic; • Increase inter-Institutional collaborations; • It will focus on areas that are of high importance to Queensland and that will include regionally relevant • Strengthen collaborations on the Herston campus; diseases and those that are major causes of mortality • Diversify income sources for QIMR; and and morbidity to the community; • Increase the focus on outputs. • Excellence in research and researchers will characterise QIMR; These priorities are achieved by meeting the following measurable objectives: • The research programs of QIMR will be ﬁrmly underpinned by outstanding fundamental research • Translation; of direct relevance to the research that is closer • Scientiﬁc quality; to translation. • Commercial consequence; • Societal impacts; • International reputation.

PROGRESS

For details on how QIMR’s research has met the objectives scientiﬁc quality and international reputation in 2012-13, of translation, societal impact, commercial consequence, see page 28.

OPERATING ENVIRONMENT

RAPID GROWTH COMPETITION FOR AND RECRUITMENT FUNDING

QIMR is actively recruiting researchers in areas of high QIMR operates in a competitive environment with much strategic importance to Queensland, including tropical of its research funded by competitive grants obtained by diseases, immunotherapy and vaccine development, cancer researchers. For 2012, QIMR achieved a 31% success rate and genetics to increase its capacity to approximately 1,000 for overall grant applications funded by the NHMRC, which staff, students and visiting scientists over the next ﬁve years. is above the national average of 23.7%. QIMR’s success rate Already, QIMR has attracted seven new research teams for NHMRC applications in the Project Grants category was in 2012-13 in its Departments of Biology; Immunology; 29.4% as opposed to the national average of 20.5%. Genetics and Computational Biology in the Cancer and Infectious Diseases Programs. The successful recruitment and retention of leading Australian and international scientists in Queensland and at QIMR will be a critical issue in a highly competitive sector.

Page 13 OUR PEOPLE

At 30 June 2012, QIMR had 601 full-time and part-time ﬁgure takes into account the number of permanent full-time employees and 120 students. 81.9% of the Institute’s equivalent (FTE) employees as at 1 July 2012, an increase employees (including casuals) are employed on ﬁxed-term in recruitment for new positions and the number of staff contracts due to the nature of research funding being reliant on members who voluntarily ceased or resigned from the short-term grants. organisation. In fact, 87.5% of FTE staff who were employed with QIMR as at 1 July 2012 were still employed at QIMR as at QIMR has experienced a low rate of staff turnover in 2012–13, 30 June 2013). with the separation or turnover rate sitting at 14.4%. This

WORKFORCE PLANNING, ATTRACTION AND RETENTION

Workforce planning initiatives at QIMR include: ensure growth in research staff is effectively supported into the future. • an Education and Higher Degrees Program to attract students to medical research and a career at QIMR; To meet QIMR’s strategic aim of attracting staff in the areas • the ongoing support for a culture of work/life balance to of Molecular and Cellular Biology, Cancer Biology, Infectious attract and retain employees; Diseases, Bioinformatics and Systems Biology, Chemistry, Population and Clinical Sciences, throughout 2012-13 the • maximising remuneration beneﬁts for employees through Institute has targeted these areas and attracted researchers highly effective salary packaging options; and from over 24 countries. • provision of childcare arrangements for early year The majority of QIMR staff are employed under the QIMR childcare places. Enterprise Agreement 2011, which is complemented by a While ongoing resource planning at QIMR is limited by short range of workforce policies that not only support the operation term funding cycles for research employees; QIMR’s Support of the Enterprise Agreement and the achievement of strategic Division has planned resourcing and stafﬁng requirements to objectives, but foster a high performance culture.

ETHICS AND CODE OF CONDUCT

QIMR has a Code of Conduct which sets out expected and updated to reﬂect changes made by the Queensland workplace for conduct, relationships and behaviour of staff. Government to the Public Sector Ethics Act 1994. The Code of Conduct was most recently reviewed in 2011

WHISTLEBLOWERS PROTECTION ACT 1994

No public interest disclosures were received during the 2012-2013 reporting year.

Page 14 QIMR Annual Report 2012–2013 CARERS ACT 2008

QIMR’s Human Resource policies are regularly reviewed to options, a child care assistance policy, and definitions of a ensure that they comply with obligations set out for public carer compliant with the Act. Employees have access to authorities under the Carers Act 2008. QIMR provides information regarding benefits and policy on the QIMR staff access to flexible working arrangements, flexible leave intranet.

STAFFING

Supporting the ongoing quality of research, QIMR employed 53 Fellows in 2012-13.

REVIEW OF EQUAL OPPORTUNITIES

Ensuring QIMR has gender equality, QIMR has reviewed science. The Director has established a regular meeting with the guidelines endorsed by the Council of the Australian representatives from across QIMR to review the proﬁle of Academy of Science to ensure that women and men QIMR, identifying any problems, evaluating initiatives and have equal opportunities to pursue a successful career in discussing improvements and new ideas.

WOMEN AT QIMR

Women play an important role at QIMR with 62.1% of the At QIMR: total workforce being female and 62.8% of our students • Women hold 36.3% of all scientific leadership positions. being female. Women have significant roles in the Support Division, such as the Safety Manager, Regulatory Affairs • Of the 17 newly created Team Head roles, seven are Manager, Animal Facility Manager, Flow Cytometry Manager held by women (41%). and the Chairperson of the Higher Degrees Committee. • 30% of QIMR Council is female. Women also hold significant senior management roles, such as Chief Operating Officer, Cancer Program Coordinator, and • 50% of the Support Management Team is female; this Biology Department Coordinator. includes the Chief Financial Officer and Senior Manager External Relations.

FLEXIBLE WORKING POLICIES

QIMR has ﬂexible working hours, job share and part-time employment options, to assist with balancing work and personal lives. Women are more likely to be part-time with 28% of staff on part-time arrangements and currently two positions have job share occupants who are female.

Page 15 QIMR CHILDCARE ASSISTANCE

QIMR has secured a number of places with a local childcare centre for infants under the age of two years, to assist employees returning to the workforce after becoming a parent.

NURSING MOTHERS

Within the new building, QIMR has a room speciﬁcally designed to cater for nursing mothers.

INDIGENOUS WORKFORCE DEVELOPMENT INITIATIVES

Reﬂecting the value QIMR places on being informed • increase the capability of QIMR’s non-indigenous by the community, our Indigenous Health Research researchers to appropriately conduct Indigenous program has adopted a governance model that seeks Health research both internal and external input; a committee of QIMR • increase awareness and appreciation of Aboriginal and researchers and an advisory group of external members Torres Strait Islander cultures. with expertise in “Service Provision”, “Policy Development” and “Research”. Together, these groups serve to advise As a world leading medical research facility, QIMR is about the viability of workforce development, research and dedicated to translating discovery into treatment, diagnostics communication activities. and prevention strategies, being informed by and engaging stakeholders with vested interest and capacity to inﬂuence Within the space that is workforce development, we Indigenous health. strive to: • increase the number of Aboriginal and Torres Strait QIMR has also commenced an Indigenous cadetship Islander researchers at QIMR for a third year science student through the Queensland Department of Education, Employment and • support the ongoing development of the Indigenous Workplace Relations. health research workforce

Page 16 QIMR Annual Report 2012–2013 INFORMATION SYSTEMS AND RECORDKEEPING

A review of QIMR’s recordkeeping has streamlined and TRIM Context has enabled QIMR to maximise the value of consolidated physical and electronic documents to keep records with consistent and timely capture. It also improves full and accurate records of its activities in accordance accessibility, reduces duplication and promotes information- with the Public Records Act 2002, Information Standard sharing across the organisation. 40 and Information Standard 31. As part of the records management program, the QIMR Recordkeeping Policy Records are not disposed of, or archived, unless their 2008 was established and adopted to provide an disposal is authorised under the Public Records Act 2002 organisation-wide policy on the management of QIMR or by reference to the Retention and Disposal Schedule documents and records, both hardcopy and electronic. approved by Queensland State Archives (QSA). All QIMR records are registered into TRIM Context before transfer QIMR has implemented an ofﬁcial records and electronic to the off-site storage provider or QSA. All QIMR hardcopy document management system called Total Records and records stored off-site are managed under legislatively Information Management (TRIM) Context. This provides a appropriate risk management standards and guidelines. single, standardised system that promotes ﬁle sharing and secures access to QIMR’s records. The implementation of

Page 17 OUR GOVERNANCE

COUNCIL PURPOSE AND MEMBERSHIP

In accordance with Part 2, Section 4A of the Queensland of Medical Research (“The Council”). Under the Statutory Institute of Medical Research Act 1945, QIMR is controlled Bodies Financial Arrangements Act 1982, the QIMR Council and governed by The Council of the Queensland Institute is a statutory body.

FUNCTIONS OF THE COUNCIL

The functions of the Council are to: • invest monies raised or accepted by the Council for the purposes of the Institute; and • control and manage the Institute; • invest monies derived from any property or other • raise and accept monies for the purposes of invested monies of the Council for the purposes of the Institute; the Institute.

MEMBERSHIP OF THE COUNCIL

The Council consists of at least seven, but not more than 11, members appointed by the Governor in Council.

Under the QIMR Act the Minister for Health is to recommend persons to be appointed as member of the Council. The Minister may have regard to the skills experience and expertise of a person in any of the following areas: • corporate governance; • public or academic administration; • health or clinical research; • health ethics; • ﬁnancial management; • fundraising; • any other area the Minister considers to be relevant to the functions of the Council.

Page 18 QIMR Annual Report 2012–2013 MEMBERS OF COUNCIL

THE HON PAUL DE JERSEY AC

Paul de Jersey was appointed Chair of the QIMR Council on 20 June 2013.

He came to the role from a lengthy legal and judicial career. Admitted to the Bar in 1971, where he practised substantially in commercial and constitutional law, he was appointed as a Judge of the Supreme Court of Queensland in 1985, and then Chief Justice of Queensland in 1998. His earlier judicial duties had included chairmanship of the Queensland Law Reform Commission and presidency of the Queensland Industrial Court.

A strong supporter of local not-for-proﬁt organisations, the Chief Justice acts as patron for a number of organisations including the Medico-Legal Society of Queensland, the Queensland Justices Association Inc and the UQ Pro Bono Law Centre, and has in the past led the board of the Australian Cancer Society (for three years) and the Queensland Cancer Fund, now the Queensland Cancer Council (for 10 years).

The Chief Justice is a Companion of the Order of Australia (2000), was awarded a Centenary Medal (2003), and holds Honorary Doctorates from the University of Queensland and the University of Southern Queensland .

MR CHRISTOPHER COYNE

Christopher Coyne was the Acting Chair of QIMR Council until 20 June 2013, and a member of the QIMR Finance and Audit Committee and the Executive Employment and Remuneration Committee until March 2013.

Mr Coyne is a solicitor of the Supreme Court of Queensland and an accredited specialist in the ﬁeld of Commercial Litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law ﬁrm Clayton Utz from 1984 to 2004.

Mr Coyne now practices on his own account. He was appointed an Adjunct Professor of The University of Queensland School of Law in 2002. Mr Coyne is a Director of Lexon Insurance Pty Ltd (Queensland Law Society, Singapore Captive Insurer), a Director of the Incorporated Council of Law Reporting for the State of Queensland, past president Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee.

PROFESSOR BRYAN CAMPBELL AM MD BS FRACP FRACMA

Professor Campbell was Acting Deputy Chair of QIMR Council unil 20 June 2013. He was formerly Chief Health Ofﬁcer of Queensland and Head of The University of Queensland Medical School.

He has been a Councillor of the Royal Australasian College of Physicians, the Royal Australian College of Medical Administrators and a member of the NHMRC. He was Deputy Chair of the Australian Health Ethics Committee and a member of the NHMRC Embryo Research Licensing Committee until June 2006.

Professor Campbell is the Chair of the QIMR Finance and Audit Committee and a Member of the Executive Employment and Remuneration Committee.

Page 19 DISTINGUISHED PROFESSOR JUDITH CLEMENTS BAppSc MAppSc PhD

DP Clements has over 20 years’ experience as a researcher in biomedical research, primarily in the general ﬁeld of molecular endocrinology. Her areas of expertise include prostate, ovarian and breast cancer, as well as biomarkers for cancer progression, kallikrein proteases and new therapeutic targets.

She is currently Scientific Director of the Australian Prostate Cancer Research Centre Queensland and Program Leader of the Cancer Program within the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), at the new Translational Research Institute on the Princess Alexandra Hospital Biomedical Precinct. She coordinates the Australian Prostate Cancer BioResource, a national tissue bank for prostate cancer research. She is also an NHMRC Principal Research Fellow and an NHMRC Academy member since 2009. In 2007, Professor Clements was awarded the prestigious international Frey-Werle Foundation Gold Medal for her significant contributions to the kallikrein protease field. She was awarded the Queensland Women in Technology Biotech Outstanding Achievement Award for 2012, and has been recently awarded the prestigious title of Distinguished Professor at QUT.

DP Clements is Chair of the QIMR Appointment and Promotions Committee.

ASSOCIATE PROFESSOR PAULA MARLTON MB BS (Hons I) FRACP FRCPA

Associate Professor Marlton is the Head of Leukaemia and Lymphoma Services at the Princess Alexandra Hospital where she is also Deputy Director of Haematology. Her previous appointments include three years at the MD Anderson Cancer Centre in Houston, Texas. She has extensive experience in clinical research incuding the role of principal investigator for national multi-centre trials and supervisor of molecular translational research associated with trials. She was the founding Chair of the Australasian Leukaemia and Lymphoma Group (LLG) Laboratory Science Committee and has established and continues to direct the ALLG Tissue Bank. Her other professional roles include Medical Advisor and board member of the Leukaemia Foundation, member of several drug advisory boards and government and college advisory committees as well as a wide range of academic and clinical service roles.

Associate Professor Marlton is a member of the QIMR Appointments and Promotions Committee.

DR JEANNETTE YOUNG MB BS MBA FRACMA FFPH AFACHSM

Dr Young is the Chief Health Officer for Queensland, a role she has filled since August 2005. Prior to this, she held the position of Executive Director of Medical Services at the Princess Alexandra Hospital in Brisbane and has previously worked in a range of positions in Queensland and in Sydney. She has specialist qualifications as a Fellow of the Royal Australasian College of Medical Administrators and as a Fellow by Distinction of the Faculty of Public Health of the Royal College of Physicians of the United Kingdom. She is an Adjunct Professor at QUT and Griffith University.

As Chief Health Ofﬁcer, she is responsible for such matters as health disaster planning and response; aero-medical retrieval services; licensing of private hospitals; and policy regarding research; organ and tissue donation services; cancer screening services; communicable diseases; environmental health, preventive health and other population health services; blood, poisons and medicines.

Dr Young is a member of numerous state and national committees and boards including the NHMRC, the Australian Health Protection Principal Committee, the Jurisdictional Blood Committee, the Organ and Tissue Jurisdictional Advisory Committee, the Australian National Preventive Health Agency Advisory Council and the National Screening Committee.

Page 20 QIMR Annual Report 2012–2013 PROFESSOR NICHOLAS FISK MBBS PhD MBA FRANZCOG FRCOG DDU CMFM GAICD

Professor Fisk is Executive Dean of the Faculty of Health Sciences at The University of Queensland. He is a Board Member of the Metro North Hospital and Health Service and of Diamantina Health Partners. He practices as a maternal-fetal medicine specialist at the Royal Brisbane and Women’s Hospital, and leads a research group in The University of Queensland Centre for Clinical Research (UQCCR).

Between 1992 and 2007 he was Professor of Obstetrics and Fetal Medicine at Imperial College, London and Queen Charlotte’s Hospital, London. His main research interests have been in monochorionic placentation and human fetal stem cell biology. He has authored over 400 publications, is a past President of the International Fetal Medicine and Surgery Society, and is a member of several editorial boards including PLoS Medicine.

Professor Fisk is a member of the QIMR Appointments and Promotions Committee.

MR GREG BAYNTON BBus M Econ St MBA FFINSA (To 12/10/12)

Greg Baynton is the founder and Managing Director of Orbit Capital, a boutique investment and advisory company. He has a background in merchant banking and Queensland Treasury, and has experience in infrastructure investment, capital raisings, Initial Public Offerings (IPO), pre-IPO funding, corporate structuring and corporate governance.

Mr Baynton is currently Director of COALBANK Limited and NEXTDC Limited and was a Director of Tissue Therapies Limited and PIPE Networks Limited.

Mr Baynton is a Fellow of the Financial Services Institute of Australasia.

PROFESSOR ALAN PETTIGREW BSc (Hons) PhD FAICD

Professor Pettigrew is a Fellow of the Australian Institute of Company Directors. He has held a range of academic and senior executive appointments at a number of Australian universities, having served as Deputy Chair of the Academic Board at the University of Sydney, Pro Vice-Chancellor (Biological Sciences) at The University of Queensland, and Deputy Vice-Chancellor (Academic) at the University of NSW.

Professor Pettigrew served as the inaugural Chief Executive Ofﬁcer of the National Health and Medical Research Council. In 2005, he was appointed Vice-Chancellor and Chief Executive Ofﬁcer of the University of New England. Professor Pettigrew retired from the University in 2009. He also served as a member of the Board of the Australian Universities Quality Agency until 2010.

Professor Pettigrew is currently an Adjunct Professor in the College of Medicine Biology and Environment at Australian National University and a Professorial Fellow of the LH Martin Institute at the University of Melbourne. He is a member of the Australian Government’s Cooperative Research Centres Committee and the Board of the John Curtin Medical Research Foundation. He is also Chair of the Advisory Committee for the NHMRC Centre of Research Excellence in Reducing Healthcare Associated Infection based at QUT. Professor Pettigrew is an adviser to the Chief Scientist of Australia and a consultant to the Organisation for Economic Co-operation and Development and universities on higher education leadership, management and research.

Professor Pettigrew is a member of the QIMR Appointments and Promotions Committee.

MR RODNEY WYLIE OBE BComm BA FCA FAICD

Rod Wylie is a Brisbane-based chartered accountant with substantial experience in investment, company management and corporate governance issues across a wide range of organisations, in many cases with nationwide and international activities.

He has been involved through board or council membership in the administration of a number of professional and community not-for-proﬁt groups.

Mr Wylie chairs the QIMR Investment Committee and is a member of the QIMR Finance and Audit Committee.

Page 21 MR IAN FRASER BComm FCA FAICD

Ian Fraser is a Chartered Accountant practising as a nonexecutive company director with more than 45 years’ experience as a business and accounting professional including nine years as a company director of listed and unlisted public companies and 27 years as a partner with KPMG. He retired as an audit and corporate advisory partner in 2004.

Mr Fraser is chairman of Asia Paciﬁc Data Centre Trust and a non-executive director of Wilson HTM Investment Group Ltd.

He is a member of the QIMR Investment Committee and a member of the QIMR Finance and Audit Committee.

NUMBER OF MEETINGS

Attendance by Members of Council who held ofﬁce during the 2012-13 ﬁnancial year are as follows:

Meetings Meetings Appointed members Appointed members attended attended Greg Baynton 1 of 2 Paula Marlton 5 of 7 Bryan Campbell 7 of 7 Alan Pettigrew 5 of 7 Judith Clements 5 of 7 Rod Wylie 5 of 7 Christopher Coyne 5 of 7 Jeannette Young 4 of 7 Nicholas Fisk 5 of 7 Council Secretary: Donna Hancock 7 of 7 Ian Fraser 7 of 7

REMUNERATION OF COUNCIL

The aggregate remuneration for the QIMR Council for 2012-13 was $9,418.

COMMITTEES TO COUNCIL

The Committee meets quarterly to review business and FINANCE AND AUDIT financial risk, financial operating performance and audit performance. The Committee reviews all issues and COMMITTEE recommendations arising from internal audit and the Queensland Audit Office, along with agreed management The role of the Finance and Audit Committee is to provide actions implemented to address any issues found. independent assurance and assistance to the QIMR The Finance and Audit Committee follows its terms of Council on: reference and has due regard to Queensland Treasury’s • risk, control and compliance frameworks; Audit Committee Guidelines. The Finance and Audit Committee comprises: • QIMR’s external accountability responsibilities as prescribed in the relevant legislation; and • Professor Bryan Campbell (Chair) • the appointment of the internal audit function and • Mr Christopher Coyne (until March 2013) communications with internal and external auditors. • Mr Ian Fraser The Committee is directly responsible and accountable • Mr Rodney Wylie to the QIMR Council for the exercise of its duties and responsibilities.

Page 22 QIMR Annual Report 2012–2013 APPOINTMENTS HUMAN RESEARCH AND PROMOTIONS ETHICS COMMITTEE

COMMITTEE The Human Research Ethics Committee on behalf of Council ensures the maintenance of ethical standards in human The Appointments and Promotions Committee assists research and compliance with regulatory guidelines. Council with the maintenance of academic standards at • Dr Ian Wilkey (Chair) QIMR by reviewing proposals for the appointment and promotion of Faculty staff. The committee comprises: • Dr Roger Allison • Distinguished Professor Judith Clements (Chair) • Ms Madeline Brennan (Council Member) • Mrs Gwen Eardley • Professor Nick Fisk (Council Member) • Mr Angus Edmonds • Associate Professor Paula Marlton (Council Member) • Professor Barbara Leggett • Professor Alan Pettigrew (Council Member) • Mrs Mary Mackenzie • Dr Joanne Aitken (Director, Viertel Cancer Epidemiology • Dr Peter Roeser Unit, Cancer Queensland) • Mr David Russell • Professor Julie Campbell • Dr Tom Sculley (to November 2012) • Professor Alan Cowman (Walter and Eliza Hall Institute • Mr John Stead of Medical Research) • Associate Professor Katharine Trenholme • Professor Tony Evans (Director, Cancer Therapeutics CRC Pty Ltd) • Dr Brett Stringer (from June 2013) • Professor Bob Graham (Executive Director, Victor • Ms Donna Hancock Chang Cardiac Research Institute) • Professor Andrew Grulich (The Kirby Institute, UNSW) • Dr Jurgen Michaelis (Chair, Bio Innovation SA) ANIMAL ETHICS • Professor Joe Trapani (Peter MacCallum Cancer Centre) COMMITTEE

• Professor Frank Gannon (ex ofﬁcio) The QIMR Animal Ethics Committee on behalf of Council ensures the maintenance of ethical standards in animal research and compliance with regulatory guidelines in the INVESTMENT COMMITTEE use of animals in medical research.

The Investment Committee is responsible for overseeing the investment of QIMR Council Funds. • Mr Rod Wylie (Chair) THE PHASE II AND III • Mr Bruce Phillips (to May 2013) BUILDING PROJECT • Mr Michael Sargent • Mr John Allpass STEERING COMMITTEE

• Mr Ian Fraser • Professor Frank Gannon (Chair) • Mr Greg Baynton (to October 2012) • Professor Greg Anderson (Deputy Director) • Mr Alan Stockman (Project Director) (to August 2012) EXECUTIVE EMPLOYMENT • Mr John Parnell (Project Manager) • Professor Grant Ramm (Staff Association AND REMUNERATION Representative) • Ms Donna Hancock (Chief Operating Ofﬁcer) COMMITTEE • Dr Joseph Pereira (Senior Manager Scientiﬁc Services) The Executive Employment and Remuneration Committee is responsible for reviewing the terms and conditions relating to the appointment and remuneration of senior management. • Professor Bryan Campbell • Mr Christopher Coyne (to March 2013)

Page 23 RISK MANAGEMENT

The review and management of risk at QIMR is undertaken improve any identiﬁed gaps in controls. The review process by QIMR Council through the Finance and Audit Committee. records all incidents reported to Committees, Management QIMR management maintains a register of potential or Council and allocates those incidents to risk categories. If risks applicable to functions of the Institute. A schedule a risk has not previously been described in the register, it is of quarterly reviews incorporates the actions required to added in the appropriate category and controls developed.

INTERNAL AUDIT

Internal audit is a fundamental part of corporate governance The approach taken to identifying areas of significant risk that ensures that QIMR operates effectively, efficiently and combines a focus on both cyclical reviews of core business economically. The Finance and Audit Committee acts as a processes as well as reviews of key risk areas. KPMG’s forum to oversee the planning, performance and reporting of integrated governance, risk and controls framework builds the internal auditor. on a traditional internal audit model to take a holistic view of QIMR’s key objectives, risks, controls and supporting The role of internal audit is to provide independent, structure across the organisation. objective assurance and advice designed to assist QIMR in accomplishing its objectives by bringing a systematic, In formulating an internal audit plan for presentation to the disciplined approach to evaluating and improving the Finance and Audit Committee for approval, consideration appropriateness and effectiveness of risk management and was given to past internal audit findings, recent and internal control. forthcoming changes in systems and processes, key business risks and the period since the last internal audit The internal audit contractor (KPMG) met with the Finance of each core business process. An annual internal audit and Audit Committee on the following occasions during the plan was prepared and presented to the Finance and Audit period 1 July 2012 – 30 June 2013: Committee prior to the commencement of the financial year. • 31 August 2012, The internal audit function has observed the terms of its • 23 November 2012, and charter and has due regard to Queensland Treasury’s Audit Committee Guidelines. • 1 March 2013.

EXTERNAL SCRUTINY

QIMR was not subject to any reports of any parliamentary committees, the Crime and Misconduct Commission or the Queensland Ombudsman.

OPEN DATA

For information on consultancies and overseas travel for QIMR please visit the Queensland Government Open Data website at qld.gov.au/data.

Page 24 QIMR Annual Report 2012–2013 OUR MANAGEMENT

DIRECTOR AND CEO, PROFESSOR FRANK GANNON

Professor Frank Gannon is QIMR’s seventh Director and 2000-2008, he contributed to a monthly editorial to EMBO CEO. In this role he is responsible for the work undertaken Reports of which he was founding Senior Editor. He also by the Institute, management of employees and the writes extensively on diverse topics related to science policy. development of the strategies of the Institute, under the Professor Gannon has seven patent applications, four of overall control of the Council. Professor Frank Gannon joined which are active at present and was the founder of both QIMR as Director and CEO in January 2011. Previously, Bimini Ltd (1990) and Elara Pharmaceuticals (2006). He Professor Gannon was the Director General at the Science was a member of the interim Board of Science Foundation Foundation Ireland (SFI) from 2007. Ireland from 2002 to 2004 and was elected as a Member of Academia Europea in 2005, Royal Irish Academy in 2007 From 1994-2007, Professor Gannon was the Executive and the Mexican Academy of Medicine in 2008. Director of the European Molecular Biology Organisation (EMBO) and Senior Scientist at the European Molecular In 2012, Professor Gannon was appointed as a Queensland Biology Laboratory (EMBL), based in Germany; and Director Academy of Arts and Science Fellow. of the National Diagnostic Centre and Associate Professor in the Department of Microbiology at University College He has been awarded honorary Doctorates by the Galway, Ireland (1981-1994). University of Jozsef Attila, Szeged (Hungary), The University of Queensland and Queens University Belfast He obtained a Bachelor of Science from the National (Northern Ireland). University of Ireland, Galway in 1970; a PhD from the University of Leicester, England in 1973; was a post-doctoral He has served on a range of high-level scientiﬁc advisory fellow at the University of Madison Wisconsin, USA from boards at institutes in Norway, Poland, South Africa and 1973 to 1975; and Chargé de Recherche in INSERM at the Australia and was co-founder of the European Life Sciences University of Strasbourg, France from 1975 to 1981, after Forum (ELSF) and the Initiative for Science Europe (ISE) that which he returned to Galway. played signiﬁcant roles in the establishment of the European Research Council (ERC). His major research interest is the expression and functional regulation of the oestrogen receptor, which plays a major He was Vice President of the European Heads of role in breast cancer and osteoporosis. These studies Research Council and an advisor to the European Union have provided leads to novel treatments or therapeutic Commissioner for Research and Innovation prior to his move approaches to these and other cancers. to Brisbane.

Professor Gannon has authored over 200 research articles published in international journals. In addition, from

Page 25 Council ORGANISATIONAL CHART Director

Chief Operating Officer and Secretary to Council

Genetics & Immunology Biology Computational Biology Department Coordinator Department Coordinator Department Coordinator

Chief Financial Ofﬁcer Bone Marrow Transplantation Oncogenomics Skin Carcinogenesis

Chief Human Resources Ofﬁcer Immunology in Cancer & Infection Cancer Genetics Signal Transduction

Senior Manager Clinical Immunoheamatology Molecular Cancer Epidemiology Protein Discovery Centre External Relations

Senior Manager Antigen Presentation Genomic Biology Inﬂammation Biology Scientiﬁc Services & Immunoregulation

Senior Manager Translational Functional Cancer Genomics HIV Molecular Virology Research Support & Governance Leukaemia Research

Manager Council Business Tumour Micro-environment Functional Genetics Clinical Tropical Medicine

Cancer Immunoregulation Cancer & Population Studies Molecular Parasitology and Immunotherapy

Molecular Vaccinology Gynaecological Cancers Molecular Vaccinology

Cellular Immunology Cancer Control Group Mosquito Control

Bacterial Pathogenesis Immunology and Infection Cancer Aetiology & Prevention & Scabies

Biomarkers & Biology of Tumour Immunology Bioinformatics Infection Related Cancers

Inﬂammation Biology Inﬂammatory Bowel Disease Iron Metabolism

Malaria Immunology Membrane Transport Lung Inﬂammation & Infection

Human Immunity Genetic Epidemiology

Molecular Immunology Systems Neuroscience

Inﬂammatory Bowel Disease Molecular Epidemiology

Hepatic Fibrosis Neurogenetics

Neuroimaging Genetics

Asthma Genetics

Statistical Genetics

Quantitative Genetics

Page 26 QIMR Annual Report 2012–2013 Aboriginal and Deputy Director Torres Strait Islanders Health Research Manager

Cell & Molecular Biology Population Health Department Coordinator Department Coordinator

Leukaemia Foundation Cancer & Population Studies Cancer Program Coordinator Control of Gene Expression Gynaecological Cancers

Signal Transduction Cancer Control Group

Radiation Biology & Oncology Cancer Aetiology & Prevention

Conjoint Gastroenterology Molecular Cancer Epidemiology

Drug Discovery Group Molecular Parasitology Infectious Diseases Program Coordinator Cancer Drug Mechanism

Protein Discovery Centre

HIV Molecular Virology

Bacterial Pathogenesis & Scabies

Hepatic Fibrosis Mental Health / Complex Disorders Program Coordinator Membrane Transport

Epigenetics

Iron Metabolism

Key

Laboratory is also represented in another department

Page 27 OUR PERFORMANCE

QIMR’s mission is to deliver better health through medical • Translation research. This is achieved through outstanding fundamental • Scientiﬁc quality and translational research with the ultimate goal being the translation into clinical practice in the form of improved • Commercial consequence diagnostics, prevention and treatment strategies. In order • Societal impacts to measure the performance of QIMR’s research with consequences, the following outputs are considered: • International reputation TRANSLATION

Investigating the world’s most deadly diseases, from cancer to infectious diseases, to mental health and a range of TRANSLATION FACILITIES complex disorders, QIMR is dedicated to improving the health of people across Queensland, Australia and the world. QIMR is one of Australia’s only fully integrated biomedical research and development centres. Within the Institute, there The Institute is committed to making fundamental scientific is the capability to translate fundamental basic research from discoveries and translating them into disease prevention the discovery phase through development, scale-up and measures and treatments. manufacture, to Phase I and II clinical trials. The first of its kind in Queensland, QIMR is truly a translational medical research institute, taking discoveries QIMR also has facilities for the good manufacture practice from bench to bedside. (GMP) manufacture of cell-based and molecular therapies. Co-located within the Institute is an associated commercial Translational research highlights for 2012-13 include: Phase I/II clinical trials facility, Q-Pharm Pty Ltd, allowing • Identifying that a treatment currently being trialled for QIMR scientists and external clients the extended capability leukaemia may also be effective against brain cancer; for taking research findings from bench to the bedside. • Trialling tocilizumab (a drug used to treat rheumatoid arthritis) for the treatment of asthma; • Carrying out research into the factors that affect graft- Q-GEN versus-host disease in people who have received a bone marrow transplant leading to several changes in Q-Gen is licensed by the Therapeutic Goods Administration clinical treatment to alleviate graft-versus-host disease (TGA) for the maintenance and storage of working cell after the transplant; banks, the storage on site of cellular products and the management and release of cellular therapies for humans. • Successfully completing the Phase I clinical trials for a The TGA license makes Q-Gen one of a very small number new nasopharyngeal carcinoma therapy; of organisations in Australia able to store human and non- • Commencing human trials of malaria treatments human samples under GMP conditions. and vaccines; Q-Gen is one of the largest GMP facilities in Australia, • Developing and trialling immunotherapy with 13 ISO Class 7 clean rooms. Each clean room is fully treatments against: equipped for the manufacture of clinical therapies. - nasopharyngeal carcinoma, Q-Gen provides QIMR with a unique facility to conduct its - brain cancer, translational research and processes for clinical therapies - lymphoma and and is currently utilised in the manufacture of a number of - cytomegalovirus; and QIMR sponsored developmental immunotherapies and the production of material for malaria trials. • Discovering that HIV protease inhibitors also kill malaria parasites.

Page 28 QIMR Annual Report 2012–2013 for Women, Westmead Hospital, Mercy Hospital Q-PHARM for Women); • Adoptive immunotherapy for EBV associated with In order to facilitate the translation of QIMR’s research into nasopharyngeal carcinoma (Princess Alexandra Hospital, clinical practice, Q-Pharm is a related entity with QIMR Queen Mary Hospital, University of Hong Kong); holding a 24.5% share. Q-Pharm is a specialist contract research organisation that conducts early phase clinical • Surveillance of skin cancer rates in organ transplant trials of pharmaceutical and biotechnology products patients (Princess Alexandra Hospital, Prince Charles spanning the areas of therapeutic, diagnostic and disease Hospital); prevention agents. • Genome expression profiling of squamous cell carcinoma with perineural invasion (Princess The company offers the best appointed early phase clinical Alexandra Hospital); trials facilities in Australasia, including recruitment and outpatient clinics, a specialised 18-bed clinic for the conduct • Collaborating on new drugs and vaccines for cancer of the most medically demanding trials and an open plan 24 and infectious diseases with UQ and Emory University bed facility for larger healthy volunteer trials. (Georgia, USA); • Forming the Queensland Mental Health Research Alliance with the Queensland Brain Institute and CLINICAL Queensland Health’s West Moreton Hospital and Health Service; COLLABORATIONS • Biology of cystic fibrosis lung disease, particularly Pseudomonas infection (Prince Charles Hospital, Because of its close proximity to major teaching hospitals Royal Children’s Hospital); and The University of Queensland Medical School, QIMR • Samples from patients with acute myeloid leukaemia for is ideally placed for clinical research collaborations. It has a study (Royal Adelaide Hospital); proud history of working closely with hospitals, in particular • Queensland Head and Neck Cancer Centre (Princess the RBWH. Clinicians have research groups in QIMR Alexandra Hospital); and medical researchers in QIMR have clinical sessions at the RBWH. QIMR’s researchers also have significant • Genetic screening of patients with iron overload relationships with clinicians nationally and internationally. In disorders (RBWH, Greenslopes Private Hospital); 2012-13, QIMR researchers collaborated with clinicians in • Skin cell samples patients with ataxia-telangiectasia over 75 projects, in a number of hospitals. and other hereditary ataxias (Royal Children’s Hospital);

QIMR funded four projects through their annual QIMR- • Factors affecting response to treatment for acute Clinician Research Collaboration Awards 2012, fostering ulcerative colitis (RBWH); clinical collaboration to advance translational research. • Diagnostic test for psychosis and dementia (Prince of Projects included: Wales Hospital, RBWH); • The relationship between hormone receptor signalling • Samples of brain cancer tumours for molecular analysis and obesity in endometrial cancer; and biobanking (RBWH); • New non-invasive methods to detect progression of • Clinical assessment of immunity monitoring to identify liver disease and identify patients at highest risk of bone marrow transplant patients at high risk of cirrhosis-related mortality; complications from CMV infection (RBWH); • The role of SerpinB2 in pre-eclampsia; and • Predictors of response to chemotherapy in ovarian cancer (Mater Mothers’ Hospital); • Searching for genetic differences between monozygous twin pairs discordant for epilepsy. • Response of ovarian cancer cell lines to statins (Mater Mothers’ Hospital); In 2012-13, QIMR researchers collaborated with clinicians • Mechanisms of metastasis in breast cancer (RBWH); in over 75 projects, in a number of hospitals. These collaborations included: • Genotyping patients to ﬁnd factors affecting response to treatment for acute ulcerative colitis (RBWH); • Clinical trial of tocilizumab (a drug used to treat rheumatoid arthritis) for the treatment of asthma (Royal • CMV infection in renal transplant patients (Prince Children’s Hospital, Princess Alexandra Hospital, Prince Charles Hospital); Charles Hospital); • Analysis of clinical dataset for melanoma (Princess • Epstein-Barr virus (EBV) -speciﬁc T cells as therapy Alexandra Hospital); and for recurrent EBV-positive lymphomas (Princess • Initiated a study to investigate potential use of immune Alexandra Hospital); monitoring to identify high risk patients for future • Ovarian Cancer Prognosis and Lifestyle (OPAL) study enrolment in a clinical trial (Prince Charles Hospital). (Royal Brisbane and Women’s Hospital, Royal Hospital

Page 29 Results VACCINE DEVELOPMENT In 2012-13, QIMR’s clinical collaborations produced a range of significant outcomes, including: Vaccine research requires a multi-disciplinary strategy which involves expertise in basic and applied immunology, • Identification of a drug target for brain cancer that has a pathogenesis, molecular and structural biology with treatment currently being trialled against leukaemia; preclinical and clinical trials methodology. • Development of new rapid and inexpensive tools to QIMR encompasses this varied expertise within a single screen for genetic mutations which are associated with institution and the QIMR Centre for Immunotherapy and iron disorders, which can aid clinicians in diagnosis; Vaccine Development (CIVD) harnesses this to advance the • Demonstration of the relationship between conditioning science of vaccine development. It provides opportunities for intensity and graft-versus-host-disease leading to its members to develop collaborative links with national and reduced intensity stem cell transplantation. Now half international academic institutions and the biotechnology of all stem cell transplantation are undertaken in this industry and also provides a platform for young Australian fashion; and international scientists to develop new techniques in the field of vaccine research. • Demonstration of the relationship of granulocyte-colony stimulating factor (G-CSF) mobilised blood products to The CIVD has strong links with the biotechnology industry graft-versus-host-disease and graft-versus leukaemia. and health institutions that are being leveraged to translate Now more than 80% of transplantation undertaken with the outcomes of research from bench to bedside, and G-CSF mobilized products; which will have significant implications for improving health • Demonstration that treatment using growth factor after outcomes for Australians. This collaborative program is also bone marrow transplant may exacerbate graft-versus- aiming to bring new technologies to Queensland and create host disease. Clinical practices have changed so that training and employment opportunities for Queenslanders. growth factors are now avoided after transplant; CIVD has unique expertise and resources in antigen • Demonstration of the critical role of tumour necrosis discovery with a strong focus on immunomics, factor (TNF) in mediating graft-versus-host-disease. bioinformatics and high throughput re-sequencing. TNF monoclonal antibodies are now used routinely in This approach allows rapid whole genome scanning of clinical bone marrow transplantation; infectious pathogens and cancer antigens to map novel vaccine determinants. • Contribution to the diagnostic and management guidelines for bipolar disorder (through the Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines); CURRENT CLINICAL • Illustration that ingenol mebutate (an existing product) can remove sun damaged skin cells (UV-mutated TRIALS keratinocytes) and therefore potentially avoid skin cancers and is now used in a product available for sale; Fundamental research at QIMR in 2012-13 underpinned a number of clinical trials that may ultimately lead to improved • Identification of two antioxidants which reduce the liver treatment options for patients. These included: injury associated non-alcoholic fatty liver disease, one of the most common disorders in the world; and • Testing a group A streptococcus vaccine; • Discovery that HIV protease inhibitors also kill malaria • Using immunotherapy for the treatment of parasites. This can reduce co-infection, a major cytomegalovirus (CMV) disease after bone marrow problem in developing countries. transplantation; • Assessing the safety of immunotherapy treatment for virus-specific brain cancer, glioblastoma multiforme; • Trialling immunotherapy following chemotherapy for metastatic EBV-associated nasopharyngeal carcinoma; • Carrying out an experimental study to characterise biochemistry during malaria infection in healthy volunteers; and • Testing antimalarial drugs in healthy human volunteers.

Page 30 QIMR Annual Report 2012–2013 SCIENTIFIC QUALITY

QIMR prides itself on being one of the largest and most This year, QIMR researchers have been published in a range successful medical research facilities in Australia, attracting of high impact scientific journals such as Nature, Nature exceptional scientists and students to carry out high quality Genetics, and the New England Journal of Medicine. These research aimed at preventing and curing disease throughout papers include: Australia and the world. • Identification of 23 new prostate cancer susceptibility QIMR has demonstrated its commitment to scientific loci using the iCOGS custom genotyping array in quality in a number of ways in 2012-13 including producing Nature Genetics; 638 peer reviewed publications, securing more than • Health education package to prevent worm infections $18 million of competitive NHMRC funding and producing in Chinese schoolchildren in the New England Journal a range of excellent world-class research outcomes across of Medicine; and its laboratories. • Identification of risk loci with shared effects on five QIMR will continue to strive for the highest standard of major psychiatric disorders: a genome-wide analysis in scientific quality by attracting outstanding researchers, The Lancet. producing and contributing to publications including high-impact journals, and gaining ongoing support from funding bodies to continue medical research.

PUBLICATIONS

Publications and citations are a key indicator of achievement and excellence in academic research and are a core output of QIMR. Conﬁrming the ongoing pursuit of excellence in science, researchers at QIMR contributed to 638 scientiﬁc publications. Of these publications, 54 were published in high impact journals (those with an impact factor over 10).

In a ranking of research institutes, prestigious publication, Nature, ranked QIMR ﬁrst in Australia amongst medical research institutes for research articles and reviews.

Scientiﬁc publications

700

600

500

400

300 PUBLICATIONS 200

100

0 2009 2010 2011 2012 2013 YEAR Articles High Impact (publications in journals with impact factors of 10 or more)

(*Publications in journals with impact factors of 10 or more)

Page 31 FUNDING

QIMR was recognised and gained support for its scientiﬁc and fellowship announcements in late 2012, for funding innovation, with researchers securing more than $18 million commencing in 2013. in funding from the NHMRC in the latest round of grants

20 NHMRC GRANTS AWARDED ($ MILLIONS) 15 (excluding Fellowships)

10 $MILLIONS

0 2009 2010 2011 2012 2013 YEAR Grants

FELLOWSHIPS AWARDS

QIMR employed 38 NHMRC Fellows in 2012-13 to support QIMR scientists received over 50 local and international the quality of ongoing research at the Institute and 53 fellows awards in the last ﬁnancial year, including: in total. • Professor Adele Green AC received the Queensland Australian of the Year, from the Australia Day Council; • Professor Grant Montgomery was recognised by the INVITED LECTURES Society for Reproductive Biology as an international leader in reproductive biology; and QIMR researchers were invited to speak about their work at • Dr Ashraful Haque was awarded an Australian Society for over 265 lectures in 2012-13, almost double on 2011-12s 140 Medical Research (ASMR) Senior Researcher Award for lectures. Invited lectures included: research excellence. • Professor Mark Smyth presenting at the Cancer Immunotherapy Consortium in Washington DC in April 2013; POSTGRADUATE • Dr Christian Engwerda delivering a presentation at the International Centre for Genetic Engineering and STUDENTS Biotechnology in Delhi in October 2012; and • Associate Professor Nathan Subramaniam presenting at QIMR is committed to encouraging today’s students to pursue the Institute of Molecular and Cell Biology in Singapore in science as a rewarding , exciting and challenging career. June 2013. The Institute relies on students to help carry out its research, but in return, QIMR offers students the opportunity to experience excellent research facilities, support services, an extensive network of international and national research collaborations, and work with the internationally- recognised QIMR scientists. All these elements provide an outstanding environment for advanced training in health and biomedical research.

Page 32 QIMR Annual Report 2012–2013 During 2012-13, the Institute welcomed 15 new PhD QIMR’s Higher Degrees Committee (HDC) also awarded students and 13 new Honours students. It was an excellent additional funding to help current students complete their year for graduations with over 20 PhD students and five degree programs. Top-up scholarships were awarded to ten Honours students graduating. During the year, the Institute of the top second-year PhD students and eight Honours also admitted four new MPhil, six course work Masters and Masters students were also awarded scholarships. students, and one student on the Indigenous cadet In addition, the HDC offered 13 PhD students financial program. We also welcomed more than 24 new visiting assistance to help them attend and present their work students, many from overseas. at overseas conferences through the presentation of travel awards. To assist students with the ongoing challenge of inadequate funding in post-graduate study, in 2012, QIMR launched The Australian scientific community recognises the quality eight QIMR International PhD Scholarships, to help attract of QIMR’s postgraduate students, with several receiving exceptional international students to QIMR. The first external awards for their research, including Michelle Neller, students will start at QIMR in July 2013. who won the Post-graduate Student Award at the Australian Society for Medical Research’s Health and Medical Research Awards.

CASE STUDY

Dr Bryan Day and Professor Andrew Boyd

QIMR scientists have identified a new target Most significantly, the protein can be directly targeted for treating aggressive brain tumours. with a treatment the laboratory has already developed, and which is currently in clinical trial for use in Professor Andrew Boyd and Dr Bryan Day have shown leukaemia patients. that a particular protein – EphA3 - is found in up to half the cases of glioblastoma multiforme (GBM), and GBM is the most common primary adult brain cancer, particularly in the most aggressive cases. They have and is nearly always fatal. It kills about 1000 Australians shown that EphA3 is required for GBM cells to grow and every year, most within two years of diagnosis. form tumours. Professor Andrew Boyd first discovered the protein EphA3 in leukaemia cells in 1992.

Page 33 COMMERCIAL CONSEQUENCE

QIMR supports its mission for better health by connecting companies. In 2012-13, 13 new projects were established with industry to boost health outcomes and economic with companies attracting approximately $3 million in benefits. By working with commercial organisations, QIMR external revenue. This is a significant increase on 2011- has been able to develop cancer therapeutics, diagnostic 12, when only seven new projects were established, and targets, cancer vaccines and infectious disease vaccines. $2 million was earned in external revenue. QIMR is a strong research partner of Queensland companies CBio Limited By collaborating with companies on a number of and Ecobiotics Limited. commercially significant projects, QIMR has further cemented its reputation for excellence. Contract research carried out in QIMR has resulted in the discovery and development of cancer therapeutic agents QIMR undertakes industry sponsored collaborative research and other commercial products. with a large number of local, national and international companies. Currently, QIMR has contracts with over 30 In 2012-13, QIMR worked to develop a more comprehensive national and international biotechnology and pharmaceutical commercialisation strategy that was launched in July 2013.

PATENT PORTFOLIO

New treatment patents

Vaccine patents

Delivery platforms patents

Diagnostic patents

Drug target patents

Medical device patents

RESEARCH AGREEMENTS Research service agreements Clinical trial agreements Intellectual property agreements Others

Page 34 QIMR Annual Report 2012–2013 RELATED COMMERCIAL Vaccine Solutions Pty Ltd QIMR is a shareholder in Vaccine Solutions Pty Ltd, a ENTITIES company established to commercialise intellectual property resulting from the CRC for Vaccine Technology. Trust for Cooperative Research Centre (CRC) for Vaccine Q-Pharm Pty Limited Technology (CRCVT Trust I) Q-Pharm Pty Limited is a specialised contract research organisation that undertakes a broad range of early phase QIMR is the Trustee of the CRC for Vaccine Technology (Phase I and Phase II) clinical trials for clients in the global Trust, a trust managing shares in VacTx Ltd on behalf of the pharmaceutical and biotechnology industries. QIMR holds participants of the CRC. a 24.5% share and Q-Pharm pays a licence fee per annum to QIMR to lease ofﬁce, laboratory and clinical trial ward facilities in the Clive Berghofer Cancer Research Centre, and Trust for the Cooperative Research for information technology services and stores services. Centre (CRC) for Vaccine Technology (CRCVT Trust II)

QIMR is the Trustee of the CRC for Vaccine Technology (CRC –VT) Trust (CRCT Trust II), a trust responsible for managing patent families and licensing agreements on behalf of those participating in the CRC for Vaccine Technology, which was abolished in June 2006.

Page 35 SOCIETAL IMPACTS

In order to achieve QIMR’s mission of better health through Professor David Whiteman, the head of QIMR’s Cancer medical research, its researchers target some of the world’s Control Group, is bringing together Australia’s seven major most debilitating diseases, including cancer, malaria and oesophageal cancer research teams, to form a Centre of mental illnesses. Gaining support from funding bodies, the Research Excellence. government and the community, QIMR has an obligation to demonstrate the value of medical research in improving Professor Whiteman’s research has already shown that health and the quality of life and addressing the major health heavy alcohol consumption more than doubles the risk of needs of society. dying from a particular type of oesophageal cancer. More than three drinks a day, over a lifetime, make a person more likely to get oesophageal squamous cell carcinoma ADDRESSING SOCIETY’S (OSCC) and more likely to die from it. QIMR has also developed a prediction model to identify HEALTH NEEDS people at high risk of developing another subtype – oesophageal adenocarcinoma (OAC). Cancer Triple-negative breast cancer With one in two Australians being diagnosed with cancer before the age of 85, half of QIMR’s research is focused on Breast cancer research is a QIMR strength and in 2012-13 the genetic and environmental causes of cancer and looking the Institute published several signiﬁcant ﬁndings into triple- at ways to improve the prevention, diagnosis and treatment negative breast cancer (TNBC), a particular subtype with a of cancer. poor prognosis.

About 15-20 per cent of breast cancers do not have any of Oesophageal Cancer the three receptors usually found on breast cancer cells. This subtype, TNBC, usually affects younger women and there is an urgent clinical need for new treatment options.

Professor Kum Kum Khanna and Dr Fares Al-Ejeh from QIMR’s Signal Transduction Laboratory have shown that a particular new combination of treatments can stop breast cancer recurrence and regrowth in mice.

Researchers had previously noted that TNBC tumours had an overload of proteins known as EGFR, which encourage the cancer’s growth. Dr Al-Ejeh has shown that targeting radiation specifically to the EGFR, along with a dramatically reduced dose of chemotherapy, not only destroys the original cancer, but also the cancer stem cells which drive Professor Frank Gannon, The Honourable Tanya Plibersek MP and Professor the cancer’s recurrence. David Whiteman at the announcement of the $2.4 million NHMRC award for a Centre of Research Excellence for oesophageal cancer. Meanwhile, eminent cancer immunologist Professor The incidence of oesophageal cancer is rising faster than Mark Smyth has published significant findings into a new any other cancer in Australia. About 1000 people are treatment target for triple-negative breast cancer. diagnosed each year and seven in 10 will die within five Professor Smyth joined QIMR in 2013 to establish the years. The main risk factors are acid reflux and obesity and Immunology in Cancer and Infection Laboratory. the common reflux condition Barrett’s Oesophagus can also lead to cancer. He was part of an international team which found that an enzyme known as CD73 makes TNBC less responsive In August 2012, QIMR was awarded $2.4 million by the to chemotherapy. The enzyme sits on the surface of Federal Government to study the causes of oesophageal cancer cells and produces the immune suppressive cancer and work towards new prevention strategies molecule, adenosine. and treatment. High levels of the enzyme, known as CD73, predicted a poorer response to chemotherapy and lower survival rates in mice.

Page 36 QIMR Annual Report 2012–2013 Infectious diseases Mental health and

QIMR was established in 1945 to combat tropical diseases complex disorders affecting Queensland, and infectious disease remains a The focus of the Mental Health and Complex Disorders cornerstone of the Institute. QIMR is a world leader in a research program is to combine the existing strengths of range of conditions including malaria, HIV, schistosomiasis QIMR’s work in genetics and population health with new and scabies. Some of these may not be a major problem techniques in neurosciences. in Australia yet, but QIMR takes its global responsibilities very seriously, fully aware of the ease with which infection can spread. Migraine

Migraine is a common and distressing brain disorder which Malaria causes severe headaches lasting up to 72 hours. It affects about 14% of adults. Symptoms include throbbing, aura, Malaria kills up to one million people world-wide each year nausea, vomiting, and light and noise sensitivity. and is a significant cause of morbidity in some of Australia’s neighbouring countries. QIMR is playing a key role in finding Dr Dale Nyholt, from QIMR’s Neurogenetics Laboratory, has urgently needed vaccines by running human malaria trials played a key role in the world’s largest study of migraines, and attracting funding from international organisations such which has discovered five new genetic regions linked to as the Bill and Melinda Gates Foundation and Medicines for their onset. Malaria Venture. In all, the international team confirmed 12 genetic regions In 2012-13, Professor James McCarthy, Coordinator of associated with migraine susceptibility, opening new doors QIMR’s Infectious Disease Program, commenced a trial to understanding what causes the debilitating headaches. where volunteers are infected with a very small controlled dose of malaria before emerging drugs and vaccines The study compared the results from 29 different genomic are tested on them. Their immune responses are closely studies, including over 100,000 samples from both migraine analysed to measure the efficacy of the treatments. patients and control samples.

Volunteers ﬁnish the trial without a trace of malaria in Researchers believe many of the genetic regions are their body. interconnected and could be disrupting the internal regulation of tissue and cells in the brain. Chikungunya Anorexia Chikungunya is a viral disease spread to humans by mosquitoes. It was ﬁrst described in Tanzania in 1952, and QIMR is playing a key role in the world’s largest genetic roughly translates from the Makonde language as “that investigation of anorexia nervosa. which bends up” in a graphic description of the joint pain it causes. The Anorexia Nervosa Genetics Initiative (ANGI) was established in May 2013, to recruit 8000 women from Since then, outbreaks and epidemics have been reported Australia, US, Sweden and Denmark, in a bid to identify in tropical Africa and Asia, but also much closer to home. which genes play a role in risk for the eating disorder. Papua New Guinea recorded thousands of cases in 2013 and there has also been a marked increase in cases Professor Nick Martin, Head of QIMR’s Genetic diagnosed in Australia, from travellers who have recently Epidemiology group, is leading the data collection team in arrived in the country. Australia.

Although locally-acquired Chikungunya has not been Anorexia nervosa is an eating disorder associated with low detected in Australia, mosquitoes capable of transmitting body weight, difﬁculty maintaining a healthy body weight, the virus occur in north Queensland. The two principal fear of weight gain, and an extreme focus on weight and mosquitoes involved in the spread are Aedes aegypti, which shape. It affects all age groups, but is particularly common in is found in North Queensland, and Aedes albopictus which is adolescent girls, affecting one in every 100. only found in a few locations in the Torres Strait.

Professor Andreas Suhrbier’s Inﬂammation Biology Laboratory looks at alphaviruses, like Chikungunya and Ross River, which cause arthritis. His research aims to understand how the viruses cause protracted rheumatic disease in humans so that better treatments can be developed. The laboratory has also been involved in the preclinical testing of a number of new Chikungunya virus vaccines.

Page 37 EDUCATION PROGRAM COMMUNITY

There has been a notable decline in the number of students ENGAGEMENT AND MEDIA completing science degrees, so to address this issue, QIMR’s Education Program aims to encourage students to QIMR puts a high priority on keeping the community consider a career in science. informed of its work and research outcomes through a variety of channels. In 2012-13, over 600 students and teachers visited QIMR taking part in either the High School Lecture Series or the The External Relations Department’s Community Day in the Life of a Scientist program Engagement Program delivers tours and speaking engagements to increase public awareness and support for In November 2012, QIMR launched the Day In the Life QIMR’s research. of a Scientist laboratory experience for senior science students. The program allows up to 24 students to perform In 2012-13, over 5000 people toured QIMR or heard from a hands-on investigation in QIMR’s state-of-art education a QIMR guest speaker. QIMR also kept the community laboratory, purpose built with excellent facilities. The informed through a series of research roadshows hosted at different experiments on offer were created to meet teacher, Mt Gravatt, Indooroopilly, Caloundra and Redcliffe. school and student needs and have been aligned to the senior biology curriculum. Since its launch, almost 150 The past year has also been a busy year for the Institute Queensland senior science students have undertaken the in terms of media stories, with an average of four stories Day In the Life of a Scientist laboratory experience. per day (over the entire year) with extensive national and international print, television, radio and online coverage on a More than 450 students participated in the annual High range of QIMR’s research and events including: School Lecture Series in April 2013 when they heard ﬁrst • Associate Professor David Harrich’s HIV hand from researchers about science and potential career nullbasic discovery; options and tour the QIMR facilities. • Professor Adele Green’s Nambour Study and resulting discovery that daily sunscreen use can prevent skin cancer and aging; • The ofﬁcial opening of QIMR new research facility by philanthropist Mr Chuck Feeney; and • Professor Georgia Chenevix-Trench’s work on the world’s largest study on identifying the genetic risk of breast, prostate and ovarian cancer.

QIMR’s public seminar program continues to provide opportunities for members of the public, community groups, and health specialists to hear from the Institute’s researchers, with almost 300 people attending four different forums. A Cancer Forum was held in August 2012, a Mental Health and Ageing Forum in October 2012, a Leukaemia Forum jointly held with the Leukaemia Foundation Queensland was held in November 2012, and an Infectious Diseases Forum in April 2013.

Page 38 QIMR Annual Report 2012–2013 Associate Professor David Harrich, Head of QIMR’s Molecular Virology Laboratory, has developed a way to use HIV to beat HIV.

Associate Professor David Harrich, Head of QIMR’s Molecular Virology Laboratory, has developed a way to use HIV to beat HIV. After researching HIV/ AIDS for almost 30 years, he has discovered how to modify a protein in the virus so that it instead provides strong, lasting protection from infection. He is now moving toward developing this modiﬁed protein “Nullbasic” for human trials.

Globally, HIV/AIDS is now a pandemic and ranks as one of the largest killers of any infectious disease, responsible for more than 25 million deaths worldwide. The successful development of this type of one-off treatment would also have economic implications. HIV patients currently take a regime of drugs for the rest of their lives, which can be a CASE signiﬁcant ﬁnancial burden. Associate Professor Harrich runs the only research laboratory and containment facilities in Queensland STUDY working with the HIV virus. Associate Professor Harrich utilises QIMR’s new state-of-the-art containment facilities to carry out his work.

(left) Associate Professor David Harrich from QIMR’s HIV Molecular Virology Laboratory

Page 39 INTERNATIONAL REPUTATION

Attracting researchers, funding and collaborators from around the world, QIMR is an internationally recognised centre for medical research.

CASE STUDY

QIMR researchers have reported huge Intestinal worms such as roundworm, whipworm, success with a cartoon DVD promoting and hookworm are a major issue in rural Chinese hygiene across rural China. communities and can lead to malnutrition and stunted growth and cognitive development in children. “The Magic Glasses” movie has been screened in Worldwide, two billion people are infected with schools in Hunan province, showing children how parasitic worms. to avoid parasitic worm infection, a major issue in In the cartoon, when a small child puts on “magic rural communities. glasses” they can suddenly see worm eggs and larvae Professor Don McManus and PhD student Franziska in bright colours. Bieri, from QIMR’s Molecular Parasitology Laboratory, along with colleagues from The University of Queensland’s School of Population Health and Hunan Institute of Parasitic Diseases, showed that infection rates halved when the 10 minute cartoon was played in schools.

Page 40 QIMR Annual Report 2012–2013 OVERSEAS TRAVEL INTERNATIONAL

Travel by researchers and support staff is critical to LECTURES facilitate collaborations and ensure the Institute keeps pace with new technologies and techniques. For details In 2012-13, researchers from QIMR attended and presented on QIMR’s overseas travel in 2012-13 please visit at over 120 lectures throughout the world, reﬂecting its www.qimr.edu.au/annualreport. strong international reputation, including: • Professor Michael Breakspear lectured on complex brain networks at the University of Zurich in Switzerland; • Associate Professor Andreas Surhbier delivered a presentation on chikungunya virus, rheumatoid arthritis and viral RNA persistence at Emory University in Atlanta, Georgia, USA; and • Professor Geoff Hill presented on the immunotherapy of graft-versus-host disease at the International Society of Cell Therapy in Auckland, New Zealand.

For a full list of international lectures please see our Invited Lectures table on page 104.

MAJOR INTERNATIONAL COLLABORATIONS

Collaborations are important for sharing resource and QIMR has a diverse research program as demonstrated by expertise, facilitating joint research and publications and the extensive range of international collaborations including building networks and relationships, all of which are essential the following: for scientiﬁc excellence.

Cancer

Project Research Collaborating countries Ovarian Cancer Association Studying genetic and environmental Belgium, Canada, Denmark, Finland, Consortium risk factors to inform preventive efforts, Germany, Japan, Netherlands, Poland, screening, future drug development and UK, US treatment. Breast Cancer Association Analysing genetic and epidemiological Belgium, Canada, Cyprus, Denmark, Consortium data from breast cancer studies from France, Finland, Germany, Ireland, Italy, around the world. Japan, Korea, Malaysia, Mexico, The Netherlands, Nigeria, Norway, Poland, Russia, Singapore, Spain, Sweden, Taiwan, Thailand, UK, US International Melanoma Genetics Identifying new melanoma risk genes Argentina, Brazil, Chile, Colombia, Consortium and assessing genetic and environmental France, Germany, Israel, Italy, Latvia, interactions. Mexico, The Netherlands, Poland, Scotland, Slovenia, Spain, Sweden, UK Uruguay,US, Uruguay. Consortium for Investigators of Working on genetic modifiers of cancer Austria, Belgium, Canada, Colombia, Modifiers of BRCA1/2 (CIMBA) risk in BRCA1 and BRCA2 mutation Czech Republic, Denmark, Iceland, carriers. The aim of CIMBA is to provide Italy, Israel,Latvia, Lithuania, Germany, sufficient sample sizes to allow large scale The Netherlands, France, Hungary, studies in order to evaluate reliably the Pakistan, Poland, Portugal, Korea, effects of genetic modifiers. Russia, Italy, Malaysia, Singapore, Spain, South Africa, Sweden, UK, USA

Page 41 Project Research Collaborating countries Collaborative Group on Hormonal Canada, Denmark, Germany, Israel, Cancers Italy, The Netherlands, Poland, Sweden, UK, US kConfab (Kathleen Cunningham Understanding the genetics of familial Australia, New Zealand Foundation Consortium for breast cancer. Research into Familial Breast Cancer) Colon Cancer Family Registry Increasing the understanding of multiple Canada, New Zealand, Spain, US factors affect familial colorectal cancer. PRACTICAL Searching for genetic markers and Sweden, Denmark, Japan, USA, prostate cancer risk. Norway, Bulgaria, Ireland, Spain, Romania, Sweden, Finland, Thailand, India, UK, Germany, USA, Switzerland, China

Infectious Diseases

Project Research Collaborating countries Eliminate Dengue Project Developing a biological control to UK, US, Vietnam. eliminate dengue fever. International Research Alliance for Developing strategies for eliminating US, Switzerland, Mexico, UK, China. Schistosomiasis Elimination schistosomiasis from developing countries worldwide.

Mental Health and Complex Disorders

Project Research Collaborating countries International Schizophrenia Identifying the genetic causes of Ireland, Sweden, UK, US Consortium schizophrenia. Psychiatric Genome Wide Analysing the genetic causes of attention US, Sweden Association Studies Consortium deficit and hyperactivity disorder, autism, bipolar disorder, major depressive disorder, and schizophrenia. International IBD Consortium Investigating the genetics of inflammatory Germany, Belgium, the Netherlands, bowel disease. Italy, France, Sweden, UK, Canada, USA, New Zealand International Headache Genetics Genetic causes and background of Finland, Germany, Iceland, the Consortium headache and related disorders. Netherlands, Norway, Spain, UK Evidence-based Network for the Determining genetic variants’ significance France, USA, The Netherlands, Interpretation of Germline Mutant in predisposition to breast and ovarian Germany, Italy, UK Alleles (ENIGMA) consortium cancer.

Page 42 QIMR Annual Report 2012–2013 OUR RESEARCH ACHIEVEMENTS

CANCER PROGRAM

Coordinator: Professor Georgia Chenevix-Trench underlying an individual’s cancer risk; studying the molecular changes that occur in precursor lesions that can give rise The Cancer Program looks closely at skin cancers, including to cancer and those that occur during the formation of a melanoma; hormone-related cancers, such as those of the tumour and its subsequent metastasis; and developing breast, prostate, ovary and endometrium; leukaemia and and testing novel therapies for cancer in the laboratory and lymphoma, including exploring the complications that can clinical trials. arise after transplantation; brain tumours; and tumours of the gastrointestinal tract. A widely based interest in metasteses By working with clinical oncologists, pathologists and is found in many of the cancer research groups. biobanks, members of the Cancer Program are leading or part of large international consortia and making great Laboratories within the Cancer Program work on identifying advances into the understanding of the genes that the genetic, epigenetic and environmental risk factors predispose individuals to many types of cancer.

ANTIGEN PRESENTATION AND IMMUNOREGULATION

Group Leader: Dr Kelli MacDonald transplantation and is highly effective in suppressing graft-versus-host disease. Furthermore, the group The Antigen Presentation and Immunoregulation Laboratory has developed strategies to specifically expand aims to investigate how donor and host antigen presenting this population in vivo, highlighting the capacity to cells (APCs) respond following bone marrow stem cell manipulate this population to control graft-versus-host transplantation (SCT). Basic research in immunology using disease post transplant. pre-clinical models follows three streams: APC development, antigen presentation, and APC induced T cell responses and • Demonstrated that immune-suppression in graft- their regulation. Importantly, these studies should lead to versus-host-disease results from corrupted antigen the development of new therapeutic protocols that can be presentation post transplant. translated to clinical practice to improve transplant outcome. • Identified non-haematopoietic APC responsible for the induction of graft-versus-host disease post transplant. Highlights: • Received NHMRC Project grant funding to study the role of MMP-9-expressing macrophages in chronic liver disease • Identified for the first time a CD8+FoxP3+ regulatory T cell (Treg) population that develops following stem cell

Page 43 BONE MARROW TRANSPLANTATION

Senior Scientist: Professor Geoff Hill, Highlights: Department Coordinator: Immunology • Deﬁned the type of cells involved in antigen The Bone Marrow Transplantation Laboratory uses pre- presentation after bone marrow transplantation. clinical transplant models to dissect the immunological • Deﬁned IL-6 as a major pathological cytokine during mechanisms of transplant rejection and aims to improve graft-versus-host disease. patient outcome through new therapies to prevent and treat graft-versus-host disease. Research focuses on pathways • Characterised a new regulatory T cell subset. of alloreactivity leading to graft-versus-host disease and • Characterised type I interferon as the major cytokine graft-versus-leukaemia (GVL) effects. The ultimate aim is to controlling anti-leukaemia effects after BMT. generate testable therapeutic interventions that attenuate graft-versus-host disease and improve GVL. • Characterised defects in immune function induced by graft-versus-host disease.

CANCER AETIOLOGY AND PREVENTION

Team Head: Associate Professor Rachel Neale Highlights:

The Cancer Aetiology and Prevention team covers three • Awarded a grant to conduct trial of vitamin D broad research areas: causes and management of supplementation in 25,000 Australian adults. pancreatic cancer; role of vitamin D in human health; and • Published a paper showing that we can predict vitamin causes and management of non-melanoma skin cancer. D deﬁciency with reasonable accuracy. This has led to a new grant application to validate this tool. • Published for the ﬁrst time an association between human papilloma viral load and risk of cutaneous squamous cell carcinoma.

CANCER AND POPULATION STUDIES

Senior Scientist: Professor Adèle Green AC Highlights:

The Cancer and Population Studies Group aims to • Showed that people with naevi (moles) on the arms are understand the causes of cancer and how to better prevent more likely to develop basal cell carcinomas than those and manage cancer. The group investigates the roles without. of environmental and personal factors in the causation • Contributed insights into the role of nutrients in the of cancer and its precursors, and in cancer prognosis. causation of basal cell carcinoma and squamous cell The group collaborates with clinicians, statisticians and carcinoma. behavioural scientists and also with laboratory scientists to better understand the underlying mechanisms of • Validated the use of skin surface microtopography as carcinogenesis. Particular focuses currently are cancers of a measure of skin photoaging in people aged 40 and the skin and of the colon. over, though not past age 70 years. • Published a chapter on the epidemiology of melanoma The group aims to assess the contributions of personal in the major US textbook on women’s health. factors (including psychological and social needs) and environmental factors to quality of life, disease prognosis • Showed that the prevalence of weekend sunburn is still and survival in patients with early stage, invasive cutaneous high in Queensland especially in young male adults. melanoma in Queensland, Australia. • Published evidence from a randomised trial that sunscreen can slow the prevention of skin photoaging changes.

Page 44 QIMR Annual Report 2012–2013 CANCER CONTROL

Group Leader: Professor David Whiteman, Queenslanders to be followed up for the next 10 years. In Department Coordinator: Population Health 2012-13, the group completed the ﬁrst data linkages to external health registers to capture skin cancer events in the The Cancer Control Group has two major areas of QSkin population. research focus: melanoma and skin cancer; and upper gastrointestinal neoplasia. In addition, the Group Leader is Highlights: also a co-investigator on projects investigating pancreatic, • Awarded $2.5 million for a NHMRC Centre of Research thyroid, cervical and liver cancer. Excellence. The group has primary strength in epidemiological • Completed data linkage for the QSkin study. approaches to the study of cancer. Historically, the focus has been directed towards cancers of two main organ systems: • Developed models to describe the incidence of the skin, and the gastro-intestinal tract. oesophageal adenocarcinoma in the Australian population. The group’s largest enterprise currently is the QSkin • Published more than 10 publications. study, a prospective cohort study of more than 43,000

CANCER DRUG MECHANISM

Team Head: Dr Glen Boyle is investigating the molecular mechanisms involved in the progression and metastasis of melanoma, head and neck The recently formed Cancer Drug Mechanisms Group cancer, as well as cutaneous squamous cell carcinoma. combines expertise in cancer biology with drug studies. These molecular mechanisms also impact on drug resistance of cancers. The identification and understanding The group’s work on cancer biology currently focuses of aberrantly regulated pathways in these cancers is crucial on understanding the development and progression of prior to the design or identification of suitable agents to treat cancers of the skin and oral cavity. Specifically, the group these diseases.

CANCER GENETICS

Group Leader: Professor Georgia Chenevix-Trench • Demonstrated in mouse models of the efficacy of anti- EGFR directed radioimmunotherapy combined with The Cancer Genetics Laboratory investigates why some radio-sensitising chemotherapy and PARP inhibitor for people get cancer, and how these cancers, particularly those the treatment of triple negative breast cancer. of the breast, ovary and stomach, develop from a normal cell. The laboratory also looks at why these cancers are • Demonstrated the value of restoring DNA from archival often found together in the same families and share many formalin fixed paraffin embedded tissues for genomic similar characteristics. profiling by SNP-CGH analysis. • Shown that women from breast cancer families who do Highlights: not carry mutations in BRCA1 or BRCA2, but instead • Completed the first analyses of the largest cancer are in the top quartile of polygenic risk, have a risk of genetics experiment ever undertaken. developing contralateral breast cancer that is similar to that of a BRCA2 mutation carrier. • Identified 49 genetic polymorphisms associated with risk of breast cancer. • Developed mouse models of breast-to-brain metastasis and shown that an activating mutation in the EGFR • Identified nine new ovarian cancer risk loci. gene can render a tumorigenic breast line capable of • Demonstrated that the polymorphisms at the TERT colonising the brain. gene that underlie breast and ovarian cancer risk are usually distinct from those associated with telomere length.

Page 45 CANCER IMMUNOREGULATION AND IMMUNOTHERAPY

Team Head: Dr Michele Teng Highlights:

The Cancer Immunoregulation and Immunotherapy Group • Demonstrated that Tim-3 positive Tregs are selectively looks at tumour induced immune suppression, Tregs, IL-23 enriched in tumours but not in the periphery and and checkpoint receptors (PD-1/TIM-3/LAG-3). therefore represent a novel target for depletion. • Demonstrated that skewing the balance between IL-12/IL-23 can resolve nascent tumour in a de novo mouse model of cancer.

CONJOINT GASTROENTEROLOGY

Laboratory Head: Professor Barbara Leggett well as identifying genes hypermethylated in these cancer subgroups. The main focus of the Conjoint Gastroenterology Laboratory is in understanding the molecular, histological, clinical and • Described a new type of chromosomal instability epidemiological features of a particular class of polyps called associated with BRAF mutation that is defined by serrated polyps, as well as the cancers they may develop regional copy number variation. into. The group is studying a large series of colorectal polyps • Reviewed over 6,000 bowel polyps to establish the and cancers using technologies to examine genome-wide frequency of different polyp types and identified a study changes in DNA methylation, gene expression and copy population to examine the molecular features of polyps number variation. The laboratory aims to identify molecular at different stages of progression. changes associated with high risk of polyp progression, and to identify key pathways altered in colorectal • Commenced collaboration with QIMR’s Cancer and cancer subgroups. Population Studies Group to examine epidemiological aspects of serrated polyp development. Highlights: • Demonstrated that expression of the BRAF V600E • Completed a proof of principle pilot DNA methylation mutation in the adult mouse intestine leads to microarray project that identified cancer subgroups hyperplasia, which likely equates to early serrated polyp based on BRAF and KRAS mutation status, as development.

CONTROL OF GENE EXPRESSION

Laboratory Head: Professor Frank Gannon, analysis of the processes by which the estrogen receptor CEO and Director recruited the RNA polymerase and initiated transcription (Métivier et al., Cell 115, 2003; Métivier et al., EMBO The Control of Gene Expression laboratory has recently reports 7, 2006). started at QIMR, focussing on the control of gene expression. The leader of the laboratory, Frank Gannon, has A focus on histone modiﬁcations that occur in conjunction been active in this area of research for very many years, but with the onset and silencing of transcription has been the had interrupted his research career when he took a position focus of the work of Dr Jason Lee who has joined the as Director General of Science Foundation Ireland, the laboratory. His research activities grow from the histone national funding agency in Ireland. He moved to Brisbane modiﬁcation aspects through to the effects of modifying as the Director and CEO of QIMR in 2011 and now has enzymes on other cellular targets and their consequences in established a research activity there. cellular physiology.

The research of the group is designed to achieve a better Whereas the focus of the group radiates from the estrogen understanding of the speciﬁcs of the control of gene receptor, the general questions of epigenetic control of expression. The most recent research on which the current gene expression will be examined in diverse systems. In all projects are built was the demonstration of transient cyclical cases the aim is to develop insights that can be translated to DNA methylation and demethylation (Kangaspeska et al., different disease settings. Nature 452, 2008). This work followed from earlier detailed

Page 46 QIMR Annual Report 2012–2013 DRUG DISCOVERY

Group Leader: Professor Peter Parsons Highlights:

The Drug Discovery Group combines expertise in • Confirmed that the efficacy of EBC-46 is due to cancer biology with genomics and drug discovery. Cell haemorrhagic necrosis. communication networks in serious cancers reveal • Discovered EBC-46-like molecules in other responses that provide opportunities for prevention plant species. and treatment. • Noted first indications that the efficacy of EBC-46 in vivo can be inhibited by pharmacological agents.

FUNCTIONAL CANCER GENOMICS

Team Head: Dr Stacey Edwards Highlights:

The Functional Cancer Genomics team is focused on • Published paper in the American Journal of Human post-GWAS (genome-wide association studies) functional Genetics; Functional Variants at the 11q13 Breast characterisation of breast and ovarian cancer genetics. Cancer Risk Loci Regulate Cyclin D1 Expression through Long-Range Enhancers. More than 60 different breast cancer risk loci and nine • Published in Nature Genetics; Multiple independent ovarian cancer loci have now been discovered via GWAS, variants at the TERT locus are associated with telomere but until recently it has not been possible to identify the length and risks of breast and ovarian cancer. variants that are directly responsible for the increased risk. Importantly, the majority of variants lie within non-coding • Authored paper in Nature Genetics; DNaseI- regions of the genome and appear to act as enhancers hypersensitive exons co-localize with promoters and of genes through long-range interactions mediated by the distal regulatory elements. formation of chromatin loops. Over the last year, the team • Published senior author review in Genes, have developed a successful strategy for analysing these Chromosomes and Cancer. regulatory regions to narrow down the candidate causative variants at each area and describe their likely actions in breast cancer.

FUNCTIONAL GENETICS

Team Head: Dr Juliet French Highlights:

The Function Genetics Group is focused on the post-GWAS • Authored a paper in Nature Genetics describing the functional characterisation of breast and ovarian cancer loci. fine-mapping of the TERT locus for breast cancer risk In collaboration with geneticists at Cambridge and QIMR and functional follow-up. the Group is fine-mapping breast cancer loci to pinpoint the • Published in American Journal of Human Genetics likely causal variants. The majority of variants fall in non- describing the fine-mapping of the genetic association coding regions of the genome suggesting the regulatory at 11q13 and functional follow-up. elements and non-coding RNAs are likely mechanisms of the associated risk.

Page 47 GENOMIC BIOLOGY

Team Head: Dr Nicole Cloonan Our current research focus is determining the relationship between miRNAs and drug sensitivity, with the short term aim Choice of chemotherapy has relied on data from populations of using these as markers in personalised therapy, and the rather than individuals, but the recently available cancer long term aim of using these as adjunct chemosensitisers. genomic data shows that every cancer is different. To personalise therapy, doctors need to move away from Highlights: treating cancers based on where they develop in the body, • Identiﬁed the relationship between miRNAs and EGRF and instead move towards treating what has gone wrong in inhibitor sensitivity. the cells of the individual patient. • Identiﬁed novel biology behind miR-139’s link to metastasis and migration function.

GYNAECOLOGICAL CANCERS

Group Leader: Associate Professor Penny Webb • Observed that aspirin use may be associated with a reduced risk of endometrial cancer, particularly among The Gynaecological Cancers Group investigates all aspects obese women. of cancer, particularly gynaecological cancer, from aetiology to diagnosis, patterns of care, quality of life and survival. • Observed that only about one third of women with A particular focus is on the role of environmental (non- ovarian cancer complete the recommended six cycles of genetic) factors and the interaction between genetic and combination chemotherapy. environmental factors in the causation of gynaecological • Published a paper suggesting that although obese cancer. More recently, this has extended to assessing women are at greatly increased risk of endometrial how gynaecological cancers are managed in Australia and cancer, if they lose weight their risk is reduced again. investigating the role of lifestyle in determining quality of life and survival after a diagnosis of cancer. Much of this work is • Contributed to international pooled analyses showing conducted within three national population-based studies: that tubal sterilization reduces risk of ovarian cancer but the Australian Ovarian Cancer Study (AOCS), the Ovarian smoking increases risk of the mucinous subtype. Cancer Patterns of Care Study (POCS) and the Australian • Showed women with ovarian cancer report needing National Endometrial Cancer Study (ANECS). ongoing assistance to deal with psychological and physical needs over the ﬁrst two years after ﬁrst-line Highlights: treatment. Risk factors for unmet needs included older • Conducted an international pooled analysis showing age, advanced disease, anxiety, depression, insomnia that obesity is associated with increased risks of and lower social support. non-serous ovarian cancer, but does not appear to increase risk of the most common and most aggressive high-grade serous subtype.

IMMUNOLOGY IN CANCER AND INFECTION

Senior Scientist: Professor Mark Smyth • Demonstrated that NK cells contribute to the pre- metastatic niche. The Immunology in Cancer and Infection Group study the immune reaction to cancer in mouse models and cancer • Showed that IL-12 and IL-23 have opposing roles in patients (most notably in multiple myeloma). immune-mediated tumour dormancy. • Demonstrated that NLRP3 promotes skin cancer Highlights: in mice. • Showed that CD73-deﬁcient mice are resistant to • Showed that non classical MHC H2-M3 recognises carcinogenesis. Ly-49A. • Identiﬁed that radiotherapy combines with • Showed that host immunity contributes to antibody-based immunotherapy in mouse models anti-melanoma activity of Braf inhibitors. of breast cancer.

Page 48 QIMR Annual Report 2012–2013 LEUKAEMIA FOUNDATION OF QUEENSLAND LABORATORY

Group Leader: Professor Andrew Boyd Highlights:

The Leukaemia Foundation Group are investigating • Discovered the role of EphA3 in glioma. tumour-associated genes in cancer, in particular Eph, • Identiﬁed EphA4 as a target in motor nerve injury and ephrin and Nﬁb in leukaemia, sarcomas and brain tumours. disease. The group’s research includes basic cancer biology and development of targeted therapies.

MOLECULAR CANCER EPIDEMIOLOGY

Group Leader: Associate Professor Amanda Spurdle • Published a statistical model for classification of variants in MMR genes. The Molecular Cancer Epidemiology Laboratory studies breast, ovarian, endometrial, colon and prostate cancer, • Demonstrated inadequacy of collection of family history with a focus on identifying molecular signatures of normal data in the clinical setting, and poor referral of patients and tumour tissue that can point to the genetic and for genetic testing. environmental causes of these cancers. The laboratory • Applied five tier quantitative and qualitative classification covers a range of projects with the themes of cancer system to an international database of MMR gene epidemiology and molecular pathology. variants. Highlights: • Investigated endometrial tumour features as positive and negative predictors of germline MMR gene • Demonstrated that a BRCA1 variant with intermediate mutation status. functional activity are associated with moderate risk of cancer.

ONCOGENOMICS

Senior Scientist: Professor Nick Hayward Highlights:

The Oncogenomics Laboratory researches the genetics • Helped identify a variant in the FTO gene associated and genomics of melanoma, mouse models of multiple with melanoma risk in the general population. endocrine neoplasia type 1 and the molecular genetics of • Helped identify a recurrent activating ‘drug targetable’ Barrett’s oesophagus and oesophageal cancer. mutation in RAC1 that occurs in 5% of sun exposed melanomas. The laboratory is interested in investigating the process of cancer development at the level of individual cancer • Completed the largest and most comprehensive predisposition genes, and by looking at the whole genome genetic analysis of melanomas of unknown primary, scale. Better understanding the genetic events that cause revealing insights into the origin of this rare subset of cancer is hoped to lead to better ways of diagnosing or tumours. treating cancers in the future. • Completed the ﬁrst population-based study of germline BAP1 mutations in uveal melanoma cases. • Helped show that a germline BAP1 splice mutation in a family with uveal and cutaneous melanoma also confers predisposition to paraganglioma.

Page 49 RADIATION BIOLOGY AND ONCOLOGY

Group Leader: Professor Martin Lavin Highlights:

The Radiation Biology and Oncology Group is focuses on: • Generated the first stem cells from patients with A-T. • Investigating the molecular basis of autosomal • Produced two rat models for A-T. recessive ataxias including ataxia-telangiectasia (A-T) • Generated first mouse model for ataxia oculomotor and ataxia oculomotor apraxia type 2 (AOA2); apraxia type 2. • Early detection of prostate cancer; and • Identified new autophosphorylation sites during ATM • Venomics-developing a serum tube for analyte activation. determination. • Demonstrated that ATM-dependent Rad50 phosphorylation is important in DNA repair and cell cycle control. • Demonstrated a novel role for SMG-1 protein in stress granule formation. • Cloned and characterised genes from a snake venom gland.

SIGNAL TRANSDUCTION

Group Leader: Professor Kum Kum Khanna Highlights:

The Signal Transduction Group’s major focus of research • Developed a novel combination therapy that prevents is on signalling pathways that maintain genome stability breast cancer recurrence in preclinical models. during normal cell division cycle and in the face of DNA • Provided a mechanistic explanation as to how KAP1 damage. The group seek to exploit dysregulation of phosphorylation might regulate heterochromatin repair. these pathways in breast cancer to develop new targeted therapeutic approaches. • Generated a mouse model of SSB1 and uncovered its essential developmental role in the regulation of skeletogenesis. • Contributed signiﬁcantly to the development of a therapeutic approach against glioblastoma; radioimmunotherapy using anti-EphA3 antibody.

Page 50 QIMR Annual Report 2012–2013 TUMOUR MICRO-ENVIRONMENT

Team Head: Dr Andreas Moller of distant organs by modifying cell differentiation and behaviours to generate permissive environments (pre- The Tumour Microenvironment Team investigates how metastatic niches) at these sites. These pre-metastatic epithelial cancer cells interact with surrounding non-tumour niches promote metastatic growth of subsequently arriving stromal cells to enable tumour progression and metastatic tumour cells, and the aim is to translate findings into spread to distant tissues. prognostic, diagnostic and curative treatment options for cancer patients. Work in the laboratory focuses on how low oxygen (hypoxic) environments and other stress conditions experienced by Highlights: tumours change the interaction and communication between the tumour cells and fibroblasts, immune and endothelial • Investigated pre-metastatic niche induced by tumour cells, with a focus on three main processes crucial to tumour cell hypoxia. progression. Firstly, the group is interested how tumour • Found neo-angiogenesis is controlled by Siah ubiquitin cells initiate new blood vessel formation (neo-angiogenesis) ligases. under hypoxia and ways to prevent or alter these processes. Secondly, the laboratory investigates the mechanisms • Determined the underlying mechanisms of pre- that control epithelial to mesenchymal transition (EMT), an metastatic niche formation. essential process for tumour cells to invade the stroma, • Determined that the hypoxic response pathway in enter the vascular system and metastasise to distant tissues. breast cancer cells mediates pre-metastatic niche formation in distant tissues. The third research topic of the laboratory centres around investigating how a hypoxic tumour can alter the tissue • Identificated that the hypoxia-regulator Siah controls neo-angiogenesis in breast cancer.

TRANSLATIONAL LEUKAEMIA RESEARCH

Team Head: Dr Steven Lane Highlights:

The Translational Leukaemia Research Team is researching • Identiﬁed novel pathways of stem cell mobilisation. myeloid blood cancers such as acute myeloid leukaemia • Identiﬁed genetic susceptibilities of leukaemia stem (AML), myelodysplastic syndrome (MDS) and the cells. myeloproliferative neoplasms (MPN). These are very aggressive and rapidly fatal blood cancers that are among • Targeted disease-initiating stem cell populations the most common types of cancer affecting Australians. through targeted inhibitors of Jak2 signalling or through The laboratory’s efforts are concentrated on understanding inhibition of self-renewal pathways within stem cell how leukaemia stem cells in AML and MPN are able to populations. regenerate leukaemia (or cause relapse in patients), even after cytotoxic chemotherapy. To achieve this, research has focused on generating robust models of leukaemia and dissecting the pathways of self-renewal in leukaemia stem cells and normal blood stem cells.

Page 51 INFECTIOUS DISEASES

Coordinator: Professor James McCarthy aims to use strong collaborations to improve the health of many. QIMR’s Infectious Diseases Program studies how a range of important pathogenic organisms cause illness, investigates QIMR is a founding member of the Queensland Tropical improved diagnosis and treatment techniques and develops Health Alliance (QTHA), which is designed to enhance vaccines to prevent infections. The Program focuses its work collaborations and networking in tropical health issues, and on conditions that have major impacts in the developing the Australian Infectious Diseases Research Centre (AID), world and tropical regions. which supports research into diseases such as malaria, dengue fever and schistosomiasis. QIMR’s collaboration The Program researches HIV, cytomegalovirus (CMV), with James Cook University, Grifﬁth University, QUT, and The Epstein-Barr virus (EBV), mosquito-borne viruses; bacteria University of Queensland through the QTHA and again with such as streptococci; and parasites such as malaria, the University of Queensland though AID brings strength and intestinal protozoa, worms and scabies. focus for plans to address serious tropical and infectious disease issues through Queensland, across Australia, and in Working closely with clinicians, other research institutes, and the Asia-Paciﬁc region. pharmaceutical companies, the Infectious Disease Program

BACTERIAL PATHOGENESIS

Group Leader: Professor Sri Sriprakash Highlights:

The Bacterial Pathogenesis Laboratory undertakes research • Found the population endemic for Streptococcus into the two human pathogens Streptococcus pyogenes pyogenes and S. dysgalactiae subsp equisimilis and Streptococcus dysgalactiae subsp equisimilis. S. colonisation exhibit increased recovery of novel pyogenes is a leading cause of bacterial related death in recombinants with possible increased pathogenic humans. Streptococcus dysgalactiae subsp equisimilis is a potential. related species whose contribution to disease is only now • Designed and demonstrated the efﬁcacy against S. being understood. These two bacterial species cause a pyogenes infection of recombinant vaccine candidate number of diseases that target different organs in the body. representing variants from the conserved regions of the The laboratory’s research is aimed at understanding the M protein. By this design, the group have eliminated the pathogenic processes associated with infection by these need for using extraneous sequences for maintaining organisms, and developing novel strategies to prevent the conformation of the vaccine candidate. streptococcal disease. • Showed that past infection with SIC-positive group The group also has a research interest in bacterial A streptococcus is a risk factor for chronic kidney colonisation of medical devices. The insertion of a catheter disease and that SIC seropositivity is predictive of poor into a vein provides a portal by which bacteria can cross the prognosis of CKD patients. skin and enter normally sterile body sites, thereby causing disease. The group in interested in characterising the pathogenic and non-pathogenic species that colonise these devices, identifying the sources of bacterial contamination, and ultimately developing novel technologies or practices that reduce device colonisation.

Page 52 QIMR Annual Report 2012–2013 BIOINFORMATICS

Team Head: Dr Lutz Krause • Started de novo sequencing of Schistosoma bovis genome. The Bioinformatics Team develops and applies bioinformatics methods in the context of biomedical research. It specialises • Established several bioinformatics pipelines for in biomarker discovery, infectious diseases and genetics and analysing next-generation sequencing data, which are epigenetics of complex disorders. widely used for calling SNPs and analysing RNAseq, MeDIP-seq and Chip-seq data. The Team’s research focus is on investigating the role of the • Identified mutations and rearrangements important human microbiota in health and disease, revealing the role of for cancer initiation and progression using whole- epigenetics in depression and the discovery of biomarkers genome and exome sequencing of oesophageal for progression, personalised treatment and prognosis of adenocarcinoma samples in collaboration with oesophageal adenocarcinoma. Princess Alexandra Hospital and the Institute for Highlights: Molecular Bioscience. • Identified potential biomarkers for prognosis • Conducted a genome-wide epigenetic association and personalised treatment in oesophageal study in oesophageal adenocarcinoma and Barrett’s adenocarcinoma. oesophagus. • Published a genome-wide epigenetic association study • Investigated the role of human microbiota in various in the context of major depressive disorder. diseases and disorders including cystic fibrosis, diabetes and parasite-bacteria co-infections.

BIOMARKERS AND BIOLOGY OF INFECTION RELATED CANCERS

Team Head: Dr Jason Mulvenna • Characterised proteomics of Necator americanus for hookworm genome project. Highlights: • Discovered potential miRNA markers for • Characterised structure of TSP-2, a vaccine antigen for nasopharyngeal carcinoma. schistosomiasis.

CELLULAR IMMUNOLOGY

Group Leader: Associate Professor Scott Burrows Highlights:

The Cellular Immunology Group focuses on the T cell • Showed that the dominant T cells of the immune immune response to viral infection, particularly Epstein-Barr system remain stable throughout life. virus which causes glandular fever and is associated with • Showed that individual T cells of the immune system various malignancies and autoimmunity. The molecular are programmed to recognise peptides of a particular interactions that control the speciﬁcity of T cells recognition size. of virus-infected cells are complex and could hold the key to preventing Epstein-Barr virus associated diseases. • Showed that very minor genetic differences between people can have a major inﬂuence on their immune response to pathogens.

Page 53 CLINICAL TROPICAL MEDICINE

Senior Scientist: Professor James McCarthy A particular interest in this laboratory is the study of drug resistance in a range of parasites, and the development of The Clinical Tropical Medicine Laboratory investigates novel diagnostic techniques. how parasites such as the malaria parasite, hookworm, threadworm and scabies cause disease and how they Highlights: become resistant to drugs used to treat them. The group • Deﬁned the effectiveness of the experimental also identiﬁes new drugs and drug targets, and develops antimalarial OZ439. novel diagnostic techniques. • Developed tests to measure the prevalence and The focus of this laboratory is to apply modern techniques intensity of parasite infections in East Timor. in microbiology, molecular biology and immunology to study clinical problems associated with infectious diseases in • Developed a system to undertake experimental blood tropical environments. stage Plasmodium vivax malaria infections. • Begun a Phase I study of a new vaccine for group A streptococcus.

HIV MOLECULAR VIROLOGY

Group Leader: Associate Professor David Harrich Highlights:

The HIV Molecular Virology Group investigates fundamental • Showed a novel protein inhibitor of HIV called Nullbasic mechanisms of virus replication with an overall goal to provided excellent protection from infection in human identify key virus and host interactions required to support cells in vitro. optimal virus replication. A main research direction is analysis • Identified two cellular proteins that enable early steps of of a HIV-1 specific process called reverse transcription by HIV-1 infection. which the viral RNA genome is converted into DNA that can be inserted into human chromosomes, a permanent • Discovered two unidentified host proteins controlling and irreversible event. Using biochemical assays developed the function of an important HIV-1 regulatory protein at QIMR, the Molecular Virology Group identified human called Rev. proteins subverted by HIV to complete reverse transcription. • Challenged the role of a host protein called PRMT6 as an HIV-1 restriction factors. A role for PRTM6 in regulating a critical HIV-1 protein called Tat, other than on increased protein stability, remains unclear.

HUMAN IMMUNITY

Team Head: Dr John Miles Highlights:

The Human Immunity Laboratory studies the immune • Deconstructed the proliferating neonate T cell processes which determine the host’s response to infectious repertoire. disease, cancer and innocuous agents. The team’s research • Led the ﬁrst study to deep sequence the human alpha/ focuses on T cells and their ligands, exploring receptor beta T cell repertoire over decades of life. genetics, biology, engagement and molecular structure across a number of human disease systems. The team • Described the antigen recognition compartmentalisation used information from these basic studies to modify T cell of the human T cell repertoire. interactions and T cell repertoires for use in rational vaccine • Authored two reviews on manipulating the immune design and therapeutic interventions. system for therapeutic purposes. • Involved in studies revealing the basic mechanisms behind human T cell function.

Page 54 QIMR Annual Report 2012–2013 IMMUNOLOGY AND INFECTION

Group Leader: Dr Christian Engwerda Highlights:

The Immunology and Infection Laboratory continues to try • Identified Blimp-1 as an important T cell transcription and understand why some immune responses safely control factor for inducing immunoregulatory IL-10 during parasite growth and protect against re-infection, whereas malaria and leishmania. others cause disease during malaria and leishmaniasis. • Showed that CTLA-4 blocks anti-malaria immune The research has moved from a primary focus on studying responses. immune regulation during parasite infections in pre-clinical models of disease to validating our findings from these • Discovered that a specialised T cell population models using samples from patients and volunteers produces IL-17 very early during leishmania infection deliberately infected with the parasites that the laboratory and suppresses the ability of monocytes to kill works on. parasites. • Identified new and critical roles for monocytes in visceral leishmaniasis. • Discovered that type I interferons suppress anti- parasitic T cell responses in a pre-clinical model of visceral leishmaniasis, as well as in clinical samples from leishmania patients.

INFLAMMATION BIOLOGY

Group Leader: Professor Andreas Suhrbier • Uncovered the similarity in the inflammatory disease seen in chikungunya virus and rheumatoid arthritis, The Inflammation Biology Laboratory is developing and which suggests drugs being developed for rheumatoid exploiting knowledge about interactions between viruses arthritis may find utility in the treatment of alphaviral and the immune system to develop new anti-cancer, antiviral diseases such as Ross River virus and chikungunya and anti-inflammation strategies. disease. Highlights: • Showed that deficiency in interferon responses in alphaviral infections is sufficient for haemorrhagic fever • Illustrated the utility of ingenol mebutate for field- and shock. directed therapy of actinic keratoses to prevent future development of skin cancers.

MALARIA BIOLOGY

Laboratory Head: Associate Professor Don Gardiner Highlights:

The Malaria Biology Laboratory researched the molecular • Completed the ﬁrst ever screen for anti-transmission and cellular processes involved in critical phases of the blocking agents for malaria. malaria parasite life cycle in order to identify novel drug • Identiﬁed a novel orally bioavailable anti-malaria targets and to translate fundamental biological research compound. into new interventions for the control of malaria. The laboratory had a fully integrated research program that used • Solved the crystal structure of the P. falciparum M18 established research methods in conjunction with recent aspartyl aminopeptidase. advances in malaria transgenics, molecular modelling and in vivo and in vitro testing.

Page 55 MALARIA IMMUNOLOGY

Team Head: Dr Ashraful Haque Highlights:

The Malaria Immunology Team use state of the art in vivo • Demonstrated that CD8- dendritic cells are techniques to assess the immune response to Plasmodium suppressed via type I interferon signalling during infection. The Team’s aim is to modulate the immune system experimental malaria. to improve control of parasites. • Used mathematical and in vivo modelling techniques to determine that parasite sequestration in peripheral tissues drives large increases in parasite biomass during severe malaria. • Demonstrated the role of IRF7 in suppressing T cell immunity to Plasmodium.

MOLECULAR IMMUNOLOGY

Team Head: Dr Michelle Wykes • Investigating the kinetics of red cell clearance during malaria. The Molecular Immunology Team focuses on three areas: Highlights: • Identifying the role of PD-1 in malaria; • European Journal of Immunology commissioned a • Exploring their role of synthetically generated commentary on the group’s publication showing why immunological proteins as novel therapies for antibody-based malaria vaccines may not protect. malaria; and

MOLECULAR PARASITOLOGY

Senior Scientist: Professor Don McManus • Defined the risk factors for helminth infections in a rural and a peri-urban setting of the Dongting Lake The Molecular Parasitology Laboratory researches the area, China. biology, pathogenesis and epidemiology of parasitic worms that cause major clinical disease (schistosomiasis, • Completed a five-year longitudinal assessment of the echinococcosis (hydatid disease), soil transmitted downstream impact on schistosomiasis transmission in helminthiases), with the aim of developing new public health China following closure of the Three Gorges Dam. interventions, including vaccines, and diagnostic procedures • Demonstrated that the insulin receptor is an effective that will lead to their elimination through integrated control. transmission blocking veterinary vaccine target for zoonotic Schistosoma japonicum. Highlights: • Completed a cluster-randomised trial demonstrating • Determined the diagnostic value of non- that a video-based health education package prevents invasive biomarkers for stage-specific diagnosis soil-transmitted helminth infections in Chinese of hepatic fibrosis in patients with advanced school children. schistosomiasis japonica. • Published a major article in the New England Journal of • Identified signalling pathways as putative targets for Medicine describing the highly successful outcome of a control interventions against schistosomiasis. health education package to prevent worm infections in • Completed a five year longitudinal study of Chinese schoolchildren. schistosomiasis transmission in an endemic area in • Published a major review article in the New England Schuan Province, China. Journal of Medicine on chronic enteropathogens in • Undertook an extensive proteomic characterisation of returning travellers. Echinococcus granulosus hydatid cyst fluid from sheep, • Published a major review on the structure and function cattle and humans. of invertebrate Kunitz serine protease inhibitors. • Defined a role for peroxisome proliferator-activated • Completed a draft genomic sequence for Echinococcus receptors in the immunopathology of schistosomiasis. granulosus in collaboration with Chinese colleagues. • Showed the value of schistosomiasis research in the Dongting Lake region and its impact on local and national control strategies in China.

Page 56 QIMR Annual Report 2012–2013 MOLECULAR VACCINOLOGY

Group Leader: Professor Denise Doolan, Highlights: Department Coordinator: Biology • Identified four new malaria antigens as targets of The Molecular Vaccinology Laboratory’s research is focused infection-blocking protective immunity against malaria, on rational vaccine design, primarily for malaria, and and showed that antigen combinations are more encompasses core themes of: effective than individual antigens. • Established that antigens that are highly reactive for • Basic research on immune mechanisms and adjuvant T cells are not dominant for antibodies and are highly activity; conserved; these data overturn conventional dogma • Antigen and epitope discovery from genomic sequence and suggest that new strategies are required for T cell data using protein microarrays and epitope prediction based vaccine development. algorithms with biologically relevant laboratory and field • Produced protein microarrays for Plasmodium vivax to specimens; and identify excellent candidates for a malaria vaccine or • Pre-clinical research and development of antigen and diagnostic test. epitope based molecular vaccine technologies. • Identified an adjuvant that activates dermal dendritic cells, a specialised cell type shown to be important for cross-presenting antigens and activating CD8+ T cells. • Developed a high throughput adjuvant screening assay to identify novel adjuvants to enhance cell mediated immunity. • Showed that a natural product derived from rainforests can protect against malaria, in a mouse model. • Evaluated a novel platform technology capable of presenting multiple epitopes from a complex pathogen in an authentic manner that maintains the native antigenic structure. • Evaluated the vaccine potential of a novel bacterial platform shown to be effective for drug delivery.

MOSQUITO CONTROL

Group Leader: Professor Brian Kay Highlights:

Research in the Mosquito Control Laboratory focuses on • Wrote and edited a book on a world-first eradication of the biology and control of mosquito-borne viruses such as the Australian southern saltmarsh mosquito from New dengue, Ross River virus and Barmah Forest virus. This Zealand. laboratory is designated by the World Health Organization • Completed of a 5,000 household survey of Brisbane to (WHO) as an official global Collaborating Centre for determine presence of exotic mosquitoes. Environmental Management for Vector Control. • Identified several proteins which can be used to The laboratory specialises in designing new mosquito determine mosquito age. surveillance and control strategies and has strong • Conducted the first Wolbachia release for dengue collaborative linkages with dengue prevention research control in Vietnam. groups in Vietnam and Australia. Mosquito Control researchers also work directly with State and local government in Queensland on mosquito control and all mosquito-transmitted arboviruses.

Page 57 PROTEIN DISCOVERY CENTRE

Group Leader: Professor Jeff Gorman Highlights:

The QIMR Protein Discovery Centre is a state-of-the- • Characterised the proteomic component of A549 cells art facility recognised as a world leader in the mass regulated by RSV infection and deduced associated spectrometry and proteomics ﬁeld and is one of the most pathways. advanced and best equipped of its kind in Australia. • Developed a methodology for identifying speciﬁc The centre collaborates broadly on both national and proteoforms from ambiguous protein group international projects. database entries. The centre aims to discover the identities of proteins involved • Developed and deployed high-performance proteomic in or affected by physiological and disease processes and approaches for analysing catalytic properties and the ways in which these proteins function and interact and substrates of Kallikrein proteases that putatively to develop techniques to observe stimulated cells and the contribute to prostate cancer progression. reaction within cell proteins. • Produced recombinant RSV-NS1 protein using cell free and bacterial expression systems for structural biology and protein-protein interaction studies. • Advanced the knowledge of protein expression in the matrix of developing cartilage chondrocytes. • Produced proteomic data to revolutionalise annotation of the fungal pathogens of wheat. • Developed and validated methods for production of versatile probes of the calcitonin receptor. • Characterised asparagine hydroxylation sites on the TRPV3 protein. • Developed advanced proteomic methodologies to facilitate Rio Tinto Ride to Conquer Cancer projects involving ephrin signalling and cancer vaccines.

TUMOUR IMMUNOLOGY

Group Leader: Professor Rajiv Khanna Highlights: • Completed Phase I clinical trial on adoptive The major goal of the Tumour Immunology Laboratory is immunotherapy for stage IV nasopharyngeal carcinoma to obtain a deeper understanding of the mechanisms by (in collaboration with University of Hong Kong). which an immune response to tumours may be generated, augmented and exploited for the treatment of these cancers. • Developed novel T cell based therapy for the treatment of brain cancer, glioblastoma. • Completed pre-clinical studies on the prophylactic vaccine for human cytomegalovirus to prevent birth defects. • Completed clinical testing of a new diagnostic test to predict cytomegalovirus-associated complications in transplant patients.

Page 58 QIMR Annual Report 2012–2013 MENTAL HEALTH/COMPLEX DISORDERS

Coordinator: Professor MICHAEL BREAKSPEAR animals and humans and the genetic basis for a number of conditions. QIMR’s Mental Health/Complex Disorders Program combines a number of disciplines to study the genetic Using brain imaging, computational modelling and and multi-factorial environmental inﬂuences in a range epidemiological studies, the Mental Health/Complex of diseases from schizophrenia and depression to Disorders Program works to bring public awaress and haemochromatosis and migraine. These conditions hold an betterunderstanding to mental illness and complex enormous burden of illness and unmet research need. disorders, while working to improve outcomes and recovery for those suffering with these diseases. QIMR utilises imaging and gene sequencing technologies to provide unprecedented insight into the biology of cells,

ASTHMA GENETICS

Team Head: Dr Manuel Ferreira Highlights: • Identified 10 loci influencing allergic sensitisation. The Asthma Genetics Team aims to identify genetic variants that influence the risk of developing asthma, understand how • Identified two new loci for asthma. genetic variants influence the risk of asthma and establish • Identified an additional regulatory variant in the IL6R clinical trials to test new treatments for asthma. gene that associates with asthma risk.

GENETIC EPIDEMIOLOGY

Senior Scientist: Professor Nick Martin • Discovered a new locus for melanoma on chromosome one. The Genetic Epidemiology Laboratory investigates • Contributed to genome-wide association scan (GWAS) the pattern of disease in families to assess the relative meta-analysis, which found 65 new loci for platelets importance of genes and environment in a variety of with strong therapeutic potential. important health problems and to locate the genes responsible using genome-wide association analysis. • Contributed to GWAS meta-analysis, which discovered six new loci for male pattern baldness with overlap with Highlights: prostate cancer and other diseases. • Played a leading role in the Enhancing Neuroimaging • Contributed data that uncovering three new loci Genetics through Meta-Analysis (ENIGMA) consortium for eczema. and identified the first confirmed locus for a brain • Contributed to discovery of a new susceptibility locus imaging phenotype, for hippocampal volume on near ODZ4 for bipolar disorder. chromosome 12. • Contributed to GWAS showing a tentative association • Conducted the first full genome sequencing project with depression on chromosome three. for a complex trait, which resulted in finding a causal variant for melanoma in MITF. • Contributed to study finding new variants for menopause and triple-negative breast cancer. HEPATIC FIBROSIS

Group Leader: Professor Grant Ramm, disease and the mechanisms associated with both their Department Coordinator: Cell and Molecular Biology transformation into collagen-producing myofibroblastic cells, as well as their role in wound healing in the regenerating liver The Hepatic Fibrosis Laboratory investigates the cellular and following liver insult. molecular mechanisms of scar tissue formation in the liver. This leads to fibrosis and cirrhosis in adult liver diseases, Highlights: such as haemochromatosis and in children, in diseases such • Demonstrated a role for diabetes as a risk as cystic fibrosis and biliary atresia. factor for severe hepatic fibrosis in patients with The group is funded by the NHMRC to further investigate haemochromatosis. the role of hepatic stellate cells in human chronic liver

Page 59 INFLAMMATORY BOWEL DISEASES GROUP

Group Leader: Dr Graham Radford-Smith Highlights:

Inflammatory bowel diseases (IBD) are a group of diseases • Awarded grant for an ulcerative colitis GWAS. that affect the colon and small intestine, including Crohn’s • Carried out an immunochip study in collaboration with disease and ulcerative colitis. They affect up to one in every the International IBD Genetics Consortium, leading to a 200 Australians. Nature publication. IBD is a medical condition that affects the gastrointestinal • Consolidated a major collaboration with Amgen system, or gut. People with this illness often have ongoing (translational IBD research program). symptoms of tummy pain, diarrhoea, the passing of • Analysed GWAS and immunochip data to identify blood, and weight loss. They can also suffer from other molecular signatures for IBD sub-phenotypes, including conditions that affect the skin, eyes and joints. Patients acute severe colitis (and its response to different need medication for long periods of time and many have therapies) and colorectal cancer complicating colitis. bowel surgery. IBD affects both males and females, including children. • Carried out parallel studies in colorectal cancer cases complicating ulcerative colitis using exome sequencing, The group focuses on: to identify novel SNPs in this sub-group. • Identified genes associated with Crohn’s disease and • Executed a GWAS in patients with refractory ulcerative colitis. ulcerative colitis. • The role of paneth cells in ileal Crohn’s Disease. • Completion of the first phase of the Crohn’s disease • Determined disease-specific gene expression PBS study – this has investigated factors that signatures. significantly influence maintenance of response to anti- • Incidence and prevalence of inflammatory bowel TNF therapy across Australia and New Zealand. disease in south-east Queensland. • A research project looking into the causes of inflammatory bowel disease.

IRON METABOLISM

Group Leader: Professor Greg Anderson, Deputy Director Highlights:

The Iron Metabolism Laboratory focuses on understanding • Showed a critical role for hephaestin and related the homeostasis of the essential trace element iron in the oxidases in iron absorption. body and the natural history of disorders of iron metabolism, • Assessed the combined effects of multiple hepatic such as the iron loading disease haemochromatosis. The toxins (iron, alcohol, fat) on liver disease progression. laboratory’s work takes a broad approach from basic • Identified factors responsible for regulating molecular mechanisms to clinical applications. iron homeostasis in thalassaemia and other haemolytic anaemias. • Defined the effects of transfusion therapy on iron and haematological parameters in patients with beta thalassaemia. • Identifed mutations in iron-related genes in the Chinese population. • Assessed the efficacy of nanoparticulate oral iron supplements in rodent models.

Page 60 QIMR Annual Report 2012–2013 LUNG INFLAMMATION AND INFECTION

Team Head: Dr David Reid Highlights:

The Lung Inflammation and Infection Team have focused • Developed a cystic fibrosis mouse model on a new on the role of iron in promoting bacterial infection in the genetic background. This will allow novel approaches cystic fibrosis lung and whether this in turn is related to to elucidation of the underlying mechanisms of disease dysregulation of cell iron homeostasis in cystic fibrosis. pathogenesis in this lethal genetic disease. The team have spent the year breeding the necessary • Developed therapeutic approaches targeting bacterial mouse models and conducting preliminary analyses of iron iron homeostasis, which appear very active against phenotype, while collecting samples from human subjects to bacterial biofilms. conduct an epidemiological study of gene mutations related • Developed methods to examine neutrophil function in to iron homeosatsis in CF patients. The team now has the the lung and demonstration that the oxidative burst required flow cell bacterial biofilm models to allow testing of potential of airway neutrophils from CF patients is new therapeutic compounds. affected by airway environmental conditions. • Commenced a new collaboration with a bacteriophage company based in US.

MEMBRANE TRANSPORT

Group Leader: Associate Professor Nathan Subramaniam Highlights:

The major focus of the Membrane Transport Group is aimed • Showed that the presence of excess iron in at understanding how iron levels in the body are regulated, combination with a high calorie diet significantly the genes involved, their mechanism of action, and the potentiates the progression of non-alcoholic fatty liver role iron plays in various disorders including liver disease disease, a relatively benign condition, to non-alcoholic and cancer. steatohepatitis with fibrosis, a disorder with significant associated morbidity and mortality. • Demonstrated in mouse models of haemochromatosis that, contrary to anecdotal belief, iron accumulation in the liver does not reflect iron loading of other organs, and is therefore not a suitable surrogate for assessment of disease potential in other organs in cases of iron overload. • Identified novel mutations in patients with atypical iron overload through novel screening strategies. • Developed and established novel and cost-effective next-generation sequencing tools for the rapid screening of genes involved in iron metabolism. • Demonstrated that in mouse studies treatment with an antioxidant and a common spice can reduce liver injury associated with excess iron and a high calorie diet.

Page 61 MOLECULAR EPIDEMIOLOGY

Group Leader: Professor Grant Montgomery, Department risk, demonstrating that the genetic factors underlying Coordinator: Genetics and Computational Biology disease are similar in European and Japanese populations, and obtaining new funding to identify the The Molecular Epidemiology Laboratory seeks to identify specific genes and pathways underlying increased genes and gene pathways contributing to risk for common disease risk. human diseases. The laboratory is a world leader in the genetics of endometriosis and works on melanoma, • Completed PhaseI genotyping for a genome-wide inflammatory bowel disease and a range of other diseases association study (GWAS) in carefully selected including asthma, migraine, depression, and alcohol, refractory and non-refractory cases to identify specific nicotine and drug dependence. The group maintains a large genes that either alone or together with key clinical biobank supporting projects in the laboratory and major variables will predict the risk of developing medically collaborations with QIMR’s Statistical Genetics, Genetic refractory ulcerative colitis. Epidemiology, Oncogenomics, Asthma Genetics and • Discovered new genomic regions associated with Neurogenetics Laboratories. increased melanoma risk including discovery of novel rare variants that predisposes to familial and Highlights: sporadic melanoma. • Led significant advances in understanding genes and • Contributed to an international consortium analysing pathways contributing to risk for endometriosis by the complex regulation of gene expression and the role finding additional genomic regions associated with of genetic varaints affecting complex disease.

NEUROGENETICS

Group Leader: Dr Dale Nyholt Highlights:

The Neurogenetics Group’s focus is on the genetic analysis • Reported six novel risk loci for androgenetic alopecia of migraine, endometriosis and traits comorbid with migraine and their association with Parkinson’s disease and including depression and epilepsy. The primary goal of this decreased fertility. research is to identify genetic risk factors that lead to new • Discovered four novel risk genes for migraine knowledge of the underlying biological pathways contributing without aura. to disease pathophysiology. • Identified five new loci in a large endometriosis meta-analysis. • Reported five novel risk loci for migraine.

NEUROIMAGING GENETICS

Group Leader: Dr Margie Wright • Identified associations between specific genes and measures of brain structure and connectivity. The Neuroimaging Genetics Group focuses on elucidating the neurobiological and genetic causes of major mental • Conducted the first GWAS meta-analysis of illnesses through the integration of structural and functional childhood intelligence. neuroimaging, measures of cognition and health and well • Identified genetic variants associated with being, and behavioural and molecular genetic approaches. bipolar disorder. The primary goal of this research is the identification of the genes and pathways that influence the structure and • Identified seven loci affecting mean telomere length. function of the human brain, and provide a window into the The findings support a causal role of telomere-length biological mechanisms leading to mental illness. variation in some age-related diseases. • Carried out GWAS met-analysis to identify genetic Highlights: variants associated with personality traits. Variation • Showed for the first time developmental changes in in personality is predictive of many outcomes in life, structural connectivity and network efficiency. including mental health. • Provided evidence for a role of genetic factors in several key brain metrics.

Page 62 QIMR Annual Report 2012–2013 QUANTITATIVE GENETICS

Team Head: Dr Sarah Medland Highlights:

The Quantitative Genetics Team has focused on elucidating • Published work on the genetics of the biological pathways inﬂuencing common psychiatric educational attainment. conditions including attention deﬁcit hyperactivity disorder • Launched a new study on severe morning sickness. and substance use disorders.

STATISTICAL GENETICS

Team Head: Associate Professor Stuart MacGregor Highlights:

The Statistical Genetics Team studies the role that genetic • Identified a genetic variant in the obesity gene FTO that variation plays in determining risk of disease and its risk confers risk of melanoma. factors. The laboratory develops and applies statistical • Identified 16 new genetic variants influencing corneal genetic methods to gene mapping studies across a wide thickness, several of which confer high risk for the eye range of traits and diseases. disease keratoconus. One major focus is understanding genetic and epigenetic • Identified 24 new genetic variants conferring risk of variation in various cancers including melanoma, ovarian myopia. cancer, and oesophageal cancer. Ultimately this work will • Found common genetic variants which predispose lead to better understanding of why particular individuals Barrett’s oesophagus. are affected by cancer or why they respond poorly to cancer treatment.

Another major interest is ophthalmological genetics, with work ongoing to identify the speciﬁc genes involved in both eye disease and in underlying quantitative risk factors.

SYSTEM NEUROSCIENCE

Group Leader: Professor Michael Breakspear Highlights:

Systems Neuroscience is an approach to brain sciences • Detected a biomarker for risk of bipolar disorder. that seeks the fundamental principles of brain organisation, • Developed a new diagnostic test for cerebral palsy. dynamics and function across a hierarchy of spatial and temporal scales. It is a rapidly growing ﬁeld that differs • Created an imaging test for major depression. considerably from the traditional reductionist paradigm in neuroscience that seeks purely sufﬁcient causes for local phenomena. In contrast, systems neuroscience seeks unifying explanations for emergent phenomena.

Page 63 SUPPORTING OUR RESEARCH

SUPPORT DIVISION

Dedicated Support Division staff are committed to providing The Division also oversaw the procurement of resources to the high level of support required to keep QIMR researchers equip the Institute’s research laboratories including world at the forefront of medical research and helping make class histology and flow cytometry imaging facilities. This successful research happen. equipment includes a laser scanning confocal microscope, a laser capture microscope, three bright field microscopes QIMR’s Support Division, formerly the Corporate Division, for deconvolution and time lapse experiments. In addition comprises five departments: to securing and installing this equipment, the Division also • Scientific Services; recruited specialist staff to manage these state of the art facilities, all of which supports the Institute’s scientists to • Human Resources; carry out their research more effectively and efficiently. • Finance and Administration; Support Division staff have also been instrumental in • Research Support and Governance; and establishing QIMR’s partnership in the Herston Imaging • External Relations. Research Facility, a purpose built research imaging facility to be built on the Herston campus, with partners UQ, QUT and Key activities in 2012-2013 have included the project Metro North Hospital and Health Service. management of the Bancroft Centre refurbishment which follows the completion of QIMR Central and Support To ensure ongoing support for the QIMR’s researchers, Division’s management of the relocation of laboratories and the Support Division has contributed to securing new offices in to the new premises. funding and diversifying income sources with efforts directed at assisting scientists in their development of grant In line with the Institute’s recruitment strategy to attract the applications, identifying and pursuing opportunities for best and brightest, the Support Division has successfully engagement with commercial entities and fundraising. supported the recruitment and appointment of seven new research groups.

COMMUNITY SUPPORT

QIMR’s research relies upon the support of community Feeney who founded The Atlantic Philanthropies. Mr Feeney groups, individuals and corporate sponsors. The funds these pioneered the term of ‘giving while living’; donating $233 dedicated groups and individuals raise and donate supports million towards biomedical research in Queensland. the Institute’s scientists and allows them to continue Mr Feeney helped fund QIMR’s newest facility through a their work. $27.5 million donation and performed the opening ceremony on 5 December 2012. December 2012 saw the ofﬁcial opening of QIMR’s newest building, a 15 ﬂoor state-of-the-art facility. QIMR was 2012 marked the second Rio Tinto Ride to Conquer fortunate to play host to a number of our supporters on the Cancer, which was held on 18-19 August and raised a day of the opening, including American philanthropist Chuck record-breaking $5.2 million for QIMR’s cancer research.

Page 64 QIMR Annual Report 2012–2013 Over 2,000 registered riders took part in the two day, 200 QIMR also recognises contributions made by monthly kilometre Ride from Brisbane to Wivenhoe Dam and back. donors; planned givers who kindly made provision for the Money raised from this signature event has funded 17 Institute in their Wills; long-term and new supporters who cancer research projects. The Institute would like to thank arranged activities and events to raise funds for QIMR’s the event’s naming right sponsor Rio Tinto; “powered by” research such as Sunny and Fred Drescher and long-term sponsor, Sunsuper; the Ausenco Foundation and those that supporters such as Mr Barry and Mrs Maureen Stevenson, participated in the event as a rider or volunteer. Mrs Elsie Hayes and the late Mr Kevin Hayes.

QIMR was also excited to team up with the Royal Brisbane The Institute received a generous gift from a new donor in and Women’s Hospital Foundation and announce the June 2013. Mr Kelvin David Garland left a $1 million gift to launch of a new fundraising event, called the Weekend to QIMR in his Will. Mr Garland’s kind gift will assist the Institute End Women’s Cancers. The 60 kilometre walk will be held in continuing its research into some of the world’s most in October 2013, and will raise funds for women’s cancer debilitating and deadly diseases. research and clinical care at QIMR and RBWH. QIMR congratulated its long-time Ambassador, Mr Rupert The William and Hilde Chenhall Research Trust continued McCall, on being named in the 2013 Queen’s Birthday to support QIMR in 2012–13. The Trust funds the Honours List. QIMR nominated Mr McCall for an award in bioinformatics unit at QIMR, which is helping to bring the the Order of Australia in recognition of more than a decade Institute’s researchers a step closer to understanding the of volunteering his time and talents to support and promote underlying genetic causes of cancer. medical research.

Perpetual demonstrated its ongoing support for QIMR Each year QIMR also acknowledges community members research, by funding Dr John Miles, from the Human for their outstanding support of medical research. In 2012, Immunity Team to carry out his work into better recipients of the QIMR Ambassador Awards included: Bev understanding and using T cells in the ﬁght against cancer. and Ed Dignam, Jenny Davidson, Members of the Mermaid Beach Bowls Club and Ladies Sewing Group.

THANK YOU TO THE FOLLOWING DONORS

Mr Sid Faithfull Estate of Sylvia Amelia Austin Brisbane Family Law Centre

Estate of Gloria Pierce (in memory) Estate of Norman Charles Peters Elsie Hayes and the Late Kevin Hayes

Walking on Sunshine Estate of Elaine Jane Weedon The Powell Family

Keith Maher (in memory of Merle Maher) Barry and Mrs Maureen Stevenson Estate of Athol A Card

Clive Berghofer BT Financial Group Fitton Insurance Brokers

Estate of Mr Kelvin David Garland One One One Eagle Street George Landers

Rio Tinto Ausenco Tim and Kym Reid

Estate of Ralph Brian Stubbs Estate of Late Phyllis Dowling Mrs Marceline Jarvis (in memory)

Sunsuper Pty Ltd Mr Ron McLaughlin Kevin and Dallas Bedford

In Vitro Technologies Life Science Queensland Community Foundation Joan Daniel and the Late Henry Daniel (in memory of Rhys Pengelly) Biniris (Aust) Pty Ltd

Page 65 FINANCIAL STATEMENTS

OPERATING RESULT

The operating result for the 2012-13 financial year was a The Council’s total funding resources, including amounts surplus of $17.2 million after providing for depreciation of under management at 30 June 2013 totalled $140.6 $9.2 million. This surplus includes recognition of capital million (2011-12: $145.4 million), of which $21.3 million grants from The Atlantic Philanthropies towards the was represented by capital grants (2011-12: $40.2 million). construction of the Medical Research Centres ($5.5 million). The decrease in funds held during the year is mainly due to payment for progress of the refurbishment works undertaken The Council’s financial structure is based on the management in relation to the Bancroft Centre. of operating and grant funds. Competitive research grant funding spent in the 2012-13 financial year was $43.3 Refurbishment of the Bancroft Centre is the third phase of million (2011-12: $$40.2 million), representing 44% of total the Medical Research Centre construction project and is income from continuing operations, excluding capital grants. fully funded with total contributions from the Commonwealth A majority of the Council’s core funding is provided as an Government ($110.0 million), the Queensland State operating grant from the Department of Health, Queensland Government ($35.0 million), and The Atlantic Philanthropies (2012-13: $14 million; 2011-12: $14 million). ($27.5 million).

CONTENTS

Statement of Comprehensive Income Statement of Cash Flows Statement of Financial Position Notes to and forming part of the Financial Statements Statement of Changes in Equity Management certiﬁcate

GENERAL INFORMATION

These ﬁnancial statements cover the Council of the A description of the nature of the Council’s operations Queensland Institute of Medical Research and its jointly and its principal activities is included in the notes to the controlled entities. ﬁnancial statements.

The Council of the Queensland Institute of Medical Research For information in relation to the Institute’s financial is a Queensland statutory body established under the statements please call +61 7 3362 0222, email enquiries@ Queensland Institute of Medical Research Act 1945. qimrberghofer.edu.au or visit the statutory body’s website www.qimrberghofer.edu.au The statutory body is controlled by the State of Queensland which is the ultimate parent. Amounts shown in these financial statements are rounded to thousands and therefore may not add to the exact sub-totals The head office and principal place of business of the or totals. statutory body is: 300 Herston Road, Herston QLD 4006

Page 66 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Statement of Comprehensive Income for the year ended 30 June 2013

Notes 2013 2012 $'000 $'000 Income from continuing operations Grants and other contributions 2a 72,851 65,403 Commercial revenue 3 4,164 3,103 Other revenue 4 12,436 11,842 Total revenue 89,451 80,348

Capital grants 2b 5,500 11,400 Gains/(losses) 5 7,804 (3,034) Total income from continuing operations 102,755 88,714

Expenses from continuing operations Employee expenses 6 44,672 40,874 Supplies and services 7 26,219 21,711 Depreciation and amortisation 8 9,183 6,205 Other expenses 9 4,919 4,999 Finance costs 454 268 Share of (gain)/loss of equity accounted investees 23 70 (19) Total expenses from continuing operations 85,517 74,038

Operating result from continuing operations 17,238 14,676

Other comprehensive income

Items that will not be reclassified subsequently to operating result Increase/(decrease) in asset revaluation surplus 19 8,871 (179) Total items that will not be classified subsequently to operating result 8,871 (179)

Total other comprehensive income 8,871 (179)

Total comprehensive income 26,109 14,497

The accompanying notes form part of these statements.

Page 67 The Council of The Queensland Institute of Medical Research Statement of Financial Position as at 30 June 2013

Notes 2013 2012 $'000 $'000

Current assets Cash and cash equivalents 10 62,751 82,234 Receivables 11 9,925 8,822 Inventories 12 273 256 Prepayments 1,044 269

Total current assets 73,993 91,581

Non-current assets Other financial assets 13 77,808 63,202 Intangible assets 14 551 636 Property, plant and equipment 15 272,177 241,173 Investments accounted for using the equity method 23 251 321 Total non-current assets 350,787 305,332

Total assets 424,780 396,913

Current liabilities Payables 16 6,067 3,682 Accrued employee benefits 17 3,632 4,067 Unearned revenue 18 19,260 19,408 Total current liabilities 28,959 27,157

Non-current liabilities Accrued employee benefits 17 869 913 Total non-current liabilities 8 69 913

Total liabilities 29,828 28,070

Net assets 394,952 368,843

Equity Accumulated surplus 347,133 329,895 Asset revaluation surplus 19 47,819 38,948 Total equity 394,952 368,843

The accompanying notes form part of these statements.

Page 68 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Statement of Changes in Equity for the year ended 30 June 2013

Accumulated Asset revaluation Total surplus surplus (note 19) $'000 $'000 $'000

Balance as at 1 July 2012 329,895 38,948 368,843 Operating result from continuing operations 17,238 - 17,238 Increase in asset revaluation surplus - 8,871 8,871 Balance as at 30 June 2013 347,133 47,819 394,952

Balance as at 1 July 2011 315,219 39,127 354,346 Operating result from continuing operations 14,676 - 14,676 Decrease in asset revaluation surplus - (179) (179) Balance as at 30 June 2012 329,895 38,948 368,843

The accompanying notes form part of these statements.

Page 69 The Council of The Queensland Institute of Medical Research Statement of Cash Flows for the year ended 30 June 2013

Notes 2013 2012 $'000 $'000

Cash flows from operating activities Inflows: Grants and other contributions 71,376 63,146 Capital grants 5,500 11,400 Commercial revenue 4,073 3,181 Other income 8,229 10,536 GST collected 144 618 Outflows: Employee expenses (44,743) (40,162) Supplies and services (24,896) (21,226) Finance costs (454) (268) GST paid (2) (84) Other (4,880) (4,241) Net cash provided by operating activities 20 14,347 22,900

Cash flows from investing activities Outflows: Sale of property, plant and equipment (64) - Investments in other financial assets (2,560) (3,843) Acquisition of property, plant and equipment (31,206) (49,276) Net cash used in investing activities (33,830) (53,119)

Net decrease in cash and cash equivalents (19,483) (30,219) Cash and cash equivalents at beginning of financial year 82,234 112,453 Cash and cash equivalents at end of financial year 10 62,751 82,234

The accompanying notes form part of these statements.

Page 70 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Objectives and principal activities of the Council Note 1: Summary of significant accounting policies Note 2: Grants and other contributions Note 3: Commercial revenue Note 4: Other revenue Note 5: Gains/(losses) Note 6: Employee expenses Note 7: Supplies and services Note 8: Depreciation and amortisation Note 9: Other expenses Note 10: Cash and cash equivalents Note 11: Receivables Note 12: Inventories Note 13: Other financial assets Note 14: Intangible assets ` Note 15 Property, plant and equipment Note 16: Payables Note 17: Accrued employee benefits Note 18: Unearned revenue Note 19: Asset revaluation surplus by class Note 20: Reconciliation of operating surplus to net cash from operating activities Note 21: Commitments for expenditure Note 22: Contingencies Note 23: Jointly controlled entities Note 24: Trust transactions and balances Note 25: Key management personnel and remuneration Note 26: Financial instruments Note 27: Events occurring after balance date Note 28: Economic dependency

Page 71 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Objective and principal activities of the Council

The objective of the Council is to control and manage the operations of the Queensland Institute of Medical Research (the Institute). The Council has been established to conduct research into all branches of medical science. It operates predominantly in one geographical area, being Queensland, Australia, although it has research collaborations across Australia and overseas.

The Council recently constructed a new building (referred to as 'QIMR Central') and has now entered into the third construction phase which is the refurbishment of the existing Bancroft Centre. The project has been funded by contributions from the Federal Government of $110m, the Queensland State Government of $35m and The Atlantic Philanthropies of $27.5m.

The majority of the Council's funding is generated from competitive, peer reviewed research grants, commercial and other earned revenue. The Council also receives an annual operational grant from the Department of Health, Queensland (Queensland Health). Further funding is generated from donations, fundraising and investment activities performed under the guidance of the Council. Also refer to note 28.

1. Summary of significant accounting policies

(a) Statement of compliance

The Council has prepared this financial report in compliance with section 43 of the Financial and Performance Management Standard 2009 .

These financial statements are general purpose financial statements, and have been prepared on an accrual basis in accordance with Australian Accounting Standards and Interpretations. In addition, the financial statements have regard to Treasury's Minimum Reporting Requirements for the year ended 30 June 2013, and other authoritative pronouncements.

With respect to compliance with Australian Accounting Standards and Interpretations, the Council has applied those requirements applicable to not-for-profit entities, as the Council is a not-for-profit statutory body. Except where stated, the historical cost convention is used.

(b) The reporting entity

The financial statements include the value of all revenues, expenses, assets, liabilities and equity of the Council. The Council had no material controlled entities as at 30 June 2013.

(c) Jointly controlled entities Jointly controlled entities are those where the Council has joint control, established by contractual agreement. As at 30 June 2013, the Council had entered into two material joint ventures - Vaccine Solutions Pty Ltd and Q-Pharm Pty Ltd. Where the Council has a claim over the equity of the joint venture, the interest is brought to account by using the equity method of accounting. The investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the Council's share of net assets of the joint venture. In addition, the Council's share of the profit or loss of the joint venture is included in the Council's operating result. This is the case for Q-Pharm Pty Ltd. Vaccine Solutions Pty Ltd is not equity accounted as the Council has no claim over the equity of the joint venture. Further details of the Council's interest in jointly controlled operations including audit arrangements are contained in note 23.

(d) Trust transactions and balances

The Council undertakes certain trustee transactions on behalf of the Cooperative Research Centre Vaccine Technology (CRCVT) and its employees' research activities.

As the Council acts only in a custodial role in respect of these transactions and balances, they are not recognised in the financial statements, but are disclosed in note 24.

(e) Grants and other contributions

Grants, contributions, donations, bequests, gifts and fundraising that are non-reciprocal in nature are recognised as revenue in the year in which the Council obtains control over them. Where grants are received that are reciprocal in nature, revenue is recognised over the term of the funding agreements.

Contributed assets are recognised at their fair value. Contributions of services are recognised only when a fair value can be determined reliably and the services would be purchased if they had not been donated.

(f) Commercial revenue

Page 72 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

User charges and fees from commercial services and recoveries of expenditure incurred by associated bodies which use the Council's laboratory consumables and services are recognised as revenue when the revenue has been earned and can be measured reliably with a sufficient degree of certainty. This involves either invoicing for related goods/services and/or the recognition of accrued revenue. User charges and fees are controlled by the Council where they can be deployed for the achievement of Council objectives.

(g) Interest, dividends and distributions

Revenue for interest on cash and cash equivalents is recognised on an accrual basis. Revenue for dividends and distributions from managed funds classified as financial instruments held at fair value through profit or loss are recognised when the Council's right to receive payment is established.

(h) Imputation credits As an endorsed income tax exempt charity, imputation credits attached to franked dividends received by the Council are refundable and may be claimed retrospectively after the end of the financial year. Imputation credits are brought to account when the right to receive the credits is established.

(i) Cash and cash equivalents For the purposes of the Statement of Financial Position and the Statement of Cash Flows, cash assets include all cash and cheques receipted but not banked at 30 June as well as deposits at call with financial institutions.

(j) Receivables

Trade debtors are recognised at the amounts due at the time of sale or service delivery i.e. the agreed purchase/contract price. Settlement of these amounts is required within 30 days from invoice date.

The collectability of receivables is assessed periodically with provision being made for impairment. All known bad debts are written- off at financial year end. Other debtors generally arise from transactions outside the usual operating activities of the Council and are recognised at their assessed values. Terms are a maximum of one month, no interest is charged and no security is obtained.

(k) Inventories

Inventories are represented by consumable laboratory supplies valued at the lower of cost and net realisable value.

Cost is assigned on a weighted average basis and includes expenditure incurred in acquiring the inventories and bringing them to their existing condition, except for training costs which are expensed as incurred.

Net realisable value is determined by estimating the selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

No inventory assets have been classified as inventories held for distribution.

(l) Acquisitions of assets

Actual cost is used for the initial recording of all non-current physical and intangible asset acquisitions. Cost is determined as the value given as consideration plus costs incidental to the acquisition, including all other costs incurred in getting the assets ready for use. However, any training costs are expensed as incurred. Where assets are received free of charge from another Queensland Government entity, the acquisition cost is recognised as the gross carrying amount in the books of the transferor immediately prior to the transfer together with any accumulated depreciation.

Assets acquired at no cost or for nominal consideration, other than from an involuntary transfer from another Queensland Government entity, are recognised at their fair value at date of acquisition in accordance with AASB 116 Property, Plant and Equipment.

(m) Property, plant and equipment

Items of property, plant and equipment with a cost or other value equal to or in excess of the following thresholds are recognised for financial reporting purposes in the year of acquisition:

Class Threshold

Buildings $10,000

Page 73 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Plant and equipment $5,000 Heritage & cultural $5,000

Items with a lesser value are expensed in the year of acquisition.

The Council occupies three buildings situated on Crown land reserved and set apart for hospital purposes. The land is under the control of Queensland Health on behalf of The State of Queensland.

Leases for the land and buildings known as the Bancroft Centre and the Clive Berghofer Cancer Research Centre (CBCRC) exist between the Council and The State of Queensland (represented by Queensland Health), at a nominal rental, terminating on 27 June 2066. The Bancroft Centre was constructed by the Council using grants from the Federal and Queensland State Governments. The CBCRC was constructed by the Council using grants from the Federal and Queensland State Governments, and private donors.

A lease for the land and building known as QIMR Central will be entered into between the Council and The State of Queensland (represented by Queensland Health), at nominal rental, terminating on 27 June 2066. The building was constructed by the Council using grants from the Federal and Queensland State Governments, and private donors.

As the buildings are controlled by the Council, these assets are recognised within its financial statements, not within the financial statements of Queensland Health. Any revaluation surpluses or decrements associated with these assets are recognised by the Council. Refer also notes 1(n) and 15.

(n) Valuations and revaluations of non-current physical and intangible assets

Buildings and heritage & cultural assets are measured at fair value in accordance with AASB 116 Property, Plant and Equipment and Queensland Treasury and Trade's Non-Current Asset Policies for the Queensland Public Sector . In respect of these asset classes, the cost of items acquired during the financial year has been judged by management of the Institute to materially represent their fair value at the end of the reporting period.

Where intangible assets have an active market, they are measured at fair value, otherwise they are measured at cost.

Plant and equipment is measured at cost in accordance with Treasury's Non-Current Asset Policies .

Non-current physical assets measured at fair value are independently re-valued by an external registered valuer at least once every five years with interim valuations, using appropriate indices, being otherwise performed on an annual basis where there has been a material variation in the index. Where indices are used in the revaluation process the Council ensures that the application of such indices would result in a valid estimation of the asset's fair value at reporting date. Refer to note 15 for details.

Any revaluation increment arising on the revaluation of an asset is credited to the asset revaluation surplus of the appropriate class, except to the extent it reverses a revaluation decrement for the class previously recognised as an expense. A decrease in the carrying amount on revaluation is charged as an expense, to the extent it exceeds the balance, if any, in the revaluation surplus relating to that asset class.

On revaluation, accumulated depreciation is restated proportionately with the change in the carrying amount of the asset and any change in the estimate of remaining useful life.

Separately identified components of assets are measured on the same basis as the assets to which they relate.

Heritage & cultural assets include research library monographs, Australiana and scarce items. They are measured at current replacement costs and are independently re-valued by an external registered valuer at least once every five years.

Materiality concepts under AASB 1031 Materiality are considered in determining whether the difference between the carrying amount and the fair value of an asset is material.

(o) Intangibles Intangible assets with a cost or other acquisition value equal to or greater than $100,000 are recognised in the Statement of Financial Position, items with a lesser value are expensed. Each intangible asset, less any anticipated residual value, is amortised over its estimated useful life to the Council. The residual value is zero for all the Council's intangible assets.

It has been determined that there is not an active market for any of the Council's intangible assets. As such, the assets are recognised and carried at cost less accumulated amortisation and accumulated impairment losses. No intangible assets have been classified as held for sale or form part of a disposal group held for sale. Purchased software The acquisition cost of externally purchased software has been capitalised and is being amortised on a straight-line basis over the period of the expected benefit to the Council, namely 10 years.

Page 74 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Internally generated software Expenditure on research activities relating to internally-generated intangible assets is recognised as an expense in the period in which it is incurred.

Costs associated with the development of computer software have been capitalised and are amortised on a straight line basis over the period of expected benefit to the Council, namely 10 years.

(p) Amortisation and depreciation of intangibles and property, plant and equipment

All intangible assets of the Council have finite useful lives and are amortised on a straight line basis. Property, plant and equipment is depreciated on a straight-line basis so as to allocate the net cost or re-valued amount of each asset, less its estimated residual value, progressively over its estimated useful life to the Council.

Assets under construction (work-in-progress) are not depreciated until they reach service delivery capacity. Service delivery capacity relates to when construction is complete and the asset is first put to use or is installed ready for use in accordance with its intended application. These assets are then reclassified to the relevant classes within property, plant and equipment.

Where assets have separately identifiable components that are subject to regular replacement, these components are assigned useful lives distinct from the asset to which they relate and are depreciated accordingly.

Any expenditure that increases the originally assessed capacity or service potential of an asset is capitalised and the new depreciable amount is depreciated over the remaining useful life of the asset to the Council.

The depreciable amount of improvements to or on leasehold land is allocated progressively over the estimated useful lives of the improvements or the unexpired period of the lease, whichever is the shorter. The unexpired period of a lease includes any option period where exercise of the option is probable.

Heritage & cultural assets include research library monographs, Australiana and scarce items. The service potential of these assets is not expected to diminish with time or use and therefore, they are not depreciated.

For each class of depreciable asset the following depreciation and amortisation rates are used:

Class Rate

Buildings 2% Plant and Equipment 5% - 33.3% Intangible Assets 10%

(q) Impairment of non-current assets

All non-current physical and intangible assets are assessed for indicators of impairment on an annual basis. If an indicator of possible impairment exists, the Council determines the asset's recoverable amount. Any amount by which the asset's carrying amount exceeds the recoverable amount is recorded as an impairment loss. The asset's recoverable amount is determined as the higher of the asset's fair value less costs to sell and depreciated replacement cost.

An impairment loss is recognised immediately in the Statement of Comprehensive Income, unless the asset is carried at a re- valued amount. When the asset is measured at a re-valued amount, the impairment loss is offset against the asset revaluation surplus of the relevant class to the extent available.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised as income, unless the asset is carried at a re-valued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. Refer also note 1(n).

(r) Leases Operating lease payments are representative of the pattern of benefits derived from the leased assets and are expensed in the periods in which they are incurred. (s) Other financial assets

Page 75 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Other financial assets held at fair value through profit or loss represent investments in managed funds and shares in listed companies. The investments are stated at current market value at the reporting date. Changes in the market value of these instruments, whether realised or unrealised, are recognised in the Statement of Comprehensive Income. These investments were originally classified as at fair value through profit or loss upon initial recognition and the Council manages these investments and makes purchases and sales decisions based on their fair value in accordance with the Council's documented investment strategy.

(t) Payables Trade creditors are recognised upon receipt of the goods or services ordered and are measured at the nominal amount i.e. agreed purchase/contract price, net of applicable trade and other discounts. Amounts owing are unsecured and are generally settled on 30 to 60 day terms.

(u) Financial instruments

Recognition Financial assets and financial liabilities are recognised in the Statement of Financial Position when the Council becomes party to the contractual provisions of the financial instrument.

Classification Financial instruments are classified and measured as follows: i. Cash and cash equivalents - held at fair value through profit or loss ii. Receivables - held at amortised cost iii. Other financial assets - held at fair value through profit or loss iv. Payables - held at amortised cost

The Council does not enter into transactions for hedging purposes.

All other disclosures relating to the measurement and financial risk management of financial instruments held by the Council are included in note 26.

(v) Employee benefits Employer superannuation contributions, annual leave expense and long service leave levies are regarded as employee benefits.

Workers' compensation insurance is a consequence of employing employees, but is not counted in an employee's total remuneration package. It is not an employee benefit and is recognised separately as employee related expenses.

Wages, salaries, annual leave and sick leave

Accruals for wages, salaries and annual leave expense due but unpaid at reporting date are recognised in the Statement of Financial Position at the current salary rates.

For unpaid entitlements expected to be paid within 12 months, the liabilities are recognised at their undiscounted values. Entitlements not expected to be paid within 12 months are classified as non-current liabilities and recognised at their present value, calculated using yields on Fixed Rate Commonwealth Government bonds of similar maturity, after projecting the remuneration rates expected to apply at the time of likely settlement.

Prior history indicates that on average, sick leave taken each reporting period is less than the entitlement accrued. This is expected to continue in future periods. Accordingly, it is unlikely that existing accumulated entitlements will be used by employees and no liability for unused sick leave entitlements is recognised.

As sick leave is non-vesting, an expense is recognised for this leave as it is taken.

Long service leave

Under the Queensland Government’s long service leave scheme, a levy is made on the statutory body to cover the cost of employees' long service leave. The levies are expensed in the period in which they are payable. Amounts paid to employees for long service leave are claimed from the scheme quarterly in arrears.

No provision for long service leave is recognised in the Council's financial statements, the liability being held on a whole-of- government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting .

Superannuation

Page 76 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

Employer superannuation contributions are paid to QSuper, the superannuation scheme for Queensland Government employees, at rates determined by the Treasurer on the advice of the State Actuary. Contributions are expensed in the period in which they are paid or payable. The Council's obligation is limited to its contribution to QSuper.

The QSuper scheme has defined benefit and defined contribution categories. The liability for defined benefits is held on a whole-of- government basis and reported in those financial statements pursuant to AASB 1049 Whole of Government and General Government Sector Financial Reporting .

Key management personnel and remuneration

Key management personnel and remuneration disclosures are made in accordance with section 5 of the Financial Reporting Requirements for Queensland Government Agencies issued by Queensland Treasury and Trade. Refer to note 25 for the disclosures on key management personnel and remuneration.

(w) Insurance

The Council's non-current physical assets and other risks are insured through the Queensland Government Insurance Fund (QGIF), premiums being paid on a risk assessment basis. In addition, the Council has policies with private insurance companies to cover risks not included by QGIF. The Council also pays premiums to WorkCover Queensland in respect of its obligations for employee compensation. These costs are reported in note 6.

(x) Services received free of charge or for nominal value

Contributions of services are recognised only if the services would have been purchased if they had not been donated and their fair value can be measured reliably. Where this is the case, an equal amount is recognised as revenue and an expense.

(y) Taxation

The Council is a State body as defined under the Income Tax Assessment Act 1936 and is exempt from Commonwealth taxation with the exception of Fringe Benefits Tax (FBT) and Goods and Services Tax (GST). FBT and GST are the only taxes accounted for by the Council. GST credits receivable from, and GST payable to the ATO, are recognised (refer to note 11).

(z) Issuance of financial statements The financial statements are authorised for issue by the Chairperson of Council, Director and Secretary at the date of signing the Management Certificate.

(aa) Accounting estimates and judgements

The preparation of financial statements necessarily requires the determination and use of certain critical accounting estimates, assumptions, and management judgements that have the potential to cause a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Such estimates, judgements and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in future periods as relevant.

Estimates and assumptions that have a potential significant effect are outlined in the following financial statement notes:

Grants - notes 1(e) and 18 Useful lives of intangibles and property, plant and equipment - note 1(p) Valuation of property, plant and equipment - notes 1(n) and 15 Accrued employee benefits - notes 1(v) and 17 Contingencies - note 22

(ab) Rounding and comparatives

Amounts included in the financial statements are in Australian dollars and have been rounded to the nearest $1,000 or, where that amount is $500 or less, to zero, unless disclosure of the full amount is specifically required.

Comparative information has been restated where necessary to be consistent with disclosures in the current reporting period.

(ac) New and revised accounting standards

Page 77 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

The Council did not voluntarily change any of its accounting policies during 2012-13. Australian Accounting Standards applicable for the first time for 2012-13 have had minimal effect on the Council's financial statements, as explained below.

AASB 2011-9 Amendments to Australian Accounting Standards-Presentation of items of Other Comprehensive Income [AASB 1, 5, 7, 101, 112, 120, 121, 132, 133, 134, 1039 & 1049 ] became effective from reporting periods beginning on or after 1 July 2012. The only impact for the Council is that, in the Statement of Comprehensive Income, items within the 'Other Comprehensive Income' section are now presented in different sub-sections, according to whether or not they are subsequently classifiable to the operating result. Whether subsequent reclassification is possible depends on the requirements or criteria in the accounting standard/interpretation that relates to the item concerned.

The Council is not permitted to early adopt a new or amended accounting standard ahead of the specified commencement date unless approval is obtained from the Queensland Treasury and Trade. Consequently, the Council has not applied any Australian accounting standards and interpretations that have been issued but are not yet effective. The Council applies standards and interpretations in accordance with their respective commencement dates. At the date of authorisation of the financial report, significant impacts of new or amended Australian Accounting Standards with future commencement dates are as set out below.

AASB 9 Financial Instruments (December 2010) and AASB 2010-7 Amendments to Australian Accounting Standards arising from AASB 9 (December 2010) [AASB 1, 3, 4, 5, 7, 101, 102, 108, 112, 118, 120, 121, 127, 128, 131, 132, 136, 137, 139, 1023 & 1038 and Interpretations 2, 5, 10, 12, 19 & 127] become effective from reporting periods beginning on or after 1 January 2015. The main impacts of these standards on the Council are that they will change the requirements for the classification, measurement and disclosures associated with financial assets. Under the new requirements, financial assets will be more simply classified according to whether they are measured at either amortised cost or fair value. Pursuant to AASB 9, financial assets can only be measured at amortised cost if two conditions are met. One of these conditions is that the asset must be held within a business model whose objective is to hold assets in order to collect contractual cash flows. The other condition is that the contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

The Council has commenced reviewing the measurement of its financial assets against the new AASB 9 classification and measurement requirements. However, as the classification of financial assets at the date of initial application of AASB9 will depend on the facts and circumstances existing at that date, the Council's conclusions will not be confirmed until closer to that time. At this stage, assuming no change in the types of transactions the Council enters into, it is not expected that any of the Council's financial assets will meet the criteria in AASB 9 to be measured at amortised cost. Therefore, as from the 2015-16 financial statements, all of the Council's financial assets will be required to be classified as financial assets measured at fair value and classified accordingly (instead of the measurement classifications presently used in notes 1(u) and 26). The same classification will be used for net gains/losses recognised in the Statement of Comprehensive Income in respect of those financial assets. In the case of the Council's receivables, as they are short-term in nature, the carrying amount is considered to be a reasonable approximation of fair value.

The Council will not need to restate comparative figures for financial instruments on adopting AASB 9 as from 2015-16. However, changed disclosure requirements will apply from that time. A number of one-off disclosures will be required in the 2015-16 financial statements to explain the impact of adopting AASB 9. Assuming no change in the types of financial instruments that the Council enters into no significant ongoing disclosure impacts are expected. The following new and revised standards apply as from reporting periods beginning on or after 1January 2014 - AASB 10 Consolidated Financial Statements; - AASB 11 Joint Arrangements; - AASB 12 Disclosure of Interests in Other Entities; - AASB 127 (revised) Separate Financial Statements; - AASB 128 (revised) Investments in Associates and Joint Ventures; and - AASB 2011-7 Amendments to Australian Accounting Standards arising from the Consolidation and Joint Arrangements Standards [AASB 1, 2, 3, 5, 7, 9, 2009-11, 101, 107, 112, 118, 121, 124, 132, 133, 136, 138, 139, 1023 & 1038 and Interpretations 5, 9, 16 & 17].

The AASB is planning to amend AASB 10. Such amendments are expected to clarify how the IASSB's principles about control of entities should be applied by not-for-profit entities in an Australian context. Hence, the Council is not yet in a position to reliably determine the future implications of these new and revised standards for the Council's financial statements. AASB 10 redefines and clarifies the concept of control of another entity, which is the basis for determining which entities should be consolidated into an entity’s financial statements. Therefore, once the AASB finalises its not-for-profit amendments to AASB 10, the Council will need to re-assess the nature of its relationships with other entities, including entities that are not currently consolidated.

Page 78 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

AASB 11 deals with the concept of joint control, and sets out new principles for determining the type of joint arrangement that exists which, in turn, dictates the accounting treatment. The new categories of joint arrangements under AASB 11 are more aligned to the actual rights and obligations of the parties to the arrangement. Subject to any not-for-profit modifications yet to be made to AASB 11, the Council will need to assess the nature of any arrangements with other entities to determine whether a joint arrangement exists in terms of AASB 11. If a joint arrangement does exist, the Council will need to follow the relevant accounting treatment specified in either AASB 11 or the revised AASB 128, depending on the nature of the joint arrangement.

AASB 12 contains a wide range of new disclosure requirements in respect of interests in other entities, whether those entities are controlled entities, associates, joint arrangements, or structured entities that are not consolidated. The volume and nature of disclosures that the Council will be required to make as from its 2013-14 financial statements will depend on the Council's eventual assessment of the implications of the new and revised standards listed above, particularly AASB 10, AASB 11 and AASB 128.

AASB 13 Fair Value Measurement applies from reporting periods beginning on or after 1 January 2013. AASB 13 sets out a new definition of 'fair value', as well as new principles to be applied when determining the fair value of assets and liabilities. The new requirements will apply to all of the Council's assets and liabilities (excluding leases) that are measured and/or disclosed at fair value or another measurement based on fair value. The potential impacts of AASB 13 relate to the fair value measurement methodologies used, and financial statement disclosures made in respect of, such assets and liabilities. The Council has commenced reviewing its fair value methodologies (including instructions to valuers, data used and assumptions made) for all items of property, plant and equipment measured at fair value to determine whether those methodologies comply with AASB 13. To the extent that the methodologies do not comply, changes will be necessary. While the Council is yet to complete this review, no significant changes are anticipated, based on the fair value methodologies presently used. Therefore, at this stage, no consequential material impacts are expected for the Council's property, plant and equipment as from 2013-14.

AASB 13 will require an increased amount of information to be disclosed in relation to fair value measurements for both assets and liabilities. To the extent that any fair value measurement for an asset or liability uses data that is not 'observable' outside the Council, the amount of information to be disclosed will be relatively greater. All other Australian accounting standards and interpretations with future commencement dates are either not applicable to the Council's activities, or have no material impact on the Council.

Page 79 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

2013 2012 $'000 $'000 2. Grants

(a) Grants and other contributions

Grants - National Health & Medical Research Council 26,101 24,018 Grants - Queensland Health 13,969 13,969 Grants - Other 11,685 10,691 Grants - NHMRC overheads support funding (IRIISS) 4,550 4,473 Grants - National Institutes of Health 1,767 2,215 Grants - Cancer Council Queensland 1,618 1,273 Donations and fundraising 9,080 6,486 Bequests 4,081 2,278 Total 72,851 65,403

(b) Capital grants

Grants - Medical Research Centre 5,500 11,400

Capital grant received for the Medical Research Centre in 2012-13 from The Atlantic Philanthropies. This grant is solely for the construction and fit out of the QIMR Medical Research Centre building on the Herston site.

3. Commercial revenue

Commercial and contract research 2,746 1,503 Sundry tenants recoveries 955 1,052 Rent 463 548 Total 4,164 3,103

4. Other revenue

Reimbursements 4,546 3,432 Investment distributions 4,241 2,531 Interest 3,661 5,838 Other (12) 41 Total 12,436 11,842

5. Gains/(losses)

Net gain/(loss) on market value of other financial assets 7,804 (3,034) Total 7,804 (3,034)

The Council holds financial assets including managed funds and listed shares (refer notes 13 and 26). The performance of managed funds investments improved in 2012-13 compared with the previous year which was impacted by market volatility.

2013 2012

Page 80 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

$'000 $'000 6. Employee expenses

Employee benefits Wages and salaries 34,898 33,067 Employer superannuation contributions * 4,702 3,710 Annual leave expense * 3,603 3,018 Long service leave levy * 874 617 Other employee benefits 320 244 44,397 40,656 Employee related expenses Fringe benefits tax expense 102 61 Workers' compensation premium * 83 73 Other employee related expenses 90 84 275 218

Total 44,672 40,874

* Refer to note 1(v)

The number of employees including both full-time employees and part-time employees measured on a full-time equivalent basis is: 503 446

7. Supplies and services

Supplies and consumables 17,845 13,821 Consultants and contractors 5,332 3,328 Travel 1,585 1,434 Minor equipment and software purchases 1,413 2,987 Rent 44 141 Total 26,219 21,711

8. Depreciation and amortisation

Buildings 5,023 2,595 Plant and equipment 4,075 3,525 Intangibles 85 85 Total 9,183 6,205

The Council's property, plant and equipment includes heritage assets such as research library monographs, Australiana and scarce items. The service potential of these assets is not expected to diminish with time or use and therefore, they are not depreciated. Refer to notes 1(p) and 15.

2013 2012 $'000 $'000

Page 81 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

9. Other expenses

Scientific collaboration distributions 4,053 3,551 Insurance 496 404 Audit & other fees - internal 165 101 Legal expenses 105 128 Audit fees - external * 63 87 Net loss on sale of property, plant and equipment 39 757 Net gain on foreign exchange transactions (2) (32) Impairment charge -3 Total 4,919 4,999

* Total external audit fees to be paid to the Queensland Audit Office relating to the 2012-13 financial year are estimated to be $79,000 (2012: $62,500). There are no non-audit services included in this amount.

10. Cash and cash equivalents

Imprest accounts 11 Cash at bank 10,201 6,415 Term deposits 52,549 75,818 Total 62,751 82,234

The Council's cash and cash equivalents include $19.3m (2012: $19.4m) in research grant funding and $21.3m (2012: $40.2m) in capital grant funding received but not yet spent.

11. Receivables

Trade debtors 4,233 4,142 NHMRC grants 3,600 2,274 Accrued interest 422 567 GST receivable 391 533 Long service leave reimbursements 122 261 Other 1,157 1,045 Total 9,925 8,822

12. Inventories

Supplies and consumables - at cost 273 256 Total 273 256

During the 2012-13 reporting period, $1.1 million of inventories (2012: $1.1 million) were expensed. All inventories on hand at 30 June are expected to be utilised within 12 months.

13. Other financial assets

Other financial assets at fair value through profit or loss: Managed fund investments 77,778 63,176 Shares - US listed entities * 30 26 Total 77,808 63,202 2013 2012 $'000 $'000 13. Other financial assets (cont'd)

Page 82 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

* QIMR holds shares in Sequenom Inc. which were acquired as a result of the takeover of Gemini PLC, in which QIMR held shares originally. These shares are quoted on the NASDAQ exchange in the United States of America and are recorded at their market value at the reporting date.

14. Intangible assets

Software purchased: At cost 679 679 Less: Accumulated amortisation (246) (178) 433 501 Software internally generated: At cost 172 172 Less: Accumulated amortisation (54) (37) 118 135

Total 551 636

Page 83 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

14. Intangible assets (cont'd)

Intangibles reconciliation generated Software purchased Total 2013 2013 2013 $'000 $'000 $'000 Carrying amount at 1 July 2012 135 501 636 Acquisitions - - - Disposals - - - Transfers between classes - - - Amortisation (17) (68) (85) Carrying amount at 30 June 2013 118 433 551

generated Software purchased Total 2012 2012 2011 $'000 $'000 $'000 Carrying amount at 1 July 2011 153 569 722 Acquisitions - - - Disposals - - - Transfers between classes - - - Amortisation (18) (68) (86) Carrying amount at 30 June 2012 135 501 636

Page 84 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

5 July 1905 4 July 1905 $'000 $'000 15. Property, plant and equipment

Buildings: At fair value 259,187 251,510 Less: Accumulated depreciation (42,722) (43,451) 216,465 208,059 Heritage & cultural assets: At fair value 104 104 104 104 Plant & equipment: At cost 61,200 57,396 Less: Accumulated depreciation (37,023) (30,907) 24,177 26,489 Work in progress: At cost 31,431 6,521 31,431 6,521

Total 272,177 241,173

Buildings - Bancroft Centre and the Clive Berghofer Cancer Research Centre (CBCRC)

The Council's buildings known as the Bancroft Centre and the Clive Berghofer Cancer Research Centre were valued at 30 June 2013 for the independent valuer Davis Langdon by Damien Hirst BSc(QS)(Hons) AAIQS. The basis of the valuation is the depreciated replacement cost (DRC), calculated as replacement cost less cost to bring asset to current standards less accumulated depreciation of the expired useful life of the building.

(i) Replacement cost

The methodology applied by the valuer is a financial simulation in lieu of market value as these assets cannot be bought and sold on the open market. A replacement cost is estimated by creating a cost plan (cost estimate) of the asset through the measurement of key quantities such as: - Gross Floor Area (GFA) - Number of floors - Girth of the building - Height of the building - Number of lifts and staircases

The model developed by the valuer creates an elemental cost plan using these quantities and the model includes multiple building types and is based on the valuer’s experience of the cost of managing construction contracts.

The cost model is updated each year and tests are done to compare the model outputs on actual recent projects to ensure it produces a true representation of the cost of replacement. The costs are at Brisbane prices and published location indices are used to adjust the pricing to suit local market conditions. Live project costs from across the state are also assessed to inform current market changes that may influence the published factors.

The valuer's key assumption on the replacement cost is that their estimate is based on replacing the current function of the building with a building of the same form (size and shape). This assumption has a significant impact if an asset’s function changes.

(ii) Cost to bring to current standards

The ‘cost to bring to current standards’ is the estimated cost of refurbishing the asset to bring it to current standards. For each of the five condition ratings the estimate is based on professional opinion as well as having regard to historical project costs.

15. Property, plant & equipment (cont'd)

Page 85 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

In assessing the cost to bring to current standard a condition rating is applied based upon the following information: - Visual inspection of the asset - Asset condition data provided by the Institute's Building Services Manager - Verbal guidance from the Building Services manager - Previous reports and inspection photographs if available (to show the change in condition over time).

Category Condition Criteria 1 Very good condition Only normal maintenance required 2 Minor defects only Minor maintenance required 3 Maintenance required to return to Significant maintenance required (up to 50% of capital accepted level of service replacement cost) 4 Requires renewal Complete renewal of the internal fit out and engineering services required (up to 70% of capital replacement cost) 5 Asset unserviceable Complete asset replacement required.

These condition ratings are linked to the cost to bring to current standards.

The standard life of a mixed laboratory/office building is generally 50 years. Estimates of remaining life are based on the assumption that the asset remains in its current function and will be maintained.

Buildings have been valued on the basis that there is no residual value.

The Council has adopted the independent valuations for the Bancroft Centre and the CBCRC as fair value.

Buildings - QIMR Central

The Council's building known as QIMR Central was stated at cost at 30 June 2012. Management has no indication that there has been a significant change in value since that date. An interim valuation was carried out at 30 June 2013 using internal expert opinions and the Queensland Treasury and Trade approved 'Asset revaluation index for non–residential construction in QLD’.

This index is published by the Australian Bureau of Statistics and measures changes over time in the prices of new construction outputs for the eight Australian capital cities.

The valuation basis is at basic prices and the price excludes Goods and Services Tax (GST) and any subsidies. The price of a building is defined as excluding the price of land, site works, external services (such as drainage, water and electricity connection) and design.

The movement in the price of buildings is being measured using a component cost method. In this method, buildings are regarded as a set of standardised homogenous components. The price movement of a whole structure is effectively derived by measuring the price movements of its components.

The component prices are as close as possible to market prices; that is, they reflect not only labour, material and plant input costs, but also subcontractors' margin.

At 30 June 2013 the cumulative change in the index since the building's completion was not material (1.4%) and consequently the carrying value of the QIMR Central building was considered to be at fair value.

Heritage & cultural assets

Heritage & cultural assets consisting of research library monographs, Australiana and scarce items have been included at current replacement cost as assessed by the Approved Commonwealth Valuer (Books) Jörn Harbeck as at 18 April 2012. Management has no indication that there has been a significant change in the fair value since the last valuation.

Page 86 QIMR Annual Report 2012–2013 The CouncilofQueenslandInstituteMedicalResearch Notes toandformingpartoftheﬁnancialstatementsforyearended30June2013

15. Property, plant & equipment (cont'd)

Property, plant & equipment reconciliation Buildings Heritage & cultural Plant & equipment Work in progress Total 2013 2013 2013 2013 2013 $'000 $'000 $'000 $'000 $'000 Carrying amount at 1 July 2012 208,059 104 26,489 6,521 241,173 Acquisitions - - 6,425 24,910 31,335 Disposals - - (104) - (104) Transfers between classes 4,558 - (4,558) - - Revaluation increments 1,252 - - - 1,252 Accumulated depreciation revaluation adjustment 7,619 - - - 7,619 Depreciation/amortisation (5,023) - (4,075) - (9,098) Carrying amount at 30 June 2013 216,465 104 24,177 31,431 272,177

Buildings Heritage & cultural Plant & equipment Work in progress Total 2012 2012 2012 2012 2012 $'000 $'000 $'000 $'000 $'000 Carrying amount at 1 July 2011 77,785 283 23,960 104,259 206,287 Acquisitions - - 5,781 36,161 41,942 Disposals - - (757) - (757) Transfers between classes 132,869 - 1,030 (133,899) - Revaluation decrements - (179) - - (179) Accumulated depreciation revaluation adjustment ----- Depreciation/amortisation (2,595) - (3,525) - (6,120) Carrying amount at 30 June 2012 208,059 104 26,489 6,521 241,173

The Council has plant & equipment with an original cost of $17.6 million (2012: $16.2 million) and a written down value of zero still being used in the provision of services. The Council intends to retire these assets over the following five years. Page 87 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

2013 2012 $'000 $'000 16. Payables

Trade creditors 1,647 1,491 Other 4,420 2,191 Total 6,067 3,682

17. Accrued employee benefits

Current Accrued wages * - 963 Long service leave levy payable 211 174 Annual leave entitlements payable 2,902 2,526 Other 519 404 Total 3,632 4,067

* Accrued wages in the 2012 financial year relate to back pay under the Council's enterprise agreement.

Non current Annual leave entitlements payable 869 913 Total 869 913

18. Unearned revenue Unearned revenue 19,260 19,408 19,260 19,408

Grants b/f Grants Grant Grants c/f 1 July 2012 received expenditure 30 June 2013 National Health & Medical Research Council 9,70724,330 (26,073) 7,964 Cancer Australia 569167 (317) 419 Cancer Council Qld 1641,563 (1,618) 109 National Institutes of Health 1171,544 (1,339) 322 Other granting bodies 8,43215,508 (13,875) 10,065 Other commercial funding bodies 419- (38) 381 19,40843,112 (43,260) 19,260

Grants b/f Grants Grant Grants c/f 1 July 2011 received expenditure 30 June 2012 National Health & Medical Research Council 10,14623,579 (24,017) 9,707 Cancer Australia 1,29222 (744) 569 Cancer Council Qld 2461,191 (1,273) 164 National Institutes of Health 782,254 (2,215) 117 Other granting bodies 9,06010,891 (11,519) 8,432 Other commercial funding bodies 84344 (468) 419 21,66537,980 (40,237) 19,408

Page 88 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

2013 2012 $'000 $'000 19. Asset revaluation surplus by class Heritage & Buildings cultural Total $'000 $'000 $'000 Balance at 1 July 2012 38,944 4 38,948 Revaluation increments * 8,871 - 8,871 Balance at 30 June 2013 47,815 4 47,819

Heritage & Buildings cultural Total $'000 $'000 $'000 Balance at 1 July 2011 38,944 183 39,127 Revaluation decrements * - (179) (179) Balance at 30 June 2012 38,944 4 38,948

* Further details are presented in notes 8 and 15.

20. Reconciliation of operating surplus to net cash from operating activities

Notes Operating surplus 17,238 14,676

Depreciation and amortisation expense 8 9,183 6,205 Loss on sale of property, plant and equipment 9 39 757 Net gain on market value of other financial assets 5 (7,804) 3,034 Investment distributions other financial assets 4 (4,241) (2,531)

Change in assets and liabilities: (Increase)/decrease in trade receivables 11 (91) 77 (Increase)/decrease in GST input tax credits receivable 11 (2) 618 (Increase)/decrease in long service leave reimbursement receivables 11 139 (170) (Increase)/decrease in NHMRC grants 11 (1,326) - (Increase)/decrease in accrued interest & other receivables 11 33 1,225 (Increase)/decrease in inventories 12 (17) 21 (Increase)/decrease in prepayments (775) 132 Increase/(decrease) in accounts payable 16 2,385 211 Increase/(decrease) in accrued employee benefits 17 (479) 1,006 Increase/(decrease) in unearned revenue 18 (148) (2,257) Increase/(decrease) in GST payable 11 144 (84) (Increase)/decrease in investments accounted for using equity method 70 (20)

Net cash from operating activities 14,347 22,900

21. Commitments for expenditure

(a) Non-cancellable operating leases

Commitments under operating leases at reporting date are inclusive of anticipated GST and are payable as follows:

Page 89 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

2013 2012 $'000 $'000 21. Commitments for expenditure (cont'd)

Payable: Not later than one year 43 30 Later than one year and not later than five years 45 6 Later than five years -- Total 88 36

Operating leases have renewal options, however, no leases have escalation clauses other than in the event of payment default.

No lease arrangements create restrictions on other financing transactions.

(b) Capital expenditure commitments

Capital expenditure commitments in majority relate to the refurbishment of the Bancroft Centre (2012: refurbishment of the Bancroft Centre). The values shown are based on the committed contract value inclusive of anticipated GST.

Payable: Not later than one year 16,302 21,213 Later than one year and not later than five years 800 11,511 Later than five years -- Total 17,102 32,724

Other expenditure committed at the end of the period but not recognised in the accounts is as follows:

Payable: Not later than one year 1,122 863 Later than one year and not later than five years - - Later than five years -- Total 1,122 863

22. Contingencies

(a) Contingent assets

Contributions to Queensland Community Foundation

The QIMR Trust established a fund with the Queensland Community Foundation (QCF) for the purpose to generate future income and donations. This fund was transferred to Council upon abolition of the Trust on 1 February 2011. All contributions made to this named fund within QCF are held in trust and invested in perpetuity with net income distributed to the Council at the discretion of the Trustee in accordance with the Queensland Community Fund Declaration of Trust. The available balance of this fund was $1,314,000 at 30 June 2013 comprising total assets of $1,337,000 and total liabilities of $23,000 (net assets 2012: $823,000) of which $10,000 was contributed by the former QIMR Trust. The Council expects that earnings from the 2012-13 financial year will be brought to account during the financial year ending 30 June 2014.

(b) Contingent liabilities

There were no known contingent liabilities at 30 June 2013.

Page 90 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

23. Jointly controlled entities

(a) Q-Pharm Pty Ltd

Q-Pharm Pty Limited is a phase 1 clinical trial company. The company is a joint venture between Professors Hooper and Dickinson, the Council and The University of Queensland. The Council holds 24.5% of the shares of Q-Pharm Pty Limited (2012: 24.5%).

The Council accounts for its 24.5% interest in Q-Pharm Pty Limited on an equity accounted basis. A summary of the financial transactions and balances for Q-Pharm Pty Limited is as follows:

Q-Pharm Pty Ltd 2013 2012 $'000 $'000

Income 4,110 6,661 Expenses (4,394) (6,582) Net surplus/(deficit) (284) 79

therefore the Council's share (70) 19

Current assets 1,691 2,072 Non-current assets 224 281 Current liabilities (889) (1,044) Non-current liabilities -- Net assets 1,026 1,309

therefore the Council's share 251 321

Q-Pharm did not have any material contingent liabilities or commitments as at 30 June 2013. The Council has not individually or jointly incurred any contingent liabilities in Q-Pharm. The Council is not contingently liable for the liabilities of the other ventures of Q-Pharm. The Q-Pharm financial statements to 30 June 2013 were audited by Terry Murphy CA. Total external audit fees relating to the 2012-13 financial year are estimated to be $11,600 (2012: $13,000). There are no non-audit services included in this amount.

(b) Vaccine Solutions Pty Ltd

The Council and CSL Limited are equal shareholders in Vaccine Solutions Pty Ltd (Vaccine Solutions), a company established in 1998 to provide clinical trial sponsorship, intellectual property management and commercialisation services to the Cooperative Research Centre for Vaccine Technology (CRCVT). Following the winding up of the CRCVT, Vaccine Solutions manages a number of licensing arrangements for the benefit of the members of CRCVT Trust II. Vaccine Solutions does not own any physical or intellectual property assets on its own and is required to return 97% of all commercial income received from licensing activities to the CRCVT Trust II for distribution to members of that trust.

24. Trust transactions and balances

(a) Trust II for the CRC for Vaccine Technology (CRCVT Trust II)

The Council is the Trustee of the CRC for Vaccine Technology Trust II (CRCVT Trust II), a trust responsible for managing patent families and licensing arrangements on behalf of the participants in the CRCVT since winding up in June 2006. Income received from licensing arrangements is distributed to the members in the trust according to their participating share in the CRCVT as of June 2006. The members of the CRCVT Trust II are: The Council of the Queensland Institute of Medical Research, CSIRO, CSL Limited, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Monash University, Australian Red Cross Blood Service and La Trobe University.

Page 91 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

24. Trust transactions and balances (cont'd)

As the Council performs only a custodial role in respect of these transactions and balances, they are not recognised in the financial statements but are disclosed in these notes for the information of users.

CRC for Vaccine Technology Trust II (CRCVT Trust II) 2013 2012 $'000 $'000

Income 39 468 Expenses (163) (246) Trust net surplus/(deficit) before distributions (124) 222

Cash 374 200 Receivables 140 435 Total assets 514 635

Payables 14 11 Beneficiaries entitlements payable 500 624 Total liabilities 514 635

Trust net assets --

KPMG is the auditor of CRCVT Trust II. Total external audit fees relating to the 2012-13 financial year are estimated to be $5,500 (2012: $12,111). There are no non-audit services included in this amount.

(b) Employee Research Services The Council undertakes a custodial role in respect of transactions and balances relating to Employee Research Services (ERS). They are not recognised in the financial statements but are disclosed in these notes for the information of users.

Employee Research Services

Income 1,070 753 Expenses (1,173) (871) Decrease in net balance (103) (118)

Cash held in short term deposits 2,111 2,214 Total trust assets 2,111 2,214

25. Key management personnel and remuneration

(a) Key management personnel

The following details for key management personnel include those positions that had authority and responsibility for planning, directing and controlling the activities of the Institute during 2012-13. Further information on these positions can be found in the body of the annual report under the section relating to management.

Page 92 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

25. Key management personnel and remuneration (cont'd)

Current incumbents Position Responsibilities Contract classification and Date appointed to appointment authority position The Hon Paul de Jersey AC 20 June 2013 - Chairperson of Council Prof. Bryan Campbell 9 September 2011 The functions of the Council - Member of Council are to: Mr Christopher Coyne (a) control and manage the 9 September 2011 - Member of Council Institute; Dist. Prof. Judith Clements (b) raise and accept moneys 9 September 2011 - Member of Council for the purposes of the Prof. Nicholas Fisk Institute; 9 September 2011 - Member of Council (c) invest moneys raised and Appointed by Governor in Mr Ian Fraser accepted by the Council for Council, s10 QIMR Act 1945 9 August 2012 - Member of Council the purposes of the Instittute; Assoc. Prof. Paula Marlton and 9 September 2011 - Member of Council (d) invest moneys derived Prof. Alan Pettigrew from any property or other 9 September 2011 - Member of Council invested moneys of the Mr Rod Wylie Council for the purposes of 9 September 2011 - Member of Council the Institute. Dr. Jeannette Young 9 September 2011 - Member of Council The Director is responsible for Appointed by Governor in 4 January 2011 work and efficient and Council, s10 QIMR Act 1945 Director/CEO effective administration of the Council

(b) Remuneration

The Chairperson and members of Council receive sitting fees in line with the 'Remuneration of part-time Chairs and Members of Government Boards, Committees and Statutory Authorities' guideline issued by the Queensland Department of Justice and Attorney-General.

The remuneration policy for the Director/CEO is set by Council as provided for under the Queensland Institute of Medical Research Act 1945. The remuneration and other terms of employment for the Director/CEO are specified in the employment contract. The contract provides for the provision of other benefits including motor vehicles.

The remuneration package for the Director/CEO comprises the following components:

i. Short term employee benefits which include - Base – consisting of base salary, allowances and leave entitlements paid and provided for the entire year or for that part of the year during which the Director/CEO occupied the specified position. Amounts disclosed equal the amount expensed in the Statement of Comprehensive Income. - Non-monetary benefits – consisting of provision of vehicle together with fringe benefits tax applicable to the benefit.

ii. Long term employee benefits include long service leave accrued.

iii. Post employment benefits include superannuation contributions.

iv. Redundancy payments are not provided for within the Director/CEO's contract of employment. The contract of employment provides only for notice periods or payment in lieu of notice on termination, regardless of the reason for termination.

v. There are no performance bonuses paid or payable to the Director/CEO.

Total remuneration is calculated on a ‘total cost’ basis and includes the base and non-monetary benefits, long term employee benefits and post employment benefits:

Page 93 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

25. Key management personnel and remuneration (cont'd)

1 July 2012 - 30 June 2013

Short term employee Long term employee Post employment Total benefits benefits benefits remuneration Position Base Non-monetary benefits $'000 $'000 $'000 $'000 $'000 Council Acting Chairpersons (2)2 - - - 2 Council Members (10)8 - - - 8 Director/CEO548 59 11 23 641 Total558 59 11 23 651

1 July 2011 - 30 June 2012

Short term employee Long term employee Post employment Total benefits benefits benefits remuneration Position Base Non-monetary benefits $'000 $'000 $'000 $'000 $'000 Council Chairperson (1) and Acting Chairperson (1) 39 - - 3 42 Council Members (10)9 - - - 9 Director/CEO514 56 11 16 597 Total562 56 11 19 648

The table above does not include $65,000 in fringe benefits tax paid by Council in 2012-13 in relation to key management remuneration (2012: $23,000). The increase is due to a change in tax legislation.

26. Financial instruments

(a) Categorisation of financial instruments

The Council has the following categories of financial assets and financial liabilities: 2013 2012 Category Notes $'000 $'000 Financial assets Cash and cash equivalents 10 62,751 82,234 Receivables 11 9,925 8,822 Managed fund investments and US listed shares 13 77,808 63,202 150,484 154,258

Financial liabilities Financial liabilities measured at amortised cost: Payables 16 (6,067) (3,682) (6,067) (3,682)

(b) Financial risk management

The Council's activities expose it to a variety of financial risks - interest rate risk, credit risk, liquidity risk and market risk.

Financial risk management is implemented pursuant to Government and Council policy. These policies focus on the unpredictability of financial markets and seek to minimise potential adverse effects on the financial performance of the Council.

Page 94 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

26. Financial instruments (cont'd)

All financial risk is managed by the Institute under policies approved by the Council. The Council provides written principles for overall risk management, as well as policies covering specific areas.

The Council measures risk exposure using a variety of methods as follows:

Risk exposure Measurement method Credit risk Ageing analysis, earnings at risk Liquidity risk Sensitivity analysis Market risk Interest rate sensitivity analysis

(i) Credit risk exposure

Credit risk exposure refers to the situation where the Council may incur financial loss as a result of another party to a financial instrument failing to discharge their obligation. The maximum exposure to credit risk at balance date in relation to each class of recognised financial assets is the gross carrying amount of those assets inclusive of any provisions for impairment.

The following table represents the Council's maximum exposure to credit risk based on contractual amounts net of any allowances: 2013 2012 Note $'000 $'000 Financial assets Managed fund investments and US listed shares 13 77,808 63,202 Total 77,808 63,202

The carrying amount of receivables represents the maximum exposure to credit risk. As such, receivables are not included in the above disclosure. No collateral is held as security and no credit enhancements relate to financial assets held by the Council.

The Council manages credit risk through the use of a credit management strategy. This strategy aims to reduce the exposure to credit default by ensuring that the Council invests in secure assets and monitors all funds owed on a timely basis. Exposure to credit risk is monitored on an ongoing basis.

No financial assets and financial liabilities have been offset and presented net in the Statement of Financial Position.

The method for calculating any provision for impairment is based on past experience, current and expected changes in economic conditions and changes in client credit ratings. These economic and geographic changes form part of the Council's documented risk analysis assessment in conjunction with historic experience and associated industry data. This analysis has identified that none of the Council's financial assets are impaired and subsequently provisions for impairment have not been raised. No financial assets have had their terms renegotiated so as to prevent them from being past due or impaired, and are stated at the carrying amounts as indicated. Ageing of past due but not impaired financial assets is disclosed in the following tables. No financial assets were assessed as being impaired as at 30 June 2013:

2013 Financial assets past due but not impaired Not due and Not due Overdue overdue Note < 30 days 30-60 days 61-90 days > 90 days Total Total $'000 $'000 $'000 $'000 $'000 $'000 Financial assets Receivables 11 7,640 646 406 1,233 2,285 9,925 Total 7,640 646 406 1,233 2,285 9,925

Page 95 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

26. Financial instruments (cont'd)

2012 Financial assets past due but not impaired Not due and Not due Overdue overdue Note < 30 days 30-60 days 61-90 days > 90 days Total Total $'000 $'000 $'000 $'000 $'000 $'000 Financial assets Receivables 11 5,324 824 1,975 699 3,498 8,822 Total 5,324 824 1,975 699 3,498 8,822

(ii) Liquidity risk

Liquidity risk refers to the situation where the Council may encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset.

The Council is exposed to liquidity risk in respect of its payables.

The Council manages liquidity risk through the use of a liquidity management strategy. This strategy aims to reduce the exposure to liquidity risk by ensuring the Council has sufficient funds available to meet employee and supplier obligations as they fall due. This is achieved by ensuring that minimum levels of cash are held within the various bank accounts so as to match the expected duration of the various employee and supplier liabilities.

The following table sets out the liquidity risk of financial liabilities held by the Council. It represents the contractual maturity of financial liabilities, calculated based on undiscounted cash flows relating to the liabilities at reporting date. The undiscounted cash flows in these tables may differ from the amounts included in the Statement of Financial Position that are based on discounted cash flows.

2013 Payable in < 1 year 1-5 years > 5 years Total Note $'000 $'000 $'000 $'000 Financial liabilities Payables 16 (6,067) --(6,067) Total (6,067) --(6,067)

2012 Payable in < 1 year 1-5 years > 5 years Total Note $'000 $'000 $'000 $'000 Financial liabilities Payables 16 (3,682) --(3,682) Total (3,682) --(3,682)

(iii) Market risk

Market risk refers to the risk of loss arising from movements in market parameters such as exchange rates, interest rates and equity prices.

The Council does not trade in foreign currency and is not materially exposed to movements in foreign currency exchange rates. It maintains a bank account in Hong Kong with an immaterial cash balance denominated in HK$ used to fund the operations of a local study.

The Council does not undertake any hedging in relation to interest risk and manages its risk as per the Council's liquidity risk management strategy articulated in the Council's policies. The Council is exposed to movements in interest rate risk through its investment in externally managed funds and its holdings in cash and cash equivalents. An interest rate sensitivity analysis has been carried out and is presented in item (i) below.

Page 96 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

26. Financial instruments (cont'd)

The Council is exposed to price risk arising from its managed fund investments. These investments are classified as financial assets at fair value through profit or loss in the Statement of Financial Position. A price risk sensitivity analysis has been carried out and is presented in item (ii) below.

i. Interest rate sensitivity analysis

The following interest rate sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on net income if interest rates would change by +/- 1% from the year-end rates applicable to the Council's financial assets and liabilities. With all other variables held constant, the Council would experience a change in operating result and equity by $0.6 million (2012: $0.8 million). This is mainly attributable to the Council's exposure to interest rate movements in its holdings in cash and cash equivalents.

2013 Interest rate risk Carrying amount -1% +1% Financial instruments$'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Cash & cash equivalents 62,751(628) (628) 628 628 Potential impact (628) (628)628 628

2012 Interest rate risk Carrying amount -1% +1% Financial instruments$'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Cash & cash equivalents 82,234(822) (822) 822 822 Potential impact (822) (822)822 822

ii. Price risk sensitivity analysis

The following other price risk sensitivity analysis is based on a report similar to that provided to management, depicting the outcome on profit or loss if unit/share price would change by +/-1% from the year-end price applicable to the Council's other financial asset investments. With all other variables held constant, the Council would experience a change in operating result and equity by $0.8 million (2012: $0.6 million). This is mainly attributable to exposure to unit price movements in its investments managed funds and movements in market value of US listed shares.

2013 Other price rate risk Carrying amount -1% +1% Financial instruments$'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Managed funds & shares 77,808(778) (778) 778 778 Potential impact (778) (778)778 778

2012 Other price rate risk Carrying amount -1% +1% Financial instruments$'000 Profit $'000 Equity $'000 Profit $'000 Equity $'000 Managed funds & shares 63,202(632) (632) 632 632 Potential impact (632) (632)632 632

The recognised fair values of financial assets and liabilities are classified according to the following fair value hierarchy that reflects the significance of the inputs used in making these measurements:

Level 1 - fair values that reflect unadjusted quoted prices in active markets for identical assets/liabilities; Level 2 - fair values that are based on inputs that are directly or indirectly observable for the asset/liability (other than unadjusted quoted prices); and Level 3 - fair values that are derived from data not observable in a market.

Page 97 The Council of The Queensland Institute of Medical Research Notes to and forming part of the ﬁnancial statements for the year ended 30 June 2013

26. Financial instruments (cont'd)

According to the above hierarchy, the fair values of each class of asset/liabilities recognised at fair value are as follows:

2013 Classification according to fair value hierarchy Level 1 Level 2 Level 3 Total Financial assets$'000 $'000 $'000 $'000 Managed fund investments 77,778 - - 77,778 Shares-US listed entities 30 --30 Total 77,808 - - 77,808

2012 Classification according to fair value hierarchy Level 1 Level 2 Level 3 Total Financial assets$'000 $'000 $'000 $'000 Managed fund investments 63,176 - - 63,176 Shares-US listed entities 26 --26 Total 63,202 - - 63,202

The fair value of trade receivables and payables is assumed to approximate the value of the original transaction, less any provision for impairment.

27. Events occurring after balance date

On 7 August 2013 the Council of the Queensland Institute of Medical Research announced that Mr Clive Berghofer AM had made the decision to donate $50.1 million to the Institute over a period of multiple years. In recognition of its gratitude the Council decided to change its trading name from 'The Queensland Institute of Medial Research' to 'QIMR Berghofer Medical Research Institute'.

28. Economic dependency

The Council's activities are predominantly funded by grants received from a range of funding agencies, the majority of which are Commonwealth and State Government bodies. The ability of the Council to source sufficient grant funding is dependent upon those entities continuing to have the ability to fund research activities and for the Institute to be successful in its funding applications. At balance date the Council had no indication that operational and research funding would not be provided as per the funding agreements. Should unforeseen fluctuations in the amount of available grant funding occur the Council would use its cash assets (refer note 10) and managed funds investments (refer note 13) to cover short term operational cash requirements.

Page 98 QIMR Annual Report 2012–2013 The Council of The Queensland Institute of Medical Research

CERTIFICATE OF THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

These general purpose financial statements have been prepared pursuant to section 62(1) of the Financial Accountability Act 2009 (the Act), relevant sections of the Financial and Performance Management Standard 2009 and other prescribed requirements. In accordance with section 62(1)(b) of the Act we certify that in our opinion: a) the prescribed requirements for establishing and keeping the accounts have been complied with in all material respects; and b) the statements have been drawn up to present a true and fair view, in accordance with prescribed accounting standards, of the transactions of the Council of the Queensland Institute of Medical Research for the financial year ended 30 June 2013 and of the financial position of the Council at the end of that year.

Page 99 INDEPENDENT AUDITORS REPORT

Page 100 QIMR Annual Report 2012–2013 Page 101 SUPPORTING INFORMATION

AWARDS

Recipient Bestower of award Date Award Reason Aoude, Lauren Cancer Council Queensland 8/05/2013 Travel grant To attend the Society of Melanoma Research Congress, Philadelphia, November 2013 Bettington, Mark QIMR 1/04/2013 QIMR Student Symposium, Best oral presentation Winner, Early PhD category Bond, Catherine RBWH 1/10/2012 Best Basic Science Best oral presentation in basic Presentation science category Bond, Catherine RBWH 1/10/2012 Best Overall Presentation Best oral presentation at the RBWH Research Week Boyd, Andrew QIMR 12/12/2012 Ralph Doherty Science Prize Research achievement

Bunn, Patrick Institute of Glycomics, Grifﬁth University 3/06/2013 Best Oral Presentation. Best presentation at the Institute for Glycomics student forum. Burel, Julie Australian Society of Immunology 1/03/2013 Travel award To attend to the International Congress of Immunology in Milan, 22-27th August 2013 Burel, Julie QIMR Student Symposium 1/04/2013 $100 Best oral presentation in the “Early PhD” category Burel, Julie Australian Society for Parasitology 1/07/2012 Travel Award Travel award to attend ASP 2012

Butterworth, Alice Australian Society for Parasitology 1/07/2012 $2,000 Travel award to attend ASP 2012

Dutton-Regester, Ken Queensland University of Technology 1/04/2013 Outstanding doctoral thesis Awarded to top 5% of all award completed doctorates Dutton-Regester, Ken Queensland Institute of Medical 1/11/2012 Bancroft Medal Service to QIMR Education, Research Media and Fundraising activities Dutton-Regester, Ken Society for Melanoma Research 17/06/2013 Best oral abstract International Melanoma Congress presentation 2012 best oral abstract presentation Dutton-Regester, Ken Australian Association for Medical 1/08/2012 Sponsorship to attend Sponsorship to attend Science Research Institutes Science meets Parliament meets Parliament 2012 Foong Ngiow, Shin Australian Society for Immunology 30/05/2013 Travel Award 15th International Congress of Immunology Fuqua, Brie International Bioiron Society 17/04/2013 Best Oral Presentation Best Oral Presentation Award - Award - Bioiron 2013 - Bioiron 2013 - Fifth Conference Fifth Conference of the of the International Bioiron Society International Bioiron Society Goh, Justin QIMR HDC Student Committee 12/04/2013 2nd Runner up Oral Presentation

Green, Adele QLd chapter of Australia Day Council 25/11/2012 Queensland Australian of Contributions to melanoma the Year and skin cancerresearch and mentoring Haque, Ashraful ASMR 25/06/2013 ASMR QLD Health and Research Excellence Medical Research Awards: Senior Researcher Award Jordan, Susan QIMR 1/11/2012 Postdoctoral Award Top Post-doc

Koyama, Motoko Leukaemia Foundation Australia 15/11/2012 Research Australia Research in bone marrow Discovery Award transplant helping patients Lane, Steven UQ 1/05/2013 Deans Award For outstanding PhD Thesis

Leow, Herng QIMR 20/01/2013 QIMR Postgraduate Travel To attend Keystone Symposia, Award Vancouver

Page 102 QIMR Annual Report 2012–2013 Recipient Bestower of award Date Award Reason Lupton, Michelle Australian Twin Registry 16/04/2013 Travel Award Conference Travel Award

McManus, Don QIMR 1/01/2013 Senior Scientist Senior Scientist, QIMR

Mishra, Aniket Genemappers Conference 24/06/2013 Best Poster Award Best Poster

Molehin, Adebayo QIMR 24/06/2013 PhD Top-up scholarship Top-up scholarship

Molehin, Adebayo EMBL 24/06/2013 EMBL Australia Student Competitive Scholarship Scholarship Molehin, Adebayo Australian Society for Parasitology 24/06/2013 Travel Grant Competive Scholarship

Moller, Andreas National Breast Cancer Foundation 6/02/2013 Patron's Award Excellence in Science and Science Communication Montgomery, Grant Society for Reporductive Biology 28/08/2012 Fellow of Society for Internationally recognised leader Reporductive Biology in reproductive biology Neller, Michelle Australian Society for Medical Research 31/05/2013 Post-graduate Student Prestigious Award recognising Award excellence in all areas of health- related research O'Mara. Tracy QIMR 21/06/2013 Travel Grant to attend the American Association of Cancer Research Integrative Molecular Epidemiology Workshop in Boston, USA, $2000 Pattinson, David QIMR 1/09/2012 HDC Travel award To attend conferences and American Assoc Immunologists course in USA Pattinson, David Australian Society for Parasitology 1/07/2012 Travel Award Travel award to attend ASP 2012

Poo,Yee Suan EMBL 1/07/2012 Travel Grant Program award EMBL PhD Symposium

Proietti, Carla ASP 20/11/2012 $5,000 AUD OzEMalar Travel award

Proietti, Carla QIMR 1/05/2013 QIMR Travel Award To attend Malaria Gordon Conference, Italy Proietti, Carla Wellcome Trust 19/06/2013 Training Fellowship Fellowship

Rishi, Gautam International BioIron Society 1/01/2013 BIOIRON Student Bursary Student Bursary for attending the BIOIRON Congress Rishi, Gautam QIMR HDC 19/04/2013 Travel Award Conference travel

Schulte, Leigh Australian Society for Parasitology 1/09/2012 Travel Award collaborative trravel to USA

Schulte, Leigh University of Queensland 1/09/2012 Travel Award Student travel to USA

Schussek, Sophie QIMR 1/09/2012 HDC Travel award To attend conferences and American Assoc Immunologists course in USA Schussek, Sophie Australian Society for Parasitology 27/06/2013 Travel Award Travel award to attend ASP 2012

Thompson, Bryony QIMR 21/06/2013 QIMR top-up PhD competitive award scholarship Thompson, Bryony Familial Cancer Conference, Organizers 21/06/2013 1st Poster Prize Best poster selected by panel of experts: Mismatch repair gene isoforms Thompson, Bryony TCCQ 1/05/2013 TCCQ Travel Award To attend InSiGHT International meeting, Cairns Welham, Zoe QIMR 20/06/2013 QIMR Honours and Award Coursework Masters Award Welham, Zoe QUT ASBMB 1/07/2012 2012 QUT Australian Best student Society for Biochemistry and Molecular Biology Prize Whitelaw, Emma Faculty of 1000 26/06/2013 Faculty of 1000 Expert in the ﬁeld 15:57 Wilson, Jane QIMR 1/04/2013 "Highly Commended- Late Highly Commended Stage Postgraduate Study" You, Hong NHMRC 24/06/2013 Obtained Early Career Competitive Fellowship Fellowship

Page 103 LECTURES

Speaker Title of lecture Date Audience City, Country Adebayo Molehin Expression and purification of Schistosome Jun 13 ASP Conference Launceston, Australia serpins Adebayo Molehin Production of schistosome serpins Jun 13 General Brisbane, Australia Adele Green “Melanoma in Queensland: Incidence, Nov 12 COSA Plenary Brisbane, Australia Mortality and Survival” Adele Green Surviving melanoma Jul 12 Australian Skin Cancer Congress Gold Coast, Australia Adele Green Epidemiology of Melanoma Nov 12 COSA Trainees Weekend Brisbane, Australia Adele Green Melanoma in Adolescents and Young Adults Nov 12 COSA AYA Cancer Workshop Brisbane, Australia Adele Green Rewards of a research career in the fast lane May 13 St Aidan's College Brisbane, Australia Adele Green Beating cancer in the 21st century through Feb 13 Tour de Cure, Day of Inspiration Brisbane, Australia prevention Alice Butterworth Talk at Matthew Flinders Anglican College Jul 12 Students Brisbane, Australia Annual Science Colloquium Amanda Spurdle Analysis of splicing abnormalities to define Jun 13 American Society of Human Genetics San Franscisco, pathogenic variants in cancer suspectibility Conference United States genes. Amanda Spurdle Endometrial Cancer: the role of low-risk and Jun 13 Vanderbilt University staff and students Nashville, United high-risk genetic variants. States Amanda Spurdle Lows and Highs of Endometrial Cancer Jun 13 Oncogenetics Course attendees Quebec, Canada Genetics Amanda Spurdle Mismatch Repair IHC and MLH1 methylation Jun 13 REsearchers and Clinicians in gynae- Brisbane, Australia testing in endometrial cancer. oncology Amanda Spurdle Endometrial cancer: the role of low-risk and Jun 13 Human Variome Project Seminar Series Melbourne, Australia high-risk genetic variants. Amanda Spurdle The lows and highs of endometrial cancer Jun 13 Monash Health Note this might have Melbourne, Australia genetics. been in last yr - please check. Translation Precinct Seminar Series, Amanda Spurdle session “Implementing knowledge on Jun 13 InSiGHT, PEDIGREE, Familial Aspects of Kingscliffe, Australia variation and risk into clinical and population Cancer and The Human Variome Project, health practice” specialist conference meeting. Chair and organisor of session Andreas Moller Hypoxia as driver of cancer metastasis May 13 University of Tuebingen, Germany Tubingen, Germany Andreas Moller Hypoxia as a driver of pre-metastatic niche Oct 12 Sydney International Cancer Conference Sydney, Australia formation in breast cancer 2012 Andreas Moller Novel approaches to improve breast cancer Jun 12 NBCF outrach function, attendance of 20 Melbourne, Australia therapy NBCF ambassadors Andreas Moller 08/40 A prospective study to investigate Jun 12 Peter MacCallum Cancer Centre, Melbourne, Australia NSCLC during chemo-RT using serial Radiotherapy Clinicans and Clinical Trial 18F-FDG and 18F-FLT PET/CTRecent Coordinators, Nurses protocol amendment: Pre-metastatic niche sub-study Andreas Moller Immune suppression in the pre-metastatic Sep 12 Australian-New Zealand Matrix Biology Gold Coast, Australia niche as a novel mechanism of metastasis Conference promotion Andreas Moller Cancer metastasis is promoted by tumour Apr 13 Grifith University, Gold Coast Campus Gold Coast, Australia hypoxia Andreas Suhrbier Chikungunya Virus, rheumatoid arthritis & Jun 13 Emory University, School of Medicine Atlanta, United States viral RNA Persistence. Institutional 20 Andreas Suhrbier Chikungunya Virus, rheumatoid arthritis & Apr 13 Emory University, School of Medicine Atlanta, United States viral RNA Persistence. Institutional 50 Andreas Suhrbier Biomedical Biotech Research in Qld Nov 12 Austrade Bio-Luncheon #4: Workshop Heidelberg, Germany Invited attendees 12 Andreas Suhrbier Chikungunva virus & other arthritogenic Nov 12 United Nations Medical Services New York, United alphaviruses. Institutional 20 States Andreas Suhrbier Arthritogenic alphaviruses: viral persistence & Nov 12 International Conference on Clinical San Antonio, Texas, rhematic inflammation. Microbiology & Microbial Genomics United States Conference 100 Andreas Suhrbier ASMR Queensland Postgraduate Student May 13 Conference Brisbane, Australia conference commercial Biotech traslation in Australia: Careers and hurdles Andreas Suhrbier Commercial biotech traslation in Australia: Jun 12 Queensland Tropical Health Alliance Brisbane, Australia hurdles & successes Conference 60 Andreas Suhrbier Chikungunya virus, rhematoid arthritis & Sep 12 Arbovirus Research in Australia Conference Surfers Paradise, hemoorhagic shock. 150 Gold Coast Qld, Australia

Page 104 QIMR Annual Report 2012–2013 Speaker Title of lecture Date Audience City, Country Andreas Suhrbier Chikungunya virus, hemorrhagic shock & Jun 12 The University of Adelaide. The Basil Hetzel Adelaide, Australia rhematoid arthritis. Institute - Seminar Attendees 30 Andrew Boyd EphA3 as a target in brain cancer May 13 Lowy Cancer Symposium Sydney, Australia Annika Antonsson DNA tumour viruses – papillomaviruses, Aug 12 Sir Albert Sakzewski Virus Research Centre Brisbane, Australia polyomaviruses and herpesviruses Barbara Leggett Colorectal Cancer Genetics for the Practising Sep 12 Canberra Hospital Grand Rounds Canberra, Australia Physician Barbara Leggett Recognising Inherited Colorectal Cancer Oct 12 Australian Gastroenterology Week Adelaide, Australia Syndromes Barbara Leggett Serrated Polyps and Colorectal Cancer Jun 13 Gold Coast Gut Club Gold Coast, Australia Brendan Trewin Then and now-a brief history of dengue and Sep 12 Surfers Paradise, rainwater tanks in Brisbane Australia Brian Kay Dengue-risk and solutions Sep 12 Brisbane, Australia Brian Kay A tale of two organisms Sep 12 St Augustine, United States Brie Fuqua Invited Session Chair - Metals and Nov 12 Free Radical and Metal Biology 2012 Brisbane, Australia Pathophysiology Bryan Day EphA3 is a key regulator of glioma stem cells Apr 13 Stem Cell Forum Melbourne, Australia Bryony Thompson Standardised classiﬁcation of MMR variant Jun 13 Human Variome Project conference Paris, France attendees Bryony Thompson Evaluation of mismatch repair gene Jun 13 16th annual meeting Boston, United States Cameron McDonald New Insights from Atypical Disorders in the Jun 13 Australian Genome Research Facility Brisbane, Australia Molecular Age (AGRF) seminar series Cameron McDonald New Insights from Atypical Disorders in the Jun 13 Life Technologies Next-Generation Adelaide, Australia Molecular Age Sequencing Seminar Series Cameron McDonald New Insights from Atypical Disorders in the Jun 13 Life Technologies Next-Generation Brisbane, Australia Molecular Age Sequencing Seminar Series Carla Proietti Dissecting T cell and antibody Oct 12 Laboratory of Parasite Genomics, Wellcome Cambridge, United immunodominance in a complex host trust Sanger Institute Kingdom pathogen system Carla Proietti Dissecting T cell and antibody Nov 12 laboratory of Molecular Parasitology at the Oxford, United immunodominance in a complex host Weatherall Institute of Molecular Medicine, Kingdom pathogen system University of Oxford Chris Schmidt Durable, Complete Clinical Responses to Jan 13 Sydney International Workshop on Sydney, Australia Immunotherapy for Advanced Melanoma: Math Models of Tumor-Immune System Correlates, Confounders, Complexity, Dynamics Questions Christian Engwerda Immune regulation during parasite infection. Jan 13 Centre for Immunology and Infection, York, United Kingdom University of York Christian Engwerda Immune regulation during parasite infection. Oct 12 International Centre for Genetic Engineering Delhi, India and Biotechnology (ICGEB), Delhi Christian Engwerda Immune regulation during parasite infection. Feb 13 Lorne Infection and Immunity Conference, Lorne, Australia Lorne, VIC Christian Engwerda Immune regulation during parasite infection. Nov 12 American Society for Tropical Medicine Atlanta, United States and Hygiene Annual Meeting – Malaria Symposium Christian Engwerda Immune regulation during parasite infection. Jan 13 Keystone Symposium, Malaria New Orleans, United States Christian Engwerda Immune regulation during parasite infection. Oct 12 Institute of Health and biomedical Brisbane, Australia Innovation, Queensland University of Technology Christian Engwerda Immune regulation during parasite infection. Jul 12 Biology of Parasitism Course Woods Hole, MA, United States Daniel Wallace Modiﬁers of iron overload in Aug 12 Community Information Seminar on Brisbane, Australia haemochromatosis Haemochromatosis David Frazer Invited Session Chair - Signalling and Liver Jun 13 Gastroenterological Society of Australia Gold Coast, Australia Injury Research Workshop David Harrich Nullbasic: a multi-stage inhibitor of HIV for May 13 Clinicians, Nurses, Students, Scientist Melbourne, Australia investigative and therapeutic applications Alfred Hospital David Harrich Lost in translation: the unexpected role of May 13 Gladstone Institute/UCSF San Farancisco, eucaryotic translation factors in HIV-1 reverse United States transcription David Harrich Preclinical trials of a potent anti-HIV therapy Feb 13 Parliament House Committee Canberra, Australia David Harrich Stacking inhibitor checkpoints to inhibit HIV Sep 12 Burnet Institute Melbourne, Vic, replication Australia David Harrich Fatal tango: deciphering the complex dance Sep 13 University of Melbourne, Dept. of Melbourne, Vic, of HIV and host protein interactions immunology and Infectious Diseases Australia

Page 105 Lectures | continued

Speaker Title of lecture Date Audience City, Country David Whiteman Tiny steps towards the control of Mar 13 scientific staff at IARC Lyon, France oesophageal cancer David Whiteman Melanoma and other skin cancers: the May 13 scientific staff at NCI Washington, DC, Australian experience United States David Whiteman The epidemiology of oesophageal cancer Mar 13 scientific staff at Karolinska Stockholm, Sweden David Whiteman The epidemiology of keratinocyte cancers Mar 13 scientific staff at Linkoping University Linkoping, Sweden Hospital David Whiteman The epidemiology of oesophageal cancer Jul 12 Sydney Gut Club Sydney, Australia and Barrett’s oesophagus Denise Doolan Genomes to Vaccines: Translating Genomic Aug 12 Novartis Vaccines and Diagnostics S.R.L Siena, Italy Sequence Data into Effective Public Health Interventions Denise Doolan Rational design of vaccines against complex Aug 12 ICARIS 2012 Conference Taormina, Italy pathogens from genomic sequence data Denise Doolan Proteome-wide analysis for rational vaccine Apr 13 Malaria Vaccines for the World Lausanne, design Switzerland Denise Doolan Malaria vaccine development Jun 13 European Malaria Vaccine Development Berlin, Germany Association conference Denise Doolan Targeting vaccines to skin DCs for optimal May 12 4th Australasian Vaccines and Brisbane, Australia CD8+ T cell responses Immunotherapeutics Development (AVID) meeting Don Gardiner Aminopeptidases of P. falciparum Jan 13 James Cook University Cairns, Australia Don McManus Prospects for development of a Aug 12 BIG Annual Retreat 2012, Mantra Resort on Brisbane, Australia transmission blocking vaccine against Salt Beach Kingscliff Schistosoma japonicum, the cause of Asian schistosomiasis. Don McManus Current Status of the Genetics/Molecular Oct 12 International Symposium for Cestode Shanghai, China Taxonomy of Echinococcus species. Zoonosis Control, Shanghai Don McManus Towards the Elimination of Schistosomiasis Nov 12 American Society of Tropical Medicine and Atlanta, United States from Asia Through Integrated Control. Hygiene 61st Annual Meeting Don McManus Advances in Schistosomiasis Vaccine Mar 13 The Bill & Melinda Gates Foundation Seattle, United States Development; Lessons Learned and Vaccine and the National Institute of Allergy and Pipeline Consideration. Infectious Diseases. Schistosomiasis Elimination Strategy and Potential Role of Vaccine in Achieving Global Health Goals. Don McManus Current Status of Early Stage Mar 13 The Bill & Melinda Gates Foundation Seattle, United States Schistosomiasis Vaccine Candidates; and the National Institute of Allergy and Paramyosin. Infectious Diseases. Schistosomiasis Elimination Strategy and Potential Role of Vaccine in Achieving Global Health Goals. Emma Whitelaw Epigenetics, Health and Disease Jun 13 Ludwig Institute of Cancer Research Melbourne, Australia Emma Whitelaw Epigenetics, Health and Disease Jun 13 Australian Regenerative Medicine Research Melbourne, Australia Institute Frank Gannon Controlling gene expression Oct 12 Shanghai, China Frank Gannon A European Perspective on Peer Review Feb 13 Policy makers Canberra, Australia Frank Gannon How the Estrogen Receptor works and how Nov 12 Scientists Nathan, Qld, Australia to stop it Frank Gannon Understanding how the oestrogen receptor Sep 12 Clinicians Brisbane, Australia works: Does it matter to clinicians? Franziska Bieri Towards integrated control. A video-based Nov 12 American Society of Tropical Medicine and Atlanta USA, United intervention prevents soil-transmitted Hygiene Annual Meeting States helminth infections in Chinese schoolchildren. Franziska Bieri Health education works! Video-based health Jun 13 XVIII International Congress for Tropical Rio de Janeiro, Brazil education prevents soil-transmitted helminth Medicine and Malaria (STH) infections in Chinese schoolchildren. Geoff Hill IL-17 differentiation and transplant outcome Feb 12 American Society of Bone Marrow San Diego, United Transplantation States Geoff Hill New donor issues May 12 Australian Bone Marrow Donor Registry Sydney, Australia Geoff Hill Cytokines in transplantation Apr 12 The Transplant Society of Australia & New Canberra ACT, Zealand Australia Geoff Hill Interferons in haematological malignancies: Dec 12 Australian Society for Immunology Melbourne Vic, Revisiting the 1990's Australia Geoff Hill Immunetherapy of GVHD Apr 13 International Society of Cell Therapy Auckland, New Zealand Georgia Chenevix- Identification of multiple new breast cancer Mar 13 Lorne Cancer Conference Lorne, Australia Trench susceptibility loci, and of variants in the TERT gene associated with telomere length and risk of both breast and ovarian cancer

Page 106 QIMR Annual Report 2012–2013 Speaker Title of lecture Date Audience City, Country Georgia Chenevix- Australian Ovarian Cancer Study Mar 13 Australia and New Zealand Gynecological Gold Coast, Australia Trench Oncology Group Georgia Chenevix- Risk Prediction in BRCA1/2 Carriers Sep 12 Collaborative Oncological Gene- Quebec City, Canada Trench Environment Study Symposium Glen Boyle Skin cancer & melanoma - everything you May 13 Rotary Club Hervey Bay, Australia ever wanted to know. Glen Boyle Everything you wanted to know about skin May 13 CCQ Biggest Morning Tea Hervey Bay, Australia cancer & melanoma Graeme Walker Mapping meanoma resistance genes Jul 13 Melanoma clinicians and researchers Washington DC, United States Graeme Walker Discovering genes and pathways involved in Oct 12 Genetics Society of America Mouse Monterey, CA, United naevus and melanoma development using Molecular Genetics Conference States the Collaborative Cross Graeme Walker Using te Collaborative cross to map genes May 13 Asian Society for Pigment Cell Research/ Sydney, Australia for nevus and melanoma development Australian Society for Dermatological Research Graeme Walker Session chair: Photobiology Dec 12 Mutagenesis and Experimental Mutagenesis Adelaide, Australia Society of Australia Graeme Walker Session chair: Melanoma May 13 Asian Society for Pigment Cell Research/ Sydney, Australia Australian Society for Dermatological Research conference. Graham Kay Over 50 years of X inactivation research, but Mar 13 Australian Society of Cytogeneticists 2013 Brisbane, Australia still much more to know. Conference Graham Kay Characterising histone modifications Jun 13 Short Course in Medical Genetics and Gold Coast, Australia Genetic Pathology June 2013, The Royal College of Pathologists of Australasia (RCPA) and the Human Genetics Society of Australasia Graham Radford-Smith The ANZ and International IBD Consortia, Sep 12 Scientists, Clinicians, Dieticians, Palmerston North, genetic advances, and how we plan to tackle Nutritionists New Zealand genotype-phenotype associations Graham Radford-Smith Acute, severe ulcerative colitis - management Aug 12 Clinicians Perth, Australia and outcomes Graham Radford-Smith Fistulizing Perianal Crohn’s Disease – the Oct 12 Clinicians, scientists Adelaide, Australia APEC study Graham Radford-Smith Genetic predictors of refractory UC Oct 12 Clinicians, scientists Adelaide, Australia Graham Radford-Smith Telehealth for Inflammatory Bowel Disease - Mar 13 Clinicians Sydney, Australia Queensland Graham Radford-Smith Primary Sclerosing Cholangitis Mar 13 Clinicians Melbourne, Australia Graham Radford-Smith Anti-TNF therapy for Crohn’s disease across Mar 13 Clinicians, industry Sydney, Australia the ANZ – patient characteristics and therapeutic outcomes Grant Montgomery Endometriosis susceptibility genes Sep 13 The Ritchie Centre Colloquium Melbourne, Australia Grant Montgomery Genetic risk factors for endometriosis Nov 12 SRB Symposium on Endometriosis, Aust Adelaide, Australia Health & Medical Research Congress Grant Montgomery From benchside to bedside – translating Mar 13 Perpetual Daniel O'Connor Lecture, Brisbane, Australia endometriosis research Australasian Gynaecological Endoscopy & Surgery Grant Montgomery Meta-analysis of GWA studies identifies new Mar 13 Society for Gynaecological Investigation Orlando, United endometriosis risk loci States Grant Ramm The intrahepatic fibrotic response Jun 13 Australian Liver Association (of Gold Coast, Australia Gastroenterological Society of Australia) Greg Anderson Population and clinical studies of Nov 12 The 3rd Asia Pacific Iron Academy Taipei, Taiwan haemochromatosis Conference. Taipei, Taiwan Greg Anderson Iron and infection Nov 12 The 3rd Asia Pacific Iron Academy Taipei, Taiwan Conference Greg Anderson Convergence and divergence in metal Nov 12 The First China Conference on Bio-Trace Shanghai, China transport: A comparison of iron and Elements manganese Greg Anderson Invited Session Moderator - Basic Aspects of Apr 13 Bioiron 2013 - 5th Congress of the London, United Iron Control and Biology International Bioiron Society Kingdom Greg Anderson Invited Session Convenor and Chair - Bioiron Apr 13 Bioiron 2013 - 5th Congress of the London, United – Biometals Joint Session International Bioiron Society Kingdom Greg Anderson Invited Session Chair - Session 4. Invited Jun 13 Gastroenterological Society of Australia Gold Coast, Australia talks and free papers Hepatology Research Workshop Greg Anderson Invited Session Chair - Hepatic Iron Jun 13 Gastroenterological Society of Australia Gold Coast, Australia Metabolism and Free Papers Research Workshop James Hardy Is water sensitive urban design causing an Sep 12 Surfers Paradise, urban mosquito problem? Australia

Page 107 Lectures | continued

Speaker Title of lecture Date Audience City, Country James McCarthy Challenges in Malaria Research, Progress Oct 12 Conference attendees Basel, Switzerland Towards Elimination James McCarthy American Society of Tropical Medicine and Nov 12 Conference attendees Atlanta, United States Hygiene James McCarthy ASID 2012 meeting - Experimentally induced Jun 13 Meeting attendees Fremantle, Australia blood-stage Plasmodium vivax infections in healthy volunteers James McCarthy 9th Indo-Australian Biotechnology Apr 13 Attendees Melbourne, Australia Conference - Global health priorities in infection and immunity James McCarthy Imperial College Lecture May 13 College Oxford, United Kingdom James McCarthy Jenner Institute Seminar, Oxford University May 13 Students and attendees Oxford, United Kingdom Jason Lee Non-histone Methylation: Another layer of Apr 13 Emory University Scientific Staff and Atlanta, United States Epigenetic regulation students Jeffrey Gorman A Proteomic View of the Suppression of Nov 12 Omics Australasia Symposium 2012 Freemantle, Australia Host Cell Antiviral Responses by Respiratory Syncytial Virus Jeffrey Gorman Proteomic dissection of the battle between Mar 13 Australian Institute of Bioengineering and Brisbane, Australia respiratory syncytial virus and epithelial cells NanoTechnology, University of Queensland during infection Jodie Painter Genetics and Epidemiology of Endometriosis Jun 13 Australasian Gynaecological Endoscopy & Brisbane, Australia Surgery XXII Annual Scinetific Meeting 2013 Jodie Painter Genetic link between endometriosis and Jun 13 E2C2 consortium meeting attendees Washington DC, endometrial cancer United States John Miles Exploring the frequency and repertoire of Aug 12 Science Kingscliffe, Australia naive antigen-specific T cell precursors in human newborns John Miles Emerging T cell technologies Dec 12 Science Melbourne, Australia Jonathan Beesley High-throughput genotyping Jun 13 Fluidigm Educational Workship Adelaide, Australia Jonathan Darbro Role of seasonal temperature variation in Sep 12 Surfers Paradise, dengue virus transmission Australia Joshua Horne-Debets PD-1 and chronic malaria Dec 12 Australian Society of Immunology Melbourne, Australia Juliet French Functional Variants at the 5q11 Breast Aug 13 Familial Aspects of Cancer Conference Cairns, Australia Cancer Risk Locus Regulate MAP3K1 Expression through Long-Range Enhancers Juliet French Functional Analysis of Candidate SNPs Jul 13 FOCI meeting Bethesda, United States Juliet French Cancer Genetics Lecture 1 Aug 13 BIOC3003 students, Unitversity of Brisbane, Australia Queensland Juliet French Cancer Genetics Lecture 2 Sep 13 BIOC3003 students, Unitversity of Brisbane, Australia Queensland Juliet French Cancer Genetics Lecture 3 Sep 13 BIOC3003 students, Unitversity of Brisbane, Australia Queensland Juliet French Cancer Genetics Lecture 4 Sep 13 BIOC3003 students, Unitversity of Brisbane, Australia Queensland Kate Mounsey NHMRC grant writing workshop - Invited Jul 13 University of the Sunshine Coast Sunshine Coast, presenter Australia Katja Fischer Novel insights into an old disease: recent Jun 13 International Alliance for the Control of Atlanta, United States findings in scabies mite biology Scabies, Inaugural Meeting Atlanta, GA, USA, Kelli MacDonald Haematopoietic Antigen Presenting Cells: Feb 13 American Society of Bone Marrow Salt Lake City, United Emerging Regulators of GVHD Transplantation States Kelli MacDonald A new class of Treg to Subvert MHC 1 Jun 12 The Transplant Society of Australia & New Canberra ACT, Restricted Alloreactive T cell Responses Zealand Australia Kelli MacDonald Haematopoietic Antigen Presenting Cells: Dec 12 Australian Society for Immunology Melbourne Vic, Emerging Regulators of GVHD Australia Kum Kum Khanna Danish Cancer Society Research Center Jan 13 Copenhagen, Denmark Kum Kum Khanna Institute of Molecular Cancer Research Jun 13 Zurich, Australia Lawrie Powell Reversal of cirrhosis in haemochromatosis Jun 13 Asia Pacific Association for the Study of the Singapore, Singapore and Wilson disease. Liver, Liver Week 2013 Lawrie Powell Highlights of APASL 2013 Jun 13 Asia Pacific Association for the Study of the Singapore, Singapore Liver, Liver Week 2013 Lawrie Powell Invited Session Chair - Metabolic Diseases Jun 13 Asia Pacific Association for the Study of the Singapore, Singapore Liver, Liver Week 2013 Leon Hugo Identification of protein biomarkers of ageing Sep 12 Surfers paradise, prominent dengue and malaria vectors Australia

Page 108 QIMR Annual Report 2012–2013 Speaker Title of lecture Date Audience City, Country Leon Hugo Transcriptional and proteomic age grading Nov 12 Atlanta, United States for mosquitoes Lutz Krause Calypso – An online platform for mining, Oct 12 International computational biologists Bertinoro, Italy visualizing and comparing multiple 16S rDNA samples Lutz Krause Mining heterogeneous data-sets in the Oct 12 Scientists of the Nestle Research Centre Lausanne, context of biomedical research – from Switzerland biomarkers for cancer to the human gut microbiota Lutz Krause Statistical analysis of 16S rDNA samples Oct 12 Scientists Lausanne, using the Calypso software Switzerland Lutz Krause Metagenomics - characterizing the Jul 12 Scientists and postgraduate students Brisbane, Australia composition and function of natural microbial communities Lutz Krause Mining and Comparing Multiple 16S rDNA May 12 Lung researchers Brisbane, Australia Samples Malcolm Jones Surface proteins of schistosomes Jul 12 European Multicolloquim for Parasitology Cluj-Napoca, Romania, Romania Malcolm Jones Schistosomes, eggs and magnets Jun 13 University of California San Francisco San Francisco, Australia Malcolm Jones Schistosomes, eggs and magnets Jun 13 Department of Urology, Stanford University Palo Alto, United States Manuel Ferreira Barbara Ell Seminar Series Lecture, Victor Apr 13 Research Institute Seminar Sydney, Australia Chang Cardiac Research Institute Marcela Montes De The role of Blimp-1 in malaria pathogenesis. Dec 12 Australian Society for Immunology Melbourne, Australia Oca Margie Wright The Queensland Twin Imaging Study (QTIMS) Mar 13 Scientists - Brain Imaging Conf. Hawaii, United States Margie Wright Older Australian Twins Study (OATS): a twin Apr 13 Scientists and Policy Makers - OECDHUGO Singapore, Singapore study of brain ageing Session Mark Bettington The Histological Interface Between May 13 The ‘Gnomes’ Anatomical Pathology Noosa, Australia Microvesicular Hyperplastic Polyp and Meeting Sessile Serrated Adenoma Mark Smyth Combination therapy with targeted agents May 13 ASMR Postgraduate Student Conference Brisbane, Australia and cancer immunotherapy Mark Smyth Combination therapy with targeted agents Apr 13 Cancer Immunotherapy Consortium Washington DC, and cancer immunotherapy United States Martin Lavin Ataxia Oculomotor Apraxia type 2 : How Sep 12 Fourth Genome Dynamics in Neuroscience Oslo, Norway Senataxin Functions to Maintain Genome Meeting Stability Martin Lavin Radiation-associated Repair Proteins and Nov 12 28th RBC-NIRS International Symposium Kyoto, Japan DNA Repair Network Martin Lavin A-T clinic, RCH, Brisbane Jun 12 A-T Clinical Research Conference Cambridge, United Kingdom Meru Sheel The role of monocytes in visceral Dec 12 Australian Society for Immunology Melbourne, Australia leishmaniasis. Michael Breakspear Nested network dynamics of endogeous Sep 12 Attendees Magdeburg, Germany cortical activity Michael Breakspear Functional Brain Connectivity Dec 12 Students and attendees Brisbane, Australia Michael Breakspear Clinical and Translational Modelling Dec 12 Attendees Brisbane, Australia Michael Breakspear Computational Models of cortical oscillations Jun 13 Workshop attendees Vancouver, Canada Michael Breakspear Human Brain Mapping workshop Jun 12 Workshop attendees Seattle, United States Michael Breakspear Multistability in the human brain Sep 12 Max Planck Institute Cologne, Germany Michael Breakspear Complex brain networks Sep 12 University of Zurich Zurich, Switzerland Michelle Wykes Restoration of long term protection against Jan 13 Keystone “Malaria” meeting New Orleans, malaria in mice without PD-1 Australia Michelle Wykes Subversion of immunological memory of Dec 12 Australian Society of Immunology Melbourne, Australia malaria by Programmed cell death 1 and B cell Activating Factor Michelle Wykes Mechanisms of subversion of Malaria Nov 12 NIH Washington, Australia Immunity Nathan Subramaniam Iron: the good, bad and ugly Jun 13 National University Health Service Grand Singapore, Singapore Rounds: Clinicians, Nurses, Afﬁliated health staff Nathan Subramaniam Iron disorders in the genomic era: Insights Jun 13 Institute of Molecular and Cell Biology, Singapore, Singapore from genetic, molecular and cellular studies Biopolis Nathan Subramaniam Iron in health and disease: insights from Nov 12 Mater Medical Research Institute Brisbane, Australia genetic, cellular and molecular studies

Page 109 Lectures | continued

Speaker Title of lecture Date Audience City, Country Nick Hayward Dissecting the genetic landscape of Aug 12 Peter MacCallum Cancer Centre Melbourne, Australia melanoma through family and tumor sequencing Nick Hayward Dissecting the genetic landscape of Sep 12 Sanford-Burnham Medical Research La Jolla, United melanoma through family and tumor Institute States sequencing Nick Hayward Dissecting The Genetic Landscape Of Oct 12 Centre for Cancer Biology/Hanson Institute Adelaide, Australia Melanoma Nick Hayward Dissecting The Genetic Landscape Of Oct 12 Griffith University Gold Coast, Australia Melanoma Nick Martin How much variance have GWAS studies Aug 12 GeneMappers Conference Port Douglas , explained? Australia Nick Martin The bivariate heritability of alcohol and Sep 12 16th Congress of the International Society Sapporo, Japan nicotine dependence for Biomedical Research on Alcoholism Nick Martin What is the total SNP-associated heritability Nov 12 American Society of Human Genetics 2012 San Francisco, United for alcohol dependence Annual Meeting States Nick Martin Ten hard questions in the current state of Nov 12 Connecting Biobanks 2012 Utrecht, The complex genetic diseases Netherlands Nick Martin Progress in the Genetics of Complex Dec 12 Frontiers in Biomedical Research Hong Kong, Hong Diseases Kong Nick Martin Historical context and current challenges in Mar 13 2013 International Workshop on Statistical Boulder, United complex trait genetics Genetic Methods for Human Complex Traits States Nick Martin The forgotten heritability of social scientific Jun 13 4th Workshop of the Social Science Rotterdam, The outcomes Genetic Association Consortium Netherlands Nick Martin Trying to crack the molecular genetics of Jun 13 43rd Annual Meeting of the Behavior Marseille , France depression Genetics Association Nicole Cloonan Decoding miRNA regulated genetic circuits Oct 13 AMATA 2013 Keynote Speaker Gold Coast, Australia Nicole Cloonan Decoding oncomiR genomic circuits Jun 13 TRI - Diamantina Institute Brisbane, Australia Nicole Cloonan De novo transcriptome assembly Jul 13 ARC Bioinformatics Centre of Excellence Brisbane, Australia Winter School Paul Clark Inosine triphosphohotase polymorphism and Sep 12 Gastroenterologists, scientists and clinical San Giovanni hepatitis C- applications and implications researchers Rotondo Foggia, Italy Paul Clark Ageing with Viral Hepatitis and Hemophilia Mar 13 General Practitioner, Hemophilia nurses and Brisbane, Australia allied health support people, Hematologists and Infectious Disease Physicians Paul Clark Genomics to better understand hepatic Mar 13 Gastroenterologists and Clinical and Basic Brisbane, Australia steatosis and dyslipidemia associated with Science researchers hepatitis C Paul Clark Viral Hepatitis: Epidemiology, Developments Jun 13 GPs Brisbane, Australia and Clinical Implications for General Practice Penny Webb Obesity and gynecological cancer: etiology May 13 American Society of Clinical Oncology Chicago, United and survival Conference States Penny Webb The epidemiology of endometrial cancer: Aug 12 Victorian Comprehensive Cancer Centre Melbourne, Australia comparing and contrasting the risk factors Conference for type 1 and type 2 tumours Penny Webb Ovarian Cancer Research Feb 13 Nurses Education Workshop Brisbane, Australia Penny Webb Understanding the causes of cancer: The May 13 Australia's Biggest Morning Tea Brisbane, Australia not-so-secret art of epidemiology Rachel Neale Vitamin D in Australia - Unanswered Nov 12 Australian Health and Medical Research Adelaide, Australia questions Congress Rachel Neale Vitamin D-What should I tell my patients? Jul 12 Australasian Skin Cancer College Annual Gold Coast, Australia Conference Rachel Neale Patterns of care in pancreatic cancer May 13 Australian Pancreatic Cancer Genome Sydney, Australia Initiative - Annual Symposium Rachel Neale Assessing the health benefits of vitamin D Jul 12 Western medicine symposium Melbourne, Australia Rachel Neale The Queensland Pancreatic Cancer Study Sep 12 University of Queensland Medical Society Brisbane, Australia Colloquim Rebekah Brennan Allelic polymorphism in the T cell receptor Dec 12 42nd Annual Scientific Meeting of the Melbourne, Australia and its impact on immune responses Australasian Society for Immunology Sarah Harten Epigenetics and Disease May 13 QUT third year B. Sc students Brisbane, Australia Sarah Medland Mar 13 International Workshop on Statistical Boulder, United Genetic Methods for Human Complex Traits States Sarah Medland Mar 13 International Workshop on Statistical Boulder, United Genetic Methods for Human Complex Traits States Sarah Medland Mar 13 International Workshop on Statistical Boulder, United Genetic Methods for Human Complex Traits States Sarah Medland Mar 13 International Workshop on Statistical Boulder, United Genetic Methods for Human Complex Traits States

Page 110 QIMR Annual Report 2012–2013 Speaker Title of lecture Date Audience City, Country Sarah Medland Mar 13 International Workshop on Statistical Boulder, United Genetic Methods for Human Complex Traits States Sarah Medland Jun 13 14th Annual MRC SGDP Summer School London, United Kingdom Scott Burrows Vaccines for Epstein Barr Virus Oct 12 13th International Union against Sexually Sydney, Australia Transmitted Infections (IUSTI) World Congress Scott Burrows The T cell immune response to Epstein-Barr Sep 12 Centre for Virus Research, Westmead Sydney, Australia virus Millennium Institute Scott Burrows The T cell immune response to Epstein-Barr Jul 12 Frontiers in Immunology Research Salzburg, Austria virus International Conference Shin Foong Ngiow The role of host immunity in mechanism of Dec 12 42nd Annual Scientific Meeting of the Melbourne, Australia action of Braf inhibitors Australasian Society of Melbourne Simon Apte International Society for Advancement of Jul 12 Conference attendees Leipzig, Germany Cytometry Sophie Schussek Validation of novel antigenic targets identified Aug 12 Novartis Vaccines Cambridge, United by whole-genome screening for next- Kingdom generation malaria vaccines Sophie Schussek Validation of novel antigenic targets identified Aug 12 Genocea Biosciences Cambridge, United by whole-genome screening for next- Kingdom generation malaria vaccines Stacey Edwards Functional variants at the 11q13 breast Feb 13 Lorne Cancer Conference Lorne, Australia cancer risk locus regulate cyclin D1 expression through long-range enhancers Stacey Edwards Breast cancer susceptibility and survival Aug 13 kconfab familial breast cancer conference Cairns, Australia at the 2q35 locus is mediated through chromatin looping with IGFBP5 Steven Lane Blood Cancer Stem Cells Jun 13 Peter MacCallum Cancer Program Melbourne, Australia Steven Lane Blood Cancer Stem Cells Sep 12 St Vincent's Institute Seminar Program Melbourne, Australia Steven Lane Tyrosine kinase inhibitors in myeloproliferative Apr 13 Private Cancer Physicians Association Brisbane, Australia neoplasms – where to from here? National Meeting Steven Lane In vivo models to understand disease biology Mar 13 Australian Society of Cytogeneticists Brisbane, Australia in Jak2V617F MPN Steven Lane Depletion of Jak2V617F MPN stem cells Jun 13 American Society of Hematology Atlanta, United States by interferon alpha in a murine model of polycythemia vera Steven Lane Depletion of Jak2V617F MPN stem cells Jun 13 Haematology Society of Australasia Plenary Melbourne, Australia by interferon alpha in a murine model of Session polycythemia vera Steven Lane Disease models to understand myeloid blood Sep 12 Haematology Society of Australia, SA. Adelaide, Australia cancers Keynote speaker Stuart MacGregor Genome-wide association analyses identify Jun 13 Association for Research in Vision and Seattle, United States multiple loci associated with central corneal Ophthalmology thickness and keratoconus Tara Roberts Smg1 haploinsufficiency predisposes to Dec 12 Australasian Society of Immunology Annual Melbourne, Australia tumour formation and inflammation Conference Tara Roberts Smg1 haploinsufficiency predisposes to May 13 Australian Society for Medical Research Brisbane, Australia tumour formation and inflammation Tim Hurst impacts of Wolbachia infection on predator Sep 12 Surfers Paradise, prey relationships Australia Vicki Whitehall Genetics of Gastrointestinal Cancers: Nov 12 NHMRC Adelaide, Australia Colorectal Vicki Whitehall Serrated Neoplasia Pathway Jun 13 Royal Australian College of Pathologists Gold Coast, Australia Pathology Update Yen Tan Under-referral of women with hereditary Jun 13 14th Biennial Meeting of the International Vancouver, Canada endometrial cancer to genetic services: Gynecologic Cancer Society – IGCS 2012 Suggestions to facilitate referral of patients at increased risk of Lynch syndrome. Yen Tan Under-referral of women with hereditary Jun 13 Royal Brisbane & Women’s Hospital Brisbane, Australia endometrial cancer to genetic services: 21st Annual Health Care Symposium: Suggestions to facilitate referral of patients at Personalized Health Care increased risk of Lynch syndrome Yen Tan Knowledge, attitudes and referral of Lynch Jun 13 Australian Society for Psychosocial Melbourne, Australia syndrome patients to genetic services: A Obstetrics and Gynaecology (ASPOG) 38th qualitative study Annual Scientific Meeting 2012

Page 111 PATENTS Patent families managed by QIMR

Title Inventor(s) Application Number

Novel molecules Toni Antalis; John Hooper PCT/AU1998/000085

Immunogenic agent and pharmaceutical composition for use against Michael Good; Mary Stevenson PCT/AU2004/000870 homologous and heterologous pathogens

Polyepitope vaccines Andreas Suhrbier; Scott Thomson; Rajiv PCT/AU1995/000461 Khanna; Scott Burrows; Barbara Coupar; Denis Moss

Synthetic peptides and vaccines comprising the same Juan Cooper; Wendy Relf; Michael Good; PCT/AU1995/000681 Allan Saul

Cytotoxic T-cell epitopes Denis Moss; Scott Burrows; Rajiv Khanna; PCT/AU1995/000140 Beverley Kerr; Jacqueline Burrows; Andreas Suhrbier

EBV CTL epitopes Rajiv Khanna; Beverley Kerr; Ihor Misko; Denis PCT/AU1997/000328 Moss; Scott Burrows

CTL epitopes from EBV Martina Sherritt; Scott Burrows; Rajiv Khanna PCT/AU1998/000531

EBV peptide epitopes, polyepitopes and delivery system therefor Rajiv Khanna; Jaikumar Duraiswamy PCT/AU2003/001451

Novel hCMV cytotoxic T cell epitopes, polyepitopes, composition comprising Rajiv Khanna; Rebecca Elkington; PCT/AU2002/000829 same and diagnostic and prophylactic and therapeutics uses therefor Susan Walker

Human cytomegalovirus immunotherapy Rajiv Khanna PCT/AU2005/001798

Peptide compounds Istvan Toth; William Gibbons PCT/GB1993/001558

Cancer drug targets and methods of diagnosis Andrew Boyd; Bryan Day; Brett Stringer PCT/AU2009/000672

Human cytomegalovirus immunotherapy Rajiv Khanna 61/347,352

Mutant TAT proteins and uses thereof David Harrich US13/292425

CMV4 improved human cytomegalovirus immunotherapy protein Rajiv Khanna AU2012904604

QIMR patent families managed outside QIMR

Title Inventor(s) Application Number

Receptor ligand system and assay Andrew Boyd US 1998/104340

Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis Andrew Boyd PCT/AU2004/000142

A method of treatment Andrew Boyd PCT/AU1999/000931

Differentiation modulating agents and uses therefor Johannes Prins PCT/AU2005/000008

Melanoma-associated MHC Class 1 Associated oligopeptide and its use Chris Schmidt PCT/EP2006/008533

Method for screening for anticancer agents Kum Kum Khanna PCT/GB2008/003390

A novel growth factor and a genetic sequence encoding same Nicholas Hayward PCT/AU1996/000094

Flavivirus replicon constructs for tumour therapy Andreas Suhrbier; Alexander Khromykh PCT/AU2006/000198

Immunogenic complexes and methods relating thereto Andreas Suhrbier; John Cooper Cox; Debbie PCT/AU0000110 Pauline Drane

Plasmodium falciparum antigens Denise Doolan; Angela Trieu; Phillip Felgner US 2012/0244178

Page 112 QIMR Annual Report 2012–2013 Patent families relating to QIMR visiting scientists and administered by other institutions

Title Inventor(s) Application Number

Prothrombin activating protein Martin Lavin PCT/AU0300406

Plasmin inhibitors from the Australian brown snake (Pseudonaja Martin Lavin PCT/AU9936922 textilis textilis)

Agents and methods for diagnosing the presence or risk of prostate cancer Martin Lavin PCT/AU09/000651

Serum preparation Martin Lavin PCT/AU11/001221

A method of treatment Andrew Boyd PCT/AU99/000931

Patent families resulting from industry sponsored contract research performed at QIMR

Title Inventor(s) Application Number

Treatment of virally induced lesions Andreas Suhrbier PCT/AU2008/000596

Use of angeloyl-substituted ingenones in combination with other agents to Andreas Suhrbier; Peter Parsons PCT/AU2006/001700 treat cancer

Treatment of solid tumours Andreas Suhrbier PCT/AU2005/001827

Chaperonin 10 modulators of toll-like receptors inducible cytokine and Andreas Suhrbier PCT/AU2005/000041 cytokine secretion

Treatment of prostate cancer Peter Parsons PCT/AU2001/000966

Therapeutic agents I Andreas Suhrbier; Peter Parsons PCT/AU2001/000679

Therapeutic agents II Andreas Suhrbier; Peter Parsons PCT/AU2001/000680

Therapeutic agents III Andreas Suhrbier; Peter Parsons PCT/AU2001/000678

Macrocyclic diterpenes for the treatment and prophylaxis of acne vulgaris Andreas Suhrbier; Peter Parsons US 7838555

Methods for treating UV-damaged skin and squarmous cell carcinoma Sarah-Jane Cozzi; Andreas Suhrbier PCT/IB2011/001910 tumors and for removing tattoos with topical ingenol mebutate

Patents Families managed by QIMR as trustee for the CRC-Vaccine Technology

Title Inventor(s) Application Number

T helper epitopes David Jackson PCT/AU2000/000070

Novel immunogenic lipopeptides comprising T-helper and cytotoxic David Jackson PCT/AU2003/001019 T lymphocyte (CTL) epitope

Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes David Jackson PCT/AU2003/001018

Truncated LHRH formulations David Jackson PCT/AU2005/001383

Immunogenic molecules David Jackson PCT/AU2006/000162

Trade marks managed by QIMR

Australian Trade Mark Mark Status Number

Queensland Institute of Medical Research Registered / Protected 1233303

QIMR Registered / Protected 1233307

Hexagons device Registered / Protected 1233317

Q-Neuro Systems Registered / Protected 1512321

Page 113 GRANTS AND FUNDING

(over $100,000)

Total Sponsor Description Term Period Funding ARC-FT Medland, Sarah - Elucidating the genetics of Attention Deficit Hyperactivity 4 yrs 2012 - 2015 609,334.00 Disorder by integrating pathway and prediction analyses ARC-UQ Lavin, Martin et al- Role of senataxin in meiotic recombination and sex 3 yrs 2013 - 2015 357,000.00 chromosome inactivation BPA Gorman, Jeffery - Melanoma Framework - HLA Characterisation 3 yrs 2012 - 2014 200,000.00 CANCERAU Pritchard, Antonia - Identifying novel tumour epitopes as targets for 3 yrs 2013 - 2015 195,102.00 immunotherapy CANCERAU Whiteman, David - Estimating the proportion of cancers in Australia that are 2 yrs 2013 - 2014 100,000.00 preventable CCQ Moller, Andreas et al - Regulation of the pre-metastatic niche by hypoxia 2 yrs 2013 - 2014 200,000.00 CCQ Walker, Graeme et al - In vivo functional dissection of the respective roles of the 2 yrs 2013 - 2014 199,782.00 CDKN2A and MTAP loci in naevus susceptibility CCQ Khanna, Kum Kum et al - Role of FBXO31 - mediated protein degradation in 2 yrs 2013 - 2014 197,551.00 mitotic progression CCQ Jordan, Susan et al - Patterns of care in renal cell carcinoma 2 yrs 2013 - 2014 188,254.00 CRCATSIH Fischer, Katja et al - Scabies mites complement inhibitors as Targets for Novel 1 yr 2013 100,000.00 Therapeutics CUCANC Koyama, Motoko - PD07: Mechanisms of antigen presentation following bone 1 yr 2013 300,000.00 marrow transplantation KLARMAN Martin, Nicholas et al - Anorexia Nervosa Genetics Initiative.[ANGI] 5 yrs 2012 - 2016 US$904,118.00 KOMEN Smyth, Mark et al - Targeting CD73 for Treatment of Triple (transferred from Peter 5 yrs 2012 - 2016 438,741.00 MacCallum Cancer Centre) LFA Lane, Steven - Regulators of epigenetic gene expression in haematopoiesis 3 yrs 2013 - 2015 120,000.00 LFA Lane, Steven - Targeting telomerase -to eradicate leaukaemia stem cells in acute 1 yr 2013 100,000.00 myeloid leukaemia NBCF French, Juliet - Post-GWAS functional characterisation (Transferred from University 4 yrs 2013 - 2016 571,154.00 of Queensland) NBCF Wiegmans, Adrian - The role of DNA damage proteins in the biology and 4 yrs 2013 - 2016 400,000.00 therapeutic response of highgrade metastatic breast cancers NBCF Edwards, Stacey -Identification of new mutation targets in breast cancer 2 yrs 2013 - 2014 315,007.00 susceptibility genes. (Transferred from University of Queensland) NBCF Moller, Andreas - Improving Chemotherapy Efficacy through Modulating Tumour 3 yrs 2012 - 2014 311,454.00 (Transferred from Peter MacCallum Cancer Centre) NBCF Moller, Andreas - The Origins of breast cancer - associated myeloid cells. 2 yrs 2013 - 2014 199,682.00 (Transferred from Peter MacCallum Cancer Centre) NHMRC-AF Smyth, Mark - NHMRC Australia Fellowship 3 yrs 2013 - 2015 1,600,000.00 NHMRCCDA Teng, Michelle - CDF- Level 1: Understanding immunosuppressive pathways in 4 yrs 2013 - 2016 303,660.00 cancer (Transferred from Peter MacCallum Cancer Centre) NHMRCECF Tey, Siok - Cell therapy to prevent and treat graft-versus-host disease after 4 yrs 2013 - 2016 359,564.00 allogeneic haematopoietic stem cell transplantation NHMRCECF Thrift, Aaron - Clinical, environmental and genetic factors and the risk of 5 yrs 2013 - 2017 325,396.00 oesophageal cancer NHMRCECF Robb, Renee - Investigation into the role of regulatory B cells in transplantation 5 yrs 2013 - 2017 324,940.00 NHMRCECF Clark, Paul - Population-level trends in hepatocellular carcinoma incidence, 4 yrs 2014 - 2017 251,695.00 treatment and mortality in Queensland, according to socio demographic factors and geographic location, with case record linkage to viral hepatitis notifications, 1996 - 2010 NHMRC-GU McManus, Donald et al - Tropical Disease - immunity, pathogenesis and vaccine 5 yrs 2013 - 2017 2,151,876.00 development: global translation (Administered by Griffith University) NHMRC-GU Engwerda, Christian et al - Tropical Disease - immunity, pathogenesis and vaccine 5 yrs 2013 - 2017 1,782,827.00 development: global translation (Administered by Griffith University) NHMRC-GU McCarthy, James et al - Tropical Disease - immunity, pathogenesis and vaccine 5 yrs 2013 - 2017 1,782,827.00 development: global translation (Administered by Griffith University) NHMRC-GU Doolan, Denise et al - Tropical Disease - immunity, pathogenesis and vaccine 5 yrs 2013 - 2017 1,398,194.00 development: global translation (Administered by Griffith University) NHMRC-GU Trenholme, Katharine et al - Development of Fragment Hits into effective 3 yrs 2013 - 2015 120,422.00 Antimalarials; Targeting Malaria Eradication (Adminsitered by Griffith University) NHMRC-PF McCarthy, James - Developing drugs and vaccines for malaria by undertaking 3 yrs 2013 - 2015 380,583.00 experimental studies in humans NHMRC-PJ Neale, Rachel et al - D-Health: A randomised trial of vitamin D for prevention of 5 yrs 2013 - 2017 2,930,705.00 cancer and mortality

Page 114 QIMR Annual Report 2012–2013 Total Sponsor Description Term Period Funding NHMRC-PJ Whiteman, David et al - PROBE-NET: The Progression of Barrett's Esophagus to 5 yrs 2013 - 2017 2,465,841.00 Cancer Network NHMRC-PJ Engwerda, Christian et al - Defining immune regulation and T cell responses during 3 yrs 2013 - 2015 690,265.00 chronic infectious disease NHMRC-PJ Montgomery, Grant - Genome-wide analysis of gene coding variants increasing 3 yrs 2013 - 2015 686,071.00 risk of endometriosis NHMRC-PJ Smyth, Mark et al - New molecules that regulate cancer immunity and therapy 4 yrs 2013 - 2016 617,503.00 NHMRC-PJ Ramm, Grant et al - Identification of the Mechanisms of Hepatic Fibrogenesis Aid 3 yrs 2013 - 2015 602,878.00 in the Detection and Prediction of Clinical Outcomes in Paediatric Cholestatic Liver Disease NHMRC-PJ Subramaniam, Nathan et al - Dissecting the TMPRSS6 regulation of iron 3 yrs 2013 - 2015 592,143.00 homeostasis NHMRC-PJ Jordan, Susan et al - The Queensland Thyroid Cancer Study 4 yrs 2013 - 2016 584,522.00 NHMRC-PJ Suhrbier, Andreas et al - Regulation of inflammation and coagulation by 3 yrs 2013 - 2015 573,628.00 microparticles containing SerpinB2 NHMRC-PJ Nyholt, Dale et al - Identification of novel common genetic risk factors for 2 yrs 2013 - 2014 560,012.00 endometriosis NHMRC-PJ Tey, Siok - Inducible caspase 9 suicide gene to improve the safety of donor T cell 3 yrs 2013 - 2015 545,681.00 addback after haploidentical stem cell transplantation NHMRC-PJ Anderson, Gregory et al - The role of soluble transferrin receptor in the regulation 3 yrs 2013 - 2015 521,219.00 of iron homeostasis NHMRC-PJ Mulvenna, Jason et al - Biomarkers for the progression of cholangiocarcinoma: 3 yrs 2013 - 2015 507,347.00 from risk factors to carcinogenesis NHMRC-PJ Whitehall, Vicki et al - KRAS- and BRAF-Mediated Methylation Signatures in 3 yrs 2013 - 2015 443,306.00 Colorectal Cancers and Polyps NHMRC-PJ Teng, Michele - The role of cytokines in tumour- induced immunosuppression 2 yrs 2013 - 2014 350,888.00 Transferred from University of Melbourne) NHMRC-PJ French, Juliet et al - Functional analysis of breast cancer susceptibility regions 2 yrs 2013 - 2014 348,498.00 (Transferred from University of Queensland) NHMRC-PJ Boyle, Glen et al - Aberrant transcriptional signalling in the progression and 3 yrs 2013 - 2015 340,931.00 metastasis of melanoma NHMRC-PJ Anderson, Gregory et al - The role of the liver in manganese homeostasis 3 yrs 2013 - 2015 336,056.00 NHMRC-PJ Walker, Graeme et al - Do ‘classical’ or ‘oxidative’ UVR-induced DNA adducts 3 yrs 2013 - 2015 324,337.00 drive melanoma induction after ultraviolet radiation NHMRC-PJ Wykes, Michelle et al - The differential contribution of Programmed death-1 ligands 3 yrs 2013 - 2015 316,556.00 to malarial imminity NHMRC-PJ Smith, Corey et al - Tracking the impact of superinfection with a common 3 yrs 2013 - 2015 306,806.00 Herpesvirus on T cell immunity in humans NHMRC-PM Smyth, Mark et al - Immune regulation, effector function and therapy (Administered 4 yrs 2013 - 2016 1,960,000.00 by Peter McCallum Cancer Centre) NHMRC-RF Webb, Penelope et al - Reducing the burden of gynaecological cancer 5 yrs 2013 - 2017 590,785.00 NHMRC-SC Warren, Timothy - The natural history of skin cancer with nerve invasion 3 yrs 2013 - 2015 117,370.00 (Transferred from Princess Alexandra Hospital) NHMRC-TF You, Hong - Identifying genes associated with parasitism, and novel drug & 3 yrs 2013 - 2015 299,564.00 vaccine targets NHMRC-TF Reynolds, Simone - Scabies mite complement inhibitors as targets for novel 3 yrs 2013 - 2015 299,564.00 therapeutics NHMRC-TF Ranjit, Najju - Insulin signalling in helminthic infections (Transferred from James 2 yrs 2013 - 2014 149,782.00 Cook University) NHMRC-TF Larsen, Jill - Defining steps in the molecular pathogenesis of lung cancer using 2 yrs 2013 - 2014 111,633.00 immortalized human bronchial epithelial cells (Transferred from University of Queensland) NHMRC-UNSW Breakspear, Michael et al - Program Grant Depressive and bipolar disorders: 5 yrs 2013 - 2017 1,000,000.00 Pathophysiology, phenotypes and treatment innovations (Administered by University of NSW) NHMRC-UNSW Breakspear, Michael et al - Brain Network Recovery Group (Brain NRG) 4 yrs 2012 - 2015 100,000.00 (Adminsitered by University of New South Wales) NHMRC-UNSW Wright, Margaret et al - The Older Australian Twins Study (OATS) of healthy brain 3 yrs 2013 - 2015 300,000.00 ageing and age-related neurocognitive disorders (Administered by University of NSW) NHMRC-UNSW Martin, Nicholas et al - CRE for improving suicide prevention in Australia through 5 yrs 2013 - 2017 103,087.00 better implementation of effective interventions, improved risk identification and evidence informed policy (Administered by University of NSW) NHMRC-UQ MacDonald, Kelli et al - Defining the role of MMP-9-expressing macrophages in 3 yrs 2013 - 2015 191,364.00 liver injury in chronic liver disease (Administered by University of Queensland) PAHF Parsons, Peter - QHNCC- Queensland Head & Neck Cancer Centre 5 yrs 2012 - 2017 3,650,000.00

Page 115 QIMR FELLOWS

Name Year Awarded Name Year Awarded

Macfarlane Burnet 1981 Michael Alpers 1992

Ralph Doherty Rod Wylie

Frank Fenner Graham Mitchell 1993

Eric French Mervyn Eadie 1994

Abraham Fryberg Bryan Emmerson

Douglas Lee Ian Wilkey

Margaret Macgregor Ted Brown 1995

Aubrey Pye Peter Doherty 1997

William Reeves Paul Korner

John Sprent Stephen Lynch

Harry Standfast Michael O’Rourke 1998

George Taylor Michael Barry 1999

John Tonge Kay Ellem

Carleton Gajdusek 1982 Ian Taylor

David Henderson Lawrie Powell 2000

Owen Powell Tom Veivers

Julie Saroso Phillip Desbrow 2001

Edwin Westaway William O’Sullivan

Vincent Zigas Diana Cavaye 2002

Anthony Epstein 1983 Mary Dunne

Douglas Gordon Clive Berghofer 2003

Elizabeth Marks Bryan Campbell

Neville Davis 1985 Sam Coco

Robert Porter Peter Wills 2004

Brian Wilson John Kerr 2005

Natth Bhamarapravati 1986 Paul Wright

Louis Miller David Lyons 2006

Eric Saint Ian Goddard 2007

Robert Shope Helen Luckoff

Bruce Watson John Garnsey 2008

The Hon Mike Ahern 1988 Graham Brown

Neville McCarthy Robert MacLennan

Gustav Nossal Peter Brooks 2009

E D O’Callaghan (posthumous) Peter Roeser

Frank Schoﬁeld David Alcorn 2011

Edward Stewart 1989 Michael Good

Tao Yixun John Hay 2012

Chamlong Harinasuta 1991

Chev Kidson

Peter Livingstone

Page 116 QIMR Annual Report 2012–2013 SCIENTIFIC PUBLICATIONS

902. Richmond-Rakerd LS, Slutske WS, Heath Lindgren CM, North KE, Heid IM.Sex-stratified Radiosensitizing Chemotherapy and PARP AC, Martin NG.Effects of Sibship Size and Genome-wide Association Studies Including Inhibitor. Journal of Nuclear Medicine. 2013. Vol Composition on Younger Brothers’ and Sisters’ 270,000 Individuals Show Sexual Dimorphism 54(6):913-921. Alcohol Use Initiation: Findings from an Australian in Genetic Loci for Anthropometric Traits. Plos Twin Sample. Alcoholism, Clinical and Experimental Genetics. 2013. Vol 9(6):e1003500. Alghowinem S, Goecke R, Wagner M, Epps J, Research. 2013. Vol 37(6):1016–1024. Breakspear M, Parker G Detecting Depression: 907. Sim X, Jensen RA, Kamran Ikram M, A Comparison between Spontaneous and 905. Randall JC, Winkler TW, Kutalik Z, Berndt Cotch MF, Li X, MacGregor S, Xie J, Smith Read Speech. Ieee International Conference On SI, Jackson AU, Monda KL, Kilpelainen TO, AV, Boerwinkle E, Mitchell P, Klein RM, Klein Acoustics, Speech and Signal Processing (Icassp Esko T, Magi R, Li S, Workalemahu T, Feitosa BEK, Glazer NL, Lumley T, McKnight B, Psaty 2013).. 2013. Vol UNKNOWN. MF, Croteau-Chonka DC, Day FR, Fall T, BM, de Jong PTVM, Hofman A, Rivadeneira Ferreira T, Gustafsson S, Locke AE, Mathieson F, Uitterlinden AG, van Duijn CM, Aspelund T, Alghowinem S, Goecke R, Wagner M, Epps I, Scherag A, Vedantam S, Wood AR, Liang L, Eiriksdottir G, Harris TB, Jonasson F, Launer J, Breakspear M, Parker G From Joyous to Steinthorsdottir V, Thorleifsson G, Dermitzakis LJ, Attia J, Baird P, Harrap S, Holliday EG, Clinically Depressed: Mood Detection Using ET, Dimas AS, Karpe F, Min JL, Nicholson Inouye M, Rochtchina E, Scott RJ, Viswanathan Spontaneous Speech. Twenty-Fifth International G, Clegg DJ, Person T, Krohn JP, Bauer S, A, GlobalBPgenConsortium, Li G, Smith NL, Flairs Conference.. 2012. Vol UNKNOWN. Buechler C, Eisinger K, DIAGRAM Consortium, Wiggins K, Kuo J, Taylor K, D., Hewitt AW, Alsop K, Fereday S, Meldrum C, deFazio A, Bonnefond A, Froguel P, MAGIC Investigators, Martin NG, Montgomery GM, Sun C, Mackey Emmanuel C, George J, Dobrovic A, Birrer MJ, Hottenga JJ, Prokopenko I, Waite LL, Harris TB, DA, Rotter JI, Tai ES, Gudnason V, Vingerling Webb PM, Stewart C, Friedlander M, Fox S, Smith AV, Shuldiner AR, McArdle WL, Caulfield JR, Siscovick DS, Wang JJ, Wong TY.Genetic Bowtell D, Mitchell G.BRCA mutation frequency MJ, Munroe PB, Gronberg H, Chen YD, Li G, Loci for Retinal Arteriolar Microcirculation. Plos and patterns of treatment response in BRCA Beckmann JS, Johnson T, Thorsteinsdottir U, One. 2013. Vol 8(6):e65804. mutation-positive women with ovarian cancer: a Teder-Laving M, Khaw KT, Wareham NJ, Zhao report from the Australian Ovarian Cancer Study JH, Amin N, Oostra BA, Kraja AT, Province A Soltani, R Wood-Baker, SS. Sohal, HK Muller, DW Reid and EH Walters. Reticular basement Group. Journal of Clinical Oncology. 2012. Vol MA, Cupples LA, Heard-Costa NL, Kaprio J, 30(21):2654-2663. Ripatti S, Surakka I, Collins FS, Saramies J, membrane vessels are increased in COPD Tuomilehto J, Jula A, Salomaa V, Erdmann J, bronchial mucosa by both Factor VIII and Collagen Amalraj, J., Cutler, S.J., Ghazawi, I., Boyle, Hengstenberg C, Loley C, Schunkert H, Lamina IV immunostaining and are hyperpermeable. G.M. and Ralph, S.J. REST negatively and ISGF3 C, Wichmann HE, Albrecht E, Gieger C, Hicks Journal of Allergy. 2012. Vol 2012 958383. positively regulates the human STAT1 gene in AA, Johansson A, Pramstaller PP, Kathiresan A Soltani, R Wood-Baker, SS. Sohal, HK Muller, melanoma. Online 18/04/2013. Molecular Cancer S, Speliotes EK, Penninx B, Hartikainen AL, DW Reid and EH Walters. Vessel-Associated Therapeutics. 2013. Vol 12(7):1288-98. Jarvelin MR, Gyllensten U, Boomsma DI, Transforming Growth Factor-Beta1 (TGF-?) Amin Al Olama A, Kote-Jarai Z, Schumacher Campbell H, Wilson JF, Chanock SJ, Farrall is increased in Bronchial Reticular Basement FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, M, Goel A, Medina-Gomez C, Rivadeneira F, membrane in COPD and Normal Smokers. Plos Severi G, Neal DE, Hamdy FC, Donovan JL, Estrada K, Uitterlinden AG, Hofman A, Zillikens One. 2012. Vol 7(6):e39736. Hunter DJ, Henderson BE, Thun MJ, Gaziano M, MC, den Heijer M, Kiemeney LA, Maschio A, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Hall P, Tyrer J, Teumer A, Volzke H, Kovacs P, Aburn MJ, Holmes CA, Roberts JA, Boonstra Canzian F, Riboli E, Key TJ, andriole G, Albanes Tonjes A, Mangino M, Spector TD, Hayward TW, Breakspear M.Critical fluctuations in cortical D, Hayes RB, Schleutker J, Auvinen A, Tammela C, Rudan I, Hall AS, Samani NJ, Attwood AP, models near instability. Front Physiol. 2012. TL, Weischer M, Stanford JL, Ostrander EA, Sambrook JG, Hung J, Palmer LJ, Lokki ML, Vol 3(331). Cybulski C, Lubinski J, Thibodeau SN, Schaid Sinisalo J, Boucher G, Huikuri H, Lorentzon M, Agrawal A, M. P., Martin NG, Lynskey MT.Do DJ, Sorensen KD, Batra J, Clements JA, Ohlsson C, Eklund N, Eriksson JG, Barlassina early experiences with cannabis vary in cigarette Chambers S, Aitken J, Gardiner RA, Maier C, C, Rivolta C, Nolte IM, Snieder H, Van der Klauw smokers? Drug and Alcohol Dependence. 2013. Vogel W, Dörk T, Brenner H, Habuchi T, Ingles MM, van Vliet-Ostaptchouk JV, Gejman PV, Shi Vol 128(3):255-259. S, John EM, Dickinson JL, Cannon-Albright J, Jacobs KB, Wang Z, Bakker SJ, Mateo Leach L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, I, Navis G, van der Harst P, Martin NG, Medland Agrawal A, Nelson EC, Littlefield AK, Bucholz Park JY, Cooney KA, Muir KR, Leongamornlert SE, Montgomery GW, Yang J, Chasman DI, KK, Degenhardt L, Henders AK, Madden PA, DA, Saunders E, Tymrakiewicz M, Mahmud N, Ridker PM, Rose LM, Lehtimaki T, Raitakari O, Martin NG, Montgomery GW, Pergadia ML, Guy M, Govindasami K, O’Brien LT, Wilkinson Absher D, Iribarren C, Basart H, Hovingh KG, Sher KJ, Heath AC, Lynskey MT.Cannabinoid RA, Hall AL, Sawyer EJ, Dadaev T, Morrison Hypponen E, Power C, anderson D, Beilby JP, Receptor Genotype Moderation of the Effects J, Dearnaley DP, Horwich A, Huddart RA, Hui J, Jolley J, Sager H, Bornstein SR, Schwarz of Childhood Physical Abuse on Anhedonia and Khoo VS, Parker CC, Van As N, Woodhouse PE, Kristiansson K, Perola M, Lindstrom J, Swift Depression. Archives of General Psychiatry. 2012. CJ, Thompson A, Dudderidge T, Ogden C, AJ, Uusitupa M, Atalay M, Lakka TA, Rauramaa Vol 69(7):732-740. Cooper CS, Lophatonanon A, Southey MC, R, Bolton JL, Fowkes G, Fraser RM, Price JF, Hopper JL, English D, Virtamo J, Le Marchand Fischer K, Krjuta Kov K, Metspalu A, Mihailov Agrawal, A., Verweij KJH, Gillespie NA, Heath L, Campa D, Kaaks R, Lindstrom S, Diver WR, E, Langenberg C, Luan J, Ong KK, Chines AC, Lessov-Schlaggar CN, Martin NG, Nelson Gapstur S, Yeager M, Cox A, Stern MC, Corral PS, Keinanen-Kiukaanniemi SM, Saaristo TE, EC, Slutske WS, Whitfield JB, Lynskey MTThe R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng Edkins S, Franks PW, Hallmans G, Shungin genetics of addiction-a translational perspective. SL, Wahlfors T, Taari K, Kujala P, Klarskov P, D, Morris AD, Palmer CN, Erbel R, Moebus S, Translational Psychiatry. 2012. Vol 17(2):e140. Nordestgaard BG, Røder MA, Frikke-Schmidt Nothen MM, Pechlivanis S, Hveem K, Narisu Aitken Schermer J, M. R., Martin NG, Lynskey R, Bojesen SE, FitzGerald LM, Kolb S, Kwon N, Hamsten A, Humphries SE, Strawbridge RJ, M, Vernon PA.The general factor of personality EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb Tremoli E, Grallert H, Thorand B, Illig T, Koenig and humor styles. Personality and Individual A, Luedeke M, Herkommer K, Meyer A, Serth W, Muller-Nurasyid M, Peters A, Boehm BO, Differences. 2013. Vol 12(4):356-65. J, Marthick JR, Patterson B, Wokolorczyk D, Kleber ME, Marz W, Winkelmann BR, Kuusisto Spurdle A, Lose F, McDonnell SK, Joshi AD, J, Laakso M, Arveiler D, Cesana G, Kuulasmaa Akbari MR, anderson LN, Buchanan DD, Shahabi A, Pinto P, Santos J, Ray A, Sellers K, Virtamo J, Yarnell JW, Kuh D, Wong A, Clendenning M, Jenkins MA, Win AK, Hopper TA, Lin HY, Stephenson RA, Teerlink C, Muller Lind L, de Faire U, Gigante B, Magnusson JL, Giles GG, Nam R, Narod S, Gallinger S, H, Rothenbacher D, Tsuchiya N, Narita S, Cao PK, Pedersen NL, Dedoussis G, Dimitriou M, Cleary SP.Germline HOXB13 p.Gly84Glu mutation GW, Slavov C, Mitev V; UK Genetic Prostate Kolovou G, Kanoni S, Stirrups K, Bonnycastle and risk of colorectal cancer. Cancer Epidemiology. Cancer Study Collaborators/British Association LL, Njolstad I, Wilsgaard T, Ganna A, Rehnberg 2013. Vol 37(4):424-427. of Urological Surgeons’ Section of Oncology; E, Hingorani A, Kivimaki M, Kumari M, Assimes UK ProtecT Study Collaborators; Australian TL, Barroso I, Boehnke M, Borecki IB, Deloukas Al-Ejeh F, Shi W, Miranda M, Simpson PT, Prostate Cancer Bioresource; PRACTICAL P, Fox CS, Frayling T, Groop LC, Haritunians T, Vargas AC, Song S, Wiegmans AP, Swarbrick Consortium, Chanock S, Gronberg H, Haiman Hunter D, Ingelsson E, Kaplan R, Mohlke KL, A, Welm AL, Brown MP, Chenevix-Trench CA, Kraft P, Easton DF, Eeles RA. A meta- O’Connell JR, Schlessinger D, Strachan DP, G, Lakhani SR, Khanna KK.Treatment of analysis of genome-wide association studies Stefansson K, van Duijn CM, Abecasis GR, Triple-Negative Breast Cancer Using Anti-EGFR- to identify prostate cancer susceptibility loci McCarthy MI, Hirschhorn JN, Qi L, Loos RJ, Directed Radioimmunotherapy Combined with

Page 117 Scientiﬁc publications | continued

associated with aggressive and non-aggressive schistosomiasis. Trends In Parasitology. 2012. Vol seroprevalence and serostability of 34 human disease. Human Molecular Genetics. 2013. Vol 28 447-454. papillomavirus types in European organ transplant 22(2):408-415. recipients. Virology. 2013. Vol NULL. Antoniou AC, Kuchenbaecker KB, Soucy Amin N, B. E., Johnson J, Chenevix-Trench P, Beesley J, Chen X, McGuffog L, Lee A, Antonsson, A.Review: antibodies to cutaneous G, Walter S, Nolte IM, kConFab Investigators, Barrowdale D, Healey S, Sinilnikova OM, human papillomaviruses. Journal of Medical Vink JM, Rawal R, Mangino M, Teumer A, Caligo MA, Loman N, Harbst K, Lindblom A, Virology. 2012. Vol 84(5):814-822. Keers JC, Verwoert G, Baumeister S, Biffar Arver B, Rosenquist R, Karlsson P, Nathanson R, Petersmann A, Dahmen N, Doering A, K, Domchek S, Rebbeck T, Jakubowska A, Anttila V, Winsvold BS, Gormley P, Kurth T, Isaacs A, Broer L, Wray NR, Montgomery GW, Lubinski J, Jaworska K, Durda K, Zlowowcka- Bettella F, McMahon G, Kallela M, Malik R, Levy D, Psaty BM, Gudnason V, Chakravarti Perlowska E, Osorio A, Durán M, andrés R, de Vries B, Terwindt G, Medland SE, Todt U, A, Sulem P, Gudbjartsson DF, Kiemeney LA, Benítez J, Hamann U, Hogervorst FB, van Os McArdle WL, Quaye L, Koiranen M, Ikram MA, Thorsteinsdottir U, Stefansson K, van Rooij TA, Verhoef S, Meijers-Heijboer HE, Wijnen Lehtimäki T, Stam AH, Ligthart L, Wedenoja J, FJ, Aulchenko YS, Hottenga JJ, Rivadeneira J, Gómez Garcia EB, Ligtenberg MJ, Kriege Dunham I, Neale BM, Palta P, Hamalainen E, FR, Hofman A, Uitterlinden AG, Hammond M, Collée JM, Ausems MG, Oosterwijk JC, Schürks M, Rose LM, Buring JE, Ridker PM, CJ, Shin SY, Ikram A, Witteman JC, Janssens Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Steinberg S, Stefansson H, Jakobsson F, Lawlor AC, Snieder H, Tiemeier H, Wolfenbuttel BH, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard DA, Evans DM, Ring SM, Färkkilä M, Artto V, Oostra BA, Heath AC, Wichmann E, Spector J, Davidson R, Cole T, Cook J, Paterson J, Kaunisto MA, Freilinger T, Schoenen J, Frants TD, Grabe HJ, Boomsma DI, Martin NG, van Douglas F, Brewer C, Hodgson S, Morrison PJ, RR, Pelzer N, Weller CM, Zielman R, Heath AC, Duijn CMGenome-wide association analysis of Walker L, Rogers MT, Donaldson A, Dorkins Madden PAF, Montgomery GW, Martin NG, coffee drinking suggests association with CYP1A1/ H, Godwin AK, Bove B, Stoppa-Lyonnet D, Borck G, Göbel H, Heinze A, Heinze-Kuhn K, CYP1A2 and NRCAM. Molecular Psychiatry. 2012. Houdayer C, Buecher B, de Pauw A, Mazoyer Williams FMK, Hartikainen A-L, Pouta A, van Vol 17(11):1116-29. S, Calender A, Léoné M, Bressac-de Paillerets den Ende J, Uitterlinden AG, Hofman A, Amin B, Caron O, Sobol H, Frenay M, Prieur F, Ferrer N, Hottenga J-J, Vink JM, Heikkilä K, Alexander Amin, N., J. J. Hottenga, N. K. Hansell, A. C. SU, Mortemousque I, Buys S, Daly M, Miron M, Muller-Myhsok B, Schreiber S, Meitinger T, Janssens, M. H. de Moor, P. A. Madden, I. V. A, Terry MU, Hopper JL, John EM, Southey Wichmann HE, Aromaa A, Eriksson JG, Traynor Zorkoltseva, B. W. Penninx, A. Terracciano, M. M, Goldgar D, Singer CF, Fink-Retter A, Tea B, Trabzuni D, Consortium. NABE, Consortium. Uda, T. Tanaka, T. Esko, A. Realo, L. Ferrucci, MK, Kaulich DU, Hansen TV, Nielsen FC, UBE, Rossin E, Lage K, Jacobs SBR, Gibbs JR, M. Luciano, G. Davies, A. Metspalu, G. R. Barkardottir RB, Gaudet M, Kirchhoff T, Joseph Birney E, Kaprio J, Penninx BW, Boomsma DI, Abecasis, I. J. Deary, K. Raikkonen, L. J. Bierut, V, Dutra-Clarke A, offit K, Piedmonte M, Kirk J, van Duijn C, Raitakari O, Jarvelin M-R, Zwart P. T. Costa, V. Saviouk, G. Zhu, A. V. Kirichenko, Cohn D, Hurteau J, Byron J, Fiorica J, Toland J-A, Cherkas L, Strachan DP, Kubisch C, Ferrari A. Isaacs, Y. S. Aulchenko, G. Willemsen, A. AE, Montagna M, Oliani C, Imyanitov E, Isaacs MD, van den Maagdenberg AMJM, Dichgans C. Heath, M. L. Pergadia, S. E. Medland, T. I. C, Tihomirova L, Blanco I, Lazaro C, Teulé A, M, Wessman M, Smith GD, Stefansson K, Daly Axenovich, E. de Geus, G. W. Montgomery, Valle JD, Gayther SA, Odunsi K, Gross J, Karlan MJ, Nyholt DR, Chasman D, Palotie A, for the M. J. Wright, B. A. Oostra, N. G. Martin, D. I. BY, Olah E, Teo SH, Ganz PA, Beattie MS, International Headache Genetics Consortium. Boomsma and C. M. van DuijnRefining genome- Dorfling CM, van Rensburg EU, Diez O, Kwong Genome-wide meta-analysis identifies new wide linkage intervals using a meta-analysis of A, Schmutzler RK, Wappenschmidt B, Engel susceptibility loci for migraine. Nat Genet Advance genome-wide association studies identifies loci C, Meindl A, Ditsch N, Arnold N, Heidemann online publication. June 23 2013. Vol (doi: influencing personality dimensions. European S, Niederacher D, Preisler-Adams S, Gadzicki 10.1038/ng.2676). Journal of Human Genetics. 2012. Vol 21(8):876- D, Varon-Mateeva R, Deissler H, Gehrig A, 882. Boraska V, Jeroncic A, Colonna V, Southam L, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes Nyholt DR, Rayner NW, Perry JR, Toniolo D, Anderson GJ, Wang F.Essential but toxic: T, de la Hoya M, Nevanlinna H, Muranen TA, Albrecht E, Ang W, Bandinelli S, Barbalic M, controlling the flux of iron in the body. Clin Exp Lespérance B, Spurdle AB, Neuhausen SL, Barroso I, Beckmann JS, Biffar R, Boomsma Pharmacol Physiol. 2012 Aug;39(8):719-24. Doi: Ding YC, Wang X, Fredericksen Z, Pankratz VS, D, Campbell H, Corre T, Erdmann J, Esko 10.1111/J.1440-1681.2011.05661. 2012. Vol Lindor NM, Peterlongo P, Manoukian S, Peissel T, Fischer K, Franceschini N, Frayling TM, 39(8):719-24. B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti Girotto G, Gonzalez JR, Harris TB, Heath AC, R, Papi L, Ottini L, Radice P, Greene MH, Heid IM, Hoffmann W, Hofman A, Horikoshi Andrews KT, Gupta AP, Tran TN, Fairlie DP, Loud JT, andrulis IL, Ozcelik H, Mulligan AU, M, Zhao JH, Jackson AU, Hottenga JJ, Jula Gobert GN, Bozdech ZComparative Gene Glendon G, Thomassen M, Gerdes AM, Jensen A, Kahonen M, Khaw KT, Kiemeney LA, Klopp Expression Profiling of P. falciparum Malaria UB, Skytte AB, Kruse TA, Chenevix-Trench N, Kutalik Z, Lagou V, Launer LJ, Lehtimaki T, Parasites Exposed to Three Different Histone G, Couch FJ, Simard J, Easton DF; CIMBA, Lemire M, Lokki ML, Loley C, Luan J, Mangino Deacetylase Inhibitors Plos One. 2012. Vol SWE-BRCA; HEBON; EMBRACE; GEMO M, Mateo Leach I, Medland SE, Mihailov 7(2):e31847. Collaborators Study; kConFab Investigators. E, Montgomery GW, Navis G, Newnham J, Common variants at 12p11, 12q24, 9p21, 9q31.2 Andrews KT, Haque A, Jones MKHDAC inhibitors Nieminen MS, Palotie A, Panoutsopoulou K, and in ZNF365 are associated with breast cancer in parasitic diseases Immunology and Cell Biology. Peters A, Pirastu N, Polasek O, Rehnstrom K, risk for BRCA1 and/or BRCA2 mutation carriers. 2012. Vol 90(1):66-77. Ripatti S, Ritchie GR, Rivadeneira F, Robino Breast Cancer Research. 2013. Vol 14(1):r33. A, Samani NJ, Shin SY, Sinisalo J, Smit JH, Andrews, D. M., Sullivan, L. C., Baschuk, N., Antonsson A, Bialasiewicz S, Rockett RJ, Jacob Soranzo N, Stolk L, Swinkels DW, Tanaka T, Chan, C. J., Berry, R., Cotterell, C. L., Lin, J., K, Bennett IC, Sloots TP.Exploring the prevalence Teumer A, Tonjes A, Traglia M, Tuomilehto J, Halse, H., Watt, S. V., Poursine-Laurent, J., of ten polyomaviruses and two herpes viruses in Valsesia A, van Gilst WH, van Meurs JB, Smith Wang, C-R., Scalzo, A. A., Yokoyama, W., breast cancer. Plos One. 2012. Vol 7(8):e39842. AV, Viikari J, Vink JM, Waeber G, Warrington Rossjohn, J., Brooks, A. G.*, and Smyth, M. NM, Widen E, Willemsen G, Wright AF, Zanke J.*Recognition of H2-M3 by Ly49A regulates Antonsson A, Michael KM, Pawlita M, Lehmann BW, Zgaga L, Boehnke M, d’Adamo AP, de mouse natural killer cell licensing and activation. MD, Nindl IDetection and typing of cutaneous Geus E, Demerath EW, den Heijer M, Eriksson Nature Immunology. 2012. Vol 13(12):1171-1177. human papillomavirus types--a comparison of three JG, Ferrucci L, Gieger C, Gudnason V, Hayward different methods. Journal of Virological Methods. C, Hengstenberg C, Hudson TJ, Jarvelin MR, Ankouane andoulo, F., Ngo Nonga, B., 2013. Vol 189(2):305-310. Kogevinas M, Loos RJ, Martin NG, Metspalu A, Monabang, C., Djapa R., Tchoumi, E., Oudou, Pennell CE, Penninx BW, Perola M, Raitakari O, N., Ndjitoyap Ndam Elie, C., McManus, Antonsson A, Pawlita M, Feltkamp MC, Bouwes Salomaa V, Schreiber S, Schunkert H, Spector D.P.Intracystic bleeding of a solitary hydatid cyst: A Bavinck JN, Euvrard S, Harwood CA, Naldi TD, Stumvoll M, Uitterlinden AG, Ulivi S, van rare complication of a rare disease in central Africa. L, Nindl I, Proby CM, Neale RE, Waterboer der Harst P, Vollenweider P, Volzke H, Wareham A case report. Case Reports In Clinical Medicine. TLongitudinal study of seroprevalence and NJ, Wichmann HE, Wilson JF, Rudan I, Xue 2013. Vol 2 163-166. serostability of the human polyomaviruses JCV Y, Zeggini E. Genome-wide meta-analysis of and BKV in organ transplant recipients. Journal of Anraku I, Rajasuriar R, Dobbin C, Brown R, common variant differences between men and Medical Virology. 2013. Vol 85(2):327-335. Lewin SR, Suhrbier A.Circulating heat shock women. Human molecular genetics. 2012. Vol 21: protein 60 levels are elevated in HIV patients and Antonsson A, Waterboer T, Bouwes Bavinck 4805-15. doi: 10.1093/hmg/dds304. are reduced by anti-retroviral therapy. Plos One. JN, Abeni D, de Koning M, Euvrard S, Feltkamp Broer L, Codd V, Nyholt DR, Deelen J, Mangino 2012. Vol 7(9):e45291. MC, Green AC, Harwood CA, Naldi L, Nindl I, M, Willemsen G, Albrecht E, Amin N, Beekman Pfister HJ, Proby CM, Quint WG, Stockfleth Anthony BJ, Ramm GA, McManus DPRole M, de Geus EJ, Henders A, Nelson CP, E, Weissenborn SJ, Pawlita M, Neale RE; of resident liver cells in the pathogenesis of Steves CJ, Wright MJ, de Craen AJ, Isaacs A, EPI-HPV-UV-CA group. Longitudinal study of

Page 118 QIMR Annual Report 2012–2013 Matthews M, Moayyeri A, Montgomery GW, gene. Hum Mol Genet. 2013. Vol doi: 10.1093/ H, van Rooij FJ, Van Wagoner DR, Vartiainen E, Oostra BA, Vink JM, Spector TD, Slagboom hmg/ddt215 Viikari J, Vollenweider P, Vonk JM, Waeber G, PE, Martin NG, Samani NJ, van Duijn CM, Weir DR, Wichmann HE, Widen E, Willemsen G, Boomsma DI. Meta-analysis of telomere length in Heilmann S, Kiefer AK, Fricker N, Drichel D, Wilson JF, Wright AF, Conley D, Davey-Smith G, 19 713 subjects reveals high heritability, stronger Hillmer AM, Herold C, Tung JY, Eriksson N, Franke L, Groenen PJ, Johannesson M, Kardia maternal inheritance and a paternal age effect. Redler S, Betz RC, Li R, Karason A, Nyholt DR, SL, Krueger RF, Laibson D, Martin NG, Meyer European Journal of Human Genetics. 2013. Vol Song K, Vermeulen SH, Kanoni S, Dedoussis G, MN, Posthuma D, Thurik AR, Timpson NJ, doi: 10.1038/ejhg.2012.303 Martin NG, Kiemeney LA, Mooser V, Stefansson Uitterlinden AG, van Duijn CM, Visscher PM, K, Richards JB, Becker T, Brockschmidt FF, Benjamin DJ, Cesarini D, Koellinger PD. GWAS Byrne EM, Gehrman PR, Medland SE, Nyholt Hinds DA, Nothen MM (2013a) androgenetic of 126,559 Individuals Identifies Genetic Variants DR, Heath AC, Madden PA, Hickie IB, Van Duijn Alopecia: Identification of Four Genetic Risk Associated with Educational Attainment. Science. CM, Henders AK, Montgomery GW, Martin NG, Loci and Evidence for the Contribution of WNT 2013. Vol doi: 10.1126/science.1235488 Wray NR. A genome-wide association study of Signaling to Its Etiology. The Journal of Investigative sleep habits and insomnia. Am J Med Genet B Dermatology. doi: 10.1038/jid.2013.43 Ripke S, Wray NR, Lewis CM, Hamilton SP, Neuropsychiatr Genet. 2013. Vol doi: 10.1002/ Weissman MM, Breen G, Byrne EM, Blackwood ajmg.b.32168 Heilmann S, Nyholt DR, Brockschmidt FF, DH, Boomsma DI, Cichon S, Heath AC, Hillmer AM, Herold C, Becker T, Martin NG, Holsboer F, Lucae S, Madden PA, Martin NG, Byrne EM, Johnson J, McRae AF, Nyholt DR, Nothen MM (2013b) No genetic support for a McGuffin P, Muglia P, Noethen MM, Penninx BP, Medland SE, Gehrman PR, Heath AC, Madden contribution of prostaglandins to the aetiology Pergadia ML, Potash JB, Rietschel M, Lin D, PA, Montgomery GW, Chenevix-Trench G, of androgenetic alopecia. The British Journal of Muller-Myhsok B, Shi J, Steinberg S, Grabe HJ, Martin NG. A genome-wide association study of Dermatology. doi: 10.1111/bjd.12292 Lichtenstein P, Magnusson P, Perlis RH, Preisig caffeine-related sleep disturbance: confirmation M, Smoller JW, Stefansson K, Uher R, Kutalik of a role for a common variant in the adenosine Lee SH, Harold D, Nyholt DR, Goddard ME, Z, Tansey KE, Teumer A, Viktorin A, Barnes MR, receptor. Sleep. 2012. Vol 35: 967-75. doi: Zondervan KT, Williams J, Montgomery GW, Bettecken T, Binder EB, Breuer R, Castro VM, 10.5665/sleep.1962 Wray NR, Visscher PM (2013) Estimation and partitioning of polygenic variation captured by Churchill SE, Coryell WH, Craddock N, Craig IW, Codd V, Nelson CP, Albrecht E, Mangino M, common SNPs for Alzheimer’s disease, multiple Czamara D, De Geus EJ, Degenhardt F, Farmer Deelen J, Buxton JL, Hottenga JJ, Fischer K, sclerosis and endometriosis. Human Molecular AE, Fava M, Frank J, Gainer VS, Gallagher PJ, Esko T, Surakka I, Broer L, Nyholt DR, Mateo Genetics 22: 832-41. doi: 10.1093/hmg/dds491 Gordon SD, Goryachev S, Gross M, Guipponi Leach I, Salo P, Hagg S, Matthews MK, Palmen M, Henders AK, Herms S, Hickie IB, Hoefels J, Norata GD, O’Reilly PF, Saleheen D, Amin Nyholt DR, Low SK, anderson CA, Painter JN, S, Hoogendijk W, Hottenga JJ, Iosifescu DV, N, Balmforth AJ, Beekman M, de Boer RA, Uno S, Morris AP, MacGregor S, Gordon SD, Ising M, Jones I, Jones L, Jung-Ying T, Knowles Bohringer S, Braund PS, Burton PR, de Craen Henders AK, Martin NG, Attia J, Holliday EG, JA, Kohane IS, Kohli MA, Korszun A, Landen AJ, Denniff M, Dong Y, Douroudis K, Dubinina E, McEvoy M, Scott RJ, Kennedy SH, Treloar SA, M, Lawson WB, Lewis G, Macintyre D, Maier Eriksson JG, Garlaschelli K, Guo D, Hartikainen Missmer SA, Adachi S, Tanaka K, Nakamura Y, W, Mattheisen M, McGrath PJ, McIntosh A, AL, Henders AK, Houwing-Duistermaat JJ, Zondervan KT, Zembutsu H, Montgomery GW. McLean A, Middeldorp CM, Middleton L, Kananen L, Karssen LC, Kettunen J, Klopp N, Genome-wide association meta-analysis identifies Montgomery GM, Murphy SN, Nauck M, Nolen Lagou V, van Leeuwen EM, Madden PA, Magi new endometriosis risk loci. Nature Genetics. WA, Nyholt DR, O’Donovan M, Oskarsson H, R, Magnusson PK, Mannisto S, McCarthy MI, 2012. Vol 44: 1355-9. doi: 10.1038/ng.2445 Pedersen N, Scheftner WA, Schulz A, Schulze TG, Shyn SI, Sigurdsson E, Slager SL, Smit Medland SE, Mihailov E, Montgomery GW, Rietveld CA, Medland SE, Derringer J, Yang J, JH, Stefansson H, Steffens M, Thorgeirsson Oostra BA, Palotie A, Peters A, Pollard H, Esko T, Martin NW, Westra HJ, Shakhbazov K, T, Tozzi F, Treutlein J, Uhr M, van den Oord Pouta A, Prokopenko I, Ripatti S, Salomaa V, Abdellaoui A, Agrawal A, Albrecht E, Alizadeh EJ, Van Grootheest G, Volzke H, Weilburg Suchiman HE, Valdes AM, Verweij N, Vinuela A, BZ, Amin N, Barnard J, Baumeister SE, Benke JB, Willemsen G, Zitman FG, Neale B, Daly Wang X, Wichmann HE, Widen E, Willemsen G, KS, Bielak LF, Boatman JA, Boyle PA, Davies M, Levinson DF, Sullivan PF. A mega-analysis Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, G, de Leeuw C, Eklund N, Evans DS, Ferhmann of genome-wide association studies for major Catapano AL, Tobin MD, Hall AS, Blakemore AI, R, Fischer K, Gieger C, Gjessing HK, Hagg S, depressive disorder. Molecular Psychiatry. 2013. van Gilst WH, Zhu H, Consortium C, Erdmann Harris JR, Hayward C, Holzapfel C, Ibrahim- Vol 18: 497-511. doi: 10.1038/mp.2012.21 J, Reilly MP, Kathiresan S, Schunkert H, Talmud Verbaas CA, Ingelsson E, Jacobsson B, PJ, Pedersen NL, Perola M, Ouwehand W, Joshi PK, Jugessur A, Kaakinen M, Kanoni S, Wray NR, Pergadia ML, Blackwood DH, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Karjalainen J, Kolcic I, Kristiansson K, Kutalik Z, Penninx BW, Gordon SD, Nyholt DR, Ripke S, Gieger C, Metspalu A, Boomsma DI, Jarvelin Lahti J, Lee SH, Lin P, Lind PA, Liu Y, Lohman K, MacIntyre DJ, McGhee KA, Maclean AW, Smit MR, Slagboom PE, Thompson JR, Spector Loitfelder M, McMahon G, Vidal PM, Meirelles JH, Hottenga JJ, Willemsen G, Middeldorp TD, van der Harst P, Samani NJ. Identification of O, Milani L, Myhre R, Nuotio ML, Oldmeadow CM, de Geus EJ, Lewis CM, McGuffin P, Hickie seven loci affecting mean telomere length and their CJ, Petrovic KE, Peyrot WJ, Polasek O, Quaye IB, van den Oord EJ, Liu JZ, Macgregor S, association with disease. Nat Genet. 2013. Vol 45: L, Reinmaa E, Rice JP, Rizzi TS, Schmidt H, McEvoy BP, Byrne EM, Medland SE, Statham 422-7, 427e1-2. doi: 10.1038/ng.2528 Schmidt R, Smith AV, Smith JA, Tanaka T, DJ, Henders AK, Heath AC, Montgomery GW, Cox HC, Lea RA, Bellis C, Carless M, Dyer Terracciano A, van der Loos MJ, Vitart V, Volzke Martin NG, Boomsma DI, Madden PA, Sullivan TD, Curran J, Charlesworth J, Macgregor S, H, Wellmann J, Yu L, Zhao W, Allik J, Attia PF. Genome-wide association study of major Nyholt D, Chasman D, Ridker PM, Schurks M, JR, Bandinelli S, Bastardot F, Beauchamp J, depressive disorder: new results, meta-analysis, Blangero J, Griffiths LR. A genome-wide analysis Bennett DA, Berger K, Bierut LJ, Boomsma DI, and lessons learned. Molecular Psychiatry. 2012. of ‘Bounty’ descendants implicates several novel Bultmann U, Campbell H, Chabris CF, Cherkas Vol 17: 36-48. doi: 10.1038/mp.2010.109 variants in migraine susceptibility. Neurogenetics. L, Chung MK, Cucca F, de andrade M, De Yang J, Loos RJ, Powell JE, Medland 2012. Vol 13: 261-6. doi: 10.1007/s10048-012- Jager PL, De Neve JE, Deary IJ, Dedoussis GV, SE, Speliotes EK, Chasman DI, Rose LM, 0325-x Deloukas P, Dimitriou M, Eiriksdottir G, Elderson MF, Eriksson JG, Evans DM, Faul JD, Ferrucci Thorleifsson G, Steinthorsdottir V, Magi R, Eggert SL, Huyck KL, Somasundaram P, Kavalla L, Garcia ME, Gronberg H, Gudnason V, Hall Waite L, Smith AV, Yerges-Armstrong LM, R, Stewart EA, Lu AT, Painter JN, Montgomery P, Harris JM, Harris TB, Hastie ND, Heath AC, Monda KL, Hadley D, Mahajan A, Li G, Kapur GW, Medland SE, Nyholt DR, Treloar SA, Hernandez DG, Hoffmann W, Hofman A, Holle K, Vitart V, Huffman JE, Wang SR, Palmer Zondervan KT, Heath AC, Madden PA, Rose R, Holliday EG, Hottenga JJ, Iacono WG, Illig T, C, Esko T, Fischer K, Zhao JH, Demirkan A, L, Buring JE, Ridker PM, Chasman DI, Martin Jarvelin MR, Kahonen M, Kaprio J, Kirkpatrick Isaacs A, Feitosa MF, Luan J, Heard-Costa NG, Cantor RM, Morton CC. Genome-wide RM, Kowgier M, Latvala A, Launer LJ, Lawlor NL, White C, Jackson AU, Preuss M, Ziegler linkage and association analyses implicate FASN in DA, Lehtimaki T, Li J, Lichtenstein P, Lichtner A, Eriksson J, Kutalik Z, Frau F, Nolte IM, Van predisposition to Uterine Leiomyomata. American P, Liewald DC, Madden PA, Magnusson PK, Vliet-Ostaptchouk JV, Hottenga JJ, Jacobs KB, Journal of Human Genetics. 2012. Vol 91: 621-8. Makinen TE, Masala M, McGue M, Metspalu Verweij N, Goel A, Medina-Gomez C, Estrada doi: 10.1016/j.ajhg.2012.08.009 A, Mielck A, Miller MB, Montgomery GW, K, Bragg-Gresham JL, Sanna S, Sidore C, Mukherjee S, Nyholt DR, Oostra BA, Palmer Tyrer J, Teumer A, Prokopenko I, Mangino M, Esposito T, Lea RA, Maher BH, Moses D, Cox LJ, Palotie A, Penninx B, Perola M, Peyser PA, Lindgren CM, Assimes TL, Shuldiner AR, Hui HC, Magliocca S, Angius A, Nyholt DR, Titus Preisig M, Raikkonen K, Raitakari OT, Realo J, Beilby JP, McArdle WL, Hall P, Haritunians T, Kay T, Gray NA, Rastaldi MP, Parnham A, A, Ring SM, Ripatti S, Rivadeneira F, Rudan I, T, Zgaga L, Kolcic I, Polasek O, Zemunik T, Gianfrancesco F, Griffiths LR. Unique X-linked Rustichini A, Salomaa V, Sarin AP, Schlessinger Oostra BA, Junttila MJ, Gronberg H, Schreiber familial FSGS with co-segregating heart block D, Scott RJ, Snieder H, St Pourcain B, Starr JM, S, Peters A, Hicks AA, Stephens J, Foad NS, disorder is associated with a mutation in the NXF5 Sul JH, Surakka I, Svento R, Teumer A, Tiemeier Laitinen J, Pouta A, Kaakinen M, Willemsen

Page 119 Scientiﬁc publications | continued

G, Vink JM, Wild SH, Navis G, Asselbergs FW, Ardjmand A, Bock CE, Shahrokhi S, Lincz LF, Hodgkin’s lymphoma. Genes, Chromosomes and Homuth G, John U, Iribarren C, Harris T, Launer Boyd AW, Burns GF, Thorne RF.Fat1 cadherin Cancer. 2013. Vol 52(5):467-79. L, Gudnason V, O’Connell JR, Boerwinkle E, provides a novel minimal residual disease marker in Cadby G, Palmer LJ, James AL, Musk AW, acute lymphoblastic leukemia. Hematology. 2013. Bain AL, Shi W, Khanna KK.Mouse models uncap Ingelsson E, Psaty BM, Beckmann JS, Waeber Vol [Epub ahead of print]. novel roles of SSBs. Cell Res. 2013. Vol 23(6):744- G, Vollenweider P, Hayward C, Wright AF, 745. Rudan I, Groop LC, Metspalu A, Khaw KT, van Asselbergs FW, G. Y., van Iperen EP, Sivapalaratnam S, Tragante V, Lanktree MB, Barnes DR, Barrowdale D, Beesley J, Chen Duijn CM, Borecki IB, Province MA, Wareham X; kConFab Investigators; Australian Ovarian NJ, Tardif JC, Huikuri HV, Cupples LA, Atwood Lange LA, Almoguera B, Appelman YE, Barnard J, Baumert J, Beitelshees AL, Bhangale TR, Cancer Study Group, James PA, Hopper JL, LD, Fox CS, Boehnke M, Collins FS, Mohlke Goldgar D, Chenevix-Trench G, Antoniou KL, Erdmann J, Schunkert H, Hengstenberg Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, AC, Mitchell G.Estimating single nucleotide C, Stark K, Lorentzon M, Ohlsson C, Cusi D, polymorphism associations using pedigree data: Staessen JA, Van der Klauw MM, Pramstaller Liu K, McDonough CW, Meijs MF, Middelberg RP, Musunuru K, Nelson CP, O’Connell JR, applications to breast cancer. British Journal of PP, Kathiresan S, Jolley JD, Ripatti S, Jarvelin Cancer. 2013. Vol 108(12):2610-2622. MR, de Geus EJ, Boomsma DI, Penninx B, Padmanabhan S, Pankow JS, Pankratz N, Wilson JF, Campbell H, Chanock SJ, van Rafelt S, Rajagopalan R, Romaine SP, Schork Barnes EC, Choomuenwai V, andrews KT, Quinn der Harst P, Hamsten A, Watkins H, Hofman NJ, Shaffer J, Shen H, Smith EN, Tischfield RJ, Davis RADesign and synthesis of screening A, Witteman JC, Zillikens MC, Uitterlinden SE, van der Most PJ, van Vliet-Ostaptchouk libraries based on the muurolane natural product AG, Rivadeneira F, Kiemeney LA, Vermeulen JV, Verweij N, Volcik KA, Zhang L, Bailey KR, scaffold Organic & Biomolecular Chemistry. 2012. SH, Abecasis GR, Schlessinger D, Schipf S, Bailey KM, Bauer F, Boer JM, Braund PS, Vol 10(20):4015-23. Stumvoll M, Tonjes A, Spector TD, North KE, Burt A, Burton PR, Buxbaum SG, Chen W, Batouli SA, Sachdev PS, Wen W, Wright MJ, Lettre G, McCarthy MI, Berndt SI, Heath AC, Cooper-Dehoff RM, Cupples LA, Dejong JS, Suo C, Ames D, Trollor JN.The heritability of Madden PA, Nyholt DR, Montgomery GW, Delles C, Duggan D, Fornage M, Furlong CE, brain metabolites on proton magnetic resonance Martin NG, McKnight B, Strachan DP, Hill Glazer N, Gums JG, Hastie C, Holmes MV, Illig spectroscopy in older individuals. Neuroimage. WG, Snieder H, Ridker PM, Thorsteinsdottir T, Kirkland SA, Kivimaki M, Klein R, Klein BE, 2012. Vol 62(1):281-289. U, Stefansson K, Frayling TM, Hirschhorn Kooperberg C, Kottke-Marchant K, Kumari M, Lacroix AZ, Mallela L, Murugesan G, Ordovas J, JN, Goddard ME, Visscher PM. FTO genotype Bauer MJ, Georgousakis MM, Vu T, Ouwehand WH, Post WS, Saxena R, Scharnagl is associated with phenotypic variability of Henningham A, Hofmann A, Rettel M, Hafner H, Schreiner PJ, Shah T, Shields DC, Shimbo D, body mass index Nature Genetics. 2012. Vol LM, Sriprakash KS, McMillan DJ.Evaluation of Srinivasan SR, Stolk RP, Swerdlow DI, Taylor HA 490(7419):267-72. novel Streptococcus pyogenes vaccine candidates Jr, Topol EJ, Toskala E, van Pelt JL, van Setten incorporating multiple conserved sequences from Anttila V, Winsvold BS, Gormley P, Kurth T, J, Yusuf S, Whittaker JC, Zwinderman AH; the C-repeat region of the M-protein. Vaccine. Bettella F, McMahon G, Kallela M, Malik R, LifeLines Cohort Study, Anand SS, Balmforth 2012. Vol 30(12):2197-2205. de Vries B, Terwindt G, Medland SE, Todt U, AJ, Berenson GS, Bezzina CR, Boehm BO, McArdle WL, Quaye L, Koiranen M, Ikram MA, Boerwinkle E, Casas JP, Caulfield MJ, Clarke Baughman, H. M., Giammarco EA, Veselka L, Lehtimäki T, Stam AH, Ligthart L, Wedenoja J, R, Connell JM, Cruickshanks KJ, Davidson Schermer JA, Martin NG, Lynskey M, Vernon Dunham I, Neale BM, Palta P, Hamalainen E, KW, Day IN, de Bakker PI, Doevendans PAA Behavioral Genetic Study of Humor Styles in Schürks M, Rose LM, Buring JE, Ridker PM, PA, Dominiczak AF, Hall AS, Hartman CA, an Australian Sample. Twin Research and Human Steinberg S, Stefansson H, Jakobsson F, Lawlor Hengstenberg C, Hillege HL, Hofker MH, Genetics. 2012. Vol 15(5):663-667. DA, Evans DM, Ring SM, Färkkilä M, Artto V, Humphries SE, Jarvik GP, Johnson JA, Kaess Kaunisto MA, Freilinger T, Schoenen J, Frants BM, Kathiresan S, Koenig W, Lawlor DA, M?rz Becherel OJ, Yeo AJ, Stellati A, Heng EY, Luff J, RR, Pelzer N, Weller CM, Zielman R, Heath AC, W, Melander O, Mitchell BD, Montgomery GW, Suraweera AM, Woods R, Fleming J, Carrie D, Madden PAF, Montgomery GW, Martin NG, Munroe PB, Murray SS, Newhouse SJ, Onland- McKinney K, Xu X, Deng C, Lavin MFSenataxin Borck G, Göbel H, Heinze A, Heinze-Kuhn K, Moret NC, Poulter N, Psaty B, Redline S, Rich plays an essential role with DNA damage response Williams FMK, Hartikainen A-L, Pouta A, van SS, Rotter JI, Schunkert H, Sever P, Shuldiner proteins in meiotic recombination and gene den Ende J, Uitterlinden AG, Hofman A, Amin AR, Silverstein RL, Stanton A, Thorand B, Trip silencing Plos Genetics. 2013. Vol 9(4):e1003435. N, Hottenga J-J, Vink JM, Heikkilä K, Alexander MD, Tsai MY, van der Harst P, van der Schoot E, Beesley VL, Price MA, Webb PM, O’Rourke P, M, Muller-Myhsok B, Schreiber S, Meitinger T, van der Schouw YT, Verschuren WM, Watkins Marquart L, Butow PN.Changes in supportive Wichmann HE, Aromaa A, Eriksson JG, Traynor H, Wilde AA, Wolffenbuttel BH, Whitfield JB, care needs after first-line treatment for ovarian B, Trabzuni D, Consortium. NABE, Consortium. Hovingh GK, Ballantyne CM, Wijmenga C, cancer: identifying care priorities and risk factors UBE, Rossin E, Lage K, Jacobs SBR, Gibbs JR, Reilly MP, Martin NG, Wilson JG, Rader DJ, for future unmet needs. Psychooncology. 2012. Vol Birney E, Kaprio J, Penninx BW, Boomsma DI, Samani NJ, Reiner AP, Hegele RA, Kastelein JJ, 22(7):1565-71. van Duijn C, Raitakari O, Jarvelin M-R, Zwart Hingorani AD, Talmud PJ, Hakonarson H, Elbers J-A, Cherkas L, Strachan DP, Kubisch C, Ferrari CC, Keating BJ, Drenos F.Large-Scale Gene- Benyamin, B., B. Pourcain, O. S. Davis, G. MD, van den Maagdenberg AMJM, Dichgans Centric Meta-analysis across 32 Studies Identifies Davies, N. K. Hansell, M. J. Brion, R. M. M, Wessman M, Smith GD, Stefansson K, Multiple Lipid Loci. American Journal of Human Kirkpatrick, R. A. Cents, S. Franic, M. B. Miller, Daly MJ, Nyholt DR, Chasman D, Palotie Genetics. 2012. Vol 91(5):823-838. C. M. Haworth, E. Meaburn, T. S. Price, D. A, for the International Headache Genetics M. Evans, N. Timpson, J. Kemp, S. Ring, W. Atkinson, J-A, Darren J. Gray, D.J., Clements, ConsortiumGenome-wide meta-analysis identifies McArdle, S. E. Medland, J. Yang, S. E. Harris, A.C.A, Barnes, T.S., Williams, G., McManus, new susceptibility loci for migraine Nature Genetics. D. C. Liewald, P. Scheet, X. Xiao, J. J. Hudziak, D.P., Yang, Y.R.Environmental influences on 2013. Vol 45(8):912-7. E. J. de Geus, V. W. Jaddoe, J. M. Starr, F. C. Echinococcus transmission: research priorities to Verhulst, C. Pennell, H. Tiemeier, W. G. Iacono, Apolloni, A. Sivakumaran, H. Lin, M. H. Li, D. support predictive surveillance. Global Change L. J. Palmer, G. W. Montgomery, N. G. Martin, Kershaw, M. H. Harrich, D.A mutant Tat protein Biology. 2013. Vol 19 677-688. D. I. Boomsma, D. Posthuma, M. McGue, provides strong protection from HIV-1 infection in M. J. Wright, G. Davey Smith, I. J. Deary, R. human CD4+ T cells Human Gene Therapy. 2012. Auster J, Hurst C, Neale RE, Youl P, Whiteman Plomin and P. M. VisscherChildhood intelligence Vol 24(3):270-82. DC, Baade P, Janda M.Determinants of uptake of whole-body skin self-examination in older men. is heritable, highly polygenic and associated with Apte SH, Groves PL, Skwarczynski M, Fujita Behavioral Medicine. 2013. Vol 39(2):36-43. FNBP1L. Molecular Psychiatry. 2013. Vol [Epub Y, Chang C, Toth I, Doolan DL.Vaccination with ahead of print]. lipid core peptides fails to induce epitope-specific T Auster J, Neale R, Youl P, Baade P, Gordon L, Bergin JE, N. M., Eaves LJ, Martin NG, Heath cell responses but confers non-specific protective Aitken J, Whiteman D, Janda M.Characteristics AC, Maes HH.Genetic and Environmental immunity in a malaria model. Plos One. 2012. Vol of men aged 50 years or older who do not take Transmission of Body Mass Index Fluctuation. 7(8):e40928. up skin self-examination following an educational intervention. Journal of The American Academy of Behavior Genetics. 2012. Vol 42(6):867-874. Apte SH, Redmond AM, Groves PL, Schussek Dermatology. 2012. Vol 67(1):e57-e58. Berndt, S. I., S. Gustafsson, R. Magi, A. Ganna, S, Pattinson DJ, Doolan DL.Subcutaneous E. Wheeler, M. F. Feitosa, A. E. Justice, K. cholera toxin exposure induces potent CD103+ Aya-Bonilla C, Green MR, Camilleri E, Benton L. Monda, D. C. Croteau-Chonka, F. R. Day, dermal dendritic cell activation and migration. M, Keane C, Marlton P, Lea R, Gandhi MK, T. Esko, T. Fall, T. Ferreira, D. Gentilini, A. U. European Journal of Immunology. 2013. Vol [Epub Griffiths LHigh resolution loss of heterozygosity Jackson, J. Luan, J. C. Randall, S. Vedantam, ahead of print]. screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non- C. J. Willer, T. W. Winkler, A. R. Wood, T. Workalemahu, Y. J. Hu, S. H. Lee, L. Liang, D.

Page 120 QIMR Annual Report 2012–2013 Y. Lin, J. L. Min, B. M. Neale, G. Thorleifsson, Schlessinger, V. Steinthorsdottir, D. P. Strachan, Ikram MA, Seshadri S; Cohorts for Heart and J. Yang, E. Albrecht, N. Amin, J. L. Bragg- U. Thorsteinsdottir, C. M. van Duijn, P. M. Aging Research in Genomic Epidemiology Gresham, G. Cadby, M. den Heijer, N. Eklund, K. Visscher, A. M. Di Blasio, J. N. Hirschhorn, Consortium.Common variants at 12q14 and Fischer, A. Goel, J. J. Hottenga, J. E. Huffman, I. C. M. Lindgren, A. P. Morris, D. Meyre, A. 12q24 are associated with hippocampal volume. Jarick, A. Johansson, T. Johnson, S. Kanoni, M. Scherag, M. I. McCarthy, E. K. Speliotes, K. Nature Genetics. 2012. Vol 44(5):545-551. E. Kleber, I. R. Konig, K. Kristiansson, Z. Kutalik, E. North, R. J. Loos and E. IngelssonGenome- C. Lamina, C. Lecoeur, G. Li, M. Mangino, W. wide meta-analysis identifies 11 new loci for Blokland GA, de Zubicaray GI, McMahon KL, L. McArdle, C. Medina-Gomez, M. Muller- anthropometric traits and provides insights into Wright MJ.Genetic and environmental influences Nurasyid, J. S. Ngwa, I. M. Nolte, L. Paternoster, genetic architecture. Nature Genetics. 2013. Vol on neuroimaging phenotypes: a meta-analytical S. Pechlivanis, M. Perola, M. J. Peters, M. 45(5):501-512. perspective on twin imaging studies. Twin Research Preuss, L. M. Rose, J. Shi, D. Shungin, A. V. and Human Genetics. 2012. Vol 15(3):351-371. Bettington Mark, Walker N, Clouston A, Brown Smith, R. J. Strawbridge, I. Surakka, A. Teumer, Bloom AJ, Harari O, Martinez M, Madden PA, M. D. Trip, J. Tyrer, J. V. Van Vliet-Ostaptchouk, I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and Martin NG, Montgomery GW, Rice JP, Murphy L. Vandenput, L. L. Waite, J. H. Zhao, D. Absher, SE, Bierut LJ, Goate A.Use of a predictive model F. W. Asselbergs, M. Atalay, A. P. Attwood, challenges. Histopathology. 2013. Vol 62(3):367- 86. derived from in vivo endophenotype measurements A. J. Balmforth, H. Basart, J. Beilby, L. L. to demonstrate associations with a complex locus, Bonnycastle, P. Brambilla, M. Bruinenberg, Betts, J.A., French, J,D., Brown, M.A, Edwards, CYP2A6. Human Molecular Genetics. 2012. Vol H. Campbell, D. I. Chasman, P. S. Chines, F. S.L.Long-range transcriptional regulation of breast 21(13):3050-3062. S. Collins, J. M. Connell, W. O. Cookson, U. cancer genes Genes, Chromosomes and Cancer. de Faire, F. de Vegt, M. Dei, M. Dimitriou, S. 2013. Vol 52(2):113-25. Bojesen, S. E. Pooley, K. A. Johnatty, S. Edkins, K. Estrada, D. M. Evans, M. Farrall, E. Beesley, J. Michailidou, K. Tyrer, J. M. M. Ferrario, J. Ferrieres, L. Franke, F. Frau, Bidwell, B. N., Slaney, C. Y., Withana, N. P. Edwards, S. L. Pickett, H. A. Shen, H. P. V. Gejman, H. Grallert, H. Gronberg, V. P., Forster, S., Cao, Y., Mikeska, T., Loi, S., C. Smart, C. E. Hillman, K. M. Mai, P. L. Gudnason, A. S. Hall, P. Hall, A. L. Hartikainen, andrews, D., Mangan, N. E., Samarajiwa, S.A., Lawrenson, K. Stutz, M. D. Lu, Y. Karevan, C. Hayward, N. L. Heard-Costa, A. C. Heath, de Weerd, N.A., Argani, P., M?ller, A., Smyth, R. Woods, N. Johnston, R. L. French, J. D. J. Hebebrand, G. Homuth, F. B. Hu, S. E. Hunt, M.J., anderson, R.L., Hertzog, P. J., and Parker, Chen, X. Weischer, M. Nielsen, S. F. Maranian, E. Hypponen, C. Iribarren, K. B. Jacobs, J. O. B.S.Silencing of Irf7 pathways in breast cancer M. J. Ghoussaini, M. Ahmed, S. Baynes, C. Jansson, A. Jula, M. Kahonen, S. Kathiresan, cells promotes bone metastasis through immune Bolla, M. K. Wang, Q. Dennis, J. McGuffog, F. Kee, K. T. Khaw, M. Kivimaki, W. Koenig, A. escape mechanisms. Nature Medicine. 2012. Vol L. Barrowdale, D. Lee, A. Healey, S. Lush, M. T. Kraja, M. Kumari, K. Kuulasmaa, J. Kuusisto, 19(8):1224. Tessier, D. C. Vincent, D. Bacot, F. Vergote, J. H. Laitinen, T. A. Lakka, C. Langenberg, L. J. I. Lambrechts, S. Despierre, E. Risch, H. Bieri, F., Gray, D., Raso, G., Li, Y.S., McManus, Launer, L. Lind, J. Lindstrom, J. Liu, A. Liuzzi, A. Gonzalez-Neira, A. Rossing, M. A. Pita, D.P.A systematic review of preventive health M. L. Lokki, M. Lorentzon, P. A. Madden, P. K. G. Doherty, J. A. Alvarez, N. Larson, M. educational videos targeting infectious diseases Magnusson, P. Manunta, D. Marek, W. Marz, C. Fridley, B. L. Schoof, N. Chang-Claude, in schoolchildren. American Journal of Tropical I. Mateo Leach, B. McKnight, S. E. Medland, J. Cicek, M. S. Peto, J. Kalli, K. R. Broeks, Medicine and Hygiene. 2012. Vol 87(6):972-978. E. Mihailov, L. Milani, G. W. Montgomery, V. A. Armasu, S. M. Schmidt, M. K. Braaf, L. Mooser, T. W. Muhleisen, P. B. Munroe, A. W. Bieri, F.A., Gray, D.J., Williams, G.M., Raso, G., M. Winterhoff, B. Nevanlinna, H. Konecny, Musk, N. Narisu, G. Navis, G. Nicholson, E. A. Li, Y.S., Yuan, L.P. He, Y.K., Li, R.S., Guo, F.Y, Li, G. E. Lambrechts, D. Rogmann, L. Guenel, Nohr, K. K. Ong, B. A. Oostra, C. N. Palmer, A. S.M., McManus, D.P.Health education package to P. Teoman, A. Milne, R. L. Garcia, J. J. Cox, Palotie, J. F. Peden, N. Pedersen, A. Peters, prevent worm infections in Chinese schoolchildren. A. Shridhar, V. Burwinkel, B. Marme, F. Hein, O. Polasek, A. Pouta, P. P. Pramstaller, I. New England Journal of Medicine. 2013. Vol R. Sawyer, E. J. Haiman, C. A. Wang-Gohrke, Prokopenko, C. Putter, A. Radhakrishnan, 368(17):29-38. S. andrulis, I. L. Moysich, K. B. Hopper, J. L. O. Raitakari, A. Rendon, F. Rivadeneira, I. Odunsi, K. Lindblom, A. Giles, G. G. Brenner, Rudan, T. E. Saaristo, J. G. Sambrook, A. R. Biroccio, A., Cherfils-Vicini, J., Pinte, S., H. Simard, J. Lurie, G. Fasching, P. A. Carney, Sanders, S. Sanna, J. Saramies, S. Schipf, Bauwens, S., Ye, J., Augereau, A., Jamet, K., M. E. Radice, P. Wilkens, L. R. Swerdlow, A. S. Schreiber, H. Schunkert, S. Y. Shin, S. Cervera, L., Mendez-Bermudez, A., Poncet, Goodman, M. T. Brauch, H. Garcia-Closas, M. Signorini, J. Sinisalo, B. Skrobek, N. Soranzo, D., Simonet, T., Ye, J., Augereau, A., Poncet, Hillemanns, P. Winqvist, R. Durst, M. Devilee, A. Stancakova, K. Stark, J. C. Stephens, K. D., Grataroli, R., T’kint de Rodenbeeke, C., P. Runnebaum, I. Jakubowska, A. Lubinski, Stirrups, R. P. Stolk, M. Stumvoll, A. J. Swift, E. D’Angelo, C., Scarsella, M., Cognet, C., J. Mannermaa, A. Butzow, R. Bogdanova, N. V. Theodoraki, B. Thorand, D. A. Tregouet, E. Kuilman, T., Duret, H., Lepinasse, F., Marvel, J., V. Dork, T. Pelttari, L. M. Zheng, W. Leminen, Tremoli, M. M. Van der Klauw, J. B. van Meurs, Verhoeyen, E., Cosset, F-L., Peeper, D., Smyth, A. Anton-Culver, H. Bunker, C. H. Kristensen, S. H. Vermeulen, J. Viikari, J. Virtamo, V. Vitart, M. J., Londono-Vallejo, A., Picco, V., Pages, V. Ness, R. B. Muir, K. Edwards, R. Meindl, G. Waeber, Z. Wang, E. Widen, S. H. Wild, G. G., Scoazec, J-Y, Stoppacciaro, A., Leonetti, A. Heitz, F. Matsuo, K. du Bois, A. Wu, A. Willemsen, B. R. Winkelmann, J. C. Witteman, C., Vivier, E., and Gilson, E.TRF2 inhibits a cell- H. Harter, P. Teo, S. H. Schwaab, I. Shu, X. B. H. Wolffenbuttel, A. Wong, A. F. Wright, extrinsic pathway through which natural killer cells O. Blot, W. Hosono, S. Kang, D. Nakanishi, M. C. Zillikens, P. Amouyel, B. O. Boehm, E. eliminate cancer cells. Nature Cell Biology. 2012. T. Hartman, M. Yatabe, Y. Hamann, U. Karlan, Boerwinkle, D. I. Boomsma, M. J. Caulfield, Vol 15(7):818-828. B. Y. Sangrajrang, S. Kjaer, S. K. Gaborieau, S. J. Chanock, L. A. Cupples, D. Cusi, G. V. V. Jensen, A. Eccles, D. Hogdall, E. Shen, C. Bis JC, DeCarli C, Smith AV, van der Lijn F, Dedoussis, J. Erdmann, J. G. Eriksson, P. W. Y. Brown, J. Woo, Y. L. Shah, M. Azmi, M. A. Crivello F, Fornage M, Debette S, Shulman JM, Franks, P. Froguel, C. Gieger, U. Gyllensten, A. Luben, R. Omar, S. Z. Czene, K. Vierkant, R. Schmidt H, Srikanth V, Schuur M, Yu L, Choi Hamsten, T. B. Harris, C. Hengstenberg, A. A. A. Nordestgaard, B. G. Flyger, H. Vachon, C. SH, Sigurdsson S, Verhaaren BF, DeStefano Hicks, A. Hingorani, A. Hinney, A. Hofman, K. Olson, J. E. Wang, X. Levine, D. A. Rudolph, AL, Lambert JC, Jack CR Jr, Struchalin M, G. Hovingh, K. Hveem, T. Illig, M. R. Jarvelin, A. Weber, R. P. Flesch-Janys, D. Iversen, Stankovich J, Ibrahim-Verbaas CA, Fleischman K. H. Jockel, S. M. Keinanen-Kiukaanniemi, L. E. Nickels, S. Schildkraut, J. M. Silva Idos, D, Zijdenbos A, den Heijer T, Mazoyer B, Coker A. Kiemeney, D. Kuh, M. Laakso, T. Lehtimaki, S. Cramer, D. W. Gibson, L. Terry, K. L. LH, Enzinger C, Danoy P, Amin N, Arfanakis D. F. Levinson, N. G. Martin, A. Metspalu, A. D. Fletcher, O. Vitonis, A. F. van der Schoot, C. K, van Buchem MA, de Bruijn RF, Beiser A, Morris, M. S. Nieminen, I. Njolstad, C. Ohlsson, E. Poole, E. M. Hogervorst, F. B. Tworoger, Dufouil C, Huang J, Cavalieri M, Thomson R, A. J. Oldehinkel, W. H. Ouwehand, L. J. Palmer, S. S. Liu, J. Bandera, E. V. Li, J. Olson, Niessen WJ, Chibnik LB, Gislason GK, Hofman B. Penninx, C. Power, M. A. Province, B. M. S. H. Humphreys, K. Orlow, I. Blomqvist, A, Pikula A, Amouyel P, Freeman KB, Phan TG, Psaty, L. Qi, R. Rauramaa, P. M. Ridker, S. C. Rodriguez-Rodriguez, L. Aittomaki, Oostra BA, Stein JL, Medland SE, Vasquez Ripatti, V. Salomaa, N. J. Samani, H. Snieder, K. Salvesen, H. B. Muranen, T. A. Wik, E. AA, Hibar DP, Wright MJ, Franke B, Martin T. I. Sorensen, T. D. Spector, K. Stefansson, Brouwers, B. Krakstad, C. Wauters, E. Halle, NG, Thompson PM; Enhancing Neuro Imaging A. Tonjes, J. Tuomilehto, A. G. Uitterlinden, M. K. Wildiers, H. Kiemeney, L. A. Mulot, Genetics through Meta-Analysis Consortium, M. Uusitupa, P. van der Harst, P. Vollenweider, C. Aben, K. K. Laurent-Puig, P. Altena, A. M. Nalls MA, Uitterlinden AG, Au R, Elbaz A, Beare H. Wallaschofski, N. J. Wareham, H. Watkins, Truong, T. Massuger, L. F. Benitez, J. Pejovic, RJ, van Swieten JC, Lopez OL, Harris TB, H. E. Wichmann, J. F. Wilson, G. R. Abecasis, T. Perez, J. I. Hoatlin, M. Zamora, M. P. Cook, Chouraki V, Breteler MM, De Jager PL, Becker T. L. Assimes, I. Barroso, M. Boehnke, I. B. L. S. Balasubramanian, S. P. Kelemen, L. E. JT, Vernooij MW, Knopman D, Fazekas F, Wolf Borecki, P. Deloukas, C. S. Fox, T. Frayling, L. Schneeweiss, A. Le, N. D. Sohn, C. Brooks- PA, van der Lugt A, Gudnason V, Longstreth C. Groop, T. Haritunian, I. M. Heid, D. Hunter, R. Wilson, A. Tomlinson, I. Kerin, M. J. Miller, N. WT Jr, Brown MA, Bennett DA, van Duijn CM, C. Kaplan, F. Karpe, M. F. Moffatt, K. L. Mohlke, Cybulski, C. Henderson, B. E. Menkiszak, J. Mosley TH, Schmidt R, Tzourio C, Launer LJ, J. R. O’Connell, Y. Pawitan, E. E. Schadt, D. Schumacher, F. Wentzensen, N. Le Marchand,

Page 121 Scientiﬁc publications | continued

L. Yang, H. P. Mulligan, A. M. Glendon, G. Chen, X. Weischer, M. Nielsen, S. F. Maranian, Stewart-Brown, S. Ditsch, N. Lichtner, P. Engelholm, S. A. Knight, J. A. Hogdall, C. M. J. Ghoussaini, M. Ahmed, S. Baynes, C. Schmutzler, R. K. Ito, H. Iwata, H. Tajima, K. K. Apicella, C. Gore, M. Tsimiklis, H. Song, Bolla, M. K. Wang, Q. Dennis, J. McGuffog, Tseng, C. C. Stram, D. O. van den Berg, D. H. Southey, M. C. Jager, A. den Ouweland, L. Barrowdale, D. Lee, A. Healey, S. Lush, M. Yip, C. H. Ikram, M. K. Teh, Y. C. Cai, H. Lu, A. M. Brown, R. Martens, J. W. Flanagan, J. Tessier, D. C. Vincent, D. Bacot, F. Vergote, W. Signorello, L. B. Cai, Q. Noh, D. Y. Yoo, M. Kriege, M. Paul, J. Margolin, S. Siddiqui, I. Lambrechts, S. Despierre, E. Risch, H. K. Y. Miao, H. Iau, P. T. Teo, Y. Y. McKay, N. Severi, G. Whittemore, A. S. Baglietto, L. A. Gonzalez-Neira, A. Rossing, M. A. Pita, J. Shapiro, C. Ademuyiwa, F. Fountzilas, G. McGuire, V. Stegmaier, C. Sieh, W. Muller, H. G. Doherty, J. A. Alvarez, N. Larson, M. Hsiung, C. N. Yu, J. C. Hou, M. F. Healey, C. Arndt, V. Labreche, F. Gao, Y. T. Goldberg, C. Fridley, B. L. Schoof, N. Chang-Claude, S. Luccarini, C. Peock, S. Stoppa-Lyonnet, M. S. Yang, G. Dumont, M. McLaughlin, J. J. Cicek, M. S. Peto, J. Kalli, K. R. Broeks, D. Peterlongo, P. Rebbeck, T. R. Piedmonte, R. Hartmann, A. Ekici, A. B. Beckmann, M. A. Armasu, S. M. Schmidt, M. K. Braaf, L. M. Singer, C. F. Friedman, E. Thomassen, W. Phelan, C. M. Lux, M. P. Permuth-Wey, J. M. Winterhoff, B. Nevanlinna, H. Konecny, M. ofﬁt, K. Hansen, T. V. Neuhausen, S. L. Peissel, B. Sellers, T. A. Ficarazzi, F. Barile, G. E. Lambrechts, D. Rogmann, L. Guenel, Szabo, C. I. Blanco, I. Garber, J. Narod, S. A. M. Ziogas, A. Ashworth, A. Gentry-Maharaj, P. Teoman, A. Milne, R. L. Garcia, J. J. Cox, Weitzel, J. N. Montagna, M. Olah, E. Godwin, A. Jones, M. Ramus, S. J. Orr, N. Menon, U. A. Shridhar, V. Burwinkel, B. Marme, F. Hein, A. K. Yannoukakos, D. Goldgar, D. E. Caldes, Pearce, C. L. Bruning, T. Pike, M. C. Ko, Y. R. Sawyer, E. J. Haiman, C. A. Wang-Gohrke, T. Imyanitov, E. N. Tihomirova, L. Arun, B. K. D. Lissowska, J. Figueroa, J. Kupryjanczyk, S. andrulis, I. L. Moysich, K. B. Hopper, J. L. Campbell, I. Mensenkamp, A. R. van Asperen, J. Chanock, S. J. Dansonka-Mieszkowska, Odunsi, K. Lindblom, A. Giles, G. G. Brenner, C. J. van Roozendaal, K. E. Meijers-Heijboer, A. Jukkola-Vuorinen, A. Rzepecka, I. H. Simard, J. Lurie, G. Fasching, P. A. Carney, H. Collee, J. M. Oosterwijk, J. C. Hooning, K. Pylkas, K. Bidzinski, M. Kauppila, S. M. E. Radice, P. Wilkens, L. R. Swerdlow, A. M. J. Rookus, M. A. van der Luijt, R. B. Os, Hollestelle, A. Seynaeve, C. Tollenaar, R. A. Goodman, M. T. Brauch, H. Garcia-Closas, M. T. A. Evans, D. G. Frost, D. Fineberg, E. Durda, K. Jaworska, K. Hartikainen, J. M. Hillemanns, P. Winqvist, R. Durst, M. Devilee, Barwell, J. Walker, L. Kennedy, M. J. Platte, Kosma, V. M. Kataja, V. Antonenkova, N. N. P. Runnebaum, I. Jakubowska, A. Lubinski, R. Davidson, R. Ellis, S. D. Cole, T. Bressac- Long, J. Shrubsole, M. Deming-Halverson, J. Mannermaa, A. Butzow, R. Bogdanova, N. de Paillerets, B. Buecher, B. Damiola, S. Lophatananon, A. Siriwanarangsan, P. V. Dork, T. Pelttari, L. M. Zheng, W. Leminen, F. Faivre, L. Frenay, M. Sinilnikova, O. M. Stewart-Brown, S. Ditsch, N. Lichtner, P. A. Anton-Culver, H. Bunker, C. H. Kristensen, Caron, O. Giraud, S. Mazoyer, S. Bonadona, Schmutzler, R. K. Ito, H. Iwata, H. Tajima, K. V. Ness, R. B. Muir, K. Edwards, R. Meindl, V. Caux-Moncoutier, V. Toloczko-Grabarek, Tseng, C. C. Stram, D. O. van den Berg, D. A. Heitz, F. Matsuo, K. du Bois, A. Wu, A. A. Gronwald, J. Byrski, T. Spurdle, A. B. Yip, C. H. Ikram, M. K. Teh, Y. C. Cai, H. Lu, H. Harter, P. Teo, S. H. Schwaab, I. Shu, X. Bonanni, B. Zaffaroni, D. Giannini, G. Bernard, W. Signorello, L. B. Cai, Q. Noh, D. Y. Yoo, O. Blot, W. Hosono, S. Kang, D. Nakanishi, L. Dolcetti, R. Manoukian, S. Arnold, N. K. Y. Miao, H. Iau, P. T. Teo, Y. Y. McKay, T. Hartman, M. Yatabe, Y. Hamann, U. Karlan, Engel, C. Deissler, H. Rhiem, K. Niederacher, J. Shapiro, C. Ademuyiwa, F. Fountzilas, G. B. Y. Sangrajrang, S. Kjaer, S. K. Gaborieau, D. Plendl, H. Sutter, C. Wappenschmidt, Hsiung, C. N. Yu, J. C. Hou, M. F. Healey, C. V. Jensen, A. Eccles, D. Hogdall, E. Shen, C. B. Borg, A. Melin, B. Rantala, J. Soller, M. S. Luccarini, C. Peock, S. Stoppa-Lyonnet, Y. Brown, J. Woo, Y. L. Shah, M. Azmi, M. A. Nathanson, K. L. Domchek, S. M. Rodriguez, D. Peterlongo, P. Rebbeck, T. R. Piedmonte, Luben, R. Omar, S. Z. Czene, K. Vierkant, R. G. C. Salani, R. Kaulich, D. G. Tea, M. K. M. Singer, C. F. Friedman, E. Thomassen, A. Nordestgaard, B. G. Flyger, H. Vachon, C. Paluch, S. S. Laitman, Y. Skytte, A. B. Kruse, M. ofﬁt, K. Hansen, T. V. Neuhausen, S. L. Olson, J. E. Wang, X. Levine, D. A. Rudolph, T. A. Jensen, U. B. Robson, M. Gerdes, A. M. Szabo, C. I. Blanco, I. Garber, J. Narod, S. A. A. Weber, R. P. Flesch-Janys, D. Iversen, Ejlertsen, B. Foretova, L. Savage, S. A. Lester, Weitzel, J. N. Montagna, M. Olah, E. Godwin, E. Nickels, S. Schildkraut, J. M. Silva Idos, J. Soucy, P. Kuchenbaecker, K. B. Olswold, A. K. Yannoukakos, D. Goldgar, D. E. Caldes, S. Cramer, D. W. Gibson, L. Terry, K. L. C. Cunningham, J. M. Slager, S. Pankratz, V. T. Imyanitov, E. N. Tihomirova, L. Arun, B. K. Fletcher, O. Vitonis, A. F. van der Schoot, C. S. Dicks, E. Lakhani, S. R. Couch, F. J. Hall, Campbell, I. Mensenkamp, A. R. van Asperen, E. Poole, E. M. Hogervorst, F. B. Tworoger, P. Monteiro, A. N. Gayther, S. A. Pharoah, C. J. van Roozendaal, K. E. Meijers-Heijboer, S. S. Liu, J. Bandera, E. V. Li, J. Olson, P. D. Reddel, R. R. Goode, E. L. Greene, M. H. Collee, J. M. Oosterwijk, J. C. Hooning, S. H. Humphreys, K. Orlow, I. Blomqvist, H. Easton, D. F. Berchuck, A. Antoniou, A. M. J. Rookus, M. A. van der Luijt, R. B. Os, C. Rodriguez-Rodriguez, L. Aittomaki, C. Chenevix-Trench, G. Dunning, A. M.Multiple T. A. Evans, D. G. Frost, D. Fineberg, E. K. Salvesen, H. B. Muranen, T. A. Wik, E. independent variants at the TERT locus are Barwell, J. Walker, L. Kennedy, M. J. Platte, Brouwers, B. Krakstad, C. Wauters, E. Halle, associated with telomere length and risks of breast R. Davidson, R. Ellis, S. D. Cole, T. Bressac- M. K. Wildiers, H. Kiemeney, L. A. Mulot, and ovarian cancer Nature Genetics. 2013. Vol de Paillerets, B. Buecher, B. Damiola, C. Aben, K. K. Laurent-Puig, P. Altena, A. M. 45(4):371-84. F. Faivre, L. Frenay, M. Sinilnikova, O. M. Truong, T. Massuger, L. F. Benitez, J. Pejovic, Caron, O. Giraud, S. Mazoyer, S. Bonadona, T. Perez, J. I. Hoatlin, M. Zamora, M. P. Cook, Bolderson E, Savage KI, Mahen R, Pisupati V. Caux-Moncoutier, V. Toloczko-Grabarek, L. S. Balasubramanian, S. P. Kelemen, L. E. V, Graham ME, Richard DJ, Robinson PJ, A. Gronwald, J. Byrski, T. Spurdle, A. B. Schneeweiss, A. Le, N. D. Sohn, C. Brooks- Venkitaraman AR, Khanna KK.Kruppel- Bonanni, B. Zaffaroni, D. Giannini, G. Bernard, Wilson, A. Tomlinson, I. Kerin, M. J. Miller, N. associated Box (KRAB)-associated co-repressor L. Dolcetti, R. Manoukian, S. Arnold, N. Cybulski, C. Henderson, B. E. Menkiszak, J. (KAP-1) Ser-473 phosphorylation regulates Engel, C. Deissler, H. Rhiem, K. Niederacher, Schumacher, F. Wentzensen, N. Le Marchand, heterochromatin protein 1beta (HP1-beta) D. Plendl, H. Sutter, C. Wappenschmidt, L. Yang, H. P. Mulligan, A. M. Glendon, G. mobilization and DNA repair in heterochromatin. B. Borg, A. Melin, B. Rantala, J. Soller, M. Engelholm, S. A. Knight, J. A. Hogdall, C. Journal of Biological Chemistry. 2012. Vol Nathanson, K. L. Domchek, S. M. Rodriguez, K. Apicella, C. Gore, M. Tsimiklis, H. Song, 287(33):28122-28131. G. C. Salani, R. Kaulich, D. G. Tea, M. K. H. Southey, M. C. Jager, A. den Ouweland, Bond C, Umapathy A, Buttenshaw R, Wockner Paluch, S. S. Laitman, Y. Skytte, A. B. Kruse, A. M. Brown, R. Martens, J. W. Flanagan, J. L, Leggett B and Whitehall V. Chromosomal T. A. Jensen, U. B. Robson, M. Gerdes, A. M. M. Kriege, M. Paul, J. Margolin, S. Siddiqui, instability in BRAF mutant, microsatellite stable Ejlertsen, B. Foretova, L. Savage, S. A. Lester, N. Severi, G. Whittemore, A. S. Baglietto, L. colorectal cancers. Plos One. 2012. Vol J. Soucy, P. Kuchenbaecker, K. B. Olswold, McGuire, V. Stegmaier, C. Sieh, W. Muller, H. 7(10):e47483. C. Cunningham, J. M. Slager, S. Pankratz, V. Arndt, V. Labreche, F. Gao, Y. T. Goldberg, S. Dicks, E. Lakhani, S. R. Couch, F. J. Hall, M. S. Yang, G. Dumont, M. McLaughlin, J. Bonilla, C., D. A. Lawlor, A. E. Taylor, D. J. P. Monteiro, A. N. Gayther, S. A. Pharoah, R. Hartmann, A. Ekici, A. B. Beckmann, M. Gunnell, Y. Ben-Shlomo, A. R. Ness, N. J. P. D. Reddel, R. R. Goode, E. L. Greene, M. W. Phelan, C. M. Lux, M. P. Permuth-Wey, J. Timpson, B. St Pourcain, S. M. Ring, P. M. H. Easton, D. F. Berchuck, A. Antoniou, A. Peissel, B. Sellers, T. A. Ficarazzi, F. Barile, Emmett, A. D. Smith, H. Refsum, C. E. Pennell, C. Chenevix-Trench, G. Dunning, A. M.Multiple M. Ziogas, A. Ashworth, A. Gentry-Maharaj, M. J. Brion, G. D. Smith and S. J. LewisVitamin independent variants at the TERT locus are A. Jones, M. Ramus, S. J. Orr, N. Menon, U. B-12 status during pregnancy and child’s IQ at age associated with telomere length and risks of breast Pearce, C. L. Bruning, T. Pike, M. C. Ko, Y. 8: a Mendelian randomization study in the Avon and ovarian cancer Nature Genetics. 2013. Vol D. Lissowska, J. Figueroa, J. Kupryjanczyk, longitudinal study of parents and children. Plos 45(4):371-84. J. Chanock, S. J. Dansonka-Mieszkowska, One. 2012. Vol 7(12):e51084. A. Jukkola-Vuorinen, A. Rzepecka, I. Boonstra T, Powell T, Mehrkanoon S, Bojesen, S. E. Pooley, K. A. Johnatty, S. K. Pylkas, K. Bidzinski, M. Kauppila, S. Breakspear M Effects of mnemonic load E. Beesley, J. Michailidou, K. Tyrer, J. Hollestelle, A. Seynaeve, C. Tollenaar, R. A. on cortical activity during visual working P. Edwards, S. L. Pickett, H. A. Shen, H. Durda, K. Jaworska, K. Hartikainen, J. M. memory: Linking ongoing brain activity with C. Smart, C. E. Hillman, K. M. Mai, P. L. Kosma, V. M. Kataja, V. Antonenkova, N. N. evoked responses. International Journal of Lawrenson, K. Stutz, M. D. Lu, Y. Karevan, Long, J. Shrubsole, M. Deming-Halverson, Psychophysiology. 2013. Vol [Epub ahead of print]. R. Woods, N. Johnston, R. L. French, J. D. S. Lophatananon, A. Siriwanarangsan, P.

Page 122 QIMR Annual Report 2012–2013 Boonstra, T. W. and M. BreakspearNeural Bosserhoff, A.K., Ellmann, L., Quast, A.S., Brown, F; Scott, N; Rank, G; Collinge, J; mechanisms of intermuscular coherence: Eberle, J., Boyle, G.M. and Kuphal, S.Loss of Vadolas, J; Vickaryous, N; Whitelaw, N; implications for the rectification of surface T-cadherin (CDH-13) regulates AKT signalling and Whitelaw, E; Kile, B; Jane, S; Curtis, D. ENU electromyography. Journal of Neurophysiology. desensitizes to apoptosis in melanoma. Accepted mutagenesis identifies the first mouse mutants 2012. Vol 107(3):796-807. 24/01/2013 Molecular Carcinogenesis. 2013. Vol reproducing human ß-thalassemia at the genomic [Epub ahead of print]. level. Blood, Cells, Molecules and Diseases. 2012. Boraska V, Jeroncic A, Colonna V, Southam L, Vol 50(2):86-92. Nyholt DR, Rayner NW, Perry JR, Toniolo D, Brachvogel B, Zaucke F, Dave K, Norris EL, Albrecht E, Ang W, Bandinelli S, Barbalic M, Stermann J, Dayakli M, Koch M, Gorman JJ, Buchanan DD, Win AK, Walsh MD, Walters Barroso I, Beckmann JS, Biffar R, Boomsma Bateman JF, Wilson R.Comparative Proteomic RJ, Clendenning M, Nagler B, Pearson SA, D, Campbell H, Corre T, Erdmann J, Esko Analysis of Normal and Collagen IX Null Mouse Macrae FA, Parry S, Arnold J, Winship I, Giles T, Fischer K, Franceschini N, Frayling TM, Cartilage Reveals Altered Extracellular Matrix GG, Lindor NM, Potter JD, Hopper JL, Rosty C, Girotto G, Gonzalez JR, Harris TB, Heath AC, Composition and Novel Components of the Young JP, Jenkins MA.Family History of Colorectal Heid IM, Hoffmann W, Hofman A, Horikoshi Collagen IX Interactome. Journal of Biological Cancer in BRAF p.V600E-Mutated Colorectal M, Zhao JH, Jackson AU, Hottenga JJ, Jula Chemistry. 2013. Vol 288(19):13481-13492. Cancer Cases. Cancer Epidemiology Biomarkers & A, Kahonen M, Khaw KT, Kiemeney LA, Klopp Prevention. 2013. Vol 22(5):917-926. N, Kutalik Z, Lagou V, Launer LJ, Lehtimaki T, Braskie MN, J. N., Toga AW, McMahon KL, de Lemire M, Lokki ML, Loley C, Luan J, Mangino Zubicaray GI, Martin NG, Wright MJ, Thompson Byrne EM, Carrillo-Roa T, Henders AK, M, Mateo Leach I, Medland SE, Mihailov PMHow a common variant in the growth factor Bowdler L, McRae AF, Heath AC, Martin E, Montgomery GW, Navis G, Newnham J, receptor gene, NTRK1, affects white matter. NG, Montgomery GW, Krause L, Wray Nieminen MS, Palotie A, Panoutsopoulou K, Bioarchitecture. 2012. Vol [Epub ahead of print]. NRMonozygotic twins affected with major depressive disorder have greater variance Peters A, Pirastu N, Polasek O, Rehnstrom K, Braskie MN, Jahanshad N, Stein JL, Barysheva in methylation than their unaffected co-twin. Ripatti S, Ritchie GR, Rivadeneira F, Robino M, Johnson K, McMahon KL, de Zubicaray GI, Translational Psychiatry. 2013. Vol e269. A, Samani NJ, Shin SY, Sinisalo J, Smit JH, Martin NG, Wright MJ, Ringman JM, Toga AW, Soranzo N, Stolk L, Swinkels DW, Tanaka T, Thompson PM.Relationship of a Variant in the Byrne EM, Gehrman PR, Medland SE, Nyholt Teumer A, Tonjes A, Traglia M, Tuomilehto J, NTRK1 Gene to White Matter Microstructure in DR, Heath AC, Madden PA, Hickie IB, Van Duijn Valsesia A, van Gilst WH, van Meurs JB, Smith Young Adults. Journal of Neuroscience. 2012. Vol CM, Henders AK, Montgomery GW, Martin AV, Viikari J, Vink JM, Waeber G, Warrington 32(17):5964-72. NG, Wray NRA genome-wide association study NM, Widen E, Willemsen G, Wright AF, Zanke of sleep habits and insomnia. American Journal of Braskie MN, Kohannim O, Jahanshad N, BW, Zgaga L, Boehnke M, d’Adamo AP, de Medical Genetics B: Neuropsychiatric Genetics. Chiang MC, Barysheva M, Toga AW, Ringman Geus E, Demerath EW, den Heijer M, Eriksson 2013. Vol 162(5):439-451. JG, Ferrucci L, Gieger C, Gudnason V, Hayward JM, Montgomery GW, McMahon KL, de C, Hengstenberg C, Hudson TJ, Jarvelin MR, Zubicaray GI, Martin NG, Wright MJ, Thompson Byrne EM, Johnson J, McRae AF, Nyholt DR, Kogevinas M, Loos RJ, Martin NG, Metspalu A, PM.Relation between variants in the neurotrophin Medland SE, Gehrman PR, Heath AC, Madden Pennell CE, Penninx BW, Perola M, Raitakari O, receptor gene, NTRK3, and white matter integrity in PA, Montgomery GW, Chenevix-Trench G, Salomaa V, Schreiber S, Schunkert H, Spector healthy young adults. Neuroimage. 2013. Vol [Epub Martin NGA genome-wide association study of TD, Stumvoll M, Uitterlinden AG, Ulivi S, van ahead of print]. caffeine-related sleep disturbance: confirmation der Harst P, Vollenweider P, Volzke H, Wareham of a role for a common variant in the adenosine Brewster, B L Rossiello, F French, J D Edwards, NJ, Wichmann HE, Wilson JF, Rudan I, Xue Y, receptor. Sleep. 2012. Vol 35(7):967-975. S L Wong, M Wronski, S Whiley, P Waddell, N Zeggini EGenome-wide meta-analysis of common Chen, X Bove, B Kconfab Hopper, J L John, C Keane, J P Nourse, P Crooks, D Nguyen- variant differences between men and women E M andrulis, I Daly, M Volorio, S Bernard, L Van, H Mutsando,P Mollee, RA Lea, MK Nature Genetics. 2012. Vol 21(21):4805-15. Peissel, B Manoukian, S Barile, M Pizzamiglio, GandhiHomozygous FCGR3A-158V alleles Boraska, V., Jeroncic A, Colonna V, Southam S Verderio, P Spurdle, A B Radice, P Godwin, predispose to late onset neutropenia after CHOP-R L, Nyholt DR, Rayner NW, Perry JR, Toniolo D, A K Southey, M C Brown, M A Peterlongo, P for Diffuse Large B-cell Lymphoma. Internal Albrecht E, Ang W, Bandinelli S, Barbalic M, Identification of fifteen novel germline variants in the Medicine. 2012. Vol 42(10):1113-9. Barroso I, Beckmann JS, Biffar R, Boomsma BRCA1 3’UTR reveals a variant in a breast cancer Campbell-Lloyd, A.J., Mundy, J., Deva, R., D, Campbell H, Corre T, Erdmann J, Esko T, case that introduces a functional miR-103 target Lampe, G., Hawley, C., Boyle, G., Griffin, R., Fischer K, Franceschini N, Frayling TM, Girotto site Human Mutation. 2012. Vol 33(12):1665-75. Thompson, C. and Shah P.Is Alpha-B Crystallin an G, Gonzalez JR, Harris TB, Heath AC, Heid IM, Brinkman DL, Aziz A, Loukas A, Potriquet J, Independent Marker for Prognosis in Lung Cancer? Hoffmann W, Hofman A, Horikoshi M, Zhao JH, Seymour J, Mulvenna J.Venom proteome of the Heart Lung Circ. 2013. Vol [Epub ahead of print]. Jackson AU, Hottenga JJ, Jula A, Kahonen box jellyfish Chironex fleckeri. Plos One. 2013. Vol M, Khaw KT, Kiemeney LA, Klopp N, Kutalik 7(12):e47866. Challinor VL, Stuthe JM, Parsons PG, Lambert Z, Lagou V, Launer LJ, Lehtimaki T, Lemire M, LK, Lehmann RP, Kitching W, De Voss JJ. Lokki ML, Loley C, Luan J, Mangino M, Leach Brion, M. J.Commentary: Can maternal-paternal Structure and bioactivity of steroidal saponins IM, Medland SE, Mihailov E, Montgomery GW, comparisons contribute to our understanding of isolated from the roots of Chamaelirium luteum Navis G, Newnham J, Nieminen MS, Palotie maternal pre-pregnancy obesity and its association (false unicorn). Journal of Natural Products. 2012. A, Panoutsopoulou K, Peters A, Pirastu N, with offspring cognitive outcomes? International Vol 75(8):1469-79. Polasek O, Rehnstrom K, Ripatti S, Ritchie Journal of Epidemiology. 2013. Vol 42(2):518-519. GR, Rivadeneira F, Robino A, Samani NJ, Chan, C. J., Smyth, M. J.*, Martinet, L.*Molecular Shin SY, Sinisalo J, Smit J, Soranzo N, Stolk Brodie AM, Lucas RM, Harrison SL, van der mechanisms of natural killer cell activation in L, Swinkels DW, Tanaka T, Teumer A, Tonjes Mei IA, Armstrong B, Kricker A, Mason RS, response to cellular stress. Cell Death and A, Traglia M, Tuomilehto J, Valsesia A, van McMichael AJ, Nowak M, Whiteman DC, Kimlin Differentiation. 2013. Vol (in press, 2013). Gilst WH, van Meurs JB, Smith AV, Viikari J, MG.The AusD Study: A Population-based Study Chiang MC, Barysheva M, McMahon KL, de Vink JM, Waeber G, Warrington NM, Widen of the Determinants of Serum 25-Hydroxyvitamin Zubicaray GI, Johnson K, Montgomery GW, E, Willemsen G, Wright AF, Zanke BW, Zgaga D Concentration Across a Broad Latitude Range. Martin NG, Toga AW, Wright MJ, Shapshak P, L, Wellcome Trust Case Control Consortium American Journal of Epidemiology. 2013. Vol Thompson PM.Gene network effects on brain (WTCCC), Boehnke M, d’Adamo AP, de Geus 177(9):894-903. microstructure and intellectual performance E, Demerath EW, den Heijer M, Eriksson JG, Broer L, Codd V, Nyholt DR, Deelen J, Mangino identified in 472 twins. Journal of Neuroscience. Ferrucci L, Gieger C, Gudnason V, Hayward M, Willemsen G, Albrecht E, Amin N, Beekman 2012. Vol 32(25):8732-8745. C, Hengstenberg C, Hudson TJ, Jarvelin MR, M, de Geus EJ, Henders A, Nelson CP, Kogevinas M, Loos RJ, Martin NG, Metspalu A, Steves CJ, Wright MJ, de Craen AJ, Isaacs A, Chiu YT, Liu J, Tang K, Wong YC, Khanna Pennell CE, Penninx BW, Perola M, Raitakari O, Matthews M, Moayyeri A, Montgomery GW, KK, Ling MTInactivation of ATM/ATR DNA Salomaa V, Schreiber S, Schunkert H, Spector Oostra BA, Vink JM, Spector TD, Slagboom damage checkpoint promotes androgen induced TD, Stumvoll M, Uitterlinden AG, Ulivi S, van PE, Martin NG, Samani NJ, van Duijn CM, chromosomal instability in prostate epithelial cells. der Harst P, Vollenweider P, Volzke H, Wareham Boomsma DI Meta-analysis of telomere length in Plos One. 2012. Vol 7(12):e51108. NJ, Wichmann HE, Wilson JF, Rudan I, Xue Y, 19 713 subjects reveals high heritability, stronger Zeggini EGenome-wide Meta-analysis of Common Choomuenwai V, andrews KT, Davis RA maternal inheritance and a paternal age effect. Variant Differences between Men and Women. Synthesis and antimalarial evaluation of a screening European Journal of Human Genetics. 2013. Vol Human Molecular Genetics. 2012. Vol 21(21):4805- library based on a tetrahydroanthraquinone natural [Epub ahead of print]. 4815. product scaffold Bioorganic & Medicinal Chemistry. 2012. Vol 20(24):7167-74.

Page 123 Scientiﬁc publications | continued

Chow, M. T., Sceneay, J., Paget, C., Wong, amongst Colon-CFR participants: have we been Balmaña J, Barkardottir RB, Arun BK, Rennert C. S. F., Duret, H., Tschopp, J., Moeller, A., missing anything? Familial Cancer. 2013. Vol [Epub G, Teo SH, Ganz PA, Campbell I, van der Hout and Smyth, M. J.NLRP3 suppresses NK cell- ahead of print]. AH, van Deurzen CH, Seynaeve C, Gómez mediated responses to carcinogen-induced tumors Garcia EB, van Leeuwen FE, Meijers-Heijboer and metastases. Cancer Research. 2012. Vol Codd V, Nelson CP, Albrecht E, Mangino M, HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg 72(22):5721-5732. Deelen J, Buxton JL, Hottenga JJ, Fischer K, MJ, Rookus MA, Devilee P, Verhoef S, van Os Esko T, Surakka I, Broer L, Nyholt DR, Mateo TA, Wijnen JT; HEBON; EMBRACE, Frost D, Chow, M. T., Tschopp, J., Moller, A., and Smyth, Leach I, Salo P, Hagg S, Matthews MK, Palmen Ellis S, Fineberg E, Platte R, Evans DG, Izatt M. J.NLRP3 promotes inflammation-induced skin J, Norata GD, O’Reilly PF, Saleheen D, Amin L, Eeles RA, Adlard J, Eccles DM, Cook J, cancer but is dispensable for asbestos-induced N, Balmforth AJ, Beekman M, de Boer RA, Brewer C, Douglas F, Hodgson S, Morrison PJ, mesothelioma. Immunology & Cell Biology. 2012. Bohringer S, Braund PS, Burton PR, de Craen Side LE, Donaldson A, Houghton C, Rogers Vol 90(10):983-986. AJ, Denniff M, Dong Y, Douroudis K, Dubinina E, MT, Dorkins H, Eason J, Gregory H, McCann Eriksson JG, Garlaschelli K, Guo D, Hartikainen E, Murray A, Calender A, Hardouin A, Berthet Chuah TL, Walker DG, Wei M, Scott S, Lavin AL, Henders AK, Houwing-Duistermaat JJ, MFApproaches to sensitizing glioblastoma to P, Delnatte C, Nogues C, Lasset C, Houdayer Kananen L, Karssen LC, Kettunen J, Klopp N, C, Leroux D, Rouleau E, Prieur F, Damiola F, radiotherapy: use of lentiviral vectors International Lagou V, van Leeuwen EM, Madden PA, Magi Journal of Oncology. 2012. Vol 40(6):1963-9. Sobol H, Coupier I, Venat-Bouvet L, Castera L, R, Magnusson PK, Mannisto S, McCarthy MI, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer Chuang I, Sedegah M, Cicatelli S, Spring Medland SE, Mihailov E, Montgomery GW, S, Bignon YJ; GEMO Study Collaborators, M, Polhemus M, Tamminga C, Patterson N, Oostra BA, Palotie A, Peters A, Pollard H, Zlowocka-Perlowska E, Gronwald J, Lubinski J, Guerrero M, Bennett JW, McGrath S, Ganeshan Pouta A, Prokopenko I, Ripatti S, Salomaa V, Durda K, Jaworska K, Huzarski T, Spurdle AB, H, Belmonte M, Farooq F, Abot E, Banania Suchiman HE, Valdes AM, Verweij N, Vinuela A, Viel A, Peissel B, Bonanni B, Melloni G, Ottini JG, Huang J, Newcomer R, Rein L, Litilit D, Wang X, Wichmann HE, Widen E, Willemsen G, L, Papi L, Varesco L, Tibiletti MG, Peterlongo Richie NO, Wood C, Murphy J, Sauerwein R, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, P, Volorio S, Manoukian S, Pensotti V, Arnold Hermsen CC, McCoy AJ, Kamau E, Cummings Catapano AL, Tobin MD, Hall AS, Blakemore AI, N, Engel C, Deissler H, Gadzicki D, Gehrig A, J, Komisar J, Sutamihardja A, Shi M, Epstein van Gilst WH, Zhu H, Consortium C, Erdmann Kast K, Rhiem K, Meindl A, Niederacher D, JE, Maiolatesi S, Tosh D, Limbach K, Angov J, Reilly MP, Kathiresan S, Schunkert H, Talmud Ditsch N, Plendl H, Preisler-Adams S, Engert E, Bergmann-Leitner E, Bruder JT, Doolan DL, PJ, Pedersen NL, Perola M, Ouwehand W, S, Sutter C, Varon-Mateeva R, Wappenschmidt King CR, Carucci D, Dutta S, Soisson L, Diggs Kaprio J, Martin NG, van Duijn CM, Hovatta I, B, Weber BH, Arver B, Stenmark-Askmalm M, C, Hollingdale MR, Ockenhouse CF, Richie Gieger C, Metspalu A, Boomsma DI, Jarvelin Loman N, Rosenquist R, Einbeigi Z, Nathanson TL.DNA Prime/Adenovirus Boost Malaria Vaccine MR, Slagboom PE, Thompson JR, Spector KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez Encoding P. falciparum CSP and AMA1 Induces TD, van der Harst P, Samani NJIdentification of GC, Small L, Friedlander M, Bae-Jump VL, Fink- Sterile Protection Associated with Cell-Mediated seven loci affecting mean telomere length and their Retter A, Rappaport C, Gschwantler-Kaulich Immunity. Plos One. 2013. Vol 8(2):e55571. association with disease. Nature Genetics. 2013. D, Pfeiler G, Tea MK, Lindor NM, Kaufman Vol 45(4):422-427. B, Shimon Paluch S, Laitman Y, Skytte AB, Cicek MS, Cunningham JM, Fridley BL, Serie Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, DJ, Bamlet WR, Diergaarde B, Haile RW, Le Coleman MA, Bridge JA, Lane SW, Dixon Jensen UB, Vijai J, Sarrel K, Robson M, Kauff Marchand L, Krontiris TG, Younghusband HB, CM, Hill GR, Wells JW, Thomas R, Steptoe N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen Gallinger S, Newcomb PA, Hopper JL, Jenkins RJ.Tolerance induction with gene-modified stem B, Nielsen FC, Jønson L, andersen MK, Ding MA, Casey G, Schumacher F, Chen Z, DeRycke cells and immune-preserving conditioning in primed YC, Steele L, Foretova L, Teulé A, Lazaro C, MS, Templeton AS, Winship I, Green RC, Green mice: restricting antigen to differentiated antigen- Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, JS, Macrae FA, Parry S, Young GP, Young JP, presenting cells permits efficacy. Blood. 2013. Vol Lester J, Orsulic S, Narod SA, Herzog J, Sand Buchanan D, Thomas DC, Bishop DT, Lindor 121(6):1049-1058. SR, Tognazzo S, Agata S, Vaszko T, Weaver NM, Thibodeau SN, Potter JD, Goode EL; Colon Collaborative Group on Epidemiological Studies J, Stavropoulou AV, Buys SS, Romero A, de CFR.Colorectal Cancer Linkage on Chromosomes of Ovarian Cancer, Beral V, Gaitskell K, Hermon la Hoya M, Aittomäki K, Muranen TA, Duran 4q21, 8q13, 12q24, and 15q22. Plos One. 2012. C, Moser K, Reeves G, Peto R.Ovarian cancer M, Chung WK, Lasa A, Dorfling CM, Miron Vol 7(5):e38175. and smoking: individual participant meta-analysis A; BCFR, Benitez J, Senter L, Huo D, Chan Clare Y. Slaney, andreas Möller, Paul Herzog, including 28,114 women with ovarian cancer from SB, Sokolenko AP, Chiquette J, Tihomirova L, Belinda S. ParkerThe role of Type I interferons in 51 epidemiological studies. Lancet Oncol. 2012. Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz immunoregulation of breast cancer metastasis to Vol 13(9):946-956. F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, bone Oncoimmunology. 2013. Vol 2(1):e22339. Colm Keane, Jamie P. Nourse, Maher K. Stevens K, Simard J, Pastinen T, Pankratz VS, GandhiRituximab induced Late-onset Neutropenia Clark PJ, Thompson AJ, Vock DM, Kratz offit K, Easton DF, Chenevix-Trench G, Antoniou In F. Columbus (Ed) Rituximab: Pharmacology, LE, Tolun AA, Muir AJ, McHutchison JG, AC; CIMBA.Genome-wide association study Clinical Uses and Health Effects. Hauppage, Ny: Subramanian M, Millington DM, Kelley RI, in BRCA1 mutation carriers identifies novel loci Nova Science Publishers.. 2013. Vol 85(10):810-2. Patel K.Hepatitis C virus selectively perturbs the associated with breast and ovarian cancer risk. distal cholesterol synthesis pathway in a genotype Cook MB, Shaheen NJ, anderson LA, Giffen Plos Genetics. 2013. Vol 9(3):E1003212. specific manner. Hepatology. 2012. Vol 56(1):49- C, Chow WH, Vaughan TL, Whiteman DC, Coulthard MG, Morgan M, Woodruff TM, 56. Corley DA.Cigarette smoking increases risk of Arumugam TV, Taylor SM, Carpenter TC, Barrett’s esophagus: an analysis of the Barrett’s Clark, P. J. and A. J. MuirLost in translation? Lackmann M, Boyd AW.Eph/Ephrin signaling and Esophageal Adenocarcinoma Consortium. IL28B’s discovery and the journey back to the in injury and inflammation. American Journal of Gastroenterology. 2012. Vol 142(4):744-753. patient. Hepatology. 2012. Vol 56(1):5-8. Pathology. 2012. Vol 181(5):1493-1503. Couch FJ, Wang X, McGuffog L, Lee A, Olswold Clark, P. J. and A. J. MuirOvercoming barriers Cousminer, D. L., D. J. Berry, N. J. Timpson, C, Kuchenbaecker KB, Soucy P, Fredericksen to care for hepatitis C. New England Journal of W. Ang, E. Thiering, E. M. Byrne, H. R. Taal, Z, Barrowdale D, Dennis J, Gaudet MM, Dicks Medicine. 2012. Vol 366(26):2436-2438. V. Huikari, J. P. Bradfield, M. Kerkhof, M. E, Kosel M, Healey S, Sinilnikova OM, Lee A, M. Groen-Blokhuis, E. Kreiner-Moller, M. Clendenning M, Macrae FA, Walsh MD, Walters Bacot F, Vincent D, Hogervorst FB, Peock S, Marinelli, C. Holst, J. T. Leinonen, J. R. Perry, RJ, Thibodeau SN, Gunawardena SR, Potter Stoppa-Lyonnet D, Jakubowska A; kConFab I. Surakka, O. Pietilainen, J. Kettunen, V. JD, Haile RW, Gallinger S; Colorectal Cancer Investigators, Radice P, Schmutzler RK; SWE- Anttila, M. Kaakinen, U. Sovio, A. Pouta, S. Family Registry, Hopper JL, Jenkins MA, BRCA, Domchek SM, Piedmonte M, Singer CF, Das, V. Lagou, C. Power, I. Prokopenko, D. M. Rosty C, Young JP, Buchanan DD.Absence of Friedman E, Thomassen M; Ontario Cancer Evans, J. P. Kemp, B. St Pourcain, S. Ring, A. PMS2 mutations in colon-CFR participants whose Genetics Network, Hansen TV, Neuhausen SL, Palotie, E. Kajantie, C. Osmond, T. Lehtimaki, colorectal cancers demonstrate unexplained loss Szabo CI, Blanco I, Greene MH, Karlan BY, J. S. Viikari, M. Kahonen, N. M. Warrington, of MLH1 expression. Clinical Genetics. 2013. Vol Garber J, Phelan CM, Weitzel JN, Montagna M, S. J. Lye, L. J. Palmer, C. M. Tiesler, C. 83(6):591-593. Olah E, andrulis IL, Godwin AK, Yannoukakos Flexeder, G. W. Montgomery, S. E. Medland, D, Goldgar DE, Caldes T, Nevanlinna H, Clendenning M, Walsh MD, Gelpi JB, Thibodeau A. Hofman, H. Hakonarson, M. Guxens, M. Osorio A, Terry MB, Daly MB, van Rensburg SN, Lindor N, Potter JD, Newcomb P, Bartels, V. Salomaa, J. M. Murabito, J. Kaprio, EJ, Hamann U, Ramus SJ, Toland AE, Caligo Lemarchand L, Haile R, Gallinger S; Colorectal T. I. Sorensen, F. Ballester, H. Bisgaard, D. I. MA, Olopade OI, Tung N, Claes K, Beattie Cancer Family Registry, Hopper JL, Jenkins Boomsma, G. H. Koppelman, S. F. Grant, V. W. MS, Southey MC, Imyanitov EN, Tischkowitz MA, Rosty C, Young JP, Buchanan DD.Detection Jaddoe, N. G. Martin, J. Heinrich, C. E. Pennell, M, Janavicius R, John EM, Kwong A, Diez O, of large scale 3’ deletions in the PMS2 gene O. T. Raitakari, J. G. Eriksson, G. D. Smith, E.

Page 124 QIMR Annual Report 2012–2013 Hypponen, M. R. Jarvelin, M. I. McCarthy, S. J, Manning AK, Liu CT, Kooner J, Mooser Kivimaki M, Knight B, Koskinen S, Kovacs P, Ripatti and E. WidenGenome-wide association VE, Vollenweider P, Kapur KA, Chambers J, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer and longitudinal analyses reveal genetic loci Wareham NJ, Langenberg C, Frants R, Willems- O, Lecoeur C, Li Y, Mahley R, Mangino M, linking pubertal height growth, pubertal timing and Vandijk K, Oostra BA, Willems SM, Lamina Martínez-Larrad MT, McAteer JB, McPherson childhood adiposity. Human Molecular Genetics. C, Winkler TW, Psaty BM, Tracy RP, Brody J, R, Meisinger C, Melzer D, Meyre D, Mitchell 2013. Vol 22(13):2735-2747. Chen I, Viikari J, Kähönen M, Pramstaller PP, BD, Mukherjee S, Naitza S, Neville MJ, Orrù Evans DM, St Pourcain B, Sattar N, Wood AR, M, Pakyz R, Paolisso G, Pattaro C, Pearson Cox HC, Lea RA, Bellis C, Carless M, Dyer Bandinelli S, Carlson OD, Egan JM, Böhringer D, Peden JF, Pedersen NL, Pfeiffer AF, Pichler TD, Curran J, Charlesworth J, Macgregor S, S, van Heemst D, Kedenko L, Kristiansson I, Polasek O, Posthuma D, Potter SC, Pouta Nyholt D, Chasman D, Ridker PM, Schurks M, K, Nuotio ML, Loo BM, Harris T, Garcia M, A, Province MA, Rayner NW, Rice K, Ripatti Blangero J, Griffiths LRA genome-wide analysis Kanaya A, Haun M, Klopp N, Wichmann HE, S, Rivadeneira F, Rolandsson O, Sandbaek of ‘Bounty’ descendants implicates several novel Deloukas P, Katsareli E, Couper DJ, Duncan BB, A, Sandhu M, Sanna S, Sayer AA, Scheet P, variants in migraine susceptibility. Neurogenetics. Kloppenburg M, Adair LS, Borja JB; DIAGRAM+ Seedorf U, Sharp SJ, Shields B, Sigurðsson G, 2012. Vol 13(3):261-266. Consortium; MAGIC Consortium; GLGC Sijbrands EJ, Silveira A, Simpson L, Singleton Cozzi SJ, Le TT, Ogbourne SM, James C, Investigators; MuTHER Consortium, Wilson A, Smith NL, Sovio U, Swift A, Syddall H, Suhrbier A.Effective treatment of squamous JG, Musani S, Guo X, Johnson T, Semple R, Syvänen AC, Tönjes A, Uitterlinden AG, van cell carcinomas with ingenol mebutate gel in Teslovich TM, Allison MA, Redline S, Buxbaum Dijk KW, Varma D, Visvikis-Siest S, Vitart V, immunologically intact SKH1 mice. Archives of SG, Mohlke KL, Meulenbelt I, Ballantyne CM, Vogelzangs N, Waeber G, Wagner PJ, Walley Dermatological Research. 2013. Vol 305(1):79-83. Dedoussis GV, Hu FB, Liu Y, Paulweber B, A, Ward KL, Watkins H, Wild SH, Willemsen G, Spector TD, Slagboom PE, Ferrucci L, Jula A, Witteman JC, Yarnell JW, Zelenika D, Zethelius Cozzi SJ, Ogbourne SM, James C, Rebel HG, Perola M, Raitakari O, Florez JC, Salomaa V, B, Zhai G, Zhao JH, Zillikens MC; DIAGRAM de Gruijl FR, Ferguson B, Gardner J, Lee TT, Eriksson JG, Frayling TM, Hicks AA, Lehtimäki Consortium; GIANT Consortium; Global B Pgen Larcher T, Suhrbier A.Ingenol mebutate field- T, Smith GD, Siscovick DS, Kronenberg F, van Consortium, Borecki IB, Meneton P, Magnusson directed treatment of UVB-damaged skin reduces Duijn C, Loos RJ, Waterworth DM, Meigs JB, PK, Nathan DM, Williams GH, Silander K, lesion formation and removes mutant p53 patches. Dupuis J, Richards JB, Voight BF, Scott LJ, Bornstein SR, Schwarz P, Spranger J, Karpe Journal of Investigative Dermatology. 2012. Vol Steinthorsdottir V, Dina C, Welch RP, Zeggini F, Shuldiner AR, Cooper C, Serrano-Ríos M, 132(4):1263-1271. E, Huth C, Aulchenko YS, Thorleifsson G, Lind L, Palmer LJ, Hu FB 1st, Franks PW, McCulloch LJ, Ferreira T, Grallert H, Amin N, Ebrahim S, Marmot M, Kao WH, Pramstaller PP, Craig, P.S., Woods, M., Boufana, B., Wu G, Willer CJ, Raychaudhuri S, McCarroll Wright AF, Stumvoll M, Hamsten A; Procardis O?Loughlin, B., Gimpel, J., Wells, R., Li, W., SA, Hofmann OM, Segrè AV, van Hoek M, Consortium, Buchanan TA, Valle TT, Rotter JI, McManus, D.P.Cystic echinococcosis in a fox- Navarro P, Ardlie K, Balkau B, Benediktsson Penninx BW, Boomsma DI, Cao A, Scuteri A, hound hunt worker UK. Pathogens and Global R, Bennett AJ, Blagieva R, Boerwinkle E, Schlessinger D, Uda M, Ruokonen A, Jarvelin Health. 2012. Vol 106(6):373-375. Bonnycastle LL, Boström KB, Bravenboer B, MR, Peltonen L, Mooser V, Sladek R; MAGIC Cridland JA, Curley EZ, Wykes MN, Schroder Bumpstead S, Burtt NP, Charpentier G, Chines investigators; GLGC Consortium, Musunuru K, K, Sweet MJ, Roberts TL, Ragan MA, Kassahn PS, Cornelis M, Crawford G, Doney AS, Elliott Smith AV, Edmondson AC, Stylianou IM, Koseki KS, Stacey, KJThe mammalian PYHIN gene KS, Elliott AL, Erdos MR, Fox CS, Franklin M, Pirruccello JP, Chasman DI, Johansen CT, family: phylogeny, evolution and expression. Bmc CS, Ganser M, Gieger C, Grarup N, Green T, Fouchier SW, Peloso GM, Barbalic M, Ricketts Evolutionary Biology. 2012. Vol 12 140. Griffin S, Groves CJ, Guiducci C, Hadjadj S, SL, Bis JC, Feitosa MF, Orho-Melander M, Hassanali N, Herder C, Isomaa B, Jackson AU, Melander O, Li X, Li M, Cho YS, Go MJ, Kim Croft A, Walsh A, Doecke J, Cooley R, Howlett Johnson PR, Jørgensen T, Kao WH, Kong A, YJ, Lee JY, Park T, Kim K, Sim X, Ong RT, M, Radford-Smith G.Outcomes of salvage therapy Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse Croteau-Chonka DC, Lange LA, Smith JD, for steroid-refractory acute severe ulcerative colitis: A, Lindgren CM, Lyssenko V, Marre M, Meitinger Ziegler A, Zhang W, Zee RY, Whitfield JB, ciclosporin vs. infliximab. Alimentary Pharmacology T, Midthjell K, Morken MA, Narisu N, Nilsson Thompson JR, Surakka I, Spector TD, Smit & Therapeutics. 2013. Vol 38(3):294-302. P, Owen KR, Payne F, Petersen AK, Platou C, JH, Sinisalo J, Scott J, Saharinen J, Sabatti Proença C, Prokopenko I, Rathmann W, Rayner Cromer D, Best SE, Engwerda C, Haque A, C, Rose LM, Roberts R, Rieder M, Parker AN, NW, Robertson NR, Rocheleau G, Roden M, Davenport M.Where have all the parasites gone? Pare G, O’Donnell CJ, Nieminen MS, Nickerson Sampson MJ, Saxena R, Shields BM, Shrader Modelling early malaria parasite sequestration DA, Montgomery GW, McArdle W, Masson D, P, Sigurdsson G, Sparsø T, Strassburger K, dynamics. Plos One. 2013. Vol 8(2):e55961. Martin NG, Marroni F, Lucas G, Luben R, Lokki Stringham HM, Sun Q, Swift AJ, Thorand B, ML, Lettre G, Launer LJ, Lakatta EG, Laaksonen Cromer, D., Tey, SK., Khanna, R. Davenport, Tichet J, Tuomi T, van Dam RM, van Haeften R, Kyvik KO, König IR, Khaw KT, Kaplan LM, MPEstimating CMV growth rates using only TW, van Herpt T, van Vliet-Ostaptchouk Johansson Å, Janssens AC, Igl W, Hovingh a single point Journal of Virology. 2012. Vol JV, Walters GB, Weedon MN, Wijmenga C, GK, Hengstenberg C, Havulinna AS, Hastie ND, 87(6):3376-81. Witteman J, Bergman RN, Cauchi S, Collins Harris TB, Haritunians T, Hall AS, Groop LC, FS, Gloyn AL, Gyllensten U, Hansen T, Hide Gonzalez E, Freimer NB, Erdmann J, Ejebe KG, Cross-Disorder Group of the Psychiatric WA, Hitman GA, Hofman A, Hunter DJ, Hveem Döring A, Dominiczak AF, Demissie S, Deloukas Genomics Consortium, J. Smoller, N. Craddock, K, Laakso M, Morris AD, Palmer CN, Rudan I, P, de Faire U, Crawford G, Chen YD, Caulfield K. Kendler, P. Lee, B. Neale, J. Nurnberger, S. Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden MJ, Boekholdt SM, Assimes TL, Quertermous Ripke, S. Santangelo and P. SullivanIdentification A, Walker M, Watanabe RM, Abecasis GR, T, Seielstad M, Wong TY, Tai ES, Feranil AB, of risk loci with shared effects on five major Boehm BO, Campbell H, Daly MJ, Hattersley Kuzawa CW, Taylor HA Jr, Gabriel SB, Holm H, psychiatric disorders: a genome-wide analysis. AT, Pedersen O, Barroso I, Groop L, Sladek R, Gudnason V, Krauss RM, Ordovas JM, Munroe Lancet. 2013. Vol 381(9875):1371-1379. Thorsteinsdottir U, Wilson JF, Illig T, Froguel PB, Kooner JS, Tall AR, Hegele RA, Kastelein da Silva, FA. Li, M. Rato, S. Maia, S. Malho, P, van Duijn CM, Stefansson K, Altshuler D, JJ, Schadt EE, Strachan DP, Reilly MP, Samani R. Warren, K. Harrich, D. Craige, R. Barbas Boehnke M, McCarthy MI, Soranzo N, Wheeler NJ, Schunkert H, Cupples LA, Sandhu MS, III, Carlos. Goncalves, Joao.Recombinant rabbit E, Glazer NL, Bouatia-Naji N, Mägi R, Randall Ridker PM, Rader DJ, Kathiresan S.Novel loci single-chain antibodies bind to the catalytic and J, Elliott P, Rybin D, Dehghan A, Hottenga for adiponectin levels and their influence on type 2 C-terminal domains of HIV-1 integrase protein and JJ, Song K, Goel A, Lajunen T, Doney A, diabetes and metabolic traits: a multi-ethnic meta- strongly inhibit HIV-1 replication Biotechnology and Cavalcanti-Proença C, Kumari M, Timpson NJ, analysis of 45,891 individuals. Plos Genetics. 2012. Applied Biochemistry. 2012. Vol 59(5):353-66. Zabena C, Ingelsson E, An P, O’Connell J, Luan Vol 8(3):e1002607. J, Elliott A, McCarroll SA, Roccasecca RM, Dasari, V. Smith, C. and Khanna, RRecent Pattou F, Sethupathy P, Ariyurek Y, Barter P, Davis RA, Buchanan MS, Duffy S, Avery advances in designing an effective vaccine to Beilby JP, Ben-Shlomo Y, Bergmann S, Bochud VM, Charman SA, Charman WN, White KL, prevent CMV-associated clinical diseases. Expert M, Bonnefond A, Borch-Johnsen K, Böttcher Shackleford DM, Edstein MD, andrews KT, Review of Vaccines. 2013. Vol 12(6):661-76. Y, Brunner E, Bumpstead SJ, Chen YD, Chines Camp D, Quinn RJAntimalarial Activity of P, Clarke R, Coin LJ, Cooper MN, Crisponi L, Pyrroloiminoquinones from the Australian Marine Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan Day IN, de Geus EJ, Delplanque J, Fedson AC, Sponge Zyzzya Journal of Medicinal Chemistry. X, Scott RA, Henneman P, Heid IM, Kizer JR, Fischer-Rosinsky A, Forouhi NG, Franzosi MG, 2012. Vol 55(12):5851-8. Lyytikäinen LP, Fuchsberger C, Tanaka T, Morris Galan P, Goodarzi MO, Graessler J, Grundy AP, Small K, Isaacs A, Beekman M, Coassin Daxinger, L; Oey, H; Apedaile, A; Sutton, J; S, Gwilliam R, Hallmans G, Hammond N, Han S, Lohman K, Qi L, Kanoni S, Pankow JS, Uh Ashe, A and E Whitelaw (2012) A forward X, Hartikainen AL, Hayward C, Heath SC, HW, Wu Y, Bidulescu A, Rasmussen-Torvik genetic screen identifies eukaryotic translation Hercberg S, Hillman DR, Hingorani AD, Hui J, LJ, Greenwood CM, Ladouceur M, Grimsby initiation factor 3, subunit H (eIF3h), as an enhancer Hung J, Kaakinen M, Kaprio J, Kesaniemi YA,

Page 125 Scientiﬁc publications | continued

of variegation in the mouse. Genes, Genomes, Absher D, Albert CM, Alonso A, Arking DE, de Computing and Computer-Assisted Intervention. Genetics G3. 2012. Vol 2(11):1393-6. Bakker PI, Balkau B, Barlassina C, Benaglio P, 2012. Vol 15(Part 3):305-312. Bis JC, Bouatia-Naji N, Brage S, Chanock SJ, Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Chines PS, Chung M, Darbar D, Dina C, Dörr Derycke MS, Gunawardena SR, Middha S, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, M, Elliott P, Felix SB, Fischer K, Fuchsberger Asmann YW, Schaid DJ, McDonnell SK, Riska Lim YC, offenhäuser C, Charmsaz S, Cooper C, de Geus EJ, Goyette P, Gudnason V, Harris SM, Eckloff BW, Cunningham JM, Fridley BL, LT, Ellacott JK, Harding A, Leveque L, Inglis TB, Hartikainen AL, Havulinna AS, Heckbert Serie DJ, Bamlet WR, Cicek MS, Jenkins MA, P, Allan S, Walker DG, Lackmann M, Osborne SR, Hicks AA, Hofman A, Holewijn S, Hoogstra- Duggan DJ, Buchanan D, Clendenning M, G, Khanna KK, Reynolds BA, Lickliter JD, Berends F, Hottenga JJ, Jensen MK, Johansson Haile RW, Woods MO, Gallinger SN, Casey G, Boyd AW.EphA3 maintains tumorigenicity and is A, Junttila J, Kääb S, Kanon B, Ketkar S, Khaw Potter JD, Newcomb PA, Le Marchand L, Lindor a therapeutic target in glioblastoma multiforme. KT, Knowles JW, Kooner AS, Kors JA, Kumari NM, Thibodeau SN, Goode EL.Identification of Cancer Cell. 2013. Vol 23(2):238-248. M, Milani L, Laiho P, Lakatta EG, Langenberg Novel Variants in Colorectal Cancer Families by High-Throughput Exome Sequencing. Cancer Day FL, Jorissen RN, Lipton L, Mouradov D, C, Leusink M, Liu Y, Luben RN, Lunetta KL, Epidemiology Biomarkers & Prevention. 2013. Vol Sakthianandeswaren A, Christie M, Li S, Tsui Lynch SN, Markus MR, Marques-Vidal P, 22(7):1239-1251. C, Tie J, Desai J, Xu Z-Z, Molloy P, Whitehall Mateo Leach I, McArdle WL, McCarroll SA, V, Leggett BA, Jones IT, McLaughlin S, Ward Medland SE, Miller KA, Montgomery GW, Diemert DJ, Pinto AG, Freire J, Jariwala A, RL, Hawkins NJ, Ruskiewicz AR, Moore J, Morrison AC, Müller-Nurasyid M, Navarro P, Santiago H, Hamilton RG, Periago MV, Loukas Busam D, Zhao Q, Strausberg RL, Gibbs P, Nelis M, O’Connell JR, O’Donnell CJ, Ong KK, A, Tribolet L, Mulvenna J, Correa-Oliveira R, Sieber OM. PIK3CA and PTEN gene and exon Newman AB, Peters A, Polasek O, Pouta A, Hotez PJ, Bethony JM.Generalized urticaria mutation-specific clinicopathologic and molecular Pramstaller PP, Psaty BM, Rao DC, Ring SM, induced by the Na-ASP-2 hookworm vaccine: associations in colorectal cancer. Clinical Cancer Rossin EJ, Rudan D, Sanna S, Scott RA, Sehmi implications for the development of vaccines Research. 2013. Vol 19(12):3285-96. JS, Sharp S, Shin JT, Singleton AB, Smith AV, against helminths. Journal of Allergy and Clinical Soranzo N, Spector TD, Stewart C, Stringham Immunology. 2012. Vol 130(1):169-76. de Bock CE, Ardjmand A, Molloy TJ, Bone HM, Tarasov KV, Uitterlinden AG, Vandenput SM, Johnstone D, Campbell DM, Shipman KL, L, Hwang SJ, Whitfield JB, Wijmenga C, Wild Ding YC, McGuffog L, Healey S, Friedman Yeadon TM, Holst J, Spanevello MD, Nelmes G, SH, Willemsen G, Wilson JF, Witteman JC, E, Laitman Y, ShimonPaluch S, Kaufman Catchpoole DR, Lincz LF, Boyd AW, Burns GF, Wong A, Wong Q, Jamshidi Y, Zitting P, Boer B, Liljegren A, Lindblom A, Olsson H, Thorne RF.The Fat1 cadherin is overexpressed JM, Boomsma DI, Borecki IB, van Duijn CM, Kristoffersson U, Stenmark Askmalm M, Melin and an independent prognostic factor for survival Ekelund U, Forouhi NG, Froguel P, Hingorani B, Domchek SM, Nathanson KL, Rebbeck TR, in paired diagnosis-relapse samples of precursor A, Ingelsson E, Kivimaki M, Kronmal RA, Kuh Jakubowska A, Lubinski J, Jaworska K, Durda B-cell acute lymphoblastic leukemia. Leukemia. D, Lind L, Martin NG, Oostra BA, Pedersen NL, K, Gronwald J, Huzarski T, Cybulski C, Byrski 2012. Vol 26(5):918-926. Quertermous T, Rotter JI, van der Schouw YT, T, Osorio A, Ramony Cajal T, Stavropoulou AV, Verschuren WM, Walker M, Albanes D, Arnar Benítez J, Hamann U, Rookus MA, Aalfs CM, de Moor MH, Costa PT, Terracciano A, Krueger DO, Assimes TL, Bandinelli S, Boehnke M, de de Lange J, MeijersHeijboer HE, Oosterwijk RF, de Geus EJ, Toshiko T, Penninx BW, Esko Boer RA, Bouchard C, Caulfield WL, Chambers JC, van Asperen CJ, GomezGarcia EB, T, Madden PA, Derringer J, Amin N, Willemsen JC, Curhan G, Cusi D, Eriksson J, Ferrucci L, Hoogerbrugge N, Jager A, van der Luijt RB, G, Hottenga JJ, Distel MA, Uda M, Sanna S, van Gilst WH, Glorioso N, de Graaf J, Groop Easton DF, Peock S, Frost D, Ellis SD, Platte Spinhoven P, Hartman CA, Sullivan P, Realo L, Gyllensten U, Hsueh WC, Hu FB, Huikuri R, Fineberg E, Evans DG, Lalloo F, Izatt L, A, Allik J, Heath AC, Pergadia ML, Agrawal A, HV, Hunter DJ, Iribarren C, Isomaa B, Jarvelin Eeles RA, Adlard J, Davidson R, Eccles DM, Lin P, Grucza R, Nutile T, Ciullo M, Rujescu D, MR, Jula A, Kähönen M, Kiemeney LA, van Cole T, Cook J, Brewer C, Tischkowitz M, Giegling I, Konte B, Widen E, Cousminer DL, der Klauw MM, Kooner JS, Kraft P, Iacoviello Godwin AK, Pathak HB, StoppaLyonnet D, Eriksson JG, Palotie A, Peltonen L, Luciano L, Lehtimäki T, Lokki ML, Mitchell BD, Navis Sinilnikova OM, Mazoyer S, Barjhoux L, Leone M, Tenesa A, Davies G, Lopez LM, Hansell G, Nieminen MS, Ohlsson C, Poulter NR, Qi M, GauthierVillars M, CauxMoncoutier V, de NK, Medland SE, Ferrucci L, Schlessinger D, L, Raitakari OT, Rimm EB, Rioux JD, Rizzi F, Pauw A, Hardouin A, Berthet P, Dreyfus H, Fert Montgomery GW, Wright MJ, Aulchenko YS, Rudan I, Salomaa V, Sever PS, Shields DC, Ferrer S, CollongeRame MA, Sokolowska J, Janssens AC, Oostra BA, Metspalu A, Abecasis Shuldiner AR, Sinisalo J, Stanton AV, Stolk Buys SS, Daly MB, Miron A, Terry MB, Chung GR, Deary IJ, Räikkönen K, Bierut LJ, Martin RP, Strachan DP, Tardif JC, Thorsteinsdottir U, WK, John EM, Southey MC, Goldgar DE, Singer NG, van Duijn CM, Boomsma DI.Meta-analysis Tuomilehto J, van Veldhuisen DJ, Virtamo J, CF, Tea Maria MK, GschwA non-synonymous of genome-wide association studies for personality. Viikari J, Vollenweider P, Waeber G, Widen E, polymorphism in IRS1 modifies risk of developing Molecular Psychiatry. 2012. Vol 17(3):337-349. Cho YS, Olsen JV, Visscher PM, Willer C, Franke breast and ovarian cancers in BRCA1 and ovarian Delahanty RJ, Xiang YB, Spurdle A, Beeghly- L; Global BPgen Consortium; CARDIoGRAM cancer in BRCA2 mutation carriers. Cancer Fadiel A, Long J, Thompson D, Tomlinson I, Consortium, Erdmann J, Thompson JR; Epidemiology Biomarkers & Prevention. 2012. Vol Yu H, Lambrechts D, Dörk T, Goodman MT, PR GWAS Consortium, Pfeufer A; QRS 21(8):1362-70. Zheng Y, Salvesen HB, Bao PP, Amant F, GWAS Consortium, Sotoodehnia N; QT-IGC Dixon KJ, Munro KM, Boyd AW, Bartlett PF, Beckmann MW, Coenegrachts L, Coosemans Consortium, Newton-Cheh C; CHARGE-AF Turnley AM.Partial change in EphA4 knockout A, Dubrowinskaja N, Dunning A, Runnebaum Consortium, Ellinor PT, Stricker BH, Metspalu A, mouse phenotype: loss of diminished GFAP IB, Easton D, Ekici AB, Fasching PA, Halle MK, Perola M, Beckmann JS, Smith GD, Stefansson upregulation following spinal cord injury. Neurosci Hein A, Howarth K, Gorman M, Kaydarova D, K, Wareham NJ, Munroe PB, Sibon OC, Milan Lett. 2012. Vol 525(1):66-71. Krakstad C, Lose F, Lu L, Lurie G, O’Mara T, DJ, Snieder H, Samani NJ, Loos RJIdentification Matsuno RK, Pharoah P, Risch H, Corssen M, of heart rate-associated loci and their effects on DJ Smith, GJ anderson, DW Reid. Accurate Trovik J, Turmanov N, Wen W, Lu W, Cai Q, cardiac conduction and rhythm disorders. Nature determination of iron status in cystic fibrosis Zheng W, Shu XO.Polymorphisms in inflammation Genetics. 2013. Vol 45(6):621-631. will avoid the hazards of inappropriate iron pathway genes and endometrial cancer risk. supplementation. Journal of Cystic Fibrosis. 2012. Dennis EL, J. N., McMahon KL, de Zubicaray Cancer Epidemiology Biomarkers & Prevention. Vol 12(3):303-304. GI, Martin NG, Hickie IB, Toga AW, Wright MJ, 2013. Vol 22(2):216-223. Thompson PM.Development of Brain Structural DJ Smith, IL Lamont, GJ anderson, DW Reid. den Hoed M, Eijgelsheim M, Esko T, Brundel Connectivity between Ages 12 and 30: A 4-Tesla Targeting iron uptake to control P. aeruginosa BJ, Peal DS, Evans DM, Nolte IM, Segrè AV, Diffusion Imaging Study in 439 Adolescents and infections in cystic fibrosis. European Respiratory Holm H, Handsaker RE, Westra HJ, Johnson Adults. Neuroimage. 2013. Vol 64 671-684. Journal. 2012. Vol [Epub ahead of print]. T, Isaacs A, Yang J, Lundby A, Zhao JH, Kim Dennis EL, J. N., Toga AW, Johnson K, YJ, Go MJ, Almgren P, Bochud M, Boucher Doecke JD, Simms LA, Zhao ZZ, Huang N, McMahon KL, de Zubicaray GI, Martin NG, G, Cornelis MC, Gudbjartsson D, Hadley D, Hanigan K, Krishnaprasad K, Roberts RL, Hickie IB, Wright MJ, Thompson PM.Changes van der Harst P, Hayward C, den Heijer M, andrews JM, Mahy G, Bampton P, Lewindon P, in Anatomical Brain Connectivity Between Ages Igl W, Jackson AU, Kutalik Z, Luan J, Kemp Florin T, Lawrance IC, Gearry RB, Montgomery 12 and 30: A Hardi Study of 467 Adolescents and JP, Kristiansson K, Ladenvall C, Lorentzon GW, Radford-Smith GL.Genetic susceptibility in Adults. Proceedings Ieee International Symposium M, Montasser ME, Njajou OT, O’Reilly PF, IBD: overlap between ulcerative colitis and Crohn’s On Biomedical Imaging. 2012. Vol 2012 904-908. Padmanabhan S, St Pourcain B, Rankinen T, disease. Inflammatory Bowel Diseases. 2013. Vol 19(2):240-245. Salo P, Tanaka T, Timpson NJ, Vitart V, Waite Dennis EL, J. N., Toga AW, McMahon KL, de L, Wheeler W, Zhang W, Draisma HH, Feitosa Zubicaray GI, Martin NG, Wright MJ, Thompson Dong Y, Stephens C, Walpole C, Swedberg MF, Kerr KF, Lind PA, Mihailov E, Onland-Moret PM.Test-retest reliability of graph theory measures JE, Boyle GM, Parsons PG, McGuckin NC, Song C, Weedon MN, Xie W, Yengo L, of structural brain connectivity. Medical Image MA, Harris JM, Clements JA. Paclitaxel

Page 126 QIMR Annual Report 2012–2013 resistance and multicellular spheroid formation Earl ST, Richards R, Johnson LA, Flight S, Journal of Human Genetics. 2012. Vol 91(4):621- are induced by kallikrein-related peptidase 4 anderson S, Liao A, de Jersey J, Masci PP, 628. in serous ovarian cancer cells in an ascites Lavin MFIdentification and characterisation of mimicking microenvironment Plos One. 2013. Vol Kunitz-type plasma kallikrein inhibitors unique to Ekeruche-Makinde J, Clement M, Cole DK, 8(2):e57056. Oxyuranus sp. snake venoms Biochimie. 2012. Vol Edwards ES, Ladell K, Miles JJ, Matthews 94(2):365-73. KK, Fuller A, Lloyd KA, Madura F, Dolton GM, Dong, Y., Stephens, C., Walpole, C., Swedberg, Pentier J, Lissina A, Gostick E, Baxter TK, J.E., Harris, J.M., Boyle, G.M., Parsons, P.G., Ebejer JL, D. D., van der Werf J, Wright MJ, Baker BM, Rizkallah PJ, Price DA, Wooldridge McGuckin, M.A. and Clements, J.A. Paclitaxel Montgomery G, Gillespie NA, Hickie IB, Martin L, Sewell AK.T-cell receptor-optimized peptide Resistance and Multicellular Spheroid Formation NG, Medland SE.Genome-wide association skewing of the T-cell repertoire can enhance are Induced by Kallikrein-Related Peptidase 4 study of inattention and hyperactivity-impulsivity antigen targeting. Journal of Biological Chemistry. in Serous Ovarian Cancer Cells in an Ascites measured as quantitative traits. Twin Research and 2012. Vol 287(44):37269-37281. Mimicking Microenvironment. Plos One. 2013. Vol Human Genetics. 2013. Vol 16(2):560-574. 8(2):e57056. Ekeruche-Makinde J, Miles JJ, van den Ebejer JL, M. S., van der Werf J, Gondro C, Berg HA, Skowera A, Cole DK, Dolton Doolan, D. L. and S. H. ApteAddressing Henders AK, Lynskey M, Martin NG, Duffy G, Schauenburg AJ, Tan MP, Pentier JM, the bottleneck at clinical testing of candidate DLAttention deficit hyperactivity disorder in Llewellyn-Lacey S, Miles KM, Bulek AM, malaria vaccines. Pathog Glob Health. 2012. Vol Australian adults: prevalence, persistence, conduct Clement M, Williams T, Trimby A, Bailey M, 106(6):321-322. problems and disadvantage. Plos One. 2012. Vol Rizkallah P, Rossjohn J, Peakman M, Price DA, 7(10):e47404. Burrows SR, Sewell AK, Wooldridge LPeptide Dorrance AM, De Vita S, Radu M, Reddy PN, length determines the outcome of TCR/peptide- McGuinness MK, Harris CE, Mathieu R, Lane Eeles RA, Olama AA, Benlloch S, Saunders MHCI engagement. Blood. 2013. Vol 121(7):1112- SW, Kosoff R, Milsom MD, Chernoff J, Williams EJ, Leongamornlert DA, Tymrakiewicz 1123. DA.The Rac GTPase effector p21-activated kinase M, Ghoussaini M, Luccarini C, Dennis J, is essential for hematopoietic stem/progenitor Jugurnauth-Little S, Dadaev T, Neal DE, Ellingson JM, S. W., Richmond-Rakerd LS, cell migration and engraftment. Blood. 2013. Vol Hamdy FC, Donovan JL, Muir K, Giles GG, Martin NG.Investigating the Influence of Prenatal 121(13):2474-82. Severi G, Wiklund F, Gronberg H, Haiman CA, androgen Exposure and Sibling Effects on Alcohol Schumacher F, Henderson BE, Le Marchand Use and Alcohol Use Disorder in Females from Dowty J, Win A, Buchanan D, Lindor N, L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Opposite-Sex Twin Pairs.. Alcoholism, Clinical and Macrae F, Clendenning M, Antill Y, Thibodeau Chanock SJ, Berndt SI, Albanes D, andriole Experimental Research. 2013. Vol 37(5):868-76. S, Casey G, Gallinger S, Le Marchand L, G, Schleutker J, Weischer M, Canzian F, Riboli Newcomb P, Haile R, Young G, James P, Giles E, Key TJ, Travis RC, Campa D, Ingles SA, Ellis, M.K., Yang, Y.R., McManus, D.P., Gray, G, Gunawardena S, Leggett B, Gattas M, John EM, Hayes RB, Pharoah PD, Pashayan D.J., Wang, X.L., Yang, S.K., Ross, A.G., Boussioutas A, Ahnen D, Baron J, Parry S, N, Khaw KT, Stanford JL, Ostrander EA, Williams, G.M.Evaluation of the tuberculosis Goldblatt J, Young J, Hopper J and Jenkins Signorello LB, Thibodeau SN, Schaid D, Maier programme in Ningxia Hui Autonomous Region, the M.Cancer Risks for MLH1 and MSH2 Mutation C, Vogel W, Kibel AS, Cybulski C, Lubinski People’s Republic of China: a retrospective case Carriers. Human Mutation. 2013. Vol 34(3):490- J, Cannon-Albright L, Brenner H, Park JY, study. Bmc Public Health. 2012. Vol 12 1110. 497. Kaneva R, Batra J, Spurdle AB, Clements JA, Engelman D, Martin DL, Hay RJ, Chosidow O, Duarte-Carvajalino JM, Jahanshad N, Lenglet Teixeira MR, Dicks E, Lee A, Dunning AM, McCarthy JS, Fuller LC, Steer AC.Opportunities C, McMahon KL, de Zubicaray GI, Martin NG, Baynes C, Conroy D, Maranian MJ, Ahmed S, to investigate the effects of ivermectin mass drug Wright MJ, Thompson PM, Sapiro G.Hierarchical Govindasami K, Guy M, Wilkinson RA, Sawyer administration on scabies. Parasit Vectors. 2013. topological network analysis of anatomical human EJ, Morgan A, Dearnaley DP, Horwich A, Vol 6 106. brain connectivity and differences related to sex Huddart RA, Khoo VS, Parker CC, Van As NJ, and kinship. Neuroimage. 2012. Vol 59(4):3784- Woodhouse CJ, Thompson A, Dudderidge T, Engwerda, C. & Belz, G.4th Australasian vaccines 3804. Ogden C, Cooper CS, Lophatananon A, Cox and immunotherapeutic development meeting. A, Southey MC, Hopper JL, English DR, Aly Immunology & Cell Biology. 2012. Vol 90(10):921- Dubois L, Ohm Kyvik K, Girard M, Tatone- M, Adolfsson J, Xu J, Zheng SL, Yeager M, 924. Tokuda F, Pérusse D, Hjelmborg J, Skytthe A, Kaaks R, Diver WR, Gaudet MM, Stern MC, Engwerda, C.R. & Good, M.F.Immunology. Rasmussen F, Wright MJ, Lichtenstein P, Martin Corral R, Joshi AD, Shahabi A, Wahlfors T, Platelets kill the parasite within. Science. 2012. Vol NG.Genetic and Environmental Contributions to Tammela TL, Auvinen A, Virtamo J, Klarskov 338(6112):1304-1305. Weight, Height, and BMI from Birth to 19 Years of P, Nordestgaard BG, Røder MA, Nielsen SF, Age: An International Study of Over 12,000 Twin Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Engwerda, C.R., Minigo, G., Amante, F.H. & Pairs. Plos One. 2012. Vol 7(2):e30153. Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai McCarthy, J.S.Experimentally induced blood stage Q, McDonnell SK, Rinckleb AE, Drake B, Colditz Dulhunty JM, Suhrbier A, Macaulay GA, Brett malaria infection as a tool for clinical research. G, Wokolorczyk D, Stephenson RA, Teerlink C, JC, van Straaten AV, Brereton IM, Farmer Trends In Parasitology. 2012. Vol 28(11):515-521. Muller H, Rothenbacher D, Sellers TA, Lin HY, JF.Guide-wire fragment embolisation in paediatric Slavov C, Mitev V, Lose F, Srinivasan S, Maia Esposito T, Lea RA, Maher BH, Moses D, Cox peripherally inserted central catheters. Medical S, Paulo P, Lange E, Cooney KA, Antoniou HC, Magliocca S, Angius A, Nyholt DR, Titus Journal of Australia. 2012. Vol 196(4):250-255. AC, Vincent D, Bacot F, Tessier DC; COGS– T, Kay T, Gray NA, Rastaldi MP, Parnham A, Dutton-Regester,K. and N. K. HaywardWhole Cancer Research UK GWAS–ELLIPSE (part Gianfrancesco F, Griffiths LRUnique X-linked genome and exome sequencing of melanoma: of GAME-ON) Initiative; Australian Prostate familial FSGS with co-segregating heart block a step toward personalized targeted therapy. Cancer Bioresource; UK Genetic Prostate disorder is associated with a mutation in the Advances In Pharmacology. 2012. Vol 65 399-435. Cancer Study Collaborators/British Association NXF5 gene Human Molecular Genetics. 2013. Vol of Urological Surgeons’ Section of Oncology; 22(18):3654-66. DW Reid, SC Bell.ICU outcomes in CF following UK ProtecT (Prostate testing for cancer and Evans DM, Zhu G, Dy V, Heath AC, Madden invasive ventilation. Respirology. 2013. Vol Treatment) Study Collaborators; PRACTICAL PA, Kemp JP, McMahon G, St Pourcain B, UNKNOWN. (Prostate Cancer Association Group to Timpson NJ, Golding J, Lawlor DA, Steer Investigate Cancer-Associated Alterations E Roehrer, E Cummings, P Turner, J Hauser, C, Montgomery GW, Martin NG, Smith GD, in the Genome) Consortium, Kote-Jarai Z, H Cameron-Tucker, S Beggs, N Micallef, CE Whitfield JB.Genome-Wide Association Study Easton DF.Identification of 23 new prostate Wainwright, J Cheney, M Jessup, H Saddington, Identifies Loci Affecting Blood Copper, Selenium cancer susceptibility loci using the iCOGS custom L Ellis, EH Walters, DW Reid.Supporting and Zinc. Human Molecular Genetics. 2013. Vol genotyping array. Nature Genetics. 2013. Vol Cystic Fibrosis with ICT. Health Technology and [Epub ahead of print]. 45(4):385-391. Informatics. 2012. Vol 183 137-41. Evens AM, Choquet S, Kroll-Desrosiers AR, Eggert SL, Huyck KL, Somasundaram P, Kavalla Earl ST, Masci PP, de Jersey J, Lavin MF, Dixon Jagadeesh D, Smith SM, Morschhauser R, Stewart EA, Lu AT, Painter JN, Montgomery JDrug development from Australian elapid snake F, Leblond V, Roy R, Barton B, Gordon LI, GW, Medland SE, Nyholt DR, Treloar SA, venoms and the Venomics pipeline of candidates Gandhi MK, Dierickx D, Schiff D, Habermann Zondervan KT, Heath AC, Madden PA, Rose L, for haemostasis: Textilinin-1 (Q8008), Haempatch™ TM, Trappe RPrimary CNS Post-transplant Buring JE, Ridker PM, Chasman DI, Martin NG, (Q8009) and CoVase™ (V0801) Toxicon. 2012. Vol Lymphoproliferative Disease (PTLD): An Cantor RM, Morton CCGenome-wide Linkage 59(4):456-63. International Report of 84 Cases in the Modern and Association Analyses Implicate FASN in Era. American Journal of Transplantation. 2013. Predisposition to Uterine Leiomyomata. American Vol 13(6):1512-22.

Page 127 Scientiﬁc publications | continued

Faber K, Bullinger L, Ragu C, Garding A, M. Betts, J. A. Carroll, T. Bailey, P. J. Dicks, K, Matsuo K, Wu AH, Radice P, Teo SH, Shu Mertens D, Miller C, Martin D, Walcher D, E. Beesley, J. Tyrer, J. Maia, A. T. Beck, A. XO, Blot W, Kang D, Hartman M, Sangrajrang Döhner K, Döhner H, Claus R, Plass C, Sykes Knoblauch, N. W. Chen, C. Kraft, P. Barnes, D. S, Shen CY, Southey MC, Park DJ, Hammet F, SM, Lane SW, Scholl C, Fröhling S.CDX2-driven Gonzalez-Neira, A. Alonso, M. R. Herrero, D. Stone J, Veer LJ, Rutgers EJ, Lophatananon leukemogenesis involves KLF4 repression and Tessier, D. C. Vincent, D. Bacot, F. Luccarini, C. A, Stewart-Brown S, Siriwanarangsan P, deregulated PPARgamma signaling. The Journal of Baynes, C. Conroy, D. Dennis, J. Bolla, M. K. Peto J, Schrauder MG, Ekici AB, Beckmann Clinical Investigation. 2013. Vol 123(1):219-314. Wang, Q. Hopper, J. L. Southey, M. C. Schmidt, MW, dos Santos Silva I, Johnson N, Warren M. K. Broeks, A. Verhoef, S. Cornelissen, S. H, Tomlinson I, Kerin MJ, Miller N, Marme F, Faber MT, Kjær SK, Dehlendorff C, Chang- Muir, K. Lophatananon, A. Stewart-Brown, S. Schneeweiss A, Sohn C, Truong T, Laurent- Claude J, andersen KK, Høgdall E, Webb PM, Siriwanarangsan, P. Fasching, P. A. Loehberg, Puig P, Kerbrat P, Nordestgaard BG, Nielsen Jordan SJ; Australian Cancer Study (Ovarian C. R. Ekici, A. B. Beckmann, M. W. Peto, J. SF, Flyger H, Milne RL, Perez JI, Menendez Cancer); Australian Ovarian Cancer Study dos Santos Silva, I. Johnson, N. Aitken, Z. P, Muller H, Arndt V, Stegmaier C, Lichtner P, Group, Rossing MA, Doherty JA, Lurie G, Sawyer, E. J. Tomlinson, I. Kerin, M. J. Miller, N. Lochmann M, Justenhoven C, Ko YD, Gene Thompson PJ, Carney ME, Goodman MT, Marme, F. Schneeweiss, A. Sohn, C. Burwinkel, ENvironmental Interaction and breast CAncer Ness RB, Modugno F, Edwards RP, Bunker CH, B. Guenel, P. Truong, T. Laurent-Puig, P. (GENICA) Network, Muranen TA, Aittomaki Goode EL, Fridley BL, Vierkant RA, Larson MC, Menegaux, F. Bojesen, S. E. Nordestgaard, B. K, Blomqvist C, Greco D, Heikkinen T, Ito H, Schildkraut J, Cramer DW, Terry KL, Vitonis G. Nielsen, S. F. Flyger, H. Milne, R. L. Zamora, Iwata H, Yatabe Y, Antonenkova NN, Margolin AF, Bandera EV, Olson SH, King M, Chandran M. P. Arias Perez, J. I. Benitez, J. Anton-Culver, S, Kataja V, Kosma VM, Hartikainen JM, U, Kiemeney LA, Massuger LF, van Altena H. Brenner, H. Muller, H. Arndt, V. Stegmaier, Balleine R, kConFab Investigators, Tseng CC, AM, Vermeulen SH, Brinton L, Wentzensen N, C. Meindl, A. Lichtner, P. Schmutzler, R. K. Berg DV, Stram DO, Neven P, Dieudonne AS, Lissowska J, Yang HP, Moysich KB, Odunsi K, Engel, C. Brauch, H. Hamann, U. Justenhoven, Leunen K, Rudolph A, Nickels S, Flesch-Janys Kasza K, Odunsi-Akanji O, Song H, Pharaoh C. Aaltonen, K. Heikkila, P. Aittomaki, K. D, Peterlongo P, Peissel B, Bernard L, Olson P, Shah M, Whittemore AS, McGuire V, Sieh Blomqvist, C. Matsuo, K. Ito, H. Iwata, H. Sueta, JE, Wang X, Stevens K, Severi G, Baglietto L, W, Sutphen R, Menon U, Gayther SA, Ramus A. Bogdanova, N. V. Antonenkova, N. N. Dork, McLean C, Coetzee GA, Feng Y, Henderson SJ, Gentry-Maharaj A, Pearce CL, Wu AH, T. Lindblom, A. Margolin, S. Mannermaa, A. BE, Schumacher F, Bogdanova NV, Labreche Pike MC, Risch HA, Jensen A; Ovarian Cancer Kataja, V. Kosma, V. M. Hartikainen, J. M. Wu, F, Dumont M, Yip CH, Taib NA, Cheng CY, Association Consortium.Cigarette smoking and A. H. Tseng, C. C. Van Den Berg, D. Stram, Shrubsole M, Long J, Pylkas K, Jukkola- risk of ovarian cancer: a pooled analysis of 21 D. O. Lambrechts, D. Peeters, S. Smeets, A. Vuorinen A, Kauppila S, Knight JA, Glendon case-control studies. Cancer Causes Control. Floris, G. Chang-Claude, J. Rudolph, A. Nickels, G, Mulligan AM, Tollenaar RA, Seynaeve CM, 2013. Vol 24(5):989-1004. S. Flesch-Janys, D. Radice, P. Peterlongo, P. Kriege M, Hooning MJ, van den Ouweland Farzan SF, Waterboer T, Gui J, Nelson HH, Li Z, Bonanni, B. Sardella, D. Couch, F. J. Wang, AM, van Deurzen CH, Lu W, Gao YT, Cai H, Michael KM, Perry AE, Spencer SK, Demidenko X. Pankratz, V. S. Lee, A. Giles, G. G. Severi, Balasubramanian SP, Cross SS, Reed MW, E, Green AC, Pawlita M, Karagas MR.Cutaneous G. Baglietto, L. Haiman, C. A. Henderson, B. Signorello L, Cai Q, Shah M, Miao H, Chan CW, alpha, beta and gamma human papillomaviruses E. Schumacher, F. Le Marchand, L. Simard, Chia KS, Jakubowska A, Jaworska K, Durda in relation to squamous cell carcinoma of the skin: J. Goldberg, M. S. Labreche, F. Dumont, M. K, Hsiung CN, Wu PE, Yu JC, Ashworth A, A population-based study. International Journal of Teo, S. H. Yip, C. H. Ng, C. H. Vithana, E. N. Jones M, Tessier DC, Gonzalez-Neira A, Pita Cancer. 2013. Vol 133(7):1713-1720. Kristensen, V. Zheng, W. Deming-Halverson, G, Alonso MR, Vincent D, Bacot F, Ambrosone S. Shrubsole, M. Long, J. Winqvist, R. Pylkas, CB, Bandera EV, John EM, Chen GK, Hu JJ, Fernández-Rhodes L, Demerath EW, Cousminer K. Jukkola-Vuorinen, A. Grip, M. andrulis, I. Rodriguez-Gil JL, Bernstein L, Press MF, DL, Tao R, Dreyfus JG, Esko T, Smith AV, L. Knight, J. A. Glendon, G. Mulligan, A. M. Ziegler RG, Millikan RM, Deming-Halverson Gudnason V, Harris TB, Launer L, McArdle PF, Devilee, P. Seynaeve, C. Garcia-Closas, M. SL, Nyante S, Ingles SA, Waisﬁsz Q, Tsimiklis Yerges-Armstrong LM, Elks CE, Strachan DP, Figueroa, J. Chanock, S. J. Lissowska, J. H, Makalic E, Schmidt D, Bui M, Gibson L, Kutalik Z, Vollenweider P, Feenstra B, Boyd Czene, K. Klevebring, D. Schoof, N. Hooning, Muller-Myhsok B, Schmutzler RK, Hein R, HA, Metspalu A, Mihailov E, Broer L, Zillikens M. J. Martens, J. W. Collee, J. M. Tilanus- Dahmen N, Beckmann L, Aaltonen K, Czene MC, Oostra B, van Duijn CM, Lunetta KL, Perry Linthorst, M. Hall, P. Li, J. Liu, J. Humphreys, K, Irwanto A, Liu J, Turnbull C, Familial Breast JR, Murray A, Koller DL, Lai D, Corre T, Toniolo K. Shu, X. O. Lu, W. Gao, Y. T. Cai, H. Cox, A. Cancer Study (FBCS), Rahman N, Meijers- D, Albrecht E, Stöckl D, Grallert H, Gieger C, Balasubramanian, S. P. Blot, W. Signorello, L. Heijboer H, Uitterlinden AG, Rivadeneira F, Hayward C, Polasek O, Rudan I, Wilson JF, B. Cai, Q. Pharoah, P. D. Healey, C. S. Shah, stralian Breast Cancer Tissue Bank (ABCTB) He C, Kraft P, Hu FB, Hunter DJ, Hottenga JJ, M. Pooley, K. A. Kang, D. Yoo, K. Y. Noh, D. Investigators, Olswold C, Slager S, Pilarski R, Willemsen G, Boomsma DI, Byrne EM, Martin Y. Hartman, M. Miao, H. Sng, J. H. Sim, X. Ademuyiwa F, Konstantopoulou I, Martin NG, NG, Montgomery GW, Warrington NM, Pennell Jakubowska, A. Lubinski, J. Jaworska-Bieniek, Montgomery GW, Slamon DJ, Rauh C, Lux MP, CE, Stolk L, Visser JA, Hofman A, Uitterlinden K. Durda, K. Sangrajrang, S. Gaborieau, V. Jud SM, Bruning T, Weaver J, Sharma P, Pathak AG, Rivadeneira F, Lin P, Fisher SL, Bierut McKay, J. Toland, A. E. Ambrosone, C. B. H, Tapper W, Gerty S, Durcan L, Trichopoulos LJ, Crisponi L, Porcu E, Mangino M, Zhai G, Yannoukakos, D. Godwin, A. K. Shen, C. Y. D, Tumino R, Peeters PH, Kaaks R, Campa Spector TD, Buring JE, Rose LM, Ridker PM, Hsiung, C. N. Wu, P. E. Chen, S. T. Swerdlow, D, Canzian F, Weiderpass E, Johansson M, Poole C, Hirschhorn JN, Murabito JM, Chasman A. Ashworth, A. Orr, N. Schoemaker, M. J. Khaw KT, Travis R, Clavel-Chapelon F, Kolonel DI, Widen E, North KE, Ong KK, Franceschini Ponder, B. A. Nevanlinna, H. Brown, M. A. LN, Chen C, Beck A, Hankinson SE, Berg N.Association of Adiposity Genetic Variants With Chenevix-Trench, G. Easton, D. F. Dunning, CD, Hoover RN, Lissowska J, Figueroa JD, Menarche Timing in 92,105 Women of European A. M. Functional variants at the 11q13 risk locus Chasman DI, Gaudet MM, Diver WR, Willett Descent. American Journal of Epidemiology. 2013. for breast cancer regulate cyclin D1 expression WC, Hunter DJ, Simard J, Benitez J, Dunning Vol 178(3):451-460. through long-range enhancers. American Journal of AM, Sherman ME, Chenevix-Trench G, Chanock Human Genetics. 2013. Vol 92(4):489-503. SJ, Hall P, Pharoah PD, Vachon C, Easton DF, Fischer, K. Holt, D. Currie, B. Kemp, Haiman CA, Kraft P.Genome-wide association D.Scabies: important clinical consequences Gannon, F. “Ethics and the Researcher” In Ethics studies identify four ER negative-speciﬁc breast explained by new molecular studies. Advances In For Graduate Researchers. Elsivier Insights cancer risk loci. Nature Genetics. 2013. Vol Parasitology. 2012. Vol 79 339-73. Editors: Cathriona Russell & Maureen Junker- 45(4):392-398. Kenny.. 2013. Vol NULL. Fischer, K. Irving, J. A. Pike, R. N. Buckle, Garcia-Dios DA, Lambrechts D, Coenegrachts A. M.Structural Mechanisms of lnactivation in Garcia-Closas M, C. F., Lindstrom S, L, Vandenput I, Capoen A, Webb PM, Ferguson Proteolytically lnactive Serine Proteases from Michailidou K, Schmidt MK, Brook MN, Orr N, K; ANECS, Akslen LA, Claes B, Vergote I, Sarcoptes scabiei. Proteinases As Drug Targets Rhie SK, Riboli E, Feigelson HS, Le Marchand Moerman P, Van Robays J, Marcickiewicz (Royal Society of Chemistry Publishing, Cambridge, L, Buring JE, Eccles D, Miron P, Fasching J, Salvesen HB, Spurdle AB, Amant F.High- Uk). 2012. Vol UNKNOWN. PA, Brauch H, Chang-Claude J, Carpenter throughput interrogation of PIK3CA, PTEN, KRAS, J, Godwin AK, Nevanlinna H, Giles GG, Cox Fornito A, Zalesky A, Breakspear MGraph FBXW7 and TP53 mutations in primary endometrial A, Hopper JL, Bolla MK, Wang Q, Dennis J, analysis of the human connectome: Promise, carcinoma. Gynecologic Oncology. 2013. Vol Dicks E, Howat WJ, Schoof N, Bojesen SE, progress, and pitfalls. Neuroimage. 2013. Vol [Epub 128(2):327-334. Lambrechts D, Broeks A, andrulis IL, Guenel P, ahead of print]. Burwinkel B, Sawyer EJ, Hollestelle A, Fletcher Gardiner RA, Yaxley J, Coughlin G, Dunglison French, J. D. Ghoussaini, M. Edwards, S. L. O, Winqvist R, Brenner H, Mannermaa A, N, Occhipinti S, Younie S, Carter R, Williams S, Meyer, K. B. Michailidou, K. Ahmed, S. Khan, Hamann U, Meindl A, Lindblom A, Zheng W, Medcraft RJ, Bennett N, Lavin MF, Chambers S. Maranian, M. J. O’Reilly, M. Hillman, K. Devillee P, Goldberg MS, Lubinski J, Kristensen SKA randomised trial of robotic and open V, Swerdlow A, Anton-Culver H, Dork T, Muir

Page 128 QIMR Annual Report 2012–2013 prostatectomy in men with localised prostate Gordon LG, Hirst NG, Mayne GC, Watson DI, L. Kent, N. Williams, M. J. Owen, P. Holmans, cancer Bmc Cancer. 2012. Vol 12 189. Bright T, Cai W, Barbour AP, Smithers BM, M. C. O’Donovan and A. ThaparHigh Loading Whiteman DC, Eckermann S; Australian Cancer of Polygenic Risk for ADHD in Children With Garvey G, Beesley VL, Janda M, Jacka C, Green Study Clinical Follow-Up Study Group.Modeling Comorbid Aggression. American Journal of AC, O’Rourke P, Valery PC.The development the cost-effectiveness of strategies for treating Psychiatry. 2013. Vol 170(8):909-16. of a supportive care needs assessment tool for esophageal adenocarcinoma and high-grade Indigenous people with cancer. Bmc Cancer. 2012. dysplasia. Journal of Gastrointestinal Surgery. Handoko HY, Box NF, Walker GJ.Modeling Vol 12 300-. 2012. Vol 16(8):1451-1461. epidermal melanoma in mice: moving into new realms but with unexpected complexities. Gathungu G, Kim MO, Ferguson JP, Sharma Y, Gordon, C.A., Gray, D.J., Acosta, L.G, Jarilla, Journal of Investigative Dermatology. 2013. Vol Zhang W, Ng SM, Bonkowski E, Ning K, Simms B., Ross, A. G., Gobert, G.N., Olveda, R., 132(9):2299-302. LA, Croft AR, Stempak JM, Walker N, Huang McManus, D.P.High prevalence of Schistosoma N, Xiao Y, Silverberg MS, Trapnell B, Cho JH, japonicum infection in Carabao from Samar Handoko HY, Boyle GM, Ferguson B, Muller Radford-Smith GL, Denson LA. Granulocyte- Province, the Philippines: implications for HK, Soyer HP, Walker GJPlasticity of melanoma Macrophage Colony-Stimulating Factor transmission and control. Plos Neglected Tropical in vivo: murine lesions resulting from Trp53, but Autoantibodies: A Marker of Aggressive Crohn’s Diseases. 2012. Vol 6(e1778). not Cdk4 or Arf deregulation, display neural Disease. Inflammatory Bowel Diseases. 2013. Vol transdifferentiation. Pigment Cell and Melanoma 19(8):1671-1680. Gras S, Burrows SR, Turner SJ, Sewell AK, Research. 2013. Vol 26(5):731-4. McCluskey J, Rossjohn JA structural voyage Gaudet MM, Kuchenbaecker KB, Vijai J, Klein toward an understanding of the MHC-I-restricted Handoko HY, Rodero MP, Boyle GM, Ferguson RJ, Kirchhoff T, McGuffog L, Barrowdale D, immune response: lessons learned and much B, Engwerda C, Hill G, Muller HK, Khosrotehrani Dunning AM, Lee A, Dennis J, Healey S, Dicks to be learned Immunological Reviews. 2012. Vol K, Walker GJ.UVB-Induced Melanocyte E, Soucy P, Sinilnikova OM, Pankratz VS, 250(1):61-81. Proliferation in Neonatal Mice Driven by CCR2- Wang X, Eldridge RC, Tessier DC, Vincent D, Independent Recruitment of Ly6c(low)MHCII(hi) Bacot F, Hogervorst FB, Peock S, Stoppa- Gray, D., Thrift, A.P., Williams, G.M., Feng, Macrophages. Journal of Investigative Dermatology. Lyonnet D; KConFab Investigators, Peterlongo Z., Li, Y-S., Guo, J-G., Chen, H-G., Wang, 2013. Vol 133(7):1803-12. P, Schmutzler RK, Nathanson KL, Piedmonte T-P., Xin, X-J., Zhu, R., Zhu, H-Q., Cao, C-L., M, Singer CF, Thomassen M; Ontario Cancer Lin, D-D., Zhao, Z-Y., Li, R.S., Davis, G.M., Hannani, D., Locher, C., Yamazaki, T., Colin- Genetics Network, Hansen Tv, Neuhausen SL, McManus, D.P.Five-year longitudinal assessment Minard, V., Vetizou, M., Aymeric, L., Viaud, S., Blanco I, Greene MH, Garber J, Weitzel JN, of the downstream impact on schistosomiasis Sanchez, D., Smyth, M. J., Tedder, T., Bruhns, andrulis IL, Goldgar DE, D’andrea E, Caldes transmission in China following closure of the Three P., Kroemer, G., and Zitvogel, L.Contribution T, Nevanlinna H, Osorio A, van Rensburg EJ, Gorges Dam. Plos Neglected Tropical Diseases. of humoral immune responses to the antitumor Arason A, Rennert G, van den Ouweland AM, 2012. Vol 6(4):-e1588. effects mediated by chemotherapy. Cell Death and van der Hout AH, Kets CM, Aalfs CM, Wijnen Differentiation. 2013. Vol (in press, 2013). JT, Ausems MG; HEBON; EMBRACE, Frost Green AC, Marquart L, Clemens SL, Harper CM, O’Rourke PK.Frequency of sunburn in Queensland Hansell NK, Wright MJ, Medland SE, Davenport D, Ellis S, Fineberg E, Platte R, Evans DG, TA, Wray NR, Martin NG, Hickie IB.Genetic co- Jacobs C, Adlard J, Tischkowitz M, Porteous adults: still a burning 8. Medical Journal of Australia. 2013. Vol 198(8):431-434. morbidity between neuroticism, anxiety/depression ME, Damiola F; GEMO Study Collaborators, and somatic distress in a population sample of Golmard L, Barjhoux L, Longy M, Belotti M, Griffin PM, Kevat DA, McCarthy JS, Woods adolescent and young adult twins. Psychological Ferrer SF, Mazoyer S, Spurdle AB, Manoukian ML.Chronic urticaria following acute hepatitis A. Medicine. 2012. Vol 42(6):1249-1260. S, Barile M, Genuardi M, Arnold N, Meindl A, Bmj Case Reports. 2012. Vol NULL. Sutter C, Wappenschmidt B, Domchek SM, Harari O, W. J., Bucholz K, Edenberg HJ, Heath Pfeiler G, Friedman E, Jensen UB, Robson M, Guimaraes, F. S., and Smyth, M. J.Myeloid A, Martin NG, Pergadia ML, Montgomery Shah S, Lazaro C, Mai PL, Benitez J, Southey TGF-b responsiveness promotes metastases G, Schrage A, Bierut LJ, Madden PF, Goate MC, Schmidt MK, Fasching PA, Peto J, Cancer Discovery. 2013. Vol 3(8):846-8. AM.Pathway Analysis of Smoking Quantity in Humphreys MK, Wang Q, Michailidou K, Sawyer Multiple GWAS Identifies Cholinergic and Sensory Guinovart C, Dobaño C, Bassat Q, Nhabomba EJ, Burwinkel B, Guénel P, Bojesen SE, Milne Pathways. Plos One. 2012. Vol 7(12):e50913. A, Quintó L, Manaca MN, Aguilar R, Rodríguez RL, Brenner H, Lochmann M; GENICA Network, MH, Barbosa A, Aponte JJ, Mayor AG, Renom Hartz, S. M., S. E. Short, N. L. Saccone, R. Aittomäki K, Dörk T, Margolin S, Mannermaa A, M, Moraleda C, Roberts DJ, Schwarzer E, Le Culverhouse, L. Chen, T. H. Schwantes-An, H. Lambrechts D, Chang-Claude J, Radice P, Giles Souëf PN, Schofield L, Chitnis CE, Doolan Coon, Y. Han, S. H. Stephens, J. Sun, X. Chen, GG, Haiman CA, Winqvist R, Devillee P, García- DL, Alonso PLThe role of age and exposure to F. Ducci, N. Dueker, N. Franceschini, J. Frank, Closas M, Schoof N, Hooning MJ, Cox A, Plasmodium falciparum in the rate of acquisition F. Geller, D. Gubjartsson, N. N. Hansel, C. Jiang, Pharoah PD, Jakubowska A, Orr N, González- of naturally acquired immunity: a randomized K. Keskitalo-Vuokko, Z. Liu, L. P. Lyytikainen, Neira A, Pita G, Alonso MR, Hall P, Couch FJ, controlled trial. Plos One. 2012. Vol 7(3):e32362. M. Michel, R. Rawal, A. Rosenberger, P. Scheet, Simard J, Altshuler D, Easton DF, Chenevix- J. R. Shaffer, A. Teumer, J. R. Thompson, J. Trench G, Antoniou AC, offit K.Identification of H Mutsando, M Fahim, DS Gill, CM Hawley, DW M. Vink, N. Vogelzangs, A. S. Wenzlaff, W. a BRCA2-specific modifier locus at 6p24 related Johnson, MK Gandhi, PV Marlton, HG Mar Fan, Wheeler, X. Xiao, B. Z. Yang, S. H. Aggen, A. to breast cancer risk. Plos Genetics. 2013. Vol PN MolleeHigh dose methotrexate and extended J. Balmforth, S. E. Baumeister, T. Beaty, S. 9(3):E1003173. hours high-flux hemodialysis for the treatment of Bennett, A. W. Bergen, H. A. Boyd, U. Broms, H. primary central nervous system lymphoma in a Gillespie NA, Gehrman P, Byrne EM, Kendler Campbell, N. Chatterjee, J. Chen, Y. C. Cheng, patient with end stage renal disease. American KS, Heath AC, Martin NG.Modeling the direction S. Cichon, D. Couper, F. Cucca, D. M. Dick, T. Journal of Blood Research. 2012. Vol 2(1):66-70. of causation between cross-sectional measures Foroud, H. Furberg, I. Giegling, F. Gu, A. S. Hall, of disrupted sleep, anxiety and depression in Hacker E, Nagore E, Cerroni L, Woods SL, J. Hallfors, S. Han, A. M. Hartmann, C. Hayward, a sample of male and female Australian twins. Hayward NK, Chapman B, Montgomery GW, K. Heikkila, J. K. Hewitt, J. J. Hottenga, M. Journal of Sleep Research. 2012. Vol 21(6):675- Soyer HP, Whiteman DC.NRAS and BRAF K. Jensen, P. Jousilahti, M. Kaakinen, S. J. 683. mutations in cutaneous melanoma and the Kittner, B. Konte, T. Korhonen, M. T. Landi, association with MC1R genotype: findings from T. Laatikainen, M. Leppert, S. M. Levy, R. A. Gillespie NA, H. A., Davenport TA, Hermens DF, Spanish and Austrian populations. Journal of Mathias, D. W. McNeil, S. E. Medland, G. W. Wright MJ, Martin NG, Hickie IB.The Brisbane Investigative Dermatology. 2013. Vol 133(4):1027- Montgomery, T. Muley, T. Murray, M. Nauck, K. Longitudinal Twin Study: Pathways to Cannabis 1033. North, M. Pergadia, O. Polasek, E. M. Ramos, Use, Abuse, and Dependence Project-Current S. Ripatti, A. Risch, I. Ruczinski, I. Rudan, V. Status, Preliminary Results, and Future Directions. Hamshere, M. L., K. Langley, J. Martin, S. S. Salomaa, D. Schlessinger, U. Styrkarsdottir, Twin Research and Human Genetics. 2013. Vol Agha, E. Stergiakouli, R. J. Anney, J. Buitelaar, A. Terracciano, M. Uda, G. Willemsen, X. 16(1):21-33. S. V. Faraone, K. P. Lesch, B. M. Neale, B. Wu, G. Abecasis, K. Barnes, H. Bickeboller, Franke, E. Sonuga-Barke, P. Asherson, A. Gobert, G.N., You, H., Jones, M.K., McInnes, R., E. Boerwinkle, D. I. Boomsma, N. Caporaso, Merwood, J. Kuntsi, S. E. Medland, S. Ripke, H. McManus, D.P.Differences in genomic architecture J. Duan, H. J. Edenberg, C. Francks, P. V. C. Steinhausen, C. Freitag, A. Reif, T. J. Renner, between two distinct geographical strains of the Gejman, J. Gelernter, H. J. Grabe, H. Hops, M. Romanos, J. Romanos, A. Warnke, J. Meyer, blood fluke Schistosoma japonicum reveal potential M. R. Jarvelin, J. Viikari, M. Kahonen, K. S. H. Palmason, A. A. Vasquez, N. Lambregts- phenotype basis. Molecular and Cellular Probes. Kendler, T. Lehtimaki, D. F. Levinson, M. L. Rommelse, H. Roeyers, J. Biederman, A. E. 2013. Vol 27(1):19-27. Marazita, J. Marchini, M. Melbye, B. D. Mitchell, Doyle, H. Hakonarson, A. Rothenberger, T. J. C. Murray, M. M. Nothen, B. W. Penninx, Banaschewski, R. D. Oades, J. J. McGough,

Page 129 Scientiﬁc publications | continued

O. Raitakari, M. Rietschel, D. Rujescu, N. J. Investigators; AOCS Group, Lambrechts D, Holt, Deborah C Fischer, Katja Novel insights Samani, A. R. Sanders, A. G. Schwartz, S. Zhao H, Neven P, Wildiers H, Nickels S, Flesch- into an old disease: recent developments in Shete, J. Shi, M. Spitz, K. Stefansson, G. E. Janys D, Radice P, Peterlongo P, Manoukian scabies mite biology. Current Opinion In Infectious Swan, T. Thorgeirsson, H. Volzke, Q. Wei, H. S, Barile M, Couch FJ, Olson JE, Wang X, Diseases. 2013. Vol 26(2):110-115. E. Wichmann, C. I. Amos, N. Breslau, D. S. Fredericksen Z, Giles GG, Baglietto L, McLean Cannon, M. Ehringer, R. Grucza, D. Hatsukami, CA, Severi G, offit K, Robson M, Gaudet MM, Hong XC, Xu XJ, Chen X, Li YS, Yu CH, Yuan Y, A. Heath, E. O. Johnson, J. Kaprio, P. Madden, Vijai J, Alnæs GG, Kristensen V, Børresen-Dale Chen YY, Li RD, Qiu J, Liu ZC, Yi P, Ren GH, He N. G. Martin, V. L. Stevens, J. A. Stitzel, R. B. AL, John EM, Miron A, Winqvist R, Pylkäs K, HB.Assessing the effect of an integrated control Weiss, P. Kraft and L. J. BierutIncreased genetic Jukkola-Vuorinen A, Grip M, andrulis IL, Knight strategy for schistosomiasis japonica emphasizing vulnerability to smoking at CHRNA5 in early-onset JA, Glendon G, Mulligan AM, Figueroa JD, bovines in a marshland area of hubei province, smokers. Archives of General Psychiatry. 2012. Vol García-Closas M, Lissowska J, Sherman ME, china: a cluster randomized trial. Plos Neglected 69(8):854-860. Hooning M, Martens JW, Seynaeve C, Collée Tropical Diseases. 2013. Vol 7 -e2122. M, Hall P, Humpreys K, Czene K, Liu J, Cox Hong You, H., McManus, D.P., Hu, Wei., Smout, Hatemi PK, M. R., Bailey JM, Martin NG.The A, Brock IW, Cross SS, Reed MW, Ahmed S, Different Effects of Gender and Sex on Vote M.J, Brindley, P.J., Gobert, G.N.Transcriptional Ghoussaini M, Pharoah PD, Kang D, Yoo KY, responses of in vivo praziquantel exposure in Choice. Political Research Quarterly. 2012. Vol Noh DY, Jakubowska A, Jaworska K, Durda UNKNOWN. schistosomes identifies a functional role for K, Zlowocka E, Sangrajrang S, Gaborieau V, calcium signalling pathway member CamKII. Plos Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Brennan P, McKay J, Shen CY, Yu JC, Hsu HM, Pathogens. 2013. Vol 9(e1003254). Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Hou MF, Orr N, Schoemaker M, Ashworth A, Döhner K, Vasioukhin V, Fischer T, Armstrong Swerdlow A, Trentham-Dietz A, Newcomb PA, Hosein AN, Song S, McCart Reed AE, SA.The cell fate determinant Llgl1 influences HSC Titus L, Egan KM, Chenevix-Trench G, Antoniou Jayanthan J, Reid LE, Kutasovic JR, Cummings fitness and prognosis in AML. The Journal of AC, Humphreys MK, Morrison J, Chang-Claude MC, Waddell N, Lakhani SR, Chenevix-Trench Experimental Medicine. 2013. Vol 210(1):15-22. J, Easton DF, Dunning AM.Comparison of 6q25 G, Simpson PT.Evaluating the repair of DNA breast cancer hits from Asian and European derived from formalin-fixed paraffin-embedded Heidel FH, Bullinger L, Feng Z, Wang Z, Neff Genome Wide Association Studies in the Breast tissues prior to genomic profiling by SNP-CGH TA, Stein L, Kalaitzidis D, Lane SW, Armstrong Cancer Association Consortium (BCAC). Plos One. analysis. Laboratory Investigation. 2013. Vol SA.Genetic and pharmacologic inhibition of beta- 2012. Vol 7(8):e42380. 93(6):701-710. catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012. Vol 10(4):412- Heitmann S, Gong P, Breakspear M.A Hou, X., McManus, D.P., Lou, Z, Chen, S., Li, 24. computational role for bistability and traveling Y.S.Differentiation and diagnosis of migrating waves in motor cortex. Frontiers In Computational cerebral sparganosis: 2 case reports from China. Heidi E. Lilja, Wayne A. Morrison, Xiao-Lian Neuroscience. 2012. Vol 6(67):-. Case Reports In Clinical Medicine. 2012. Vol 1 Han, Jason Palmer, Caroline Taylor, Richard 13-18. Tee, andreas Möller, Erik W Thompson, Keren Henningham A, Chiarot E, Gillen CM, Cole M AbbertonAn adipoinductive role of inflammation JN, Rohde M, Fulde M, Ramachandran V, Hoyo C, Cook MB, Kamangar F, Freedman in adipose tissue engineering: key factors in the Cork AJ, Hartas J, Magor G, Djordjevic SP, ND, Whiteman DC, Bernstein L, Brown LM, early events of neo-adipogenesis Stem Cells and Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Risch HA, Ye W, Sharp L, Wu AH, Ward MH, Developmen. 2013. Vol 22(10):1602-13. Chhatwal GS, Margarit IY, Batzloff MR, Walker Casson AG, Murray LJ, Corley DA, Nyrén O, MJ.Conserved anchorless surface proteins as Pandeya N, Vaughan TL, Chow WH, Gammon Heilmann S, Kiefer AK, Fricker N, Drichel D, group A streptococcal vaccine candidates. J Mol MD.Body mass index in relation to oesophageal Hillmer AM, Herold C, Tung JY, Eriksson N, Med (Berl).. 2012. Vol 90(10):1197-1207. and oesophagogastric junction adenocarcinomas: Redler S, Betz RC, Li R, Karason A, Nyholt DR, a pooled analysis from the International BEACON Song K, Vermeulen SH, Kanoni S, Dedoussis G, Herath NI, Spanevello MD, Doecke JD, Smith Consortium. International Journal of Epidemiology. Martin NG, Kiemeney LA, Mooser V, Stefansson FM, Pouponnot C, Boyd AW.Complex expression 2012. Vol 41(6):1706-1718. K, Richards JB, Becker T, Brockschmidt FF, patterns of Eph receptor tyrosine kinases and Hinds DA, Nothen MMandrogenetic Alopecia: their ephrin ligands in colorectal carcinogenesis. Hughes MC, Williams GM, Baker P, Green Identification of Four Genetic Risk Loci and European Journal of Cancer. 2012. Vol 48(5):753- AC.Sunscreen and Prevention of Skin AgingA Evidence for the Contribution of WNT Signaling to 762. Randomized Trial. Annals of Internal Medicine. 2013. Vol 158(11):781-790. Its Etiology Journal of Investigative Dermatology. Hibar DP, Jahanshad N, Stein JL, Kohannim O, 2013. Vol 133(8):1489-96. Toga AW, Medland SE, Hanesll NK, McMahon Hughes MC, Wright A, Barbour A, Thomas Heilmann S, Nyholt DR, Brockschmidt FF, KL, de Zubicaray GI, Montgomery GW, Martin J, Smithers BM, Green AC, Khosrotehrani Hillmer AM, Herold C, Becker T, Martin NG, NG, Wright MJ, Thompson PMAlzheimer’s K.Patients undergoing lymphadenectomy for stage Nothen MMNo genetic support for a contribution Disease Risk Gene, GAB2, is Associated with III melanomas of known or unknown primary site of prostaglandins to the aetiology of androgenetic Regional Brain Volume Differences in 755 Young do not differ in outcome. International Journal of alopecia British Journal of Dermatology. 2013. Vol Healthy Twins. Twin Research and Human Cancer. 2013. Vol [Epub ahead of print]. Genetics. 2012. Vol 15(3):286-295. 169(1):222-4. Hugo LE, Monkman J, Dave KA, Wockner Hein R, Maranian M, Hopper JL, Kapuscinski Hibar, D. P., Stein JL, Ryles AB, Kohannim LF, Birrell GW, Norris EL, Kienzle VJ, Sikulu1 MK, Southey MC, Park DJ, Schmidt MK, Broeks O, Jahanshad N, Medland SE, Hansell NK, MT, Ryan PA, Gorman JJ, KAY BH.Proteomic A, Hogervorst FB, Bueno-de-Mesquita HB, Muir McMahon KL, de Zubicaray GI, Montgomery biomarkers for ageing the mosquito Aedes aegypti KR, Lophatananon A, Rattanamongkongul S, GW, Martin NG, Wright MJ, Saykin AJ, Jack to determine risk of pathogen transmission. Plos Puttawibul P, Fasching PA, Hein A, Ekici AB, CR Jr, Weiner MW, Toga AW, Thompson One. 2013. Vol 8(3):e58656. PM; the Alzheimer?s Disease Neuroimaging Beckmann MW, Fletcher O, Johnson N, dos Hume GE, Fowler EV, Griffiths LR, Doecke InitiativeGenome-wide association identifies Santos Silva I, Peto J, Sawyer E, Tomlinson JD, Radford-Smith GL.Common PPARgamma genetic variants associated with lentiform nucleus I, Kerin M, Miller N, Marmee F, Schneeweiss variants C161T and Pro12Ala are not associated volume in N = 1345 young and elderly subjects. A, Sohn C, Burwinkel B, Guénel P, Cordina- with inflammatory bowel disease in an Australian Brain Imaging and Behavior. 2013. Vol 7(2):102- Duverger E, Menegaux F, Truong T, Bojesen SE, cohort. Journal of Gastrointestinal and Liver 115. Nordestgaard BG, Flyger H, Milne RL, Perez JI, Diseases. 2012. Vol 21(4):349-355. Zamora MP, Benítez J, Anton-Culver H, Ziogas Hollis-Moffatt JE, Phipps-Green AJ, Chapman Hurst TP, Ryan PA, KAY BH.Efficacy of residual A, Bernstein L, Clarke CA, Brenner H, Müller B, Jones GT, van Rij A, Gow PJ, Harrison insecticide, Biflex AquaMax applied as barrier H, Arndt V, Stegmaier C, Rahman N, Seal S, AA, Highton J, Jones PB, Montgomery GW, Turnbull C, Renwick A, Meindl A, Schott S, treatments for managing mosquito populations Stamp LK, Dalbeth N, Merriman TR.The renal Bartram CR, Schmutzler RK, Brauch H, Hamann in suburban residential properties in southeast urate transporter SLC17A1 locus: confirmation of U, Ko YD; GENICA Network, Wang-Gohrke S, Queensland. Journal of Medical Entomology. 2012. association with gout. Arthritis Research & Therapy. Dörk T, Schürmann P, Karstens JH, Hillemanns Vol 49(5):1021-1026. 2012. Vol 14(2):R92. P, Nevanlinna H, Heikkinen T, Aittomäki K, Hussain M, Lu G, Torres S, Edmonds J, KAY Blomqvist C, Bogdanova NV, Zalutsky IV, Holt, Deborah C Burgess, Stewart T G BH, Khromykh A, Asgari S.Effect of Wolbachia on Antonenkova NN, Bermisheva M, Prokovieva Reynolds, Simone L Mahmood, Wajahat replication of West Nile virus in mosquito cell line D, Farahtdinova A, Khusnutdinova E, Lindblom Fischer, Katja Intestinal proteases of free-living and adult mosquitoes. Journal of Virology. 2013. A, Margolin S, Mannermaa A, Kataja V, Kosma and parasitic astigmatid mites. Cell Tissue Res. Vol 87(2):851-858. VM, Hartikainen J, Chen X, Beesley J; Kconfab 2013. Vol 351(2):339-52.

Page 130 QIMR Annual Report 2012–2013 Hyungsoo Kim, Guisepinna Claps, andreas Jaclyn Sceneay, Melvyn T. Chow, Anna Chen, Jeffery JAL, Clements AA, Nguyen TY, Nguyen Möller, David Bowtell, Xin Lu, Ze’ev A. Heloise M. Halse, Christina S.F. Wong, Daniel HL, Tran HS, Le TN, Vu SN, KAY BH, Ryan RonaiSiah2 regulates tight junction integrity and M. andrews, Erica K. Sloan, Belinda S. Parker, PA.Water level flux in household containers in a cell polarity through control of ASPP2 stability David D. Bowtell, Mark J. Smyth, andreas Vietnamese village - a key determinant of Aedes Oncogene. 2013. Vol [Epub ahead of print]. MöllerPrimary tumor hypoxia recruits CD11b+/ aegypti population dynamics Plos One. 2012. Vol Ly6Cmed/Ly6G+ immune suppressor cells and 7(7):e39067. Ibiebele TI, Celia Hughes M, Nagle CM, compromises NK cell cytotoxicity in the pre- Bain CJ, Whiteman DC, Webb PM. Dietary metastatic niche Cancer Research. 2012. Vol Jeffery JM, Grigoriev I, Poser I, van der antioxidants and risk of Barrett’s esophagus and 72(16):3906-11. Horst A, Hamilton N, Waterhouse N, Bleier adenocarcinoma of the esophagus in an Australian J, Subramaniam VN, Maly IV, Akhmanova A, population. International Journal of Cancer. 2013. Jaclyn Sceneay, Mira C.P. Liu, Anna Chen, Khanna KKCentrobin regulates centrosome Vol 133(1):214-224. Christina S.F. Wong, David D. Bowtell, andreas function in interphase cells by limiting pericentriolar MöllerThe antioxidant N-acetylcysteine prevents matrix recruitment. Cell Cycle. 2013. Vol 12(6):899- Ibiebele TI, Hughes MC, Whiteman DC, Webb HIF-1 stabilization under hypoxia in vitro but does 906. PM, Australian Cancer Study Dietary patterns and not affect tumorigenesis in multiple breast cancer risk of oesophageal cancers: a population-based models in vivo Plos One. 2013. Vol 8(6):e66388. Ji Min Lee, Jason S. Lee, Hyunkyung Kim, case-control study. British Journal of Nutrition. Kyeongkyu Kim, Hyejin Park, Ji-Young Kim, 2012. Vol 107(8):1207-1216. Jahanshad N, H. D., Ryles A, Toga AW, Seung Hoon Lee, Ik Soo Kim, Joomyung Kim, McMahon KL, de Zubicaray GI, Hansell NK, Minkyoung Lee, Chin Ha Chung, Sang-Beom Ibiebele TI, Nagle CM, Bain CJ, Webb PM.Intake Montgomery GW, Martin NG, Wright MJ, Seo, Jong-Bok Yoon, Eunyoung Ko, Dong- of omega-3 and omega-6 fatty acids and risk of Thompson PM.Discovery of Genes That Affect Young Noh, Keun Il Kim, Kyeong Kyu Kim, ovarian cancer. Cancer Causes Control. 2012. Vol Human Brain Connectivity: A Genome-Wide and Sung Hee BaekEZH2 Generates a Methyl 23(11):1775-1783. Analysis of the Connectome. Proceedings Ieee Degron that Is Recognized bytheDCAF1/DDB1/ Ieguchi K, Tomita T, Omori T, Komatsu A, International Symposium On Biomedical Imaging. CUL4E3UbiquitinLigaseComplex Molecular Cell. Deguchi A, Masuda J, Duffy SL, Coulthard MG, 2012. Vol 542-545. 2012. Vol 48(4):572-86. Boyd A, Maru Y.ADAM12-cleaved ephrin-A1 Jahanshad N, K. O., Toga AW, McMahon KL, Jiao S, Hsu L, Berndt S, Bézieau S, Brenner H, contributes to lung metastasis. Oncogene. 2013. de Zubicaray GI, Hansell NK, Montgomery GW, Buchanan D, Caan BJ, Campbell PT, Carlson Vol [Epub ahead of print]. Martin NG, Wright MJ, Thompson PMDiffusion CS, Casey G, Chan AT, Chang-Claude J, International Genetics of Ankylosing Spondylitis Imaging Protocol Effects on Genetic Associations. Chanock S, Conti DV, Curtis KR, Duggan D, Consortium (IGAS), Cortes A, Hadler J, Pointon Proceedings Ieee International Symposium On Gallinger S, Gruber SB, Harrison TA, Hayes JP, Robinson PC, Karaderi T, Leo P, Cremin Biomedical Imaging. 2012. Vol 944-947. RB, Henderson BE, Hoffmeister M, Hopper JL, Hudson TJ, Hutter CM, Jackson RD, K, Pryce K, Harris J, Lee S, Joo KB, Shim Jahanshad N, Kohannim O, Hibar DP, Stein SC, Weisman M, Ward M, Zhou X, Garchon Jenkins MA, Kantor ED, Kolonel LN, Küry S, Le JL, McMahon KL, de Zubicaray GI, Medland Marchand L, Lemire M, Newcomb PA, Potter HJ, Chiocchia G, Nossent J, Lie BA, Førre SE, Montgomery GW, Whitfield JB, Martin O, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu JD, Qu C, Rosse SA, Schoen RE, Schumacher NG, Wright MJ, Toga AW, Thompson PM.Brain X, Bradbury LA, Elewaut D, Burgos-Vargas FR, Seminara D, Slattery ML, Ulrich CM, Zanke structure in healthy adults is related to serum R, Stebbings S, Appleton L, Farrah C, Lau BW, Peters U.Genome-wide search for gene-gene transferrin and the H63D polymorphism in the HFE J, Kenna TJ, Haroon N, Ferreira MA, Yang J, interactions in colorectal cancer. Plos One. 2012. gene. Proceedings of The National Academy of Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay Vol 7(12):e52535. Sciences of The United States of America. 2012. MA, Lopez-Larrea C, Deloukas P, Donnelly P; Vol 109(14):E851-E859. Jonathan Grigg, E. Haydn Walters, Sukhwinder Australo-Anglo-American Spondyloarthritis S. Sohal, Richard Wood-Baker, DW Reid, Iain Consortium (TASC); Groupe Française d’Etude Jahanshad N, R. P., Hua X, Hibar DP, Nir TM, Dickson, Michael Kirwan, Cang-Bao Xu, Lars Génétique des Spondylarthrites (GFEGS); Toga AW, Jack CR Jr, Saykin AJ, Green RC, Edvinsson, Naseem Mushtaq.Cigarette smoke Nord-Trøndelag Health Study (HUNT); Weiner MW, Medland SE, Montgomery GW, and platelet activating factor receptor-dependent Spondyloarthritis Research Consortium of Hansell NK, McMahon KL, de Zubicaray GI, adhesion of Streptococcus pneumoniae to lower Canada (SPARCC); Wellcome Trust Case Martin NG, Wright MJ, Thompson PM; the airway cells. Thorax. 2012. Vol 67(10):908-13. Control Consortium 2 (WTCCC2), Bowness P, Alzheimer?s Disease Neuroimaging Initiative. Gafney K, Gaston H, Gladman DD, Rahman Genome-wide scan of healthy human connectome Jones KL, Vari F, Keane C, Crooks P, Nourse P, Maksymowych WP, Xu H, Crusius JB, van discovers SPON1 gene variant influencing JP, Seymour LA, Gottlieb D, Ritchie DS, Gill D, der Horst-Bruinsma IE, Chou CT, Valle-Oñate dementia severity. Proceedings of The National Gandhi MKSerum CD163 and TARC as Disease R, Romero-Sánchez C, Hansen IM, Pimentel- Academy of Sciences of The United States of Response Biomarkers in Classical Hodgkin Santos FM, Inman RD, Videm V, Martin J, America. 2013. Vol 110(12):4768-4773. Lymphoma. Clinical Cancer Research. 2013. Vol Breban M, Reveille JD, Evans DM, Kim TH, 19(3):731-42. Wordsworth BP, Brown MA.Identification of Jahanshad, N., P. Kochunov, E. Sprooten, multiple risk variants for ankylosing spondylitis R. C. Mandl, T. E. Nichols, L. Almassy, J. Jordan S, Steer C, Defazio A, Quinn M, through high-density genotyping of immune-related Blangero, R. M. Brouwer, J. E. Curran, G. I. de Obermair A, Friedlander M, Francis J, O’Brien loci. Nature Genetics. 2013. Vol 45(7):730-738. Zubicaray, R. Duggirala, P. T. Fox, L. E. Hong, S, Goss G, Wyld D, Australian Ovarian Cancer B. A. Landman, N. G. Martin, K. L. McMahon, Study G, Webb P.Patterns of chemotherapy J Geake, E Dabscheck, DW Reid. HELLP S. E. Medland, B. D. Mitchell, R. L. Olvera, C. treatment for women with invasive epithelial ovarian syndrome in a 26 year old woman with Cystic P. Peterson, J. M. Starr, J. E. Sussmann, A. cancer - A population-based study. Gynecologic Fibrosis; a case report. Journal of Medical Case W. Toga, J. M. Wardlaw, M. J. Wright, H. E. Oncology. 2013. Vol 129(2):310-317. Reports. 2012. Vol 6(1):134. Hulshoff Pol, M. E. Bastin, A. M. McIntosh, I. J. Deary, P. M. Thompson and D. C. GlahnMulti-site Joshi J,Goecke R;Parker G, Michael Breakspear J Joshi, A Dhall, R Goecke, M Breakspear, genetic analysis of diffusion images and voxelwise MCan body expressions contribute to automatic G Parker Neural-net classifications for spatio- heritability analysis: A pilot project of the ENIGMA- depression analysis. Proceedings of The 10Th temporal descriptor based depression analysis. DTI working group. Neuroimage. 2013. Vol 81 Ieee International Conference On Automatic Face Pattern Recognition (Icpr) 2012 21St International 455-469. and Gesture Recognition Fg2013.. 2013. Vol Conference. 2013. Vol 2634-2638. UNKNOWN. James N. Musyoka, Mira C.P. Liu, Dodie S. Jablensky A, Angelicheva D, Donohoe GJ, Pouniotis, Christina S.F. Wong, David D. Jostins L, Ripke S, Weersma RK, Duerr RH, Cruickshank M, Azmanov DN, Morris DW, Bowtell, Peter J. Little, Robel Getachew, McGovern DP, Hui KY, Lee JC, Schumm LP, McRae A, Weickert CS, Carter KW, Chandler D, andreas Möller, Ian A. DarbySiah2-Deficient Mice Sharma Y, anderson CA, Essers J, Mitrovic Alexandrov B, Usheva A, Morar B, Verbrugghe Show Impaired Skin Wound Repair Wound Repair M, Ning K, Cleynen I, Theatre E, Spain SL, PL, Filipovska A, Rackham O, Bishop AR, and Regeneration. 2013. Vol 21(3):437-47. Raychaudhuri S, Goyette P, Wei Z, Abraham Rasmussen KØ, Dragovic M, Cooper M, Phillips C, Achkar JP, Ahmad T, Amininejad L, M, Badcock J, Bramon-Bosch E, Almeida Jayaratne N, Hughes MC, Ibiebele TI, van den Ananthakrishnan AN, andersen V, andrews OP, Flicker L, Gill M, Corvin A, MacGregor S, Akker S, van der Pols JC.Vitamin D intake in JM, Baidoo L, Balschun T, Bampton PA, Bitton Kalaydjieva L.Promoter polymorphisms in two Australian adults and the modeled effects of milk A, Boucher G, Brand S, Büning C, Cohain A, overlapping 6p25 genes implicate mitochondrial and breakfast cereal fortification. Nutrition. 2013. Cichon S, D’Amato M, De Jong D, Devaney proteins in cognitive deficit in schizophrenia. Vol 29(7):1048-1053. KL, Dubinsky M, Edwards C, Ellinghaus Molecular Psychiatry. 2012. Vol 17(12):1328-1339. D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J,

Page 131 Scientiﬁc publications | continued

Haritunians T, Hart A, Hawkey C, Hedl M, Hu carcinoma: a pooled analysis of 5,342 cases Korneva, J. V., S. A. Kornienko and M. X, Karlsen TH, Kupcinskas L, Kugathasan S, and 10,358 controls from the Ovarian Cancer K. JonesFine structure of the uteri in two Latiano A, Laukens D, Lawrance IC, Lees CW, Association Consortium. Bmc Cancer. 2013. Vol hymenolepidid tapeworm Skrjabinacanthus Louis E, Mahy G, Mansfield J, Morgan AR, 13(28):28. diplocoronatus and Urocystis prolifer (Cestoda: Mowat C, Newman W, Palmieri O, Ponsioen CY, Cyclophyllidea) parasitic in shrews that display Keller MC, G.-A. C., Wright MJ, Martin NG, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, different fecundity of the strobilae. Parasitology Corley RP, Stallings MC, Hewitt JK, Zietsch Russell RK, Sanderson JD, Sans M, Satsangi J, Research. 2012. Vol 111(4):1523-1530. Schreiber S, Simms LA, Sventoraityte J, Targan BP.The Genetic Correlation between Height and SR, Taylor KD, Tremelling M, Verspaget HW, De IQ: Shared Genes or Assortative Mating? Plos Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Vos M, Wijmenga C, Wilson DC, Winkelmann Genetics. 2013. Vol 9(4):e1003451. Tymrakiewicz M, Dadaev T, Jugurnauth-Little J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, S, Ross-Adams H, Al Olama AA, Benlloch S, Kendall BJ, Macdonald GA, Hayward NK, Halim S, Russel R, Dunning AM, Luccarini C, Zhao H; International IBD Genetics Consortium Prins JB, O’Brien S, Whiteman DC; Study of (IIBDGC), Silverberg MS, Annese V, Hakonarson Dennis J, Neal DE, Hamdy FC, Donovan JL, Digestive Health.The risk of Barrett’s esophagus Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Brant SR, Radford-Smith G, Mathew CG, associated with abdominal obesity in males and Rioux JD, Schadt EE, Daly MJ, Franke A, H, Haiman CA, Schumacher F, Henderson BE, females. International Journal of Cancer. 2013. Vol Le Marchand L, Lindstrom S, Kraft P, Hunter Parkes M, Vermeire S, Barrett JC, Cho JH.Host- 132(9):2192-2199. microbe interactions have shaped the genetic DJ, Gapstur S, Chanock S, Berndt SI, Albanes architecture of inflammatory bowel disease. Nature. Khoontawad J, Laothong U, Roytrakul S, D, andriole G, Schleutker J, Weischer M, 2012. Vol 491(7422):119-124. Pinlaor P, Mulvenna J, Wongkham C, Yongvanit Canzian F, Riboli E, Key TJ, Travis RC, Campa P, Pairojkul C, Mairiang E, Sithithaworn P, D, Ingles SA, John EM, Hayes RB, Pharoah P, Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Pinlaor S.Proteomic identification of plasma Khaw KT, Stanford JL, Ostrander EA, Signorello Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish protein tyrosine phosphatase alpha and fibronectin LB, Thibodeau SN, Schaid D, Maier C, Vogel CB, Anastasiou D, Gilliland DG, Scadden DT, associated with liver fluke, Opisthorchis viverrini, W, Kibel AS, Cybulski C, Lubinski J, Cannon- Guertin DA, Armstrong SA.mTOR complex 1 infection. Plos One. 2012. Vol 7(9):e45460. Albright L, Brenner H, Park JY, Kaneva R, plays critical roles in hematopoiesis and Pten-loss- Batra J, Spurdle A, Clements JA, Teixeira MR, evoked leukemogenesis. Cell Stem Cell. 2012. Vol Kidd TJ, Ramsay KA, Hu H, Marks GB, Govindasami K, Guy M, Wilkinson RA, Sawyer 11(3):429-39. Wainwright CE, Bye PT, Elkins MR, Robinson EJ, Morgan A, Dicks E, Baynes C, Conroy PJ, Rose BR, Wilson JW, Grimwood K, Bell D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Karl, S., L. Guti?rrez, R. Lucyk-Maurer, Kerr R, SC; the ACPinCF Investigator Group. Shared Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part Candido RR, Toh SQ, Saunders M, Shaw JA, Pseudomonas genotypes are common in of GAME-ON) Initiative; UK Genetic Prostate Suvorova A, Hofmann A, House MJ, Woodward Australian Cystic Fibrosis patients. European Cancer Study Collaborators/British Association RC, Graeff-Teixera C, St Pierre TG and J. Respiratory Journal. 2012. Vol 41(5):1091-100. of Urological Surgeons’ Section of Oncology; MKThe iron distribution and magnetic properties of UK ProtecT Study Collaborators; PRACTICAL schistosome eggshells: implications for improved Kline K, McCarthy JS, Pearson M, Loukas A, Consortium, Easton DF, Eeles RA.Fine-mapping diagnostics. Plos Neglected Tropical Diseases. Hotez PJ.Neglected tropical diseases of Oceania: identifies multiple prostate cancer risk loci at 5p15, 2013. Vol 7(e2219). review of their prevalence, distribution, and one of which associates with TERT expression. opportunities for control. Plos Neglected Tropical Human Molecular Genetics. 2013. Vol 22(12):2520- Karmarkar MG, Hule GP, Hase NK, Mehta Diseases. 2013. Vol 7(1):e1755. PR, Walter SR, Sriprakash KS.Seroprevalence 2528. of Streptococcal Inhibitor of Complement (SIC) Knaapila A, Zhu G, Medland SE, Wysocki CJ, Kottgen A, A. E., Teumer A, Vitart V, Krumsiek suggests association of streptococcal infection with Montgomery GW, Martin NG, Wright MJ, Reed J, Hundertmark C, Pistis G, Ruggiero D, chronic kidney disease. Bmc Nephrology. 2013. Vol DRA genome-wide study on the perception of the O’Seaghdha CM, Haller T, Yang Q, Tanaka 6(14):101-. odorants androstenone and Galaxolide. Chemical T, Johnson AD, Kutalik Z, Smith AV, Shi J, Senses. 2012. Vol 37(6):541-552. KAY, BH, Brown MD, Zubaidah S, Bangs Struchalin M, Middelberg RP, Brown MJ, Gaffo MJ.Field evaluations of disposable sticky lures Knight, D. A.*, Ngiow, S. F.*, Li, M., Parmenter, AL, Pirastu N, Li G, Hayward C, Zemunik T, for surveillance of Aedes aegypti and Culex T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Huffman J, Yengo L, Zhao JH, Demirkan A, quinquefasciatus (Diptera: Culicidae) in Jakarta. Yagita, H., Koya, R. C., Graeber, T., Ribas, A., Feitosa MF, Liu X, Malerba G, Lopez LM, van Medical and Veterinary Entomology. 2012. Vol McArthur, G. A., and Smyth, M. J.Host immunity der Harst P, Li X, Kleber ME, Hicks AA, Nolte [Epub ahead of print]. contributes to the anti-melanoma activity of BRAF IM, Johansson A, Murgia F, Wild SH, Bakker inhibitors. Journal of Clinical Investigation. 2013. SJ, Peden JF, Dehghan A, Steri M, Tenesa Keane C, Gill D, Vari F, Cross D, Griffiths L, Vol 123(7):1371-1381. A, Lagou V, Salo P, Mangino M, Rose LM, Gandhi MCD4(+) tumor infiltrating lymphocytes Lehtimaki T, Woodward OM, Okada Y, Tin A, are prognostic and independent of R-IPI in Kohannim O, H. D., Stein JL, Jahanshad N, Muller C, Oldmeadow C, Putku M, Czamara patients with DLBCL receiving R-CHOP chemo- Hua X, Rajagopalan P, Toga AW, Jack CR Jr, D, Kraft P, Frogheri L, Thun GA, Grotevendt A, immunotherapy. American Journal of Hematology. Weiner MW, de Zubicaray GI, McMahon KL, Gislason GK, Harris TB, Launer LJ, McArdle P, 2013. Vol 88(4):273-6. Hansell NK, Martin NG, Wright MJ, Thompson Shuldiner AR, Boerwinkle E, Coresh J, Schmidt PMDiscovery and Replication of Gene Influences H, Schallert M, Martin NG, Montgomery GW, Keating B, B. A., Walsh S, Millman J, Newman on Brain Structure Using LASSO Regression. Kubo M, Nakamura Y, Tanaka T, Munroe PB, J, Kidd K, Budowle B, Eisenberg A, Donfack Frontiers In Neuroscience. 2012. Vol (6):115. Samani NJ, Jacobs DR Jr, Liu K, d’Adamo P, J, Gasparini P, Budimlija Z, Henders AK, Ulivi S, Rotter JI, Psaty BM, Vollenweider P, Chandrupatla H, Duffy DL, Gordon SD, Hysi P, Kohannim, O., N. Jahanshad, M. N. Braskie, J. Waeber G, Campbell S, Devuyst O, Navarro Liu F, Medland SE, Rubin L, Martin NG, Spector L. Stein, M. C. Chiang, A. H. Reese, D. P. Hibar, P, Kolcic I, Hastie N, Balkau B, Froguel P, TD, Kayser M; on behalf of the International A. W. Toga, K. L. McMahon, G. I. de Zubicaray, Esko T, Salumets A, Khaw KT, Langenberg C, Visible Trait Genetics (VisiGen) Consortium. S. E. Medland, G. W. Montgomery, N. G. Martin, Wareham NJ, Isaacs A, Kraja A, Zhang Q, Wild First all-in-one diagnostic tool for DNA intelligence: M. J. Wright and P. M. ThompsonPredicting PS, Scott RJ, Holliday EG, Org E, Viigimaa genome-wide inference of biogeographic ancestry, White Matter Integrity from Multiple Common M, Bandinelli S, Metter JE, Lupo A, Trabetti appearance, relatedness, and sex with the Identitas Genetic Variants. Neuropsychopharmacology. E, Sorice R, Doring A, Lattka E, Strauch K, v1 Forensic Chip. International Journal of Legal 2012. Vol 37(9):2012-2019. Theis F, Waldenberger M, Wichmann HE, Medicine. 2013. Vol 127(3):559-72. Koning D, Costa AI, Hoof I, Miles JJ, Nanlohy Davies G, Gow AJ, Bruinenberg M, LifeLines Kelemen LE, Bandera EV, Terry KL, Rossing NM, Ladell K, Matthews KK, Venturi V, Cohort Study, Stolk RP, Kooner JS, Zhang W, MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Schellens IM, Borghans JA, Kesmir C, Price DA, Winkelmann BR, Boehm BO, Lucae S, Penninx Chang-Claude J, Köbel M, Lurie G, Thompson van Baarle D.CD8+ TCR repertoire formation is BW, Smit JH, Curhan G, Mudgal P, Plenge RM, PJ, Carney ME, Moysich K, Edwards R, guided primarily by the peptide component of the Portas L, Persico I, Kirin M, Wilson JF, Leach Bunker C, Jensen A, Høgdall E, Cramer DW, antigenic complex. Journal of Immunology. 2013. IM, van Gilst WH, Goel A, Ongen H, Hofman Vitonis AF, Olson SH, King M, Chandran U, Vol 190(3):931-939. A, Rivadeneira F, Uitterlinden AG, Imboden M, Lissowska J, Garcia-Closas M, Yang H, Webb von Eckardstein A, Cucca F, Nagaraja R, Piras Konings A, Martin L, Sharples K, Roddam L, PM, Schildkraut JM, Goodman MT, Risch HA; MG, Nauck M, Schurmann C, Budde K, Ernst Latham R, Reid DW, Lamont IL.Pseudomonas Australian Ovarian Cancer Study Group and F, Farrington SM, Theodoratou E, Prokopenko aeruginosa uses multiple pathways to acquire iron Australian Cancer Study (Ovarian Cancer); I, Stumvoll M, Jula A, Perola M, Salomaa during chronic infection in cystic fibrosis lungs. Ovarian Cancer Association ConsortiumRecent V, Shin SY, Spector TD, Sala C, Ridker PM, Infection and Immunity. 2013. Vol 81(8):2697-704. alcohol consumption and risk of incident ovarian Kahonen M, Viikari J, Hengstenberg C, Nelson CP, CARDIoGRAM Consortium, DIAGRAM

Page 132 QIMR Annual Report 2012–2013 Consortium, ICBP Consortium, MAGIC Phys Rev E Stat Nonlin Soft Matter Phys. 2012. Vol Twins Study. Journals of Gerontology Series Consortium, Meschia JF, Nalls MA, Sharma P, 86(6 Pt 1):61903. B-Psychological Sciences and Social Sciences. Singleton AB, Kamatani N, Zeller T, Burnier M, 2013. Vol [Epub ahead of print]. Attia J, Laan M, Klopp N, Hillege HL, Kloiber Lauridsen, LH, Shamaileh, HA, Edwards, SL, S, Choi H, Pirastu M, Tore S, Probst-Hensch Taran, E. Veedu, RNRapid one-step selection Lee T, Mosing MA, Henry JD, Trollor JN, NM, Volzke H, Gudnason V, Parsa A, Schmidt method for generating nucleic acid aptamers: Ames D, Martin NG, Wright MJ, Sachdev PS; R, Whitfield JB, Fornage M, Gasparini P, development of a DNA aptamer against alpha- OATS Research Team.Genetic Influences on Siscovick DS, Polasek O, Campbell H, Rudan I, bungarotoxin Plos One. 2012. Vol 7(7):e41702. Four Measures of Executive Functions and Their Covariation with General Cognitive Ability: The Bouatia-Naji N, Metspalu A, Loos RJ, van Duijn Lavin MFThe appropriateness of the mouse model CM, Borecki IB, Ferrucci L, Gambaro G, Deary Older Australian Twins Study. Behavior Genetics. for ataxia-telangiectasia: Neurological defects but 2012. Vol NULL. IJ, Wolffenbuttel BH, Chambers JC, Marz W, no neurodegeneration Dna Repair (Amst). 2013. Pramstaller PP, Snieder H, Gyllensten U, Wright Vol 12(8):612-9. Lee T, Mosing MA, Henry JD, Trollor JN, AF, Navis G, Watkins H, Witteman JC, Sanna Lammel A, Ames D, Martin NG, Wright MJ, Law MH, Macgregor S, Hayward NK. S, Schipf S, Dunlop MG, Tonjes A, Ripatti S, Melanoma Sachdev PS.Genetic influences on five measures Soranzo N, Toniolo D, Chasman DI, Raitakari genetics: recent findings take us beyond well- of processing speed and their covariation with O, Kao WH, Ciullo M, Fox CS, Caulfield M, traveled pathways. Journal of Investigative general cognitive ability in the elderly: The Older Bochud M, Gieger C.Genome-wide association Dermatology. 2012. Vol 132(7):1763-1774. Australian Twins Study. Behavior Genetics. 2012. analyses identify 18 new loci associated with serum Law MH, Montgomery GW, Brown KM, Martin Vol 42(1):96-106. urate concentrations. Nature Genetics. 2013. Vol NG, Mann GJ, Hayward NK, MacGregor S; 45(2):145-154. Li C, Lönn ME, Xu X, Maghzal GJ, Frazer Q-MEGA and AMFS Investigators.Meta-Analysis DM, Thomas SR, Halliwell B, Richardson DR, Koyama, M., Kuns, R. D., Olver, S. D., Lineburg, Combining New and Existing Data Sets Confirms anderson GJ, Stocker R.Sustained expression K. E., Lor, M., Teal, B. E., Raffelt, N. C., Leveque, that the TERT-CLPTM1L Locus Influences of heme oxygenase-1 alters iron homeostasis L., Chan, C. J., Robb, R. J., Markey, K. A., Melanoma Risk. Nature Genetics. 2012. Vol in nonerythroid cells. Free Radical Biology and Alexander, K. A., Varelias, A., Clouston, A. 132(2):485-487. Medicine. 2012. Vol 53(2):366-374. D., Smyth, M. J., MacDonald, K. P., and Hill, Lawrance IC, Murray K, Batman B, Gearry G. R.Promoting regulation via the inhibition of Li M, W. Y., Zheng XB, Ikeda M, Iwata N, Luo RB, Grafton R, Krishnaprasad K, andrews JM, DNAM-1 after transplantation. Blood. 2013. Vol XJ, Chong SA, Lee J, Rietschel M, Zhang Prosser R, Bampton PA, Cooke SE, Mahy G, 121(17):3511-3520. F, M?ller-Myhsok B, Cichon S, Weinberger Radford-Smith G, Croft A, Hanigan K.Crohn’s DR, Mattheisen M, Schulze TG, Martin NG, Kubo A, Cook MB, Shaheen NJ, Vaughan TL, disease and smoking: Is it ever too late to quit? Mitchell PB, Schofield PR, Liu JJ, Su B; MooDS Whiteman DC, Murray L, Corley DA.Sex-specific Journal of Crohns & Colitis. 2013. Vol [Epub ahead Consortium.Meta-analysis and brain imaging data associations between body mass index, waist of print]. support the involvement of VRK2 (rs2312147) circumference and the risk of Barrett’s oesophagus: Leary, S. D., M. J. Brion, D. A. Lawlor, G. D. in schizophrenia susceptibility. Schizophrenia a pooled analysis from the international BEACON Smith and A. R. NessLack of emergence of Research. 2012. Vol 142(one):200-205. consortium. Gut. 2013. Vol [Epub ahead of print]. associations between selected maternal exposures Li R, Brockschmidt FF, Kiefer AK, Stefansson Kupz, A., Scott, T. A., Belz, G. T., andrews, and offspring blood pressure at age 15 years. H, Nyholt DR, Song K, Vermeulen SH, Kanoni S, D. M., Greyer, M., Lew, A. M., Brooks, A. G., Journal of Epidemiology and Community Health. Glass D, Medland SE, Dimitriou M, Waterworth Smyth, M. J., Curtiss, R. III., Bedoui, S., and 2013. Vol 67(4):320-326. D, Tung JY, Geller F, Heilmann S, Hillmer AM, Strugnell, R. A.Contribution of Thy1+ NK cells Lee PH, P. R., Jung JY, Byrne EM, Rueckert E, Bataille V, Eigelshoven S, Hanneken S, Moebus to protective IFN-g-production during Salmonella Siburian R, Haddad S, Mayerfeld CE, Heath S, Herold C, den Heijer M, Montgomery GW, Typhimurium infections. Proceedings of The AC, Pergadia ML, Madden PA, Boomsma DI, Deloukas P, Eriksson N, Heath AC, Becker T, National Academy of Sciences of The United Penninx BW, Sklar P, Martin NG, Wray NR, Sulem P, Mangino M, Vollenweider P, Spector States of America. 2012. Vol 110(6):2252-7. Purcell SM, Smoller JW.Multi-locus genome- TD, Dedoussis G, Martin NG, Kiemeney LA, Lahmann P, Hughes M, Ibiebele T, Mulligan wide association analysis supports the role Mooser V, Stefansson K, Hinds DA, Nöthen MM, A, Kuhnle G, Webb P,Australian Ovarian Cancer of glutamatergic synaptic transmission in the Richards JB.Six novel susceptibility loci for early- Study Management Group, Group ANECS. etiology of major depressive disorder. Translational onset androgenetic alopecia and their unexpected Estimated intake of dietary phytoestrogens in Psychiatry. 2012. Vol 2(e184). association with common diseases. Plos Genetics. Australian women and evaluation of correlates of 2012. Vol UNKNOWN -. Lee SH, H.D., ?Nyholt?DR;?Gene phytoestrogen intake. Journal of Nutrition Science. Consortium;?International Endogene Li Y, Low HQ, Foo JN, Darabi H, Einarsd?ttir K, 2012. Vol 1(e11). ConsortiumGenetic and Environmental Humphreys K, Spurdle A; ANECS Group, Easton Lahmann PH, Pandeya N, Webb PM, Green Risk for Alzheimer’s disease (GERAD1) DF, Thompson DJ, Dunning AM, Pharoah PD, AC, Whiteman DC; Australian Cancer Study. Consortium,?Goddard ME,?Zondervan Czene K, Chia KS, Hall P, Liu J.Genetic Variants Body mass index, long-term weight change, and KT,?Williams J,?Montgomery GW,?Wray in ER Cofactor Genes and Endometrial Cancer esophageal squamous cell carcinoma: is the NR,?Visscher PM. Estimation and partitioning of Risk. Plos One. 2012. Vol 7(8):E42445. inverse association modified by smoking status? polygenic variation captured by common SNPs Li, D Wei , T Abbott, C. M. Harrich, D. The Cancer. 2012. Vol NULL. for Alzheimer’s disease, multiple sclerosis and Unexpected Roles of Eukaryotic Translation endometriosis. Human Molecular Genetics. 2013. Elongation Factors in RNA Virus Replication and Landers KA, Li H, Subramaniam VN, Mortimer Vol NULL. RH, Richard K.Transthyretin-thyroid hormone Pathogenesis Microbiology and Molecular Biology internalization by trophoblasts. Placenta. 2013. Vol Lee SH, Harold D, Nyholt DR, Goddard ME, Reviews. 2012. Vol 77(2):253-66. 34(8):716-8. Zondervan KT, Williams J, Montgomery GW, Li, M., X. J. Luo, M. Rietschel, C. M. Lewis, Wray NR, Visscher PMEstimation and partitioning Lane SW, De Vita S, Alexander KA, Karaman M. Mattheisen, B. Muller-Myhsok, S. Jamain, of polygenic variation captured by common SNPs M. Leboyer, M. Landen, P. M. Thompson, R, Milsom MD, Dorrance AM, Purdon A, Louis for Alzheimer’s disease, multiple sclerosis and L, Bouxsein ML, Williams DA.Rac signaling S. Cichon, M. M. Nothen, T. G. Schulze, P. endometriosis. Human Molecular Genetics. 2013. F. Sullivan, S. E. Bergen, G. Donohoe, D. W. in osteoblastic cells is required for normal bone Vol 22(4):832-841. development but is dispensable for hematopoietic Morris, A. Hargreaves, M. Gill, A. Corvin, C. development. Blood. 2012. Vol 119(3):736-744. Lee T, Crawford JD, Henry JD, Trollor JN, Hultman, A. W. Toga, L. Shi, Q. Lin, H. Shi, Kochan NA, Wright MJ, Ames D, Brodaty H, L. Gan, A. Meyer-Lindenberg, D. Czamara, Lane, S. W.Bad to the bone. Blood. 2012. Vol Sachdev PS.Mediating Effects of Processing C. Henry, B. Etain, J. C. Bis, M. A. Ikram, M. 119(2):323-325. Speed and Executive Functions in Age-Related Fornage, S. Debette, L. J. Launer, S. Seshadri, S. Erk, H. Walter, A. Heinz, F. Bellivier, J. L. Lane, S. W. and A. MullalyJak2V617F Differences in Episodic Memory Performance: A Stein, S. E. Medland, A. A. Vasquez, D. P. Hibar, myeloproliferative neoplasm stem cells and Cross-Validation Study. Neuropsychology. 2012. B. Franke, N. G. Martin and M. J. WrightAllelic interferon-alpha. Oncotarget. 2013. Vol 4(4):500- Vol 26(6):776-784. differences between Europeans and Chinese 501. Lee T, Lipnicki DM, Crawford JD, Henry JD, for CREB1 SNPs and their implications in gene Langdon AJ, Breakspear M, Coombes S.Phase- Trollor JN, Ames D, Wright MJ, Sachdev PS; expression regulation, hippocampal structure locked cluster oscillations in periodically forced OATS Research Team.Leisure Activity, Health, and and function, and bipolar disorder susceptibility. integrate-and-fire-or-burst neuronal populations. Medical Correlates of Neurocognitive Performance Molecular Psychiatry. 2013. Vol [Epub ahead of Among Monozygotic Twins: The Older Australian print].

Page 133 Scientiﬁc publications | continued

Liao LM, Vaughan TL, Corley DA, Cook MB, and survival. European Journal of Immunology. Song H, Tyrer J, Ramus S, Menon U, Gentry- Casson AG, Kamangar F, Abnet CC, Risch HA, 2012. Vol 42(12):3291-3301. Maharaj A, Gayther SA, Bandera EV, Olson SH, Giffen C, Freedman ND, Chow WH, Sadeghi Orlow I, Rodriguez-Rodriguez L, Macgregor S, Loehlin JC, M. N. S, Pandeya N, Whiteman DC, Murray LJ, General and supplementary Chenevix-Trench G.Genome-wide association Bernstein L, Gammon MD, Wu AH.Nonsteroidal factors of personality in genetic and environmental study for ovarian cancer susceptibility using pooled anti-inflammatory drug use reduces risk of correlation matrices. Personality and Individual DNA. Twin Research and Human Genetics. 2012. adenocarcinomas of the esophagus and Differences. 2013. Vol 54(6):761-766. Vol 15(5):615-623. esophagogastric junction in a pooled analysis. Loi, S., Pommey, S., Haibe Kains, B., Beavis, Gastroenterology. 2012. Vol 142(3):442-452. Lu Y, Vitart V, Burdon KP, Khor CC, P. A., Darcy, P. K., Smyth, M. J.*, and Stagg, Bykhovskaya Y, Mirshahi A, Hewitt AW, Koehn Lim YC, Roberts TL, Day B, Harding A, J.*CD73: a new therapeutic target for triple- D, Hysi PG, Ramdas WD, Zeller T, Vithana EN, Kozlov S, Kijas A, Ensbey KS, Walker D, negative breast cancer. Proceedings of The Cornes BK, Tay WT, Tai ES, Cheng CY, Liu J, Lavin MFA Role for Homologous Recombination National Academy of Sciences of The United Foo JN, Saw SM, Thorleifsson G, Stefansson and Abnormal Cell-Cycle Progression in States of America. 2013. Vol (in press, 2013). K, Dimasi DP, Mills RA, Mountain J, Ang W, Radioresistance of Glioma-Initiating Cells Molecular Long J, Zheng W, Xiang YB, Lose F, Hoehn R, Verhoeven VJ, Grus F, Wolfs R, Cancer Therapeutics. 2012. Vol 11(9):1863-72. Thompson D, Tomlinson I, Yu H, Wentzensen Castagne R, Lackner KJ, Springelkamp H, Yang J, Jonasson F, Leung DY, Chen LJ, Tham Lin, M. H. Sivakumaran, H. Apolloni, A. Wei, N, Lambrechts D, Dörk T, Dubrowinskaja N, CC, Rudan I, Vatavuk Z, Hayward C, Gibson T. Jans, D. A. Harrich, D.Nullbasic, a Potent Goodman MT, Salvesen HB, Fasching PA, Scott J, Cree AJ, MacLeod A, Ennis S, Polasek O, Anti-HIV Tat Mutant, Induces CRM1-Dependent RJ, Delahanty R, Zheng Y, O’Mara T, Healey Campbell H, Wilson JF, Viswanathan AC, Fleck Disruption of HIV Rev Trafficking Plos One. 2012. CS, Hodgson S, Risch H, Yang HP, Amant B, Li X, Siscovick D, Taylor KD, Rotter JI, Yazar Vol 7(12):e51466. F, Turmanov N, Schwake A, Lurie G, Trovik J, Beckmann MW, Ashton K, Ji BT, Bao PP, S, Ulmer M, Li J, Yaspan BL, Ozel AB, Richards Lind PA, Macgregor S, Heath AC, Madden Howarth K, Lu L, Lissowska J, Coenegrachts L, JE, Moroi SE, Haines JL, Kang JH, Pasquale PA, Montgomery GW, Martin NG, Whitfield Kaidarova D, Dürst M, Thompson PJ, Krakstad LR, Allingham RR, Ashley-Koch A; NEIGHBOR JB.Association between in vivo alcohol metabolism C, Ekici AB, Otton G, Shi J, Zhang B, Gorman Consortium, Mitchell P, Wang JJ, Wright AF, and genetic variation in pathways that metabolize M, Brinton L, Coosemans A, Matsuno RK, Halle Pennell C, Spector TD, Young TL, Klaver CC, the carbon skeleton of ethanol and NADH MK, Hein A, Proietto A, Cai H, Lu W, Dunning Martin NG, Montgomery GW, anderson MG, reoxidation in the Alcohol Challenge Twin Study. A, Easton D, Gao YT, Cai Q, Spurdle AB, Shu Aung T, Willoughby CE, Wiggs JL, Pang CP, Alcoholism, Clinical and Experimental Research. XO.Genome-wide association study identifies a Thorsteinsdottir U, Lotery AJ, Hammond CJ, 2012. Vol 36(12):2074-2085. possible susceptibility locus for endometrial cancer. van Duijn CM, Hauser MA, Rabinowitz YS, Cancer Epidemiology Biomarkers & Prevention. Pfeiffer N, Mackey DA, Craig JE, Macgregor Lind PA, Zhu G., Montgomery GW, Madden 2012. Vol 21(6):980-987. S, Wong TY.Genome-wide association analyses PA, Heath AC, Martin NG, Slutske WS.Genome- identify multiple loci associated with central corneal wide association study of a quantitative disordered Loo CKC, Algar EM, Payton DJ, Perry-Keene J, thickness and keratoconus. Nature Genetics. 2013. gambling trait. Addiction Biology. 2013. Vol Pereira TN and Ramm GA.Possible role of WT1 Vol 45(2):155-163. 18(3):511-522. in a human fetus with evolving bronchial atresia, pulmonary malformation and renal agenesis. Lubin JH, Cook MB, Pandeya N, Vaughan Liu F, v. d. L. F., Schurmann C, Zhu G, Pediatric Developmental Pathology. 2012. Vol TL, Abnet CC, Giffen C, Webb PM, Murray Chakravarty MM, Hysi PG, Wollstein A, Lao 15(1):39-44. LJ, Casson AG, Risch HA, Ye W, Kamangar O, de Bruijne M, Ikram MA, van der Lugt A, F, Bernstein L, Sharp L, Nyrén O, Gammon Rivadeneira F, Uitterlinden AG, Hofman A, Loo CKC, Pereira TN, Ramm GA. Abnormal WT1 MD, Corley DA, Wu AH, Brown LM, Chow WH, Niessen WJ, Homuth G, de Zubicaray G, expression in human fetuses with bilateral renal Ward MH, Freedman ND, Whiteman DC.The McMahon KL, Thompson PM, Daboul A, Puls R, agenesis and cardiac malformations. Birth Defects importance of exposure rate on odds ratios by Hegenscheid K, Bevan L, Pausova Z, Medland Research Part A-Clinical and Molecular Teratology. cigarette smoking and alcohol consumption for SE, Montgomery GW, Wright MJ, Wicking C, 2012. Vol 94(2):116-22. esophageal adenocarcinoma and squamous Boehringer S, Spector TD, Paus T, Martin NG, cell carcinoma in the Barrett’s Esophagus and Lopes MC, Hysi PG, Verhoeven VJ, Macgregor Biffar R, Kayser M.A genome-wide association Esophageal Adenocarcinoma Consortium. Cancer S, Hewitt AW, Montgomery GW, Cumberland P, study identifies five loci influencing facial Epidemiology. 2012. Vol 36(3):306-316. morphology in Europeans. Plos Genetics. 2012. Vol Vingerling JR, Young TL, van Duijn CM, Oostra 8(9):e1002932. B, Uitterlinden AG, Rahi JS, Mackey DA, Klaver Luciano M, Evans DM, Hansell NK, Medland CC, andrew T, Hammond CJ.Identification of SE, Montgomery GW, Martin NG, Wright MJ, Liu G, Niu S, Dong A, Cai H, anderson GJ, Han a candidate gene for astigmatism. Investigative Bates TC.A genome-wide association study for B, Nie G.A Chinese family carrying novel mutations Ophthalmology & Visual Science. 2013. Vol reading and language abilities in two population in SEC23B and HFE2, the genes responsible for 54(2):1260-1267. cohorts. Genes Brain and Behavior. 2013. Vol congenital dyserythropoietic anaemia II (CDA II) and 12(6):645-652. primary iron overload, respectively. British Journal Lose F, Srinivasan S, O’Mara T, Marquart L, of Haematology. 2012. Vol 158(1):143-5. Chambers S, Gardiner RA, Aitken JF; Australian Luciano M, Huffman JE, Arias-Vásquez A, Prostate Cancer BioResource, Spurdle AB, Vinkhuyzen AA, Middeldorp CM, Giegling I, Liu H, Wang LE, Liu Z, Chen WV, Amos CI, Batra J, Clements JA.Genetic Association of the Payton A, Davies G, Zgaga L, Janzing J, Ke X, Lee JE; Q-MEGA and AMFS Investigators; KLK4 Locus with Risk of Prostate Cancer. Plos Galesloot T, Hartmann AM, Ollier W, Tenesa GenoMEL Investigators, Iles MM, Law MH, One. 2012. Vol 7(9):E44520. A, Hayward C, Verhagen M, Montgomery Barrett JH, Montgomery GW, Taylor JC, GW, Hottenga JJ, Konte B, Starr JM, Vitart V, Loukas, A., Gaze, S., Pearson, M., Doolan, MacGregor S, Cust AE, Newton Bishop JA, Vos PE, Madden PA, Willemsen G, Konnerth D., Felgner, P., Diemert, D., McManus, D. P., Hayward NK, Bishop DT, Mann GJ, Affleck H, Horan MA, Porteous DJ, Campbell H, Driguez, P. and Bethony, J.Schistosomiasis P, Wei Q.Association between functional Vermeulen SH, Heath AC, Wright A, Polasek O, Vaccines ? New Approaches to Antigen Discovery polymorphisms in genes involved in the MAPK Kovacevic SB, Hastie ND, Franke B, Boomsma and Promising New Candidates, in Parasitic signaling pathways and cutaneous melanoma risk. DI, Martin NG, Rujescu D, Wilson JF, Buitelaar Helminths: Targets, Screens, Drugs and Vaccines Carcinogenesis. 2013. Vol 34(4):885-892. J, Pendleton N, Rudan I, Deary IJ.Genome-wide (Ed C. R. Caffrey), Wiley-Vch Verlag Gmbh & Co. association uncovers shared genetic effects among Liu YC, Miles JJ, Neller MA, Gostick E, Price Kgaa, Weinheim, Germany.. 2012. Vol NULL. personality traits and mood states. American DA, Purcell AW, McCluskey J, Burrows SR, Journal of Medical Genetics B: Neuropsychiatric Rossjohn J, Gras SHighly Divergent T-cell Lu Y, Chen X, Beesley J, Johnatty SE, Defazio Genetics. 2012. Vol 159B(6):684-695. Receptor Binding Modes Underlie Specific A; Australian Ovarian Cancer Study (AOCS) Study Group, Lambrechts S, Lambrechts Recognition of a Bulged Viral Peptide bound to Luciano M, Lopez LM, de Moor MH, Harris D, Despierre E, Vergotes I, Chang-Claude a Human Leukocyte Antigen Class I Molecule. SE, Davies G, Nutile T, Krueger RF, Esko T, J, Hein R, Nickels S, Wang-Gohrke S, Dörk Journal of Biological Chemistry. 2013. Vol Schlessinger D, Toshiko T, Derringer JL, Realo T, Dürst M, Antonenkova N, Bogdanova N, 288(22):15442-15454. A, Hansell NK, Pergadia ML, Pesonen AK, Goodman MT, Lurie G, Wilkens LR, Carney Sanna S, Terracciano A, Madden PA, Penninx B, Liu, X. Q. Stacey, K. J. Horne-Debets, J. M. ME, Butzow R, Nevanlinna H, Heikkinen T, Spinhoven P, Hartman CA, Oostra BA, Janssens Cridland, J. A. Fischer, K. Narum, D. Mackay, Leminen A, Kiemeney LA, Massuger LF, van AC, Eriksson JG, Starr JM, Cannas A, Ferrucci F. Pierce, S. K. Wykes, M. N.Malaria infection Altena AM, Aben KK, Kjaer SK, Høgdall E, L, Metspalu A, Wright MJ, Heath AC, van Duijn alters the expression of B-cell activating factor Jensen A, Brooks-Wilson A, Le N, Cook L, CM, Bierut LJ, Raikkonen K, Martin NG, Ciullo resulting in diminished memory antibody responses Earp M, Kelemen L, Easton D, Pharoah P, M, Rujescu D, Boomsma DI, Deary IJ.Longevity

Page 134 QIMR Annual Report 2012–2013 candidate genes and their association with Mattarollo, S. R., and Smyth, M. J.NKT on Human Height. Plos Genetics. 2012. Vol personality traits in the elderly. American Journal cell adjuvants in therapeutic vaccines against 8(7):e1002655. of Medical Genetics B: Neuropsychiatric Genetics. hematological cancers. Oncoimmunology. 2013. 2012. Vol 159B(2):192-200. Vol 2(2):e22615. McRae AF, W. M., Hansell NK, Montgomery GW, Martin NG.No Association Between General Luong HT, N.D., ?Painter JN, Chapman Mattarollo, S. R., Steegh, K., Li, M., Duret, H., Cognitive Ability and Rare Copy Number Variation. B, Kennedy S, Treloar SA, Zondervan KT, Ngiow, S-F., and Smyth, M. J.Transient Foxp3+ Behavior Genetics. 2013. Vol 43(3):202-207. Montgomery GW.No evidence for genetic regulatory T cell depletion enhances therapeutic association with the let-7 microRNA-binding anti-cancer vaccination targeting the immune- McRae, A., M. Richter and P. LindCase-control site or other common KRAS variants in risk of stimulatory properties of NKT cells. Immunology & association testing of common variants from endometriosis. Human Reproduction. 2012. Vol Cell Biology. 2013. Vol 91(1):105-114. sequencing of DNA pools. Plos One. 2013. Vol 27(12):3616-3621. 8(6):-e65410. Mattarollo, S. R., West, A. C., Steegh, K., Lynskey, M. T., Agrawal A, Henders A, Nelson Duret, H., Paget, C., Martin, B., Matthews, McWilliam, H.E.G., Driguez, P., Piedrafita, EC, Madden PA, Martin NGAn Australian G. M., Shortt, J., Chesi, M., Bergsagel, P. L., D., McManus, D.P. Meeusen, E.N.T.Novel Twin Study of Cannabis and Other Illicit Drug Bots, M., Zuber, J., Lowe, S. W., Johnstone, immunomic technologies for schistosome vaccine Use and Misuse, and Other Psychopathology. R. W., and Smyth, M. J.NKT cell adjuvant-based development. Parasite Immunology. 2012. Vol Twin Research and Human Genetics. 2012. Vol tumor vaccine for treatment of myc oncogene- 34(5):276-284. 15(5):631-641. driven mouse B cell lymphoma. Blood. 2012. Vol Metz SW, Gardner J, Geertsema C, Le TT, Goh 120(15):3019-3029. Ma, Y., Adjemian, S., Mattarollo, S. R., Duret, L, Vlak JM, Suhrbier A, Pijlman GP.Effective H., Steegh, K., Yamazaki, T., Aymeric, L., Yang, McDonald CJ, Wallace DF, Crawford DH, chikungunya virus-like particle vaccine produced H., Catani, J. P. P., Hannani, D., Martins, I., Subramaniam VN. Iron Storage Disease in Asia- in insect cells. Plos Neglected Tropical Diseases. Schlemmer, F., Michaud, M., Kepp, O., Galluzzi, Pacific Populations: the Importance of Non-HFE 2013. Vol 7(3):e2124. L., Tordjmann, T., Droin, N., Villeval, J-L., Mutations. Journal of Gastroenterology and Michailidou K, Hall P, Gonzalez-Neira A, Krzysiek, R., Solary, E., Murphy, K. M., Smyth, Hepatology. 2013. Vol 28(7):1087-94. Ghoussaini M, Dennis J, Milne RL, Schmidt M. J., Zitvogel, L., and Kroemer, G.Intratumor MK, Chang-Claude J, Bojesen SE, Bolla MK, antigen presentation in chemotherapy-induced McManus, D.P.Schistosomiasis in 2012 ? current status and key research priorities required for Wang Q, Dicks E, Lee A, Turnbull C, Rahman anticancer immune responses. Immunity. 2013. Vol N; Breast and Ovarian Cancer Susceptibility 38 729-741. control leading to elimination. Expert Review of Anti-Infective Therapy. 2012. Vol 10(11):1233- Collaboration, Fletcher O, Peto J, Gibson L, Ma, Y., Yamazaki, T., Yang, H., Kepp, O., 1236. Dos Santos Silva I, Nevanlinna H, Muranen TA, Galluzzi, L., Zitvogel, L., Smyth, M. J.*, and Aittomäki K, Blomqvist C, Czene K, Irwanto A, Kroemer, G.*Tumor necrosis factor is dispensable McManus, D.P., Gray, D., Zhang, W., Yang, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank for the success of immune-dependent anticancer Y. R.Diagnosis, treatment and management of M; Hereditary Breast and Ovarian Cancer chemotherapy. Oncoimmunology. 2013. Vol 2(6):- echinococcosis. Bmj. 2012. Vol 344 -e3866. Research Group Netherlands (HEBON), van e24786.. der Luijt RB, Hein R, Dahmen N, Beckman L, McManus, D.P., Li, Y.S., Williams, G.M, Meindl A, Schmutzler RK, Müller-Myhsok B, Macare C, B. T., Heath AC, Martin NG, Ettinger Bergquist, R. Gray, D.J. Challenges in Controlling Lichtner P, Hopper JL, Southey MC, Makalic U.Substantial genetic overlap between schizotypy and Eradicating Schistosomiasis. In: Emerging E, Schmidt DF, Uitterlinden AG, Hofman A, and neuroticism: a twin study. Behavior Genetics. Infectious Diseases of the 21st Century. Fong, I.W. Hunter DJ, Chanock SJ, Vincent D, Bacot F, 2012. Vol 42(5):732-742. editor. Springer, New York, Usa, 2013. 2013. Vol Tessier DC, Canisius S, Wessels LF, Haiman 265-299. CA, Shah M, Luben R, Brown J, Luccarini C, MacDonald KP, Shlomchik WD, Reddy PBiology Schoof N, Humphreys K, Li J, Nordestgaard of graft-versus-host responses: recent insights. McMillan DJ, Dr?ze PA, Vu T, Bessen DE, BG, Nielsen SF, Flyger H, Couch FJ, Wang X, Biology of Blood and Marrow Transplantation. Guglielmini J, Steer AC, Carapetis JR, Van Vachon C, Stevens KN, Lambrechts D, Moisse 2013. Vol 19(1 Suppl):S10-S14. Melderen L, Sriprakash KS, Smeesters PR.Updated model of group A Streptococcus M M, Paridaens R, Christiaens MR, Rudolph A, Madura F, Rizkallah PJ, Miles KM, Holland CJ, proteins based on a comprehensive worldwide Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Bulek AM, Fuller A, Schauenburg AJ, Miles JJ, study. Clinical Microbiology and Infection. 2013. Vol Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van Liddy N, Sami M, Li Y, Hossain M, Baker BM, 19(5):E222-E229. der Schoot CE, Guénel P, Truong T, Laurent- Jakobsen BK, Sewell AK, Cole DK.T-cell receptor Puig P, Menegaux F, Marme F, Schneeweiss specificity maintained by altered thermodynamics. McMillan DJ, Sanderson-Smith ML, Smeesters A, Sohn C, Burwinkel B, Zamora MP, Perez JI, Journal of Biological Chemistry. 2013. Vol PR, Sriprakash KS.Molecular markers for the Pita G, Alonso MR, Cox A, Brock IW, Cross 288(26):18766-18775. study of streptococcal epidemiology. Current SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin Topics In Microbiology and Immunology. 2013. Vol MJ, Miller N, Henderson BE, Schumacher F, Le Major LD, Partridge TS, Gardner J, Kent SJ, de 368 29-48. Marchand L, andrulis IL, Knight JA, Glendon G, Rose R, Suhrbier A, Schroder WA.Induction of Mulligan AM; kConFab Investigators; Australian McQuillan R, E. N., Pirastu N, Kuningas SerpinB2 and Th1/Th2 modulation by SerpinB2 Ovarian Cancer Study Group, Lindblom A, M, McEvoy BP, Esko T, Corre T, Davies G, during lentiviral infections in vivo. Plos One. 2013. Margolin S, Hooning MJ, Hollestelle A, van Kaakinen M, Lyytikainen LP, Kristiansson Vol 8(2):e57343. den Ouweland AM, Jager A, Bui QM, Stone K, Havulinna AS, Gogele M, Vitart V, Tenesa J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Malagón D, Gray D, Botterill B, Lovas E, Duke A, Aulchenko Y, Hayward C, Johansson A, Severi G, Baglietto L, Fasching PA, Haeberle L, M, Gray C, Kopp SR, Knott LM, McManus Boban M, Ulivi S, Robino A, Boraska V, Igl W, Ekici AB, Beckmann MW, Brenner H, Müller H, DP, Daly NL, Mulvenna J, Craik DJ, Jones Wild SH, Zgaga L, Amin N, Theodoratou E, Arndt V, Stegmaier C, Swerdlow A, Ashworth MK.Anthelminthic activity of the cyclotides (kalata Polasek O, Girotto G, Lopez LM, Sala C, Lahti A, Orr N, Jones M, Figueroa J, Lissowska J, B1 and B2) against schistosome parasites. J, Laatikainen T, Prokopenko I, Kals M, Viikari J, Brinton L, Goldberg MS, Labrèche F, Dumont Biopolymers. 2013. Vol [Epub ahead of print]. Yang J, Pouta A, Estrada K, Hofman A, Freimer M, Winqvist R, Pylkäs K, Jukkola-Vuorinen N, Martin NG, Kahonen M, Milani L, Heliovaara A, Grip M, Brauch H, Hamann U, Brüning T; Markey KA, Koyama M, Kuns RD, Lineburg M, Vartiainen E, Raikkonen K, Masciullo C, Starr GENICA (Gene Environment Interaction and KE, Wilson YA, Olver SD, Raffelt NC, Don AL, JM, Hicks AA, Esposito L, Kolcic I, Farrington Breast Cancer in Germany) Network, Radice P, Varelias A, Robb RJ, Cheong M, Engwerda SM, Oostra B, Zemunik T, Campbell H, Kirin Peterlongo P, Manoukian S, Bonanni B, Devilee CR, Steptoe RJ, Ramshaw HS, Lopez AF, M, Pehlic M, Faletra F, Porteous D, Pistis G, P, Tollenaar RA, Seynaeve C, van Asperen Vega-Ramos J, Lew AM, Villadangos JA, Hill Widen E, Salomaa V, Koskinen S, Fischer K, CJ, Jakubowska A, Lubinski J, Jaworska K, GR, MacDonald KP.Immune insufficiency during Lehtimaki T, Heath A, McCarthy MI, Rivadeneira Durda K, Mannermaa A, Kataja V, Kosma VM, GVHD is due to defective antigen presentation F, Montgomery GW, Tiemeier H, Hartikainen AL, Hartikainen JM, Bogdanova NV, Antonenkova within dendritic cell subsets. Blood. 2012. Vol Madden PA, d’Adamo P, Hastie ND, Gyllensten NN, Dörk T, Kristensen VN, Anton-Culver H, 119(24):5918-5930. U, Wright AF, van Duijn CM, Dunlop M, Rudan I, Slager S, Toland AE, Edge S, Fostira F, Kang Gasparini P, Pramstaller PP, Deary IJ, Toniolo D, Martin, N. G.Commentary: Discussion of ?The D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Eriksson JG, Jula A, Raitakari OT, Metspalu A, History of Twins, As A Criterion of The Relative Sueta A, Wu AH, Tseng CC, Van Den Berg D, Perola M, Jarvelin MR, Uitterlinden A, Visscher Powers of Nature and Nurture? by Francis Galton Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo PM, Wilson JF, on behalf of the ROHgen (1875). International Journal of Epidemiology. 2012. SH, Yip CH, Phuah SY, Cornes BK, Hartman M, ConsortiumEvidence of Inbreeding Depression Vol 41(4):917-19. Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen

Page 135 Scientiﬁc publications | continued

CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Jenkins MA, Buchanan DD, Potter JD, Baron G, Yang J, Dörk T, Becherel O, Grattan-Smith S, Gaborieau V, Brennan P, McKay J, Blot JA, Ahnen DJ, Moreno V, andreu M, Ponz de P, Lavin MFMitochondrial dysfunction in a novel WJ, Signorello LB, Cai Q, Zheng W, Deming- Leon M, Rustgi AK, Castells A; EPICOLON form of autosomal recessive ataxia Mitochondrion. Halverson S, Shrubsole M, Long J, Simard J, Consortium.Identification of Lynch syndrome 2013. Vol 13(3):235-45. Garcia-Closas M, Pharoah PD, Chenevix-Trench among patients with colorectal cancer. Jama. G, Dunning AM, Benitez J, Easton DF.Large- 2012. Vol 30(15):1555-1565. N Houston, N Stewart, AC Champion, DJ Smith, scale genotyping identifies 41 new loci associated SC Bell, DW Reid. Sputum neutrophils in cystic with breast cancer risk. Nature Genetics. 2013. Vol Morrison, Brian J; Hastie, Marcus L; Grewal, fibrosis display a reduced respiratory burst. Journal 45(4):353-361. Yadveer S; Bruce, Zara C; Schmidt, Chris; of Cystic Fibrosis. 2013. Vol 12(4):352-62. Reynolds, Brent A; Gorman, Jeffrey J; Lopez, Middelberg RP, Benyamin B, de Moor MH, J Alejandro;Proteomic Comparison of MCF-7 Nag A, Venturini C, Hysi PG, Arno M, Aldecoa- Warrington NM, Gordon S, Henders AK, Tumoursphere and Monolayer Cultures Plos One. Otalora Astarloa E, Macgregor S, Hewitt AW, Medland SE, Nyholt DR, de Geus EJ, Hottenga 2012. Vol 7(12):-e52692. Young TL, Mitchell P, Viswanathan AC, Mackey JJ, Willemsen G, Beilin LJ, Mori TA, Wright MJ, DA, Hammond CJ.Copy number variation at Heath AC, Madden PA, Boomsma DI, Pennell Morze CJ, Olsen CM, Perry SL, Jackman chromosome 5q21.2 is associated with intra-ocular CE, Montgomery GW, Martin NG, Whitfield LM, Ranieri BA, O’Brien SM, Cicero RA, pressure. Investigative Ophthalmology & Visual JB.Loci affecting gamma-glutamyl transferase in Whiteman DC; QSkin Study.Good test-retest Science. 2013. Vol 54(5):3607-12. reproducibility for an instrument to capture self- adults and adolescents show age x SNP interaction Naggie S, Osinusi A, Katsounas A, Lempicki and cardiometabolic disease associations. Human reported melanoma risk factors. Journal of Clinical Epidemiology. 2012. Vol 65(12):1329-1336. R, Herrmann E, Thompson AJ, Clark PJ, Patel Molecular Genetics. 2012. Vol 21(2):446-455. K, Muir AJ, McHutchison JG, Schlaak JF, Middelberg RP, Heath AC, Madden PA, Mosing MA, Medland SE, McRae A, Landers Trippler M, Shivakumar B, Masur H, Polis MA, Montgomery GW, Martin NG, Whitfield JG, Wright MJ, Martin NG.Genetic influences Kottilil S.Dysregulation of innate immunity in HCV JB.Evidence of Differential Allelic Effects between on life span and its relationship to personality: a genotype 1 IL28B unfavorable genotype patients: Adolescents and Adults for Plasma High-Density 16-year follow-up study of a sample of aging twins. Impaired viral kinetics and therapeutic response. Lipoprotein. Plos One. 2012. Vol 7(4):e35605. Psychosomatic Medicine. 2012. Vol 74(1):16-22. Hepatology. 2012. Vol 56(52):444-454.

Mika A, Reynolds SL, Pickering D, McMillan Mosing MA, Mellanby J, Martin NG, Wright Nagle C, Marquart L, Bain C, O?Brien S, D, Sriprakash KS, Kemp DJ, Fischer MJ.Genetic and Environmental Influences on Lahmann P, Quinn M, Oehler M, Obermair A, K.Complement inhibitors from scabies mites Analogical and Categorical Verbal and Spatial Spurdle A, Webb P, on behalf of the Australian promote streptococcal growth--a novel mechanism Reasoning in 12-Year Old Twins. Behavior National Endometrial Cancer Study group. in infected epidermis? Plos Neglected Tropical Genetics. 2012. Vol 42(5):722-731. Impact of weight change and weight cycling on risk of different subtypes of endometrial Diseases. 2012. Vol 6(7):e1563. Mounsey KE, McCarthy JS, Walton cancer. European Journal of Cancer. 2013. Vol SF. Mika, A. Reynolds, S. L. Mohlin, F. C. Willis, Scratching the itch: new tools to advance 49(12):2717-2726. C. Swe, P. M. Pickering, D. A. Halilovic, V. understanding of scabies. Trends In Parasitology. Wijeyewickrema, L. C. Pike, R. N. Blom, A. 2013. Vol 29(1):35-42. Nagle CM, Olsen CM, Ibiebele TI, Spurdle AB, Webb PMGlycemic index, glycemic load and M. Kemp, D. J. Fischer, K.Novel Scabies Mite Mounsey, K. E. and J. S. McCarthyTreatment and Serpins Inhibit the Three Pathways of the Human endometrial cancer risk: results from the Australian control of scabies. Current Opinion In Infectious National Endometrial Cancer study and an updated Complement System. Plos One. 2012. Vol 7(7):- Diseases. 2013. Vol 26(2):133-139. 440489. systematic review and meta-analysis. European Mudianta, WI, Skinner-Adams T, andrews Journal of Nutrition. 2013. Vol 52(2):705-715. Mika, A. Reynolds, S. L. Mohlin, F. C. Willis, KT, Davis RA, Hadi TA, Hayes PY, Garson Nagore E, Hacker E, Martorell-Calatayud A, C. Swe, P. M. Pickering, D. A. Halilovic, V. MJPsammaplysin Derivatives from the Balinese Wijeyewickrema, L. C. Pike, R. N. Blom, A. Traves V, Guillen C, Hayward NK, Whiteman Marine Sponge Aplysinella strongylata Journal of D.Prevalence of BRAF and NRAS mutations in fast- M. Kemp, D. J. Fischer, K.Novel scabies mite Natural Products. 2012. Vol 75(12):2132-43. serpins inhibit the three pathways of the human growing melanomas. Pigment Cell and Melanoma complement system. Plos One. 2012. Vol 7(7):- Mullally A, Bruedigam C, Poveromo L, Heidel Research. 2013. Vol 26(3):429-431. 440489. FH, Purdon A, Vu T, Austin R, Heckl D, Nakaya HI, Gardner J, Poo YS, Major L, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong Pulendran B, Suhrbier A.Gene profiling of Miller G, Zhu G, Wright MJ, Hansell NK, Martin SA, Williams DA, Hill GR, Ebert BL, Lane Chikungunya virus arthritis in a mouse model NG.The heritability and genetic correlates of mobile SW. Depletion of Jak2V617F myeloproliferative reveals significant overlap with rheumatoid arthritis. phone use: A twin study of consumer behavior. neoplasm-propagating stem cells by interferon- Twin Research and Human Genetics. 2012. Vol Arthritis and Rheumatism. 2012. Vol 64(11):3553- alpha in a murine model of polycythemia vera. 3563. 15(1):97-106. Blood. 2013. Vol 121(18):3692-3702. Nayler S, Gatei M, Kozlov S, Gatti R, Mar Millers EK, Johnson LA, Birrell GW, Masci PP, Mullally A, Lane SW, Brumme K, Ebert JC, Wells CA, Lavin M, Wolvetang EInduced Lavin MF, de Jersey J, Guddat LWThe structure BL.Myeloproliferative neoplasm animal models. of human microplasmin in complex with textilinin-1, pluripotent stem cells from ataxia-telangiectasia Hematology/Oncology Clinics of North America. recapitulate the cellular phenotype Stem Cells an aprotinin-like inhibitor from the Australian brown 2012. Vol 26(5):1065-81. snake Plos One. 2013. Vol 8(1):e54104. Translational Medicine. 2012. Vol 1(7):523-35. Mullally A, Poveromo L, Schneider RK, Al- Neale RE, Stiller CA, Bunch KJ, Milne E, Mineau Mishra A, Y. S., Hewitt AW, Mountain JA, Ang Shahrour F, Lane SW, Ebert BL.Distinct roles for W, Pennell CE, Martin NG, Montgomery GW, GP, Murphy MF.Familial Aggregation of Childhood long-term hematopoietic stem cells and erythroid and Adult Cancer in the Utah Genealogy. Hammond CJ, Young TL, Macgregor S, Mackey precursor cells in a murine model of Jak2V617F- DA.Genetic variants near PDGFRA are associated International Journal of Cancer. 2013. Vol [Epub mediated polycythemia vera. Blood. 2012. Vol ahead of print]. with corneal curvature in Australians. Investigative 120(1):166-72. Ophthalmology & Visual Science. 2012. Vol Neale RE, Weissenborn S, Abeni D, Bavinck JN, 53(11):7131-7136. Mulvenna J, Cantacessi C, Young ND, Kasny Euvrard S, Feltkamp MC, Green AC, Harwood M, Horak P, Aziz A, Hofmann A, Loukas Molehin, A., Gobert, G., McManus, D.P.Serine C, de Koning M, Naldi L, Nindl I, Pawlita M, A, Gasser RB.A deep exploration of the Proby C, Quint WG, Waterboer T, Wieland U, protease inhibitors of parasitic helminths. transcriptome and “excretory/secretory” proteome Parasitology. 2012. Vol 139(6):681-95. Pfister HHuman papillomavirus load in eyebrow of adult Fascioloides magna. Molecular & Cellular hair follicles and risk of cutaneous squamous cell Molenaar D, v. d. S. S., Boomsma DI, Haworth Proteomics. 2012. Vol 11(12):1340-53. carcinoma. Cancer Epidemiology Biomarkers & CM, Hewitt JK, Martin NG, Plomin R, Wright MJ, Munro KM, Dixon KJ, Gresle MM, Jonas A, Prevention. 2013. Vol 22(4):719-727. Dolan CV.Genotype by Environment Interactions in Kemper D, Doherty W, Fabri LJ, Owczarek CM, Neill AS, Nagle CM, Protani MM, Obermair Cognitive Ability: A Survey of 14 Studies from Four Pearse M, Boyd AW, Kilpatrick TJ, Butzkueven A, Spurdle AB, Webb PM.Aspirin, nonsteroidal Countries Covering Four Age Groups. Behavior H, Turnley AM.EphA4 receptor tyrosine kinase Genetics. 2013. Vol 43(3):208-219. anti-inflammatory drugs, paracetamol and risk is a modulator of onset and disease severity of of endometrial cancer: a case-control study, Moreira L, Balaguer F, Lindor N, de la experimental autoimmune encephalomyelitis (EAE). systematic review and meta-analysis. International Chapelle A, Hampel H, Aaltonen LA, Hopper Plos One. 2013. Vol 8(2):e55948. Journal of Cancer. 2013. Vol 132(5):1146-1155. JL, Le Marchand L,Gallinger S, Newcomb Murad NA, Cullen JK, McKenzie M, Ryan MT, PA, Haile R, Thibodeau SN, Gunawardena Thorburn D, Gueven N, Kobayashi J, Birrell

Page 136 QIMR Annual Report 2012–2013 Neller MA, Burrows JM, Rist MJ, Miles JJ, Journal of Virological Methods. 2012. Vol 184(1- Panagopoulos VN, T. T., Glowinski AL, Lynskey Burrows SRHigh frequency of herpesvirus-specific Two):46-54. MT, Heath AC, Agrawal A, Henders AK, clonotypes in the human T cell repertoire can Wallace L, Todorov AA, Madden PA, Moore remain stable over decades with minimal turnover. Nourse JP, Lea R, Crooks P, Wright G, Tran E, Degenhardt L, Martin NG, Montgomery H, Catalano J, Brighton T, Grigg A, Marlton Journal of Virology. 2013. Vol 87(1):697-700. GW, Nelson ECExamining the association of P, Gandhi MK The KIR2DS2/DL2 genotype is NRXN3 SNPs with borderline personality disorder Neller MA, Sewell AK, Burrows SR, Miles associated with adult persistent/chronic and phenotypes in heroin dependent cases and socio- JJTracking the repertoire of human adult and relapsed immune thrombocytopenia independently economically disadvantaged controls. Drug and neonatal T cells during ex vivo amplification. British of FCGR3a-158 polymorphisms. Blood Coagul Alcohol Dependence. 2013. Vol 128(3):187-193. Journal of Haematology. 2012. Vol 159(3):370-373. Fibrinolysis. 2012. Vol 23(1):45-50.. Pandey M, Wykes MN, Hartas J, Good MF, Nelson EC, Heath AC, Lynskey MT, Agrawal Nyholt DR, Low SK, anderson CA, Painter JN, Batzloff MR.Long-term antibody memory induced A, Henders AK, Bowdler LM, Todorov AA, Uno S, Morris AP, MacGregor S, Gordon SD, by synthetic peptide vaccination is protective Madden PA, Moore E, Degenhardt L, Martin Henders AK, Martin NG, Attia J, Holliday EG, against Streptococcus pyogenes infection and NG, Montgomery GW.PTSD risk associated McEvoy M, Scott RJ, Kennedy SH, Treloar SA, is independent of memory T-cell help. Journal of with a functional DRD2 polymorphism in heroin- Missmer SA, Adachi S, Tanaka K, Nakamura Immunology. 2013. Vol 190(6):2692-2701. dependent cases and controls is limited to Y, Zondervan KT, Zembutsu H, Montgomery amphetamine-dependent individuals. Addiction GWGenome-wide association meta-analysis Pandeya N, Green AC, Whiteman DC; Australian Biology. 2013. Vol [Epub ahead of print]. identifies new endometriosis risk loci Nature Cancer Study.Prevalence and determinants of Genetics. 2012. Vol 44(12):1355-1359. frequent gastroesophageal reflux symptoms in the Nelson EC, L. M., Heath AC, Wray N, Agrawal Australian community. Diseases of The Esophagus. A, Shand FL, Henders AK, Wallace L, Todorov Oancea I, Png CW, Das I, Lourie R, Winkler IG, 2012. Vol 25(7):573-583. AA, Schrage AJ, Saccone NL, Madden PA, Eri R, Subramaniam N, Jinnah HA, McWhinney Degenhardt L, Martin NG, Montgomery BC, Levesque JP, McGuckin MA, Duley JA, Pasricha SR, Frazer DM, Bowden DK, anderson GW.ANKK1, TTC12, and NCAM1 Polymorphisms Florin TH.A novel mouse model of veno-occlusive GJ.Transfusion suppresses erythropoiesis and and Heroin Dependence: Importance of disease provides strategies to prevent thioguanine- increases hepcidin in adult patients with beta- Considering Drug Exposure. Jama Psychiatry. induced hepatic toxicity. Gut. 2013. Vol 62(4):594- thalassemia major: a longitudinal study. Blood. 2013. Vol 70(3):325-333. 605. 2013. Vol 122(1):124-33.

Newman B, Lose F, Kedda MA, Francois M, Olsen CM, Green AC, Neale RE, Webb PM, Paternoster L, Standl M, Chen CM, Ramasamy Ferguson K, Janda M, Yates P, Spurdle AB, Cicero RA, Jackman LM, O’Brien SM, Perry A, Bønnelykke K, Duijts L, Ferreira MA, Alves Hayes SC.Possible genetic predisposition to SL, Ranieri BA, Whiteman DC.Cohort profile: the AC, Thyssen JP, Albrecht E, Baurecht H, lymphedema after breast cancer. Lymphat Res QSkin Sun and Health Study. International Journal Feenstra B, Sleiman PM, Hysi P, Warrington NM, Biol. 2012. Vol 10(1):2-13. of Epidemiology. 2012. Vol 41(4):929-929I. Curjuric I, Myhre R, Curtin JA, Groen-Blokhuis MM, Kerkhof M, Sääf A, Franke A, Ellinghaus Ngiow SF, von Scheidt B, Möller A, Smyth Olsen CM, Nagle CM, Whiteman DC, Ness D, Fölster-Holst R, Dermitzakis E, Montgomery MJ, Teng MW.The interaction between murine R, Pearce CL, Pike MC, Rossing MA, Terry SB, Prokisch H, Heim K, Hartikainen AL, Pouta melanoma and the immune system reveals that KL, Wu AH; Australian Cancer Study (Ovarian A, Pekkanen J, Blakemore AI, Buxton JL, prolonged responses predispose for autoimmunity. Cancer); Australian Ovarian Cancer Study Kaakinen M, Duffy DL, Madden PA, Heath AC, Oncoimmunology. 2013. Vol 2(2):e23036. Group, Risch HA, Yu H, Doherty JA, Chang- Montgomery GW, Thompson PJ, Matheson Claude J, Hein R, Nickels S, Wang-Gohrke S, MC, Le Souëf P; Australian Asthma Genetics Ngiow, S-F.*, Knight, D. A.*, Ribas, A., McArthur, Goodman MT, Carney ME, Matsuno RK, Lurie G. A., and Smyth, M. J.BRAF targeted therapy Consortium (AAGC), St Pourcain B, Smith GD, G, Moysich K, Kjaer SK, Jensen A, Hogdall Henderson J, Kemp JP, Timpson NJ, Deloukas and host immune reaction to melanoma. E, Goode EL, Fridley BL, Vierkant RA, Larson Oncoimmunology. 2013. Vol 2(6):-e24462. P, Ring SM, Wichmann HE, Müller-Nurasyid MC, Schildkraut J, Hoyo C, Moorman P, Weber M, Novak N, Klopp N, Rodríguez E, McArdle Nickels S, Truong T, Hein R, Stevens K, Buck RP, Cramer DW, Vitonis AF, Bandera EV, Olson W, Linneberg A, Menné T, Nohr EA, Hofman K, Behrens S, Eilber U, Schmidt M, Häberle SH, Rodriguez-Rodriguez L, King M, Brinton A, Uitterlinden AG, van Duijn CM, Rivadeneira L, Vrieling A, Gaudet M, Figueroa J, Schoof LA, Yang H, Garcia-Closas M, Lissowska J, F, de Jongste JC, van der Valk RJ, Wjst M, N, Spurdle AB, Rudolph A, Fasching PA, Anton-Culver H, Ziogas A, Gayther SA, Ramus Jogi R, Geller F, Boyd HA, Murray JC, Kim C, Hopper JL, Makalic E, Schmidt DF, Southey SJ, Menon U, Gentry-Maharaj A, Webb PM; Mentch F, March M, Mangino M, Spector TD, MC, Beckmann MW, Ekici AB, Fletcher O, Ovarian Cancer Association Consortium.Obesity Bataille V, Pennell CE, Holt PG, Sly P, Tiesler Gibson L, Silva Idos S, Peto J, Humphreys and risk of ovarian cancer subtypes: evidence CM, Thiering E, Illig T, Imboden M, Nystad W, MK, Wang J, Cordina-Duverger E, Menegaux from the Ovarian Cancer Association Consortium. Simpson A, Hottenga JJ, Postma D, Koppelman F, Nordestgaard BG, Bojesen SE, Lanng C, Endocrine-Related Cancer. 2013. Vol 20(2):251- GH, Smit HA, Söderhäll C, Chawes B, Kreiner- Anton-Culver H, Ziogas A, Bernstein L, Clarke 262. Møller E, Bisgaard H, Melén E, Boomsma DI, CA, Brenner H, Müller H, Arndt V, Stegmaier C, Olsen CM, Neale RE, Cicero RA, Jackman LM, Custovic A, Jacobsson B, Probst-Hensch NM, Brauch H, Brüning T, Harth V; Genica Network, O’brien SM, Perry SL, Ranieri BA, Whiteman Palmer LJ, Glass D, Hakonarson H, Melbye M, Mannermaa A, Kataja V, Kosma VM, Hartikainen DC.Do “personal stories” improve response rates? Jarvis DL, Jaddoe VW, Gieger C; Genetics of JM; kConFab; AOCS Management Group, Epidemiology. 2012. Vol 23(5):765-6. Overweight Young Adults (GOYA) Consortium, Lambrechts D, Smeets D, Neven P, Paridaens Strachan DP, Martin NG, Jarvelin MR, Heinrich R, Flesch-Janys D, Obi N, Wang-Gohrke S, Olsen, C. M. and A. C. GreenMore evidence of J, Evans DM, Weidinger S; EArly Genetics & Couch FJ, Olson JE, Vachon CM, Giles GG, harms of sunbed use, particularly for young people. Lifecourse Epidemiology (EAGLE) Consortium. Severi G, Baglietto L, offit K, John EM, Miron A, Bmj. 2012. Vol 345 E6101. Meta-analysis of genome-wide association studies andrulis IL, Knight JA, Glendon G, Mulligan AM, identifies three new risk loci for atopic dermatitis. Ong ML, Wikstrom ME, Fleming P, Estcourt MJ, Chanock SJ, Lissowska J, Liu J, Cox A, Cramp Nature Genetics. 2012. Vol 44(2):187-192. H, Connley D, Balasubramanian S, Dunning AM, Hertzog PJ, Hill GR, andoniou CE, Degli-Esposti Shah M, Trentham-Dietz A, Newcomb P, Titus MA.CpG pre-treatment enhances anti-viral T cell Pearce CL, Rossing MA, Lee AW, Ness RB, L, Egan K, Cahoon EK, Rajaraman P, Sigurdson immunity against cytomegalovirus. Blood. 2013. Webb PM; for Australian Cancer Study (Ovarian AJ, Doody MM, Guénel P, Pharoah PD, Vol 122(1):55-60. Cancer); Australian Ovarian Cancer Study Group, Chenevix-Trench G, Jordan SM, Stram Schmidt MK, Hall P, Easton DF, Garcia-Closas O’Sullivan T, Saddawi-Konefka R, Vermi W, DA, Chang-Claude J, Hein R, Nickels S, Lurie M, Milne RL, Chang-Claude J.Evidence of Koebel CM, Arthur C, White JM, Uppaluri R, G, Thompson PJ, Carney ME, Goodman MT, gene-environment interactions between common andrews DM, Ngiow SF, Teng MW, Smyth MJ, Moysich K, Hogdall E, Jensen A, Goode EL, breast cancer susceptibility loci and established Schreiber RD, Bui JD. Cancer immunoediting Fridley BL, Cunningham JM, Vierkant RA, environmental risk factors. Plos Genetics. 2013. Vol by the innate immune system in the absence Weber RP, Ziogas A, Anton-Culver H, Gayther 9(3):e1003284. of adaptive immunity. Journal of Experimental SA, Gentry-Maharaj A, Menon U, Ramus SJ, Medicine. 2012. Vol 209(10):1869-1882. Nourse JP, Crooks P, Keane C, Nguyen-Van Brinton L, Wentzensen N, Lissowska J, Garcia- D, Mujaj S, Ross N, Jones K, Vari F, Han E, Paget, C., Duret, H., Ngiow, S-F., Kansara, M., Closas M, Massuger LF, Kiemeney LA, Van Trappe R, Fink S, Gandhi MKExpression profiling Thomas, D., and Smyth, M. J.Studying the role Altena AM, Aben KK, Berchuck A, Doherty JA, of Epstein-Barr virus-encoded microRNAs from of the immune system on the antitumor effect of a Iversen E, McGuire V, Moorman PG, Pharoah P, paraffin-embedded formalin-fixed primary Epstein- Hedgehog inhibitor against murine osteosarcomas. Pike MC, Risch H, Sieh W, Stram DO, Terry KL, Barr virus-positive B-cell lymphoma samples. Oncoimmunology. 2012. Vol 1(8):1313-1322. Whittemore A, Wu AH, Schildkraut JM, Kjaer SK; Ovarian Cancer Association Consortium.

Page 137 Scientiﬁc publications | continued

Combined and interactive effects of environmental Perry JR, Corre T, Esko T, Chasman DI, Fischer JA, Ahnen DJ, Win AK, Potter JD, Newcomb and GWAS-identified risk factors in ovarian cancer. K, Franceschini N, He C, Kutalik Z, Mangino PA.BRAF Mutation Status and Survival after Cancer Epidemiology Biomarkers & Prevention. M, Rose LM, Vernon Smith A, Stolk L, Sulem P, Colorectal Cancer Diagnosis According to Patient 2013. Vol 22(5):880-890. Weedon MN, Zhuang WV, Arnold A, Ashworth and Tumor Characteristics. Cancer Epidemiology A, Bergmann S, Buring JE, Burri A, Chen Biomarkers & Prevention. 2012. Vol 21(10):1792- Peatey CL, Dixon MW, Gardiner DL, Trenholme C, Cornelis MC, Couper DJ, Goodarzi MO, 1798. KRTemporal evaluation of commitment to sexual Gudnason V, Harris T, Hofman A, Jones M, development in Plasmodium falciparum. Malaria Kraft P, Launer L, Laven JS, Li G, McKnight Phipps AI, Buchanan DD, Makar KW, Win AK, Journal. 2013. Vol 12(134). B, Masciullo C, Milani L, Orr N, Psaty BM; Baron JA, Lindor NM, Potter JD, Newcomb PA.KRAS-mutation status in relation to colorectal Pender MP, Csurhes PA, Pfluger CM, Burrows ReproGen Consortium, Ridker PM, Rivadeneira cancer survival: the joint impact of correlated SRCD8+ T cells far predominate over CD4+ T cells F, Sala C, Salumets A, Schoemaker M, Traglia tumour markers. British Journal of Cancer. 2013. in healthy immune response to Epstein-Barr virus M, Waeber G, Chanock SJ, Demerath EW, Vol 108(8):1757-1764. infected lymphoblastoid cell lines. Blood. 2012. Vol Garcia M, Hankinson SE, Hu FB, Hunter 120(25):5085-7. DJ, Lunetta KL, Metspalu A, Montgomery Piratae, S., S. Tesana, M. K. Jones, P. J. GW, Murabito JM, Newman AB, Ong KK, Brindley, A. Loukas, E. Lovas, V. Eursitthichai, Pentier JM, Sewell AK, Miles JJ.Advances in Spector TD, Stefansson K, Swerdlow AJ, B. Sripa, S. Thanasuwan and T. LahaMolecular T-cell epitope engineering. Front Immunol. 2013. Thorsteinsdottir U, Van Dam RM, Uitterlinden Characterization of a Tetraspanin from the Human Vol 4 133. AG, Visser JA, Vollenweider P, Toniolo D, Murray Liver Fluke, Opisthorchis viverrini. Plos Neglected A.A genome-wide association study of early Pereira TN, Lewindon PJ, Greer RM, Williamson Tropical Diseases. 2012. Vol 6(12):-. menopause and the combined impact of identified RM, Shepherd RW, Ramm. A transcriptional variants. Human Molecular Genetics. 2013. Vol Poole EM, Merritt MA, Jordan SJ, Yang HP, basis for Cystic Fibrosis liver disease: Pilot study 22(7):1465-1472. Hankinson SE, Park Y, Rosner B, Webb PM, of differentially expressed genes associated Cramer DW, Wentzensen N, Terry KL, Tworoger with hepatic fibrosis. Journal of Pediatric Pham TT, Nguyen TD, Le MH, Xuan CPT, Hoang SS.Hormonal and reproductive risk factors for Gastroenterology and Nutrition. 2012. Vol MD, Tran CT, Kutcher S, Ryan PA, KAY BH.High epithelial ovarian cancer by tumor aggressiveness. 54(3):328-35. household economic burden due to hospitalization Cancer Epidemiology Biomarkers & Prevention. of severe dengue fever cases in Can Tho, Vietnam. Permuth-Wey J, Lawrenson K, Shen HC, 2013. Vol 22(3):429-437. American Journal of Tropical Medicine and Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Hygiene. 2012. Vol 87(3):554-558. Powar MP, Martin P, Croft AR, Walsh A, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Petersen D, Stevenson AR, Lumley JW, Stitz Lee N, Larson MC, Aben KK, Anton-Culver H, Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, RW, Radford-Smith GL, Clark DA.Surgical Antonenkova N, Antoniou AC, Armasu SM; Goode EL, Lawrenson K, Buckley M, Fridley outcomes in steroid refractory acute severe Australian Cancer Study; Australian Ovarian BL, Tyrer JP, Shen H, Weber R, Karevan R, ulcerative colitis: the impact of rescue therapy. Cancer Study, Bacot F, Baglietto L, Bandera EV, Larson MC, Song H, Tessier DC, Bacot F, Colorectal Disease. 2013. Vol 15(3):374-379. Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Vincent D, Cunningham JM, Dennis J, Dicks Bloom G, Bogdanova N, Brinton LA, Brooks- E; Australian Cancer Study; Australian Ovarian Powell JE, Henders AK, McRae AF, Caracella A, Wilson A, Brown R, Butzow R, Cai Q, Campbell Cancer Study Group, Aben KK, Anton-Culver Smith S, Wright MJ, Whitfield JB, Dermitzakis I, Chang-Claude J, Chanock S, Chenevix- H, Antonenkova N, Armasu SM, Baglietto ET, Martin NG, Visscher PM, Montgomery Trench G, Cheng JQ, Cicek MS, Coetzee GA; L, Bandera EV, Beckmann MW, Birrer MJ, GW.The Brisbane Systems Genetics Study: Consortium of Investigators of Modifiers of Bloom G, Bogdanova N, Brenton JD, Brinton Genetical genomics meets complex trait genetics. BRCA1/2, Cook LS, Couch FJ, Cramer DW, LA, Brooks-Wilson A, Brown R, Butzow R, Plos One. 2012. Vol 7(4):e35430. Cunningham JM, Dansonka-Mieszkowska A, Campbell I, Carney ME, Carvalho RS, Chang- Powell JE, Henders AK, McRae AF, Kim J, Despierre E, Doherty JA, Dörk T, du Bois A, Claude J, Chen YA, Chen Z, Chow WH, Cicek Hemani G, Martin NG, Dermitzakis ET, Gibson Dürst M, Easton DF, Eccles D, Edwards R, Ekici MS, Coetzee G, Cook LS, Cramer DW, Cybulski G, Montgomery GW, Visscher PM.Congruence AB, Fasching PA, Fenstermacher DA, Flanagan C, Dansonka-Mieszkowska A, Despierre of additive and non-additive effects on gene JM, Garcia-Closas M, Gentry-Maharaj A, Giles E, Doherty JA, Dörk T, du Bois A, Dürst M, expression estimated from pedigree and SNP data. GG, Glasspool RM, Gonzalez-Bosquet J, Eccles D, Edwards R, Ekici AB, Fasching PA, Plos Genetics. 2013. Vol 9(5):e1003502. Goodman MT, Gore M, Górski B, Gronwald J, Fenstermacher D, Flanagan J, Gao YT, Garcia- Hall P, Halle MK, Harter P, Heitz F, Hillemanns Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Powell JE, Henders AK, McRae AF, Wright MJ, P, Hoatlin M, Høgdall CK, Høgdall E, Hosono Gore M, Gronwald J, Guo Q, Halle MK, Harter Martin NG, Dermitzakis ET, Montgomery GW, S, Jakubowska A, Jensen A, Jim H, Kalli KR, P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Visscher PM.Genetic control of gene expression Karlan BY, Kaye SB, Kelemen LE, Kiemeney Høgdall E, Høgdall CK, Hosono S, Jakubowska in whole blood and lymphoblastoid cell lines is LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, largely independent. Genome Research. 2012. Vol SK, Kupryjanczyk J, Lambrechts D, Lambrechts Kiemeney LA, Kjaer SK, Konecny GE, Krakstad 22(3):456-466. S, Lancaster JM, Le ND, Leminen A, Levine C, Kupryjanczyk J, Lambrechts D, Lambrechts DA, Liang D, Lim BK, Lin J, Lissowska J, Lu S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Price MA, Bell ML, Sommeijer DW, Friedlander KH, Lubinski J, Lurie G, Massuger LF, Matsuo Lissowska J, Lubinski J, Lundvall L, Lurie G, M, Stockler MR, Defazio A, Webb PM, Butow K, McGuire V, McLaughlin JR, Menon U, Massuger LF, Matsuo K, McGuire V, McLaughlin PN.Physical symptoms, coping styles and quality Modugno F, Moysich KB, Nakanishi T, Narod JR, Menon U, Modugno F, Moysich KB, of life in recurrent ovarian cancer: A prospective SA, Nedergaard L, Ness RB, Nevanlinna H, Nakanishi T, Narod SA, Ness RB, Nevanlinna population-based study over the last year of life. Nickels S, Noushmehr H, Odunsi K, Olson SH, H, Nickels S, Noushmehr H, Odunsi K, Olson S, Gynecologic Oncology. 2013. Vol 130(1):162-8. Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth- Pritchard, A. L. and N. K. HaywardMolecular LM, Pike MC, Poole EM, Raska P, Renner SP, Wey J, Pike MC, Poole EM, Qu X, Risch HA, pathways: mitogen-activated protein kinase Risch HA, Rodriguez-Rodriguez L, Rossing Rodriguez-Rodriguez L, Rossing MA, Rudolph pathway mutations and drug resistance. Clinical MA, Rudolph A, Runnebaum IB, Rzepecka IK, A, Runnebaum I, Rzepecka IK, Salvesen HB, Cancer Research. 2013. Vol 19(9):2301-2309. Salvesen HB, Schwaab I, Severi G, Shridhar V, Schwaab I, Severi G, Shen H, Shridhar V, Shu Shu XO, Shvetsov YB, Sieh W, Song H, Southey XO, Sieh W, Southey MC, Spellman P, Tajima Protani MM, Nagle CM, Webb PM.Obesity and MC, Spiewankiewicz B, Stram D, Sutphen R, K, Teo SH, Terry KL, Thompson PJ, Timorek A, ovarian cancer survival: a systematic review and Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, van den Berg D, meta-analysis. Cancer Prev Res (Phila). 2012. Vol Tworoger SS, van Altena AM, Vergote I, Vierkant Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke 5(7):901-910. RA, Vincent D, Vitonis AF, Wang-Gohrke S, S, Wentzensen N, Whittemore AS, Wik E, Palmieri Weber R, Wentzensen N, Whittemore Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng Qian J, Liu H, Wei S, Liu Z, Li Y, Wang LE, Chen AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, W, Ziogas A, Zulkifli F, Goodman MT, Hall P, WV, Amos CI, Lee JE; GenoMEL investigators, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas Easton DF, Pearce CL, Berchuck A, Chenevix- Iles MM, Law MH; Q-MEGA AMFS A, Zulkifli F, Phelan CM, Iversen E, Schildkraut Trench G, Iversen E, Monteiro AN, Gayther SA, investigators, Cust AE, Barrett JH, Montgomery JM, Berchuck A, Fridley BL, Goode EL, Schildkraut JM, Sellers TA.GWAS meta-analysis GW, Taylor J, Bishop JA, Macgregor S, Bishop Pharoah PD, Monteiro AN, Sellers TA, Gayther and replication identifies three new susceptibility DT, Mann GJ, Hayward NK, Wei QAssociation SA.Identification and molecular characterization loci for ovarian cancer. Nature Genetics. 2013. Vol between putative functional variants in the of a new ovarian cancer susceptibility locus at 45(4):362-370. PSMB9 gene and risk of melanoma--re-analysis 17q21.31. Nat Commun. 2013. Vol 4(1627). of published melanoma genome-wide association Phipps AI, Buchanan DD, Makar KW, Burnett- studies. Pigment Cell and Melanoma Research. Hartman AN, Coghill AE, Passarelli MN, Baron 2013. Vol 26(3):392-401.

Page 138 QIMR Annual Report 2012–2013 R White; P Raemer; K Naresh; S Meixlsperger; Pseudomonas aeruginosa load during treatment of A, Mielck A, Miller MB, Montgomery GW, L Pinaud; C Rooney; B Savoldo; R Coutinho; a pulmonary exacerbation in cystic fibrosis. Journal Mukherjee S, Nyholt DR, Oostra BA, Palmer C Bödör; J Gribben; H Ibrahim; M Bower; J of Cystic Fibrosis. 2013. Vol [Epub ahead of print]. LJ, Palotie A, Penninx B, Perola M, Peyser PA, Nourse; M Gandhi; J Middeldorp; F Zumla Preisig M, Raikkonen K, Raitakari OT, Realo Cader; P Murray; C Munz; M AlldayEBNA3B- Reis, M., Roy, N., Bermingham, E., Ryan, L., A, Ring SM, Ripatti S, Rivadeneira F, Rudan I, deficient EBV promotes B cell lymphomagenesis Bibiloni, R., Young, W., Krause, L., Berger, Rustichini A, Salomaa V, Sarin AP, Schlessinger in humanized mice and is found in human B.,North, M., Stelwagen, K., Reis, M.Impact D, Scott RJ, Snieder H, St Pourcain B, Starr JM, tumours. Journal of Clinical Investigation. 2012. Vol of dietary dairy polar lipids on lipid metabolism Sul JH, Surakka I, Svento R, Teumer A, Tiemeier 122(4):1487-1502. ofyoung mice fed high fat diet Journal of H, van Rooij FJ, Van Wagoner DR, Vartiainen E, Agricultural and Food Chemistry. 2013. Vol [Epub Viikari J, Vollenweider P, Vonk JM, Waeber G, R Wood-Baker, Tristram SG, R Latham, G Haug, ahead of print]. Weir DR, Wichmann HE, Widen E, Willemsen G, DW Reid, LF Roddam. Molecular identification Wilson JF, Wright AF, Conley D, Davey-Smith G, of Haemophilus influenzae in COPD is superior to Renteria, M. E., M. W. Coolen, A. L. Statham, Franke L, Groenen PJ, Johannesson M, Kardia conventional culturing methods. Brit J Med Sci. R. S. Choi, W. Qu, M. J. Campbell, S. Smith, SL, Krueger RF, Laibson D, Martin NG, Meyer 2012. Vol 69(1):37-9. A. K. Henders, G. W. Montgomery, S. J. Clark, N. G. Martin and S. E. MedlandGWAS of DNA MN, Posthuma D, Thurik AR, Timpson NJ, Raggatt LJ, Alexander KA, Kaur S, Wu AC, Methylation Variation Within Imprinting Control Uitterlinden AG, van Duijn CM, Visscher PM, MacDonald KP, Pettit AR.Absence of B cells does Regions Suggests Parent-of-Origin Association. Benjamin DJ, Cesarini D, Koellinger PDGWAS not compromise intramembranous bone formation Twin Research and Human Genetics. 2013. Vol of 126,559 Individuals Identifies Genetic Variants during healing in a tibial injury model. American 16(4):767-781. Associated with Educational Attainment. Science. Journal of Pathology. 2013. Vol 182(5):1501-1508. 2013. Vol 340(6139):1467-1471. Reynolds, S. Fischer, K.The Role of Proteolytically Rahmioglu N, Missmer SA, Montgomery GW, Inactive Serine Proteases from Sarcoptes scabiei in Ripke S, Wray NR, Lewis CM, Hamilton SP, Zondervan KT.Insights into Assessing the Genetics Complement Evasion. Proteinases As Drug Targets Weissman MM, Breen G, Byrne EM, Blackwood of Endometriosis. Curr Obstet Gynecol Rep. 2012. (Book). 2012. Vol NULL. DH, Boomsma DI, Cichon S, Heath AC, Vol 1(3):124-137. Holsboer F, Lucae S, Madden PA, Martin NG, Richie TL, Charoenvit Y, Wang R, Epstein JE, McGuffin P, Muglia P, Noethen MM, Penninx BP, Ramasamy A, K. M., Vedantam S, Gajdos ZK, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Pergadia ML, Potash JB, Rietschel M, Lin D, Couto Alves A, Lyon HN, Ferreira MA, Strachan Aguiar JC, Sacci JB Jr, Sedegah M, Nosek Muller-Myhsok B, Shi J, Steinberg S, Grabe HJ, DP, Zhao JH, Abramson MJ, Brown MA, Coin RA Jr, De La Vega P, Berzins MP, Majam VF, Lichtenstein P, Magnusson P, Perlis RH, Preisig L, Dharmage SC, Duffy DL, Haahtela T, Heath Abot EN, Ganeshan H, Richie NO, Banania JG, M, Smoller JW, Stefansson K, Uher R, Kutalik AC, Janson C, K?h?nen M, Khaw KT, Laitinen Baraceros MF, Geter TG, Mere R, Bebris L, Z, Tansey KE, Teumer A, Viktorin A, Barnes J, Le Souef P, Lehtim?ki T; Australian Asthma Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, MR, Bettecken T, Binder EB, Breuer R, Castro Genetics Consortium collaborators, Madden Hobart PM, Norman JA, Soisson LA, Hollingdale VM, Churchill SE, Coryell WH, Craddock N, PA, Marks GB, Martin NG, Matheson MC, MR, Rogers WO, Doolan DL, Hoffman SL.Clinical Craig IW, Czamara D, De Geus EJ, Degenhardt Palmer CD, Palotie A, Pouta A, Robertson trial in healthy malaria-naive adults to evaluate the F, Farmer AE, Fava M, Frank J, Gainer VS, CF, Viikari J, Widen E, Wjst M, Jarvis DL, safety, tolerability, immunogenicity and efficacy of Gallagher PJ, Gordon SD, Goryachev S, Gross Montgomery GW, Thompson PJ, Wareham N, MuStDO5, a five-gene, sporozoite/hepatic stage M, Guipponi M, Henders AK, Herms S, Hickie Eriksson J, Jousilahti P, Laitinen T, Pekkanen J, Plasmodium falciparum DNA vaccine combined IB, Hoefels S, Hoogendijk W, Hottenga JJ, Raitakari OT, O’Connor GT, Salomaa V, Jarvelin with escalating dose human GM-CSF DNA. Hum Iosifescu DV, Ising M, Jones I, Jones L, Jung- MR, Hirschhorn JN.Genome-Wide Association Vaccin Immunother. 2012. Vol 8(11). Ying T, Knowles JA, Kohane IS, Kohli MA, Studies of Asthma in Population-Based Cohorts Korszun A, Landen M, Lawson WB, Lewis G, Richmond-Sinclair NM, van der Pols JC, Green Confirm Known and Suggested Loci and Identify Macintyre D, Maier W, Mattheisen M, McGrath AC.Melanocytic naevi and basal cell carcinoma: an Additional Association near HLA. Plos One. PJ, McIntosh A, McLean A, Middeldorp CM, is there an association? Journal of The European 2012. Vol 7(9):e44008. Middleton L, Montgomery GM, Murphy SN, Academy of Dermatology and Venereology. 2012. Nauck M, Nolen WA, Nyholt DR, O’Donovan Rampton M, Walton SF, Holt DC,Pasay Vol 26(9):1092-1096. M, Oskarsson H, Pedersen N, Scheftner WA, C,Kelly A, Currie BJ,McCarthy JS, Mounsey, Schulz A, Schulze TG, Shyn SI, Sigurdsson E, KEAntibody Responses to Sarcoptes scabiei Rietveld CA, Medland SE, Derringer J, Yang J, Slager SL, Smit JH, Stefansson H, Steffens Apolipoprotein in a Porcine Model: Relevance to Esko T, Martin NW, Westra HJ, Shakhbazov K, M, Thorgeirsson T, Tozzi F, Treutlein J, Uhr M, Immunodiagnosis of Recent Infection. Plos One. Abdellaoui A, Agrawal A, Albrecht E, Alizadeh van den Oord EJ, Van Grootheest G, Volzke H, 2013. Vol 8(6):e65354. BZ, Amin N, Barnard J, Baumeister SE, Benke KS, Bielak LF, Boatman JA, Boyle PA, Davies Weilburg JB, Willemsen G, Zitman FG, Neale B, Ranasinghe, S. and McManus, D.P.Structure G, de Leeuw C, Eklund N, Evans DS, Ferhmann Daly M, Levinson DF, Sullivan PFA mega-analysis and function of invertebrate Kunitz serine R, Fischer K, Gieger C, Gjessing HK, Hagg S, of genome-wide association studies for major protease inhibitors. Developmental & Comparative Harris JR, Hayward C, Holzapfel C, Ibrahim- depressive disorder. Molecular Psychiatry. 2013. Immunology. 2012. Vol 39(3):219-227. Verbaas CA, Ingelsson E, Jacobsson B, Vol 18(4):497-511. Joshi PK, Jugessur A, Kaakinen M, Kanoni S, Rist MJ, Theodossis A, Croft NP, Neller MA, Ranganathan PN, Lu Y, Fuqua BK, Collins Karjalainen J, Kolcic I, Kristiansson K, Kutalik Z, Welland A, Chen Z, Sullivan LC, Burrows JM, JF.Immunoreactive hephaestin and ferroxidase Lahti J, Lee SH, Lin P, Lind PA, Liu Y, Lohman K, Miles JJ, Brennan RM, Gras S, Khanna R, activity are present in the cytosolic fraction of rat Loitfelder M, McMahon G, Vidal PM, Meirelles Brooks AG, McCluskey J, Purcell AW, Rossjohn enterocytes. Biomaterials. 2012. Vol 25(4):687-95. O, Milani L, Myhre R, Nuotio ML, Oldmeadow J, Burrows SR.HLA Peptide Length Preferences CJ, Petrovic KE, Peyrot WJ, Polasek O, Quaye Rao F, Chiron S, Wei Z, Fung MM, Chen Y, Control CD8+ T cell Responses. Journal of L, Reinmaa E, Rice JP, Rizzi TS, Schmidt H, Wen G, Khandrika S, Ziegler MG, Benyamin Immunology. 2013. Vol 191(2):561-571. B, Montgomery G, Whitfield JB, Martin NG, Schmidt R, Smith AV, Smith JA, Tanaka T, Waalen J, Hamilton BA, Mahata SK, O’Connor Terracciano A, van der Loos MJ, Vitart V, Volzke Robb RJ, Lineburg KE, Kuns RD, Wilson YA, DT.Genetic variation within a metabolic motif in H, Wellmann J, Yu L, Zhao W, Allik J, Attia Raffelt NC, Olver SD, Varelias A, Alexander KA, the chromogranin A (CHGA) promoter: Pleiotropic JR, Bandinelli S, Bastardot F, Beauchamp J, Teal BE, Sparwasser T, Hammerling GJ, Markey influence on cardiometabolic risk traits in twin Bennett DA, Berger K, Bierut LJ, Boomsma DI, KA, Koyama M, Clouston AD, Engwerda CR, Hill pairs. American Journal of Hypertension. 2012. Vol Bultmann U, Campbell H, Chabris CF, Cherkas GR, MacDonald KP.Identification and expansion 25(1):29-40. L, Chung MK, Cucca F, de andrade M, De of highly suppressive CD8(+)FoxP3(+) regulatory Jager PL, De Neve JE, Deary IJ, Dedoussis GV, T cells after experimental allogeneic bone marrow Reddington, JP; Perricone, SM; Nestor, CE; Deloukas P, Dimitriou M, Eiriksdottir G, Elderson transplantation. Blood. 2012. Vol 119(24):5898- Reichmann, J; Youngson, NA; Suzuki, M; MF, Eriksson JG, Evans DM, Faul JD, Ferrucci 5908. Reinhardt, D; Dunican, DS; Prendegast, JG; L, Garcia ME, Gronberg H, Gudnason V, Hall Mjoseng, H; Ramsahoye, BH; Whitelaw, E; P, Harris JM, Harris TB, Hastie ND, Heath AC, Roberts G, Green MJ, Breakspear M, Greally, JM; Adams, IR; Bickmore, WA and Hernandez DG, Hoffmann W, Hofman A, Holle McCormack C, Frankland A, Wright A, Levy Meehan RR. Redistribution of H3K27me3 upon R, Holliday EG, Hottenga JJ, Iacono WG, Illig T, F, Lenroot R, Chan HN, Mitchell PB.Reduced DNA hypomethylation results in de-repression of Jarvelin MR, Kahonen M, Kaprio J, Kirkpatrick Inferior Frontal Gyrus Activation During Response Polycomb-target genes. Genome Biology,. 2013. RM, Kowgier M, Latvala A, Launer LJ, Lawlor Inhibition to Emotional Stimuli in Youth at High Risk Vol 14(3):R35. DA, Lehtimaki T, Li J, Lichtenstein P, Lichtner of Bipolar Disorder. Biological Psychiatry. 2012. Vol P, Liewald DC, Madden PA, Magnusson PK, 74(1):55-61. Reid DW, Latham R, Lamont IL, Camara M, Makinen TE, Masala M, McGue M, Metspalu Roddam L.Molecular analysis of changes in

Page 139 Scientiﬁc publications | continued

Roberts TL, Ho U, Luff J, Lee CS, Apte SH, Ruddell RG, Ramm GAHepatic pathobiology of iron Sceneay, J., Parker, B. S., Smyth, M. J., and MacDonald KP, Raggat LJ, Pettit AR, Morrow overload. In Book: “Physiology and Pathophysiology Moller, A.Hypoxia-driven immunosuppression CA, Waters MJ, Chen P, Woods RG, Thomas of Iron In Humans”.. 2012. Vol NULL. contributes to the pre-metastatic niche. GP, St Pierre L, Farah CS, Clarke RA, Brown JA, Oncoimmunology. 2013. Vol 2(2):e22355. Lavin MFSmg1 haploinsufficiency predisposes to Saeid Mehrkanoon, Michael Breakspear, andreas tumor formation and inflammation. Proceedings of Daffertshofer, Tjeerd W Boonstra Non-identical Sceneay, J., Smyth, M. J.*, and Moller, A.*The The National Academy of Sciences of The United smoothing operators for estimating time-frequency pre-metastatic niche: finding common ground States of America. 2013. Vol 110(4):E285-294. interdependence in electrophysiological recordings. Cancer and Metastasis Reviews. 2013. Vol [Epub Eurasip Journal On Advances In Signal Processing. ahead of print]. Rogers PA, D’Hooghe TM, Fazleabas A, Giudice 2013. Vol 2013(1):73. LC, Montgomery GW, Petraglia F, Taylor Schermerhorn AC, D. O. B., Slutske WS, Emery RN.Defining future directions for endometriosis Sagulenko V, Sester DP, Idris A, Thygesen RE, Turkheimer E, Harden KP, Heath AC, research: workshop report from the 2011 World S, Cridland JA, Wijburg O, Croker B, Martin NG.offspring ADHD as a Risk Factor for Congress of Endometriosis In Montpellier, France. Vajjhala P, Roberts TL, Hill J, Silke J, Stacey Parental Marital Problems: Controls for Genetic Reproductive Sciences. 2013. Vol 20(5):483-499. KJInflammasome pathways bifurcate at ASC, and Environmental Confounds. Twin Research and activating both apoptotic and pyroptotic death Cell Human Genetics. 2012. Vol 15(6):700-713. Ross, A.G.P., Olds, G.R., Cripps, A.W., Farrar, Death and Differentiation. 2013. Vol 20(9):1149-60. J.J., McManus, D.P.Chronic enteropathogens Schulte L, Lovas E, Green K, Mulvenna J, in returning travellers. New England Journal of Saichua P, Sithithaworn P, Jariwala AR, Deimert Gobert GN, Morgan G, Jones MK.Tetraspanin-2 Medicine. 2013. Vol 368 1817-1825. DJ, Sithithaworn J, Sripa B, Laha T, Mairiang E, localisation in high pressure frozen and freeze- Pairojkul C, Periago MV, Khuntikeo N, Mulvenna substituted Schistosoma mansoni adult males Rosty C, Hewett D, Brown I, Leggett B, Whitehall J, Bethony JM.Microproteinuria during Opisthorchis reveals its distribution in membranes of tegumentary V. Serrated polyps of the large intestine: current viverrini Infection: A Biomarker for Advanced vesicles. International Journal For Parasitology. understanding of diagnosis, pathogenesis and Renal and Hepatobiliary Pathologies from Chronic 2013. Vol 43(10):785-93. clinical management. Journal of Gastroenterology. Opisthorchiasis. Plos Neglected Tropical Diseases. 2013. Vol 48(3):287-302. 2013. Vol 7(5):e2228. Sedegah M, Kim Y, Ganeshan H, Huang J, Belmonte M, Abot E, Banania JG, Farooq Rosty C, Walsh MD, Walters RJ, Clendenning Sakuishi K, Ngiow SF, Sullivan JM, Teng F, McGrath S, Peters B, Sette A, Soisson L, M, Pearson SA, Jenkins MA, Win AK, Hopper MW, Kuchroo VK, Smyth MJ, anderson Diggs C, Doolan DL, Tamminga C, Villasante E, JL, Sweet K, Frankel WL, Aronson M, Gallinger AC.TIM3+FOXP3+ regulatory T cells are tissue- Hollingdale MR, Richie TL.Identification of minimal S, Goldblatt J, Tucker K, Greening S, Gattas specific promoters of T-cell dysfunction in cancer. human MHC-restricted CD8+ T-cell epitopes within MR, Woodall S, Arnold J, Walker NI, Parry Oncoimmunology. 2013. Vol 2(4):e23849. the Plasmodium falciparum circumsporozoite protein S, Young JP, Buchanan DD.Multiplicity and (CSP). Malaria Journal. 2013. Vol 12(1):185. Molecular Heterogeneity of Colorectal Carcinomas Sakuishi, K., Ngiow, S-F., Sullivan, J. M., Teng, in Individuals With Serrated Polyposis. American M. W. L., Kuchroo, V. K., Smyth, M. J., and Seillet C, Jackson JT, Markey KA, Brady HJ, Hill Journal of Surgical Pathology. 2013. Vol 37(3):434- anderson, A. C.Tumor infiltrating Tim3+FoxP3+ GR, Macdonald KP, Nutt SL, Belz GT.CD8alpha+ 442. regulatory T cells promote exhaustion and limit DCs can be induced in the absence of transcription effector T cell function in situ. Oncoimmunology. factors Id2, Nfil3, and Batf3. Blood. 2013. Vol Rosty C, Young JP, Walsh MD, Clendenning 2013. Vol 2 e23849. 121(9):1574-1583. M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles Sandborn WJ, Gasink C, Gao LL, Blank MA, Senovilla, L., Vitale, I., Martins, I., Tailler, M., GG, Williamson EJ, English DR, Buchanan Johanns J, Guzzo C, Sands BE, Hanauer SB, Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, DD.PIK3CA Activating Mutation in Colorectal Targan S, Rutgeerts P, Ghosh S, de Villiers S., Kepp, O., Niso-Santano, M., Shen, S., Marino, Carcinoma: Associations with Molecular Features WJ, Panaccione R, Greenberg G, Schreiber S, G., Criollo, A., Job, B., Ladoire, S., Ghiringhelli, and Survival. Plos One. 2013. Vol 8(6):e65479. Lichtiger S, Feagan BG; CERTIFI Study Group. F., Sistigu, A., Yamazaki, T., Rello-Varona, S., Ustekinumab induction and maintenance therapy in Locher, C., Poirier-Colame, V., Talbot, M., Valent, Rosty C, Young JP, Walsh MD, Clendenning refractory Crohn’s disease. New England Journal of A., Berardinelli, F., Antoccia, A., Ciccosanti, F., M, Walters RJ, Pearson S, Pavluk E, Nagler Medicine. 2012. Vol 367(16):1519-1528. Fimia, G. M., Piacentini, M., Fueyo, A., Messina, B, Pakenas D, Jass JR, Jenkins MA, Win N., Li, M., Chan, C. J., Lazar, V., Lopez-Otin, AK, Southey MC, Parry S, Hopper JL, Giles Sanfilippo, P. G., Hammond CJ, Staffieri SE, C., Smyth, M. J., Zitvogel, L., Castedo, M., and Kearns LS, Melissa Liew SH, Barbour JM, GG, Williamson E, English DR, Buchanan Kroemer, G.An immunosurveillance mechanism Hewitt AW, Ge D, Snieder H, Mackinnon JR, DD.Colorectal carcinomas with KRAS mutation controls cancer cell ploidy. Science. 2012. Vol Brown SA, Lorenz B, Spector TD, Martin NG, are associated with distinctive morphological and 337(6102):1678-1684. molecular features. Modern Pathology. 2013. Vol Wilmer JB, Mackey DA.Heritability of Strabismus: 26(6):825-834. Genetic Influence Is Specific to Eso-Deviation and Service SK, Verweij KJ, Lahti J, Congdon E, Independent of Refractive Error. Twin Research and Ekelund J, Hintsanen M, Räikkönen K, Lehtimäki Roussotte FF, Jahanshad N, Hibar DP, Sowell Human Genetics. 2012. Vol 15(5):624-630. T, Kähönen M, Widen E, Taanila A, Veijola ER, Kohannim O, Barysheva M, Hansell NK, J, Heath AC, Madden PA, Montgomery GW, McMahon KL, de Zubicaray GI, Montgomery Sarker, S., Berger, B., Sultana, S., Krause, L., Sabatti C, Järvelin MR, Palotie A, Raitakari O, GW, Martin NG, Wright MJ, Toga AW, Jack CR Huq, S., Bibiloni, R., Bruttin, A., Bruessow, H.Oral Viikari J, Martin NG, Eriksson JG, Keltikangas- Jr, Weiner MW, Thompson PM; and the ADNI.A T4 Phage Cocktail Application To Human Volunteers Järvinen L, Wray NR, Freimer NB.A genome-wide commonly carried genetic variant in the delta opioid from Bangladesh Virology. 2012. Vol 434(2):222-32. meta-analysis of association studies of Cloninger’s receptor gene, OPRD1, is associated with smaller Sartor, C. E. and L. M. Grant JD, McCutcheon VV, Temperament Scales. Translational Psychiatry. 2012. regional brain volumes: Replication in elderly and Waldron M, Statham DJ, Bucholz KK, Madden Vol 2 e116. young populations. Human Brain Mapping. 2013. PA, Heath AC, Martin NG, Nelson EC.Common Vol [Epub ahead of print]. Setiawan V, Yang H, Pike M, McCann S, Yu H, heritable contributions to low-risk trauma, high-risk Xiang Y-B, Wolk A, Wentzensen N, Weiss NS WP, Rowlands IJ, Lee C, Janda M, Nagle CM, trauma, posttraumatic stress disorder, and major van den Brandt PA, van de Vijver K, Thompson Obermair A, Webb PM.Predicting positive and depression. Archives of General Psychiatry. 2012. PJ, The Australian National Endometrial Cancer negative impacts of cancer among long-term Vol 69(3):293-299. Study Group, Strom BL, Spurdle AB, Soslow endometrial cancer survivors. Psychooncology. Sawyer S, Mitchell G, McKinley J, Chenevix- RA, Shu X, Schairer C, Sacerdote C, Rohan 2012. Vol 22(9):1963-71. Trench G, Beesley J, Chen XQ, Bowtell D, Trainer TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Rowlands IJ, Redshaw M.Mode of birth and AH, Harris M, Lindeman GJ, James PA.A role for Olson SH, Moysich KB, Miller AB, McCullough women’s psychological and physical wellbeing in the common genomic variants in the assessment of ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, postnatal period. Bmc Pregnancy Childbirth. 2012. familial breast cancer. Journal of Clinical Oncology. Lissowska J, Liang X, Lacey Jr. JV, Kolonel LN, Vol 12 138. 2012. Vol 30(35):4330-4336. Henderson BE, Hankinson SE, H?kansson N, Rudd PA, Wilson J, Gardner J, Larcher T, Babarit Sceneay, J., Chow, M. T., Chen, A., Halse, H. Goodman MT, Gaudet MM, Garcia-Closas M, C, Le TT, Anraku I, Kumagai Y, Loo YM, Gale M M., Wong, C. S. F., andrews, D. M., Bowtell, D. Friedenreich CM, Freudenheim JL, Doherty J, De Jr, Akira S, Khromykh AA, Suhrbier A.Interferon D., Smyth, M. J.*, and Moller, A.*Primary tumor Vivo I, Courneya KS, Cook LS, Chen C, Cerhan response factors 3 and 7 protect against hypoxia recruits bone marrow-derived CD11b+/Ly- JR, Cai H, Brinton LA, Bernstein L, anderson Chikungunya virus hemorrhagic fever and shock. 6Cmed/Ly-6G+ and NK cells to the pre-metatstatic KE, Anton-Culver H, Schouten LJ, Horn-Ross Journal of Virology. 2012. Vol 86(18):9888-9998. niche. Cancer Research. 2012. Vol 72(16):3907- PL.Type I and II endometrial cancers: have they 3911.

Page 140 QIMR Annual Report 2012–2013 different risk factors? Journal of Clinical Oncology. orthologue of hSSB1/NABP2. Plos Genetics. 2013. Brennan P, Malekzadeh R, Pawlita M, Dawsey 2013. Vol 31(20):2607-18. Vol 9(2):e1003298. SM, Waterboer T; InterSCOPE Collaboration. InterSCOPE study: Associations between Setiawan VW, Pike MC, Karageorgi S, Deming Shin Foong Ngiow, Bianca von Scheidt, andreas esophageal squamous cell carcinoma and human SL, anderson K, Bernstein L, Brinton LA, Cai Möller, Mark J. Smyth, Michele Teng A model of papillomavirus serological markers. Journal of The H, Cerhan JR, Cozen W, Chen C, Doherty J, mouse melanoma - immune interaction reveals that National Cancer Institute. 2012. Vol NULL. Freudenheim JL, Goodman MT, Hankinson SE, prolonged responses pre-dispose for autoimmunity Lacey JV Jr, Liang X, Lissowska J, Lu L, Lurie Oncoimmunology. 2013. Vol 2(2):e23036.. Sivakumaran H, Lin M, Apolloni A, Li D, Wei G, Mack T, Matsuno RK, McCann S, Moysich T, Harrich DOverexpression of PRMT6 does not Siddiq A, C. F., Chen GK, Lindstr?m S, Eccles D, KB, Olson SH, Rastogi R, Rebbeck TR, Risch suppress HIV-1 Tat transactivation in cells naturally Millikan RC, Michailidou K, Stram DO, Beckmann H, Robien K, Schairer C, Shu XO, Spurdle AB, lacking PRMT6 Virology Journal. 2013. Vol 10 207. Strom BL, Thompson PJ, Ursin G, Webb PM, L, Rhie SK, Ambrosone CB, Aittom?ki K, Amiano Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu P, Apicella C; Australian Breast Cancer Tissue Sivaraman KK, Oellig CA, Huynh K, Atkinson H, Horn-Ross PL, De Vivo I; Australian National Bank Investigators, Baglietto L, Bandera EV, SC, Poreba M, Perugini MA, Trenholme KR, Endometrial Cancer Study Group.Age at last birth Beckmann MW, Berg CD, Bernstein L, Blomqvist Gardiner DL, Salvesen G, Drag M, Dalton JP, in relation to risk of endometrial cancer: pooled C, Brauch H, Brinton L, Bui QM, Buring JE, Whisstock JC, McGowan SX-ray crystal structure analysis in the epidemiology of endometrial cancer Buys SS, Campa D, Carpenter JE, Chasman and specificity of the Plasmodium falciparum malaria consortium. American Journal of Epidemiology. DI, Chang-Claude J, Chen C, Clavel-Chapelon aminopeptidase PfM18AAP. Journal of Molecular 2012. Vol 176(4):269-278. F, Cox A, Cross SS, Czene K, Deming SL, Biology. 2012. Vol 422(4):495-507. Diasio RB, Diver WR, Dunning AM, Durcan L, Sheel, M. & Engwerda, C.R.The diverse roles of Ekici AB, Fasching PA; Familial Breast Cancer Slutske WS, C. S., Piasecki TM, Martin monocytes in inflammation caused by protozoan Study; Heather Spencer Feigelson, Fejerman NGGenetic Overlap Between Personality and Risk parasitic diseases. Trends In Parasitology. 2012. Vol L, Figueroa JD, Fletcher O, Flesch-Janys D, for Disordered Gambling: Evidence From a National 28(10):408-416. Gaudet MM; The GENICA Consortium, Gerty SM, Community-Based Australian Twin Study. Journal of Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin Abnormal Psychology. 2013. Vol 122(1):250-55. Shen H, Fridley BL, Song H, Lawrenson K, AK, Graham N, Greco D, Hall P, Hankinson SE, Slutske WS, E. J., Richmond-Rakerd LS, Zhu Cunningham JM, Ramus SJ, Cicek MS, Tyrer Hartmann A, Hein R, Heinz J, Hoover RN, Hopper J, Stram D, Larson MC, Köbel M; PRACTICAL G, Martin NG.Shared genetic vulnerability for JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, disordered gambling and alcohol use disorder Consortium, Ziogas A, Zheng W, Yang HP, Wu Isaacs C, Jacobs KB, John EM, Justenhoven AH, Wozniak EL, Woo YL, Winterhoff B, Wik in men and women: evidence from a national C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop community-based Australian twin study. Twin E, Whittemore AS, Wentzensen N, Weber RP, M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Research and Human Genetics. 2013. Vol Lichtner P, Liu J, Lund E, Makalic E, Martin NG, 16(2):525-34. Van Den Berg D, Van Altena AM, Tworoger SS, McLean CA, Meijers-Heijboer H, Meindl A, Miron Thompson PJ, Tessier DC, Terry KL, Teo SH, P, Monroe KR, Montgomery GW, M?ller-Myhsok Smart, C. E. Askarian Amiri, M. E. Wronski, Templeman C, Stram DO, Southey MC, Sieh W, B, Nickels S, Nyante SJ, Olswold C, Overvad K, A. Dinger, M. E. Crawford, J. Ovchinnikov, D. Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, A. Vargas, A. C. Reid, L. Simpson, P. T. Song, Wang-Gohrke S, Severi G, Schwaab I, Salvesen Pharoah P, Rahman N, Rivadeneira F, Schmidt S. Wiesner, C. French, J. D. Dave, R. K. da HB, Rzepecka IK, Runnebaum IB, Rossing MA, DF, Schmutzler RK, Slager S, Southey MC, Silva, L. Purdon, A. andrew, M. Mattick, J. S. Rodriguez-Rodriguez L, Risch HA, Renner SP, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Lakhani, S. R. Brown, M. A. Kellie, S.Expression Poole EM, Pike MC, Phelan CM, Pelttari LM, Ridker PM, Schumacher FR, Severi G, Silva ID, and function of the protein tyrosine phosphatase Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Stone J, Sund M, Tapper WJ, Thun MJ, Travis receptor J (PTPRJ) in normal mammary epithelial Odunsi K, Nickels S, Nevanlinna H, Ness RB, RC, Turnbull C, Uitterlinden AG, Waisfisz Q, cells and breast tumors Plos One. 2012. Vol Narod SA, Nakanishi T, Moysich KB, Monteiro Wang X, Wang Z, Weaver J, Schulz-Wendtland 7(7):e40742. AN, Moes-Sosnowska J, Modugno F, Menon U, R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler Smart, Chanel E; Morrison, Brian J; Saunus, Jodi McLaughlin JR, McGuire V, Matsuo K, Adenan RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, M; Vargas, Ana Cristina; Keith, Patricia; Reid, NA, Massuger LF, Lurie G, Lundvall L, Lubinski Henderson BE, Chanock SJ, Garcia-Closas M, J, Lissowska J, Levine DA, Leminen A, Lee Lynne; Wockner, Leesa; Amiri, Marjan Askarian; Kraft P, Haiman CA, Vachon CM.A meta-analysis AW, Le ND, Lambrechts S, Lambrechts D, Sarkar, Debina; Simpson, Peter T;In Vitro Analysis of genome-wide association studies of breast Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer of Breast Cancer Cell Line Tumourspheres and cancer identifies two novel susceptibility loci at 6q14 SK, Kiemeney LA, Kelemen LE, Keeney GL, Primary Human Breast Epithelia Mammospheres and 20q11. Human Molecular Genetics. 2012. Vol Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji Demonstrates Inter-and Intrasphere Heterogeneity 21(24):5373-5384. BT, Jensen A, Jakubowska A, Iversen E, Hosono Plos One. 2013. Vol 8(6):-e64388. S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns Sieh W, Salvador S, McGuire V, Palmieri R, Terry Smith C, Elhassen D, Gras S, Wynn KK, Dasari P, Heitz F, Hein R, Harter P, Halle MK, Hall P, K, Rossing M, Risch H, Wu A, Webb P, Moysich V, Tellam J, Tey SK, Rehan S, Liu YC, Rossjohn Gronwald J, Gore M, Goodman MT, Giles GG, K DJ, Felberg A, Miller D, Jordan SJ, Australian J, Burrows SR, Khanna REndogenous antigen Gentry-Maharaj A, Garcia-Closas M, Flanagan Cancer Study (Ovarian Cancer), Australian presentation impacts on T-box transcription factor JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Ovarian Cancer Study Group, Goodman MT, expression and functional maturation of CD8+ T Easton DF, Dürst M, du Bois A, Dörk T, Doherty Lurie G, Chang-Claude J, Hein R, Kj?r SK, cells. Blood. 2013. Vol 120(16):3237-3245. JA, Despierre E, Dansonka-Mieszkowska A, Jensen A, H?gdall E, Bandera EV, Olson SH, Cybulski C, Cramer DW, Cook LS, Chen X, Williams-King MG, Rodriguez-Rodriguez L, Smith C, Khanna, R A new approach for cellular Charbonneau B, Chang-Claude J, Campbell I, Kiemeney LA, Marees T, Massuger LF, van Altena immunotherapy of nasopharyngeal carcinoma. Butzow R, Bunker CH, Brueggmann D, Brown AM, Ness RB, Cramer DW, Pike MC, Pearce CL, OncoImmunology Oncoimmunology. 2012. Vol R, Brooks-Wilson A, Brinton LA, Bogdanova N, Berchuck A, Schildkraut JM, Whittemore AS, 1(8):1440-1442. Block MS, Benjamin E, Beesley J, Beckmann on behalf of the Ovarian Cancer Association MW, Bandera EV, Baglietto L, Bacot F, Armasu Consortium.Tubal Ligation and the Risk of Smith DJ, anderson GJ, Lamont IL, Masel P, Bell SM, Antonenkova N, Anton-Culver H, Aben KK, Ovarian Cancer Subtypes. International Journal of SC, Reid DW.Accurate assessment of systemic Liang D, Wu X, Lu K, Hildebrandt MA; Australian Epidemiology. 2013. Vol 42(2):579-589. iron status in cystic fibrosis will avoid the hazards Ovarian Cancer Study Group; Australian Cancer of inappropriate iron supplementation. Journal of Study, Schildkraut JM, Sellers TA, Huntsman Sievert W, Macrae FA, Leggett BA. Investigating Cystic Fibrosis. 2013. Vol 12(3):303-304. D, Berchuck A, Chenevix-Trench G, Gayther iron deficiency anaemia. Medical Journal of Smith DJ, Lamont IL, anderson GJ, Reid SA, Pharoah PD, Laird PW, Goode EL, Pearce Australia. 2013. Vol 198(10):563. DW.Targeting iron uptake to control Pseudomonas CL.Epigenetic analysis leads to identification of Singh M, Hunt CR, Pandita RK, Kumar R, Yang aeruginosa infections in cystic fibrosis. European HNF1B as a subtype-specific susceptibility gene for CR, Horikoshi N, Bachoo R, Serag S, Story Respiratory Journal. 2012. Vol [Epub ahead of print]. ovarian cancer. Nat Commun. 2013. Vol 4 1628. MD, Shay JW, Powell SN, Gupta A, Jeffery J, Smith, C. and Khanna, R. Immune regulation of Shi W, Bain AL, Schwer B, Al-Ejeh F, Smith C, Pandita S, Chen BP, Deckbar D, Löbrich M, Yang human herpesviruses and its implications for human Wong L, Chai H, Miranda MS, Ho U, Kawaguchi Q, Khanna KK, Worman HJ, Pandita TK.Lamin transplantation. American Journal of Transplantation. M, Miura Y, Finnie JW, Wall M, Heierhorst A/C depletion enhances DNA damage-induced 2013. Vol 13(s3):nine-23. J, Wicking C, Spring KJ, Alt FW, Khanna stalled replication fork arrest. Molecular and Cellular Biology. 2013. Vol 33(6):1210-1222. KK.Essential developmental, genomic stability, Smyth, M. J., Sullivan, L. C., Brooks, A. and tumour suppressor functions of the mouse Sitas F, Egger S, Urban MI, Taylor PR, Abnet G., and andrews, D. M.Non-classical class I CC, Boffetta P, O’Connell DL, Whiteman DC,

Page 141 Scientiﬁc publications | continued

molecules regulating natural killer cell function. Aleman A, Alhusaini S, Almasy L, Binder EB, V, andreassen OA, Børglum AD, Mors O, Oncoimmunology. 2013. Vol 2(3):-e23336. Brohawn DG, Cantor RM, Carless MA, Corvin Mortensen PB, Werge T, Ophoff RA, Nöthen A, Czisch M, Curran JE, Davies G, de Almeida MM, Rietschel M, Cichon S, Ruggeri M, Tosato Soltani A, Sohal S, Reid DW, Weston S, Muller MA, Delanty N, Depondt C, Duggirala R, Dyer S, Palotie A, St Clair D, Rujescu D, Collier DA, K, Wood-Baker R, Walters EH.Distinctive TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill Stefansson H, Stefansson K.Common variant at characteristics of bronchial reticular basement M, Göring HH, Hagler DJ, Hoehn D, Holsboer F, 16p11.2 conferring risk of psychosis. Molecular membrane and vessel remodelling in chronic Hoogman M, Hosten N, Jahanshad N, Johnson Psychiatry. 2012. Vol [Epub ahead of print]. obstructive pulmonary disease (COPD) and MP, Kasperaviciute D, Kent JW Jr, Kochunov P, in asthma: they are not the same disease. Lancaster JL, Lawrie SM, Liewald DC, Mandl R, Stevens KN, Wang X, Fredericksen Z, Pankratz Histopathology. 2012. Vol 60(6):964-70. Matarin M, Mattheisen M, Meisenzahl E, Melle VS, Greene MH, andrulis IL, Thomassen M, Caligo M; Swedish Breast Cancer Study, Soltani A, Sohal S, Reid DW, Weston S, Muller I, Moses EK, Mühleisen TW, Nauck M, Nöthen Sweden (SWE-BRCA), Nathanson KL, K, Wood-Baker R, Walters EH.Mast cells in MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Jakubowska A, Osorio A, Hamann U, Godwin COPD airways: relationship to bronchodilator Reinvang I, Rentería ME, Rietschel M, Roffman AK, Stoppa-Lyonnet D, Southey M, Buys responsiveness and angiogenesis. European JL, Royle NA, Rujescu D, Savitz J, Schnack SS, Singer CF, Hansen TV, Arason A, offit Respiratory Journal. 2012. Vol 39(6):1361-7. HG, Schnell K, Seiferth N, Smith C, Steen VM, Valdés Hernández MC, Van den Heuvel M, van K, Piedmonte M, Montagna M, Imyanitov Spain SL, Carvajal-Carmona LG, Howarth der Wee NJ, Van Haren NE, Veltman JA, Völzke E, Tihomirova L, Sucheston L, Beattie M; KM, Jones AM, Su Z, Cazier JB, Williams J, H, Walker R, Westlye LT, Whelan CD, Agartz I, HEreditary Breast and Ovarian Cancer Group Aaltonen LA, Pharoah P, Kerr DJ, Cheadle J, Boomsma DI, Cavalleri GL, Dale AM, Djurovic Netherlands (HEBON); German Consortium for Li L, Casey G, Vodicka P, Sieber O, Lipton L, S, Drevets WC, Hagoort P, Hall J, Heinz A, Jack Hereditary Breast and Ovarian Cancer (GC- Gibbs P, Martin NG, Montgomery GW, Young CR Jr, Foroud TM, Le Hellard S, Macciardi HBOC), Neuhausen SL; CONsorzio Studi ITaliani J, Baird PN, Morreau H, van Wezel T, Ruiz- F, Montgomery GW, Poline JB, Porteous DJ, sui Tumori Ereditari Alla Mammella (CONSIT Ponte C, Fernandez-Rozadilla C, Carracedo Sisodiya SM, Starr JM, Sussmann J, Toga AW, Team), Szabo CI; kConFab, Simard J, Spurdle A, Castells A, Castellvi-Bel S, Dunlop M, Veltman DJ, Walter H, Weiner MW; Alzheimer’s AB, Healey S, Chen X, Rebbeck TR, Easton Houlston RS, Tomlinson IP.Refinement of the Disease Neuroimaging Initiative; EPIGEN DF, Chenevix-Trench G, Antoniou AC, Couch associations between risk of colorectal cancer Consortium; IMAGEN Consortium; Saguenay FJ.Evaluation of chromosome 6p22 as a breast and polymorphisms on chromosomes 1q41 and Youth Study Group, Bis JC, Ikram MA, Smith AV, cancer risk modifier locus in a follow-up study of 12q13.13. Human Molecular Genetics. 2012. Vol Gudnason V, Tzourio C, Vernooij MW, Launer BRCA2 mutation carriers. Breast Cancer Research 21(4):934-946. LJ, DeCarli C, Seshadri S; Cohorts for Heart and Treatment. 2012. Vol 136(1):295-302. and Aging Research in Genomic Epidemiology Spanevello MD, Tajouri SI, Mirciov C, Kurniawan Stewart R, Kozlov S, Matigian N, Wali G, Gatei Consortium, andreassen OA, Apostolova LG, N, Pearse MJ, Fabri LJ, Owczarek CM, Hardy M, Sutharsan R, Bellette B, Wraith-Kijas A, Bastin ME, Blangero J, Brunner HG, Buckner MP, Bradford RA, Ramunno ML, Turnley AM, Cochrane J, Coulthard M, Perry C, Sinclair RL, Cichon S, Coppola G, de Zubicaray GI, Ruitenberg MJ, Boyd AW, Bartlett PF.Acute K, Mackay-Sim A, Lavin MFA patient-derived Deary IJ, Donohoe G, de Geus EJ, Espeseth delivery of EphA4-Fc improves functional recovery olfactory stem cell disease model for ataxia- T, Fernández G, Glahn DC, Grabe HJ, Hardy after contusive spinal cord injury in rats. Journal of telangiectasia Human Molecular Genetics. 2013. J, Hulshoff Pol HE, Jenkinson M, Kahn RS, Neurotrauma. 2013. Vol 30(12):1023-1034. Vol 22(12):2495-509. McDonald C, McIntosh AM, McMahon FJ, Spurdle AB, Whiley PJ, Thompson B, Feng B, McMahon KL, Meyer-Lindenberg A, Morris Stolk L, Perry JR, Chasman DI, He C, Mangino Healey S, Brown MA, Pettigrew C; kConFab, DW, Müller-Myhsok B, Nichols TE, Ophoff RA, M, Sulem P, Barbalic M, Broer L, Byrne EM, Van Asperen CJ, Ausems MG, Kattentidt- Paus T, Pausova Z, Penninx BW, Potkin SG, Ernst F, Esko T, Franceschini N, Gudbjartsson Mouravieva AA, van den Ouweland AM; Dutch Sämann PG, Saykin AJ, Schumann G, Smoller DF, Hottenga JJ, Kraft P, McArdle PF, Porcu E, Belgium UV Consortium, Lindblom A, Pigg MH, JW, Wardlaw JM, Weale ME, Martin NG, Franke Shin SY, Smith AV, van Wingerden S, Zhai G, Schmutzler RK, Engel C, Meindl A; German B, Wright MJ, Thompson PM; Enhancing Zhuang WV, Albrecht E, Alizadeh BZ, Aspelund Consortium of Hereditary Breast and Ovarian Neuro Imaging Genetics through Meta- T, Bandinelli S, Lauc LB, Beckmann JS, Boban Cancer, Caputo S, Sinilnikova OM, Lidereau Analysis Consortium.Identification of common M, Boerwinkle E, Broekmans FJ, Burri A, R; French COVAR group collaborators, Couch variants associated with human hippocampal and Campbell H, Chanock SJ, Chen C, Cornelis MC, FJ, Guidugli L, Hansen Tv, Thomassen M, intracranial volumes. Nature Genetics. 2012. Vol Corre T, Coviello AD, d’Adamo P, Davies G, de Eccles DM, Tucker K, Benitez J, Domchek SM, 44(5):552-561. Faire U, de Geus EJ, Deary IJ, Dedoussis GV, Toland AE, Van Rensburg EJ, Wappenschmidt Deloukas P, Ebrahim S, Eiriksdottir G, Emilsson Steinberg S, de Jong S, Mattheisen M, Costas B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA V, Eriksson JG, Fauser BC, Ferreli L, Ferrucci L, J, Demontis D, Jamain S, Pietiläinen OP, Lin K, Consortium.BRCA1 R1699Q variant displaying Fischer K, Folsom AR, Garcia ME, Gasparini P, Papiol S, Huttenlocher J, Sigurdsson E, Vassos ambiguous functional abrogation confers Gieger C, Glazer N, Grobbee DE, Hall P, Haller T, E, Giegling I, Breuer R, Fraser G, Walker N, intermediate breast and ovarian cancer risk. Hankinson SE, Hass M, Hayward C, Heath AC, Melle I, Djurovic S, Agartz I, Tuulio-Henriksson Journal of Medical Genetics. 2012. Vol 49(8):525- Hofman A, Ingelsson E, Janssens AC, Johnson A, Suvisaari J, Lönnqvist J, Paunio T, Olsen L, 532. AD, Karasik D, Kardia SL, Keyzer J, Kiel DP, Hansen T, Ingason A, Pirinen M, Strengman Kolcic I, Kutalik Z, Lahti J, Lai S, Laisk T, Laven Sripa B, Brindley PJ, Mulvenna J, Laha T, E; GROUP, Hougaard DM, Orntoft T, Didriksen JS, Lawlor DA, Liu J, Lopez LM, Louwers YV, Smout MJ, Mairiang E, Bethony JM, Loukas M, Hollegaard MV, Nordentoft M, Abramova L, Magnusson PK, Marongiu M, Martin NG, Klaric A.The tumorigenic liver fluke Opisthorchis viverrini-- Kaleda V, Arrojo M, Sanjuán J, Arango C, Etain IM, Masciullo C, McKnight B, Medland SE, multiple pathways to cancer. Trends In Parasitology. B, Bellivier F, Méary A, Schürhoff F, Szoke A, Melzer D, Mooser V, Navarro P, Newman AB, 2012. Vol 28(10):395-407. Ribolsi M, Magni V, Siracusano A, Sperling Nyholt DR, Onland-Moret NC, Palotie A, Paré S, Rossner M, Christiansen C, Kiemeney LA, G, Parker AN, Pedersen NL, Peeters PH, Pistis Stagg, J., Beavis, P. A., Divisekera, U., Darcy, Franke B, van den Berg LH, Veldink J, Curran G, Plump AS, Polasek O, Pop VJ, Psaty BM, P. K., and Smyth, M. J.CD73-deficient mice S, Bolton P, Poot M, Staal W, Rehnstrom K, Räikkönen K, Rehnberg E, Rotter JI, Rudan are resistant to de novo tumorigenesis. Cancer Kilpinen H, Freitag CM, Meyer J, Magnusson P, I, Sala C, Salumets A, Scuteri A, Singleton A, Research. 2012. Vol 72 2190-2196. Saemundsen E, Martsenkovsky I, Bikshaieva Smith JA, Snieder H, Soranzo N, Stacey SN, I, Martsenkovska I, Vashchenko O, Raleva Stein JL, Medland SE, Vasquez AA, Hibar DP, Starr JM, Stathopoulou MG, Stirrups K, Stolk M, Paketchieva K, Stefanovski B, Durmishi Senstad RE, Winkler AM, Toro R, Appel K, RP, Styrkarsdottir U, Sun YV, Tenesa A, Thorand N, Pejovic Milovancevic M, Lecic Tosevski Bartecek R, Bergmann Ø, Bernard M, Brown B, Toniolo D, Tryggvadottir L, Tsui K, Ulivi S, D, Silagadze T, Naneishvili N, Mikeladze N, AA, Cannon DM, Chakravarty MM, Christoforou van Dam RM, van der Schouw YT, van Gils CH, Surguladze S, Vincent JB, Farmer A, Mitchell A, Domin M, Grimm O, Hollinshead M, van Nierop P, Vink JM, Visscher PM, Voorhuis PB, Wright A, Schofield PR, Fullerton JM, Holmes AJ, Homuth G, Hottenga JJ, Langan M, Waeber G, Wallaschofski H, Wichmann HE, Montgomery GW, Martin NG, Rubino IA, van C, Lopez LM, Hansell NK, Hwang KS, Kim S, Widen E, Wijnands-van Gent CJ, Willemsen Winkel R, Kenis G, De Hert M, Réthelyi JM, Laje G, Lee PH, Liu X, Loth E, Lourdusamy A, G, Wilson JF, Wolffenbuttel BH, Wright AF, Bitter I, Terenius L, Jönsson EG, Bakker S, Mattingsdal M, Mohnke S, Maniega SM, Nho Yerges-Armstrong LM, Zemunik T, Zgaga L, van Os J, Jablensky A, Leboyer M, Bramon E, K, Nugent AC, O’Brien C, Papmeyer M, Pütz Zillikens MC, Zygmunt M, Study TL, Arnold AM, Powell J, Murray R, Corvin A, Gill M, Morris B, Ramasamy A, Rasmussen J, Rijpkema M, Boomsma DI, Buring JE, Crisponi L, Demerath D, O’Neill FA, Kendler K, Riley B; Wellcome Risacher SL, Roddey JC, Rose EJ, Ryten M, EW, Gudnason V, Harris TB, Hu FB, Hunter Trust Case Control Consortium 2, Craddock N, Shen L, Sprooten E, Strengman E, Teumer A, DJ, Launer LJ, Metspalu A, Montgomery GW, Owen MJ, O’Donovan MC, Thorsteinsdottir U, Trabzuni D, Turner J, van Eijk K, van Erp TG, Oostra BA, Ridker PM, Sanna S, Schlessinger Kong A, Ehrenreich H, Carracedo A, Golimbet van Tol MJ, Wittfeld K, Wolf C, Woudstra S, D, Spector TD, Stefansson K, Streeten EA,

Page 142 QIMR Annual Report 2012–2013 Thorsteinsdottir U, Uda M, Uitterlinden AG, Liljedahl U, Syv?nen AC, Palotie A, Kaprio association with melanoma risk not due to BMI. van Duijn CM, Völzke H, Murray A, Murabito J, Kyvik KO, Pedersen NL, Boomsma DI, Nature Genetics. 2013. Vol 45(4):428-32. JM, Visser JA, Lunetta KL.Meta-analyses identify Spector T, Martin NG, Ripatti S, Peltonen L.A 13 loci associated with age at menopause and Genome-Wide Association Study of Monozygotic Thompson BA, Goldgar DE, Paterson C, highlight DNA repair and immune pathways. Nature Twin-Pairs Suggests a Locus Related to Variability Clendenning M, Walters R, Arnold S, Parsons Genetics. 2012. Vol 44(3):260-8. of Serum High-Density Lipoprotein Cholesterol. MT, Michael D W, Gallinger S, Haile RW, Twin Research and Human Genetics. 2012. Vol Hopper JL, Jenkins MA, Lemarchand L, Su Z, Gay LJ, Strange A, Palles C, Band G, 15(6):691-699. Lindor NM, Newcomb PA, Thibodeau SN; Whiteman DC, Lescai F, Langford C, Nanji M, Colon Cancer Family Registry, Young JP, Edkins S, van der Winkel A, Levine D, Sasieni P, Tan TC, Crawford DH, Jaskowski LA, Murphy Buchanan DD, Tavtigian SV, Spurdle AB.A Bellenguez C, Howarth K, Freeman C, Trudgill TL, Santrampurwala N, Crane D, Clouston AD, Multifactorial Likelihood Model for MMR Gene N, Tucker AT, Pirinen M, Peppelenbosch Subramaniam VN, anderson GJ, Fletcher LM.A Variant Classification Incorporating Probabilities MP, van der Laan LJ, Kuipers EJ, Drenth corn oil-based diet protects against combined Based on Sequence Bioinformatics and Tumor JP, Peters WH, Reynolds JV, Kelleher DP, ethanol and iron-induced liver injury in a mouse Characteristics: A Report from the Colon Cancer McManus R, Grabsch H, Prenen H, Bisschops model of hemochromatosis. Alcoholism, Clinical Family Registry. Human Mutation. 2013. Vol R, Krishnadath K, Siersema PD, van Baal and Experimental Research. 2013. Vol [Epub ahead 34(1):200-209. JW, Middleton M, Petty R, Gillies R, Burch N, of print]. Bhandari P, Paterson S, Edwards C, Penman Thompson BA, Greenblatt MS, Vallee MP, I, Vaidya K, Ang Y, Murray I, Patel P, Ye W, Tan YY, McGaughran J, Ferguson K, Walsh MD, Herkert JC, Tessereau C, Young EL, Adzhubey Mullins P, Wu AH, Bird NC, Dallal H, Shaheen Buchanan DD, Young JP, Webb PM, Obermair IA, Li B, Bell R, Feng B, Mooney SD, Radivojac NJ, Murray LJ, Koss K, Bernstein L, Romero A, Spurdle AB.Improving identification of lynch P, Sunyaev SR, Frebourg T, Hofstra RM, Y, Hardie LJ, Zhang R, Winter H, Corley DA, syndrome patients: A comparison of research Sijmons RH, Boucher K, Thomas A, Goldgar Panter S, Risch HA, Reid BJ, Sargeant I, data with clinical records. International Journal of DE, Spurdle AB, Tavtigian SV.Calibration of Gammon MD, Smart H, Dhar A, McMurtry H, Cancer. 2013. Vol 132(12):2876-2883. multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Ali H, Liu G, Casson AG, Chow WH, Rutter Tang CS, Ferreira MAR A gene-based test of Human Mutation. 2012. Vol 34(1):255-265. M, Tawil A, Morris D, Nwokolo C, Isaacs P, association using canonical correlation analysis Rodgers C, Ragunath K, MacDonald C, Haigh Bioinformatics. 2012. Vol 28(6):845-850. Thrift AP, Kendall BJ, Pandeya N, Vaughan C, Monk D, Davies G, Wajed S, Johnston D, TL, Whiteman DC; Study of Digestive Health.A Tang, C. S. and M. A. R. Ferreira Gibbons M, Cullen S, Church N, Langley R, GENOVA: clinical risk prediction model for Barrett esophagus. Griffin M, Alderson D, Deloukas P, Hunt SE, gene overlap analysis of GWAS results. Statistical Cancer Prev Res (Phila). 2012. Vol 5(9):1115-1523. Gray E, Dronov S, Potter SC, Tashakkori- Applications In Genetics and Molecular Biology. Ghanbaria A, anderson M, Brooks C, Blackwell 2012. Vol 11(3):6-Article 6. Thrift AP, Kendall BJ, Pandeya N, Whiteman JM, Bramon E, Brown MA, Casas JP, Corvin DCA model to determine absolute risk for Tellam, J., Lekieffre, L., Zhong, J., Lynn, D.J. A, Duncanson A, Markus HS, Mathew CG, esophageal adenocarcinoma. Clin Gastroenterol and Khanna, R. Messenger RNA sequence Palmer CN, Plomin R, Rautanen A, Sawcer Hepatol. 2013. Vol 11(2):138-144. determines the level of self-synthesis and antigen SJ, Trembath RC, Viswanathan AC, Wood N, presentation of the EBV-encoded antigen, EBNA1. Thrift AP, Nagle CM, Fahey PP, Russell A, Trynka G, Wijmenga C, Cazier JB, Atherfold P, Plos Pathogens. 2013. Vol 8(12):e1003112. Smithers BM, Watson DI, Whiteman DC.The Nicholson AM, Gellatly NL, Glancy D, Cooper influence of prediagnostic demographic and SC, Cunningham D, Lind T, Hapeshi J, Ferry Teng MW, Vesely MD, Duret H, McLaughlin N, lifestyle factors on esophageal squamous cell D, Rathbone B, Brown J, Love S, Attwood S, Towne JE, Schreiber RD, Smyth MJ. Opposing carcinoma survival. International Journal of Cancer. MacGregor S, Watson P, Sanders S, Ek W, roles for IL-23 and IL-12 in maintaining occult 2012. Vol 131(5):e759-768. Harrison RF, Moayyedi P, de Caestecker J, cancer in an equilibrium state. Cancer Research. Barr H, Stupka E, Vaughan TL, Peltonen L, 2012. Vol 72(16):3987-3996. Thrift AP, Nagle CM, Fahey PP, Smithers BM, Spencer CC, Tomlinson I, Donnelly P, Jankowski Watson DI, Whiteman DC.Predictors of survival Tey, S.K. and Khanna, R. JA; Esophageal Adenocarcinoma Genetics Autophagy mediates among patients diagnosed with adenocarcinoma Consortium; Wellcome Trust Case Control transporter associated with antigen processing- of the esophagus and gastroesophageal junction. Consortium 2.Common variants at the MHC independent presentation of viral epitopes through Cancer Causes Control. 2012. Vol 23(4):555-564. locus and at chromosome 16q24.1 predispose to MHC class I pathway. Blood. 2013. Vol 120(5):994- Barrett’s esophagus. Nature Genetics. 2012. Vol 1004. Thrift AP, Pandeya N, Smith KJ, Green 44(10):1131-1136. AC, Hayward NK, Webb PM, Whiteman Tey, SK, Khanna, R. Host immune system strikes DCHelicobacter pylori infection and the risks of Subramaniam VN, McDonald CJ, Ostini L, back: Autophagy-mediated antigen presentation Barrett’s oesophagus: a population-based case- Lusby PE, Wockner LF, Ramm GA, Wallace DF. bypasses viral blockade of the classic MHC control study. International Journal of Cancer. 2012. Hepatic iron deposition does not predict extra- class I processing pathway Autophagy. 2012. Vol Vol 130(10):2407-2416. hepatic iron loading in mouse models of hereditary 8(12):1839-41. hemochromatosis. American Journal of Pathology. Thrift AP, Pandeya N, Whiteman DCCurrent The GenoMEL Consortium, I. M., Law MH, 2012. Vol 181(4):1173-9. status and future perspectives on the etiology of Stacey SN, Han J, Fang S, Pfeiffer R, Harland esophageal adenocarcinoma. Front Oncol. 2012. M, Macgregor S, Taylor JC, Aben KK, Akslen Suhrbier A, Jaffar-Bandjee MC, Gasque Vol 2(11). PArthritogenic alphaviruses--an overview. Nature LA, Avril MF, Azizi E, Bakker B, Benediktsdottir Reviews Rheumatology. 2012. Vol 8(7):420-429. KR, Bergman W, Scarr? GB, Brown KM, Calista Thrift, A. P. and D. C. WhitemanCan we really D, Chaudru V, Fargnoli MC, Cust AE, Demenais predict risk of cancer? Cancer Epidemiology. 2013. Sukhwinder S. Sohal, David Reid, Amir Soltani, F, de Waal AC, D?bniak T, Elder DE, Friedman Vol 37(4):349-352. Chris Ward, Steven Weston, H. Konrad Muller, E, Galan P, Ghiorzo P, Gillanders EM, Goldstein Richard Wood-Baker, E. Haydn Walters.Changes AM, Gruis NA, Hansson J, Helsing P, Ho?evar Thrift, A. P. and D. C. WhitemanThe incidence in Airway Histone Deacetylase-2 in Smokers and M, H?iom V, Hopper JL, Ingvar C, Janssen of esophageal adenocarcinoma continues to rise: COPD with Inhaled Corticosteroids: A Randomized M, Jenkins MA, Kanetsky PA, Kiemeney LA, analysis of period and birth cohort effects on recent Controlled Trial. Plos One. 2013. Vol 8(5):e64833. Lang J, Lathrop GM, Leachman S, Lee JE, trends. Annals of Oncology. 2012. Vol 23(12):3155- Lubi?ski J, Mackie RM, Mann GJ, Martin NG, 3162. Sulkowski MS, Asselah T, Ferenci P, Fainboim Mayordomo JI, Molven A, Mulder S, Nagore H, Leggett B, Bessone F, Heo J, Datsenko Tian X, Zhu M, Tian Y, Ramm GA, Zhao Y, Nie E, Novakovi? S, Okamoto I, Olafsson JH, Y, Stern JO, Kukolj G, Schere J, Nehmiz G. Development of a highly efficacious membrane Olsson H, Pehamberger H, Peris K, Grasa MP, G, Steinmann GG, Bocher WO. Fladaprevir vesicle-based dual vaccine against melanoma and Planelles D, Puig S, Puig-Butille JA; Q-MEGA combined with Peginterferon Alfa-2a and Ribavirin Lewis lung carcinoma. Biomaterials. 2012. Vol and AMFS Investigators, Randerson-Moor J, in treatment-naïve patients with chronic genotype-1 33(26):6147-54. Requena C, Rivoltini L, Rodolfo M, Santinami HCV: SILEN-C1 trial. Hepatology. 2013. Vol M, Sigurgeirsson B, Snowden H, Song F, Sulem Tielbeek JJ, M. S., Benyamin B, Byrne EM, 57(6):2143-54. P, Thorisdottir K, Tuominen R, Van Belle P, van Heath AC, Madden PA, Martin NG, Wray NR, Surakka I, W. J., Perola M, Visscher PM, der Stoep N, van Rossum MM, Wei Q, Wendt J, Verweij KJ.Unraveling the genetic etiology of adult Montgomery GW, Falchi M, Willemsen G, Zelenika D, Zhang M, Landi MT, Thorleifsson G, antisocial behavior: a genome-wide association de Geus EJ, Magnusson PK, Christensen Bishop DT, Amos CI, Hayward NK, Stefansson study. Plos One. 2012. Vol (7):10-e45086. K, S?rensen TI, Pietil?inen KH, Rantanen K, Bishop JA, Barrett JH.A variant in FTO shows Tonks ID, Walker GJ, Mould AW, Ferguson B, T, Silander K, Wid?n E, Muilu J, Rahman I, Keith P, Hayward NK, Kay GFBrca1 is involved

Page 143 Scientiﬁc publications | continued

in establishing murine pigmentation in a p53 and Valery PC, Youlden DR, Baade PD, Ward LJ, Vari F, Gandhi MKBack to basics: the developmentally specific manner. Pigment Cell and Green AC, Aitken JF.Cancer incidence and complete blood cell count adds to the ability Melanoma Research. 2012. Vol 25(4):530-532. mortality in Indigenous Australian children, 1997- of immunohistochemistry in diffuse large B-cell 2008. Pediatr Blood Cancer. 2013. Vol 60(1):156- lymphoma prognosis. Leukemia & Lymphoma. Toon CW, Walsh MD, Chou A, Capper 158. 2012. Vol 53(11):2097-8. D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Van Batenburg-Eddes, T., M. J. Brion, J. Verbrugge, I., Galli, M., Smyth, M. J., Johnstone, Young JP, Win AK, Hopper JL, Crook A, von Henrichs, V. W. Jaddoe, A. Hofman, F. C. R. W., and Haynes, N. M.Enhancing the anti- Deimling A, Jenkins MA, Buchanan DD, Gill Verhulst, D. A. Lawlor, G. Davey Smith and tumor activity of radiotherapy with combinations AJ.BRAFV600E immunohistochemistry facilitates H. TiemeierParental depressive and anxiety of immune stimulatory and inhibitory antibodies. universal screening of colorectal cancers for Lynch symptoms during pregnancy and attention Oncoimmunology. 2013. Vol 1 1629-1631. Syndrome. American Journal of Surgical Pathology. problems in children: a cross-cohort consistency 2013. Vol [Epub ahead of print]. study. Journal of Child Psychology and Psychiatry. Verbrugge, I., Hagekyriakou, J., Sharp, L. L., 2013. Vol 54(5):591-600. Galli, M., West, A., McLaughlin, N. M., Duret, Tran B, Armstrong BK, Carlin JB, Ebeling PR, H., Yagita, H., Johnstone, R. W.*, Smyth, M. J.*, English DR, Kimlin MG, Rahman B, van der van der Harst P, Z. W., Mateo Leach I, Rendon and Haynes, N. M.*Radiotherapy increases the Pols JC, Venn A, Gebski V, Whiteman DC, A, Verweij N, Sehmi J, Paul DS, Elling U, Allayee permissiveness of established mammary tumors to Webb PM, Neale RE.Recruitment and results H, Li X, Radhakrishnan A, Tan ST, Voss K, rejection by immunomodulatory antibodies. Cancer of a pilot trial of vitamin D supplementation in Weichenberger CX, Albers CA, Al-Hussani A, Research. 2012. Vol 72(13):3163-3174. the general population of Australia. Journal of Asselbergs FW, Ciullo M, Danjou F, Dina C, Clinical Endocrinology & Metabolism. 2012. Vol Esko T, Evans DM, Franke L, G?gele M, Hartiala Verhoeven VJ, Hysi PG, Wojciechowski R, Fan 97(12):4473-4480. J, Hersch M, Holm H, Hottenga JJ, Kanoni S, Q, Guggenheim JA, Höhn R, Macgregor S, Kleber ME, Lagou V, Langenberg C, Lopez Hewitt AW, Nag A, Cheng CY, Yonova-Doing E, Tran B, Armstrong BK, McGeechan K, Ebeling LM, Lyytik?inen LP, Melander O, Murgia F, Zhou X, Ikram MK, Buitendijk GH, McMahon PR, English DR, Kimlin MG, Lucas R, van der Nolte IM, O’Reilly PF, Padmanabhan S, Parsa G, Kemp JP, Pourcain BS, Simpson CL, Mäkelä Pols JC, Venn A, Gebski V, Whiteman DC, Webb A, Pirastu N, Porcu E, Portas L, Prokopenko I, KM, Lehtimäki T, Kähönen M, Paterson AD, PM, Neale REPredicting vitamin D deficiency in Ried JS, Shin SY, Tang CS, Teumer A, Traglia Hosseini SM, Wong HS, Xu L, Jonas JB, older Australian adults. Clinical Endocrinology. M, Ulivi S, Westra HJ, Yang J, Hua Zhao J, Pärssinen O, Wedenoja J, Yip SP, Ho DW, 2013. Vol [Epub ahead of print]. Anni F, Abdellaoui A, Attwood A, Balkau B, Pang CP, Chen LJ, Burdon KP, Craig JE, Klein BE, Klein R, Haller T, Metspalu A, Khor CC, Tran B, Armstrong BK, McGeechan K, Ebeling Bandinelli S, Bastardot F, Benyamin B, Boehm Tai ES, Aung T, Vithana E, Tay WT, Barathi VA; PR, English DR, Kimlin MG, Lucas R, van der BO, Cookson WO, Das D, de Bakker PI, de Consortium for Refractive Error and Myopia Pols JC, Venn A, Gebski V, Whiteman DC, Webb Boer RA, de Geus EJ, de Moor MH, Dimitriou (CREAM), Chen P, Li R, Liao J, Zheng Y, Ong RT, PM, Neale RE.Predicting vitamin D deficiency in M, Domingues FS, D?ring A, Engstr?m G, Ingi Döring A; Diabetes Control and Complications older Australian adults. Clin Endocrinol (Oxf).. 2013. Eyjolfsson G, Ferrucci L, Fischer K, Galanello Trial/Epidemiology of Diabetes Interventions Vol [Epub ahead of print]. R, Garner SF, Genser B, Gibson QD, Girotto G, Fannar Gudbjartsson D, Harris SE, Hartikainen and Complications (DCCT/EDIC) Research Tran B, Jordan SJ, Lucas R, Webb PM, Neale AL, Hastie CE, Hedblad B, Illig T, Jolley J, Group, Evans DM, Timpson NJ, Verkerk AJ, R.Association between ambient ultraviolet radiation K?h?nen M, Kema IP, Kemp JP, Liang L, Lloyd- Meitinger T, Raitakari O, Hawthorne F, Spector and risk of epithelial ovarian cancer. Cancer Prev Jones H, Loos RJ, Meacham S, Medland SE, TD, Karssen LC, Pirastu M, Murgia F, Ang W; Res (Phila). 2012. Vol 5 1330-1336. Meisinger C, Memari Y, Mihailov E, Miller K, Wellcome Trust Case Control Consortium 2 Moffatt MF, Nauck M, Novatchkova M, Nutile (WTCCC2), Mishra A, Montgomery GW, Pennell Tran B, Lucas R, Kimlin M, Whiteman D, Neale T, Olafsson I, Onundarson PT, Parracciani CE, Cumberland PM, Cotlarciuc I, Mitchell P, R; Australian Cancer Study.Association between D, Penninx BW, Perseu L, Piga A, Pistis G, Wang JJ, Schache M, Janmahasatian S, Jr RP, ambient ultraviolet radiation and risk of esophageal Pouta A, Puc U, Raitakari O, Ring SM, Robino Lass JH, Chew E, Iyengar SK; Fuchs’ Genetics cancer. American Journal of Gastroenterology. A, Ruggiero D, Ruokonen A, Saint-Pierre A, Multi-Center Study Group, Gorgels TG, Rudan 2012. Vol 107(12):1803-1813. Sala C, Salumets A, Sambrook J, Schepers I, Hayward C, Wright AF, Polasek O, Vatavuk Z, Wilson JF, Fleck B, Zeller T, Mirshahi A, Müller Tran HP, Huynh TT, Nguyen YT, Kutcher S, H, Oliver Schmidt C, Sillj? HH, Sladek R, Smit C, Uitterlinden AG, Rivadeneira F, Vingerling O?Rourke P. Marquart L, Ryan PA, KAY BH.Low JH, Starr JM, Stephens J, Sulem P, Tanaka T, JR, Hofman A, Oostra BA, Amin N, Bergen entomological impact of new water supply Thorsteinsdottir U, Tragante V, van Gilst WH, AA, Teo YY, Rahi JS, Vitart V, Williams C, Baird infrastructure in southern Vietnam, with reference Joost van Pelt L, van Veldhuisen DJ, V?lker U, PN, Wong TY, Oexle K, Pfeiffer N, Mackey DA, to dengue vectors. American Journal of Tropical Whitfield JB, Willemsen G, Winkelmann BR, Young TL, van Duijn CM, Saw SM, Bailey- Medicine and Hygiene. 2012. Vol 87(4):631-639. Wirnsberger G, Algra A, Cucca F, d’Adamo AP, Danesh J, Deary IJ, Dominiczak AF, Elliott P, Wilson JE, Stambolian D, Klaver CC, Hammond Tu E, Ang DK, Bellingham SA, Hogan TV, Teng Fortina P, Froguel P, Gasparini P, Greinacher A, CJGenome-wide meta-analyses of multiancestry MW, Smyth MJ, Hill AF, van Driel IR.Both IFN-g Hazen SL, Jarvelin MR, Tee Khaw K, Lehtim?ki cohorts identify multiple new susceptibility loci for and IL-17 are required for the development of T, Maerz W, Martin NG, Metspalu A, Mitchell refractive error and myopia. Nature Genetics. 2013. severe autoimmune gastritis. European Journal of BD, Montgomery GW, Moore C, Navis G, Vol 45(6):712. Immunology. 2013. Vol 42(10):2574-83. Pirastu M, Pramstaller PP, Ramirez-Solis R, Verweij KJ, Zietsch BP, Liu JZ, Medland Schadt E, Scott J, Shuldiner AR, Davey Smith Tyrrell, J., V. Huikari, J. T. Christie, A. Cavadino, SE, Lynskey MT, Madden PA, Agrawal A, G, Gustav Smith J, Snieder H, Sorice R, Spector R. Bakker, M. J. Brion, F. Geller, L. Paternoster, Montgomery GW, Heath AC, Martin NG.No TD, Stefansson K, Stumvoll M, Wilson Tang WH, R. Myhre, C. Potter, P. C. Johnson, S. Ebrahim, association of candidate genes with cannabis Toniolo D, T?njes A, Visscher PM, Vollenweider B. Feenstra, A. L. Hartikainen, A. T. Hattersley, use in a large sample of Australian twin families. P, Wareham NJ, Wolffenbuttel BH, Boomsma A. Hofman, M. Kaakinen, L. P. Lowe, P. Magnus, Addiction Biology. 2012. Vol 17(3):687-690. DI, Beckmann JS, Dedoussis GV, Deloukas P, A. McConnachie, M. Melbye, J. W. Ng, E. A. Ferreira MA, Sanna S, Uda M, Hicks AA, Martin Verweij KJH, Y. J., Lahti J, Veijola J, Hintsanen Nohr, C. Power, S. M. Ring, S. P. Sebert, V. Penninger J, Gieger C, Kooner JS, Ouwehand M, Pulkki-R?back L, Heinonen K, Pouta A, Sengpiel, H. R. Taal, G. C. Watt, N. Sattar, C. WH, Soranzo N, Chambers JC. Pesonen AK, Widen E, Taanila A, Isohanni L. Relton, B. Jacobsson, T. M. Frayling, T. I. Seventy-five M, Miettunen J, Palotie A, Penke L, Service Sorensen, J. C. Murray, D. A. Lawlor, C. E. genetic loci influencing the human red blood cell. SK, Heath AC, Montgomery GW, Raitakari O, Pennell, V. W. Jaddoe, E. Hypponen, W. L. Nature. 2012. Vol 492(7429):369-375. K?h?nen M, Viikari J, R?ikk?nen K, Eriksson Lowe, Jr., M. R. Jarvelin, G. Davey Smith and R. van der Pols JC, Russell A, Bauer U, Neale RE, JG, Keltikangas-J?rvinen L, Lehtim?ki T, Martin M. FreathyGenetic variation in the 15q25 nicotinic Kimlin MG, Green AC.Vitamin D status and skin NG, J?rvelin MR, Visscher PM, Keller MC, & acetylcholine receptor gene cluster (CHRNA5- cancer risk independent of time outdoors: 11-year Zietsch BP.Maintenance of genetic variation in CHRNA3-CHRNB4) interacts with maternal prospective study in an Australian community. human personality: Testing evolutionary models self-reported smoking status during pregnancy to Journal of Investigative Dermatology. 2013. Vol by estimating heritability due to common causal influence birth weight. Human Molecular Genetics. 133(3):637-641. variants and investigating the effect of distant 2012. Vol 21(24):5344-5358. van Dongen J, Slagboom PE, Draisma HH, inbreeding. Evolution. 2012. Vol 66(10):3238-3251. Valery PC, Ibiebele T, Harris M, Green AC, Martin NG, Boomsma DI.The continuing value Verweij, K. J., A. A. Vinkhuyzen, B. Benyamin, Cotterill A, Moloney A, Sinha AK, Garvey G.Diet, of twin studies in the omics era. Nature Reviews M. T. Lynskey, L. Quaye, A. Agrawal, S. D. physical activity, and obesity in school-aged Genetics. 2012. Vol (13):9-640. Gordon, G. W. Montgomery, P. A. Madden, A. indigenous youths in northern australia. J Obes. C. Heath, T. D. Spector, N. G. Martin and S. 2012. Vol 2012 893508.

Page 144 QIMR Annual Report 2012–2013 E. MedlandThe genetic aetiology of cannabis and dengue virus Biochem Journal. 2012. Vol S, Madden PA, Manz N, Martin NG, McClintick use initiation: a meta-analysis of genome-wide 443(3):851-6. JN, Montgomery GW, Nurnberger JI Jr, association studies and a SNP-based heritability Rangaswamy M, Rice J, Schuckit M, Tischfield estimation. Addiction Biology. 2012. Vol [Epub Walker, L.C., Krause, L., Spurdle, A.B., Waddell, JA, Whitfield JB, Xuei X, Porjesz B, Heath AC, N., ahead of print]. Germline CNVs are not associated withglobally Edenberg HJ, Bierut LJ, Goate AM.A genome- acquired copy number changes in familial wide association study of alcohol-dependence Vimaleswaran KS, B. D., Lu C, Tikkanen E, breast tumors Breast Cancer Research and symptom counts in extended pedigrees identifies Pilz S, Hiraki LT, Cooper JD, Dastani Z, Li Treatment. 2012. Vol [Epub ahead of print]. C15orf53. Molecular Psychiatry. 2012. Vol [Epub R, Houston DK, Wood AR, Micha?lsson K, ahead of print]. Vandenput L, Zgaga L, Yerges-Armstrong LM, Wall, M., Poortinga, G., Stanley, K. L., McCarthy MI, Dupuis J, Kaakinen M, Kleber Lindemann, R. K., Bots, M., Chan, C. J., Warren H, Dudbridge F, Fletcher O, Orr ME, Jameson K, Arden N, Raitakari O, Viikari Bywater, M. J., Kinross, K., Astle, M. V., N, Johnson N, Hopper JL, Apicella C, J, Lohman KK, Ferrucci L, Melhus H, Ingelsson Waldeck, K., Hannan, K. M., Shortt, J., Smyth, Southey MC, Mahmoodi M, Schmidt MK, E, Byberg L, Lind L, Lorentzon M, Salomaa V, M. J., Lowe, S. W., Hannan, R. D., Pearson, R. Broeks A, Cornelissen S, Braaf LM, Muir Campbell H, Dunlop M, Mitchell BD, Herzig KH, B., Johnstone, R. W., and McArthur, G. A.The KR, Lophatananon A, Chaiwerawattana A, Pouta A, Hartikainen AL; Genetic Investigation mTORC1 inhibitor everolimus prevents and treats Wiangnon S, Fasching PA, Beckmann MW, Ekici of Anthropometric Traits-GIANT Consortium, Em-myc lymphoma by restoring oncogene-induced AB, Schulz-Wendtland R, Sawyer EJ, Tomlinson Streeten EA, Theodoratou E, Jula A, Wareham senescence. Cancer Discovery. 2013. Vol 3(1):82- I, Kerin M, Burwinkel B, Marme F, Schneeweiss NJ, Ohlsson C, Frayling TM, Kritchevsky 95. A, Sohn C, Guénel P, Truong T, Laurent-Puig SB, Spector TD, Richards JB, Lehtim?ki T, Wallace DFSLC40A1-R178G or R178Q and P, Mulot C, Bojesen SE, Nielsen SF, Flyger H, Ouwehand WH, Kraft P, Cooper C, M?rz W, ferroportin disease? A call for vigilance in mutation Nordestgaard BG, Milne RL, Benítez J, Arias- Power C, Loos RJ, Wang TJ, J?rvelin MR, reporting Journal of Hepatology. 2013. Vol Pérez JI, Zamora MP, Anton-Culver H, Ziogas A, Whittaker JC, Hingorani AD, Hypp?nen E.Causal 59(2):396-7. Bernstein L, Dur CC, Brenner H, Müller H, Arndt relationship between obesity and vitamin D status: V, Langheinz A, Meindl A, Golatta M, Bartram bi-directional Mendelian randomization analysis of Wallace DF, Crawford DH, Subramaniam CR, Schmutzler RK, Brauch H, Justenhoven C, multiple cohorts. Plos Medicine. 2013. Vol 10(2):- VNIron predicts tolerance in liver transplantation Brüning T; GENICA Network, Chang-Claude J, e1001383. Gastroenterology. 2012. Vol 143(3):862-5. Wang-Gohrke S, Eilber U, Dörk T, Schürmann P, Bremer M, Hillemanns P, Nevanlinna H, Vinkhuyzen AA, Pedersen NL, Yang J, Lee SH, Wallingford SC, Alston RD, Birch JM, Green Muranen TA, Aittomäki K, Blomqvist C, Magnusson PK, Iacono WG, McGue M, Madden AC.Regional melanoma incidence in England, Bogdanova N, Antonenkova N, Rogov Y, PA, Heath AC, Luciano M, Payton A, Horan M, 1996-2006: reversal of north-south latitude Bermisheva M, Prokofyeva D, Zinnatullina G, Ollier W, Pendleton N, Deary IJ, Montgomery trends among young females. British Journal of Khusnutdinova E, Lindblom A, Margolin S, GW, Martin NG, Visscher PM, Wray Dermatology. 2013. Vol [Epub ahead of print]. Mannermaa A, Kosma VM, Hartikainen JM, NR.Common SNPs explain some of the variation Wallingford SC, Pilkington SM, Massey KA, Kataja V, Chenevix-Trench G, Beesley J, Chen in the personality dimensions of neuroticism and Al-Aasswad NM, Ibiebele TI, Celia Hughes X; kConFab Investigators; Australian Ovarian extraversion. Translational Psychiatry. 2012. Vol M, Bennett S, Nicolaou A, Rhodes LE, Green Cancer Study Group, Lambrechts D, Smeets 2(4):e102. AC.Three-way assessment of long-chain n-3 PUFA A, Paridaens R, Weltens C, Flesch-Janys D, von Seidlein, L., Auburn, S., Espino, F., nutrition: by questionnaire and matched blood and Buck K, Behrens S, Peterlongo P, Bernard L, Shanks, D., Cheng, Q., McCarthy, J., Baird, K., skin samples. British Journal of Nutrition. 2012. Vol Manoukian S, Radice P, Couch FJ, Vachon C, Moyes, C., Howes, R., Menard, D., Bancone, 109(4):701-708. Wang X, Olson J, Giles G, Baglietto L, McLean G., Winasti-Satyahraha, A., Vestergaard, L. CA, Severi G, John EM, Miron A, Winqvist R, Wallingford SC, van As JA, Hughes MC, S., Green, J., Domingo, G., Yeung, S., Price, Pylkäs K, Jukkola-Vuorinen A, Grip M, andrulis Ibiebele TI, Green AC, van der Pols JC.Intake R.Review of key knowledge gaps in glucose-6- IL, Knight JA, Mulligan AM, Weerasooriya of omega-3 and omega-6 fatty acids and risk of phosphate dehydrogenase deficiency detection N, Devilee P, Tollenaar RA, Martens JW, basal and squamous cell carcinomas of the skin: a with regard to the safe clinical deployment of Seynaeve CM, Hooning MJ, Hollestelle A, longitudinal community-based study in Australian 8-aminoquinoline treatment regimens: a workshop Jager A, Tilanus-Linthorst MM, Hall P, Czene adults. Nutr Cancer. 2012. Vol 64(7):982-990. report Malaria Journal. 2013. Vol 12 112. K, Liu J, Li J, Cox A, Cross SS, Brock IW, Reed MW, Pharoah P, Blows FM, Dunning AM, Walsh AJ, Weltman M, Burger D, Vu SN, Nguyen TY, Hoang MD, Tran CT, Vu TT, Ghoussaini M, Ashworth A, Swerdlow A, Jones Vivekanandarajah S, Connor S, Howlett M, Nguyen HL, Le HS, Luu LL, Vu TQH, Ly HKK, M, Schoemaker M, Easton DF, Humphreys M, Radford-Smith G, Selby W, Veillard AS, Grimm Huynh TTT, Lam, LZY, Kutcher SC, Aaskov JG, Wang Q, Peto J, dos-Santos-Silva I.9q31.2- MC, Travis SP, Lawrance IC.Implementing Jeffery JAL, Ryan PA, KAY BH.Community-based rs865686 as a susceptibility locus for estrogen guidelines on the prevention of opportunistic control of Aedes aegypti using Mesocyclops in receptor-positive breast cancer: evidence from the infections in inflammatory bowel disease. Journal of southern Vietnam. American Journal of Tropical Breast Cancer Association Consortium. Cancer Crohns & Colitis. 2013. Vol [Epub ahead of print]. Medicine and Hygiene. 2012. Vol 86(6):850-859. Epidemiology Biomarkers & Prevention. 2012. Vol Walsh MD, Cummings MC, Pearson SA, 21(10):1783-1791. Waddell N, Stein SR, Wagner SA, Bennett Clendenning M, Walters RJ, Nagler B, Hopper I, Djougarian A, Melana S, Jaffer S, Holland Warren, K. Wei, T. Li, D. Qin, F. Warrilow, JL, Jenkins MA, Suthers GK, Goldblatt J, Tucker JF, Pogo BG, Gonda TJ, Brown MA, Leo P, D. Lin, M. H. Sivakumaran, H. Apolloni, K, Gattas MR, Arnold JL, Parry S, Macrae FA, Saunders NA, McMillan NA, Cocciardi S, Vargas A. Abbott, C. M. Jones, A. anderson, J. L. McGuckin MA, Young JP, Buchanan DD.Lynch AC, Lakhani SR, Chenevix-Trench G, Newman Harrich, D.Eukaryotic elongation factor 1 complex syndrome-associated breast cancers do not B, Francis GD.Morphological and molecular subunits are critical HIV-1 reverse transcription overexpress chromosome 11-encoded mucins. analysis of a breast cancer cluster at the ABC cofactors Proceedings of The National Academy of Modern Pathology. 2013. Vol 16(7):2214-2224. Studio in Toowong. Pathology. 2012. Vol 44(5):469- Sciences of The United States of America. 2012. 472. Wan YI, Shrine NR, Soler Artigas M, Wain LV, Vol 109(24):9587-92.. Blakey JD, Moffatt MF, Bush A, Chung KF, Wade TD, H. N., Crosby RD, Bryant-Waugh Webb, B. T., Guo AY, Maher BS, Zhao Z, van Cookson WO, Strachan DP, Heaney L, Al- R, Treasure J, Nixon R, Byrne S, Martin NGA den Oord EJ, Kendler KS, Riley BP, Gillespie Momani BA, Mansur AH, Manney S, Thomson Study of Changes in Genetic and Environmental NA, Prescott CA, Middeldorp CM, Willemsen NC, Chaudhuri R, Brightling CE, Bafadhel M, Influences on Weight and Shape Concern Across G, de Geus EJ, Hottenga JJ, Boomsma DI, Singapuri A, Niven R, Simpson A, Holloway Adolescence. Journal of Abnormal Psychology. Slagboom EP, Wray NR, Montgomery GW, JW, Howarth PH, Hui J, Musk AW, James AL; 2013. Vol 122(1):119-30. Martin NG, Wright MJ, Heath AC, Madden Australian Asthma Genetics Consortium, Brown PA, Gelernter J, Knowles JA, Hamilton SP, Wade, T. D., S. Gordon, S. Medland, C. M. MA, Baltic S, Ferreira MA, Thompson PJ, Tobin Weissman MM, Fyer AJ, Huezo-Diaz P, Bulik, A. C. Heath, G. W. Montgomery and N. G. MD, Sayers I, Hall IP.Genome-wide association McGuffin P, Farmer A, Craig IW, Lewis C, Sham MartinGenetic variants associated with disordered study to identify genetic determinants of severe P, Crowe RR, Flint J, Hettema JM.Meta-analyses eating. International Journal of Eating Disorders. asthma. Thorax. 2012. Vol 67(9):762-768. of genome-wide linkage scans of anxiety-related 2013. Vol [Epub ahead of print]. Wang JC, Foroud T, Hinrichs AL, Le NX, phenotypes. European Journal of Human Genetics. Wagstaff, K. M. Sivakumaran, H. Heaton, Bertelsen S, Budde JP, Harari O, Koller DL, 2012. Vol 20(10):1078-84. S. M. Harrich, D. Jans, D. A.Ivermectin is a Wetherill L, Agrawal A, Almasy L, Brooks AI, Webbink D, K. V., Vujic S, Martin NGWhy are specific inhibitor of importin alpha/beta-mediated Bucholz K, Dick D, Hesselbrock V, Johnson criminals less educated than non-criminals? nuclear import able to inhibit replication of HIV-1 EO, Kang S, Kapoor M, Kramer J, Kuperman

Page 145 Scientiﬁc publications | continued

Evidence from a cohort of young Australian twins. L, Winship I, Leggett B, Tucker K, Giles G, Wykes, M. N. and J. Horne-DebetsDendritic cells: Journal of Law, Economics, and Organization. 2013. Buchanan D, Clendenning M, Rosty C, Arnold The Trojan horse of malaria? International Journal Vol 29(1):115-144. J, Levine A, Haile R, Gallinger S, Le Marchand For Parasitology. 2012. Vol 42(6):583-587. L, Newcomb P, Hopper J and Jenkins M. Risks Webbink D, Vujic S, Koning P, Martin NG. The of primary extracolonic cancers following colorectal Wylie N, Adib R, Barbour AP, Fawcett J, Hill effect of childhood conduct disorder on human cancer in lynch syndrome. Journal of The National A, Lynch S, Martin I, O’Rourke TR, Puhalla H, capital. Health Economics. 2012. Vol UNKNOWN. Cancer Institute. 2012. Vol 104(18):1363-1372. Rutherford L, Slater K, Whiteman DC, Neale RE; Queensland Pancreatic Cancer Study Group. Wee, E. J. Peters, K. Nair, S. S. Hulf, T. Stein, Win AK, Hopper JL, Buchanan DD, Young JP, Surgical management in patients with pancreatic S. Wagner, S. Bailey, P. Lee, S. Y. Qu, W. J. Tenesa A, Dowty JG, Giles GG, Goldblatt J, cancer: a Queensland perspective. Anz Journal of Brewster, B. French, J. D. Dobrovic, A. Francis, Winship I, Boussioutas A, Young GP, Parry S, Surgery. 2012. Vol [Epub ahead of print]. G. D. Clark, S. J. Brown, M. A.Mapping the Baron JA, Duggan D, Gallinger S, Newcomb PA, regulatory sequences controlling 93 breast cancer- Haile RW, Le Marchand L, Lindor NM, Jenkins Xu, B., Gordon, C.A., Hu, W. McManus, D.P. associated miRNA genes leads to the identification MA.Are the common genetic variants associated Chen, H-G., Gray, D.J., Ju,C., Zeng, X-J., Gobert, of two functional promoters of the Hsa-mir-200b with colorectal cancer risk for DNA mismatch G.N., Ge, J., Lan, W-M, Xie, S-Y., Jiang, W-S., cluster, methylation of which is associated with repair gene mutation carriers? European Journal of Ross, A.G., Acosta, L.P., Olveda, R., Feng, Z.A metastasis or hormone receptor status in advanced Cancer. 2013. Vol 49(7):1578-1587. novel procedure for more precise quantification of breast cancer Oncogene. 2012. Vol 31 4182–4195. Schistosoma japonicum eggs in bovine feces. Plos Win AK, Lindor NM, Winship I, Tucker KM, Neglected Tropical Diseases. 2012. Vol 6 -e1885. Weeratunga, S. K., A. Osman, N. J. Hu, C. K. Buchanan DD, Young JP, Rosty C, Leggett B, Wang, L. Mason, S. Svard, G. Hope, M. K. Jones Giles GG, Goldblatt J, Macrae FA, Parry S, Yang H, Sun C, Fan Z, Tian X, Yan L, Du L, and A. HofmannAlpha-1 Giardin is an Annexin with Kalady MF, Baron JA, Ahnen DJ, Marchand LL, Liu Y, Chen C, Liang XJ, anderson GJ, Keelan Highly Unusual Calcium-Regulated Mechanisms. Gallinger S, Haile RW, Newcomb PA, Hopper JL, JA, Zhao Y, Nie G.Effects of gestational age and Journal of Molecular Biology. 2012. Vol 423(2):169- Jenkins MA.Risks of colorectal and other cancers surface modification on materno-fetal transfer 181. after endometrial cancer for women with lynch of nanoparticles in murine pregnancy. Scientific Reports. 2012. Vol 2 847. Wheeler, M, Chardon, A, Goubet, A, Morihiro, K, syndrome. Journal of The National Cancer Institute. Tsan, S.Y, Edwards, SL, Kodama, T, Obika, S, 2013. Vol 105(4):274-279. Yang J, Ferreira T, Morris AP, Medland SE; Veedu, R.NSynthesis of selenomethylene-locked Win AK, Parry S, Parry B, Kalady MF, Macrae Genetic Investigation of ANthropometric nucleic acid (SeLNA)-modified oligonucleotides by FA, Ahnen DJ, Young GP, Lipton L, Winship I, Traits (GIANT) Consortium; DIAbetes Genetics polymerases Chemical Communications. 2012. Vol Boussioutas A, Young JP, Buchanan DD, Arnold Replication and Meta-analysis (DIAGRAM) 48(89):11020-2.. J, Le Marchand L, Newcomb PA, Haile RW, Consortium, Madden PA, Heath AC, Martin NG, Montgomery GW, Weedon MN, Loos RJ, Frayling White KL, Vierkant RA, Fogarty ZC, Charbonneau Lindor NM, Gallinger S, Hopper JL, Jenkins TM, McCarthy MI, Hirschhorn JN, Goddard ME, B, Block MS, Pharoah PD, Chenevix-Trench G; MA.Risk of metachronous colon cancer following Visscher PM.Conditional and joint multiple-SNP for AOCS/ACS group;, Rossing MA, Cramer DW, surgery for rectal cancer in mismatch repair gene analysis of GWAS summary statistics identifies Pearce CL, Schildkraut JM, Menon U, Kjaer SK, mutation carriers. Annals of Oncology. 2013. Vol additional variants influencing complex traits. Nature Levine DA, Gronwald J, Culver HA, Whittemore 20(6):1829-1836. Genetics. 2012. Vol 44(4):369-375. AS, Karlan BY, Lambrechts D, Wentzensen Wood MJ, Powell LW, Dixon JL, Ramm N, Kupryjanczyk J, Chang-Claude J, Bandera GA.Clinical cofactors and hepatic fibrosis in Yang J, Loos R, Powell JE, Medland SE, EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, hereditary haemochromatosis: The role of diabetes Speliotes EK, Chasman DI, Rose LM, Campbell I, Goodman MT, Pejovic T, Bean Y, mellitus. Hepatology. 2012. Vol 56(3):904-11. Thorleifsson G, Steinthorsdottir V, M?gi R, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici Waite L, Vernon Smith A, Yerges-Armstrong AB, Paul J, Brown R, Flanagan JM, Harter P, Wood-Baker R, Reid D, Robinson A, Walters LM, Monda KL, Hadley D, Mahajan A, Li G, du Bois A, Schwaab I, Hogdall CK, Lundvall EH.Clinical trial of community nurse mentoring to Kapur K, Vitart V, Huffman JE, Wang SR, Palmer L, Olson SH, Orlow I, Paddock LE, Rudolph A, improve self-management in patients with COPD. C, Esko T, Fischer K, Hua Zhao J, Demirkan Eilber U, Dansonka-Mieszkowska A, Rzepecka International Journal of Chronic Obstructive A, Isaacs A, Feitosa MF, Luan J, Heard-Costa IK, Ziolkowska-Seta I, Brinton L, Yang H, Pulmonary Disease. 2012. Vol 7 407-13. NL, White C, Jackson AU, Preuss M, Ziegler Garcia-Closas M, Despierre E, Lambrechts S, A, Eriksson J, Kutalik Z, Frau F, Nolte IM, Van Vergote I, Walsh C, Lester J, Sieh W, McGuire V, Woodberry T, Minigo G, Piera KA, Amante Vliet-Ostaptchouk JV, Hottenga JJ, Jacobs KB, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, FH, Pinzon-Charry A, Good MF, Lopez JA, Verweij N, Goel A, Medina-Gomez C, Estrada Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Engwerda CR, McCarthy JS, Anstey NM.Low- K, Lynn Bragg-Gresham J, Sanna S, Sidore C, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, level Plasmodium falciparum blood-stage infection Tyrer J, Teumer A, Prokopenko I, Mangino M, Van Denberg D, Terry KL, Vitonis AF, Doherty causes dendritic cell apoptosis and dysfunction in Lindgren CM, Assimes TL, Shuldiner AR, Hui JA, Johnatty SE, Defazio A, Song H, Tyrer J, healthy volunteers. Journal of Infectious Diseases. J, Beilby JP, McArdle WL, Hall P, Haritunians T, Sellers TA, Phelan CM, Kalli KR, Cunningham 2012. Vol 206(3):333-340. Zgaga L, Kolcic I, Polasek O, Zemunik T, Oostra JM, Fridley BL, Goode EL.Analysis of over 10,000 Wray NR, Pergadia ML, Blackwood DH, Penninx BA, Juhani Junttila M, Gr?nberg H, Schreiber Cases finds no association between previously BW, Gordon SD, Nyholt DR, Ripke S, MacIntyre S, Peters A, Hicks AA, Stephens J, Foad NS, reported candidate polymorphisms and ovarian DJ, McGhee KA, Maclean AW, Smit JH, Hottenga Laitinen J, Pouta A, Kaakinen M, Willemsen cancer outcome. Cancer Epidemiology Biomarkers JJ, Willemsen G, Middeldorp CM, de Geus EJ, G, Vink JM, Wild SH, Navis G, Asselbergs FW, & Prevention. 2013. Vol 22(5):987-992. Lewis CM, McGuffin P, Hickie IB, van den Oord Homuth G, John U, Iribarren C, Harris T, Launer L, Gudnason V, O’Connell JR, Boerwinkle E, Whiteman, D. C.Prognostic sub-classifications EJ, Liu JZ, Macgregor S, McEvoy BP, Byrne EM, Cadby G, Palmer LJ, James AL, Musk AW, of T1 cutaneous melanomas based on ulceration, Medland SE, Statham DJ, Henders AK, Heath Ingelsson E, Psaty BM, Beckmann JS, Waeber tumour thickness and Clark level of invasion. Results AC, Montgomery GW, Martin NG, Boomsma DI, G, Vollenweider P, Hayward C, Wright AF, of a population-based study from the Swedish Madden PA, Sullivan PF.Genome-wide association Rudan I, Groop LC, Metspalu A, Tee Khaw Melanoma Register. British Journal of Dermatology. study of major depressive disorder: New results, K, van Duijn CM, Borecki IB, Province MA, 2013. Vol 168(4):685-686. meta-analysis, and lessons learned. Molecular Psychiatry. 2012. Vol 17(1):36-48. Wareham NJ, Tardif JC, Huikuri HV, Adrienne Whitfield JB, H. A., Madden PA, Pergadia ML, Cupples L, Atwood LD, Fox CS, Boehnke M, Montgomery GW, Martin NG.Metabolic and Wurm EM, Lin LL, Ferguson B, Lambie D, Collins FS, Mohlke KL, Erdmann J, Schunkert Biochemical Effects of Low-to-Moderate Alcohol Prow TW, Walker GJ, Soyer HP.A blueprint for H, Hengstenberg C, Stark K, Lorentzon M, Consumption. Alcoholism, Clinical and Experimental staging of murine melanocytic lesions based on the Ohlsson C, Cusi D, Staessen JA, Van der Klauw Research. 2013. Vol 37(4):575-586. Cdk4(R24C/R24C )::Tyr-NRAS model. Experimental MM, Pramstaller PP, Kathiresan S, Jolley JD, Dermatology. 2012. Vol 21(9):676-81. Ripatti S, Jarvelin MR, de Geus EJ, Boomsma DI, Whop LJ, Valery PC, Beesley VL, Moore SP, Penninx B, Wilson JF, Campbell H, Chanock SJ, Wykes, M.Why haven?t we made an efficacious Lokuge K, Jacka C, Garvey G.Navigating the van der Harst P, Hamsten A, Watkins H, Hofman vaccine for malaria?. Embo Reports. 2013. Vol cancer journey: a review of patient navigator A, Witteman JC, Carola Zillikens M, Uitterlinden 14(8):661. programs for Indigenous cancer patients. Asia- AG, Rivadeneira F, Carola Zillikens M, Kiemeney Pacific Journal of Clinical Oncology. 2012. Vol Wykes, M. N.Are plasmacytoid dendritic cells the LA, Vermeulen SH, Abecasis GR, Schlessinger 8(4):e89-e96. misguided sentinels of malarial immunity? Trends In D, Schipf S, Stumvoll M, T?njes A, Spector TD, North KE, Lettre G, McCarthy MI, Berndt SI, Win A, Lindor N, Young J, Macrae F, Young Parasitology. 2012. Vol 28(5):182-186. Heath AC, Madden PA, Nyholt DR, Montgomery G, Williamson E, Parry S, Goldblatt J, Lipton GW, Martin NG, McKnight B, Strachan DP, Hill

Page 146 QIMR Annual Report 2012–2013 WG, Snieder H, Ridker PM, Thorsteinsdottir Youlden DR, Baade PD, Valery PC, Ward LJ, communities on the inner and outer surfaces of U, Stefansson K, Frayling TM, Hirschhorn JN, Green AC, Aitken JF.Childhood cancer mortality peripheral venous catheters. European Journal of Goddard ME, Visscher PM.FTO genotype is in Australia. Cancer Epidemiology. 2012. Vol Clinical Microbiology & Infectious Diseases. 2013. associated with phenotypic variability of body mass 36(5):476-480. Vol [Epub ahead of print]. index. Nature. 2012. Vol 490(7419):267-272. Youngson, NA, Epp, T, Roberts, AR, Daxinger, Zhang, W., Wen, H., Li, J., Lin R., McManus, Yang, Y.R., Clements, A.C.A., Gray, D.J., L, Ashe, A, Huang, E, Lester, KL, Harten, SK, D.P.Immunology and immunodiagnosis of Atkinson, J-A. M., Williams, G.M., Barnes, T.S., Kay, GF, Cox, T, Matthews, JM, Chong, S and cystic echinococcosis - an update. Clinical and McManus, D.P.Impact of anthropogenic and Whitelaw, E No evidence for cumulative effects in Developmental Immunology. 2012. Vol 2012 natural environmental changes on Echinococcus a Dnmt3b hypomorph across multiple generations. -101895. transmission in Ningxia Hui Autonomous Region, the Mammalian Genome. 2013. Vol 24(five):206-17. People?s Republic of China. Parasites and Vectors. Zietsch BP, Verweij KJH, Heath AC, Madden PAF, 2012. Vol 5 146. Zarrin R, Ibiebele TI, Marks GC.Development Martin NG, Nelson EC, Lynskey MTDo shared and validity assessment of a diet quality index for etiological factors contribute to the relationship Yang, Y.R., Ellis, M.K. McManus, Australians. Asia Pacific Journal of Clinical Nutrition. between sexual orientation and depression? D.P.Immunogenetics of human echinococcosis. 2013. Vol 22(2):177-187. Psychological Medicine. 2012. Vol 42(3):521-32. Trends In Parasitology. 2012. Vol 28(10):447-454. Zhang K, R. F., Pablo Miramontes-Gonzalez J, Zinkernagel MS, Chinnery HR, Ong ML, Petitjean Yazar S, Mishra A, Ang W, Kearns LS, Mountain Hightower CM, Vaught B, Chen Y, Greenwood C, Voigt V, McLenachan S, McMenamin PG, Hill JA, Pennell C, Montgomery GW, Young TL, TA, Schork AJ, Wang L, Mahata M, Stridsberg GR, Forrester JV, Wikstrom ME, Degli-Esposti Hammond CJ, Macgregor S, Mackey DA, Hewitt M, Khandrika S, Biswas N, Fung MM, Waalen MA.Interferon gamma-Dependent Migration AW.Interrogation of the platelet-derived growth J, Middelberg RP, Heath AC, Montgomery GW, of Microglial Cells in the Retina after Systemic factor receptor alpha locus and corneal astigmatism Martin NG, Whitfield JB, Baker DG, Schork NJ, Cytomegalovirus Infection. American Journal of in Australians of Northern European ancestry: Nievergelt CM, O’Connor DTNeuropeptide Y Pathology. 2013. Vol 182(3):875-885. Results of a genome-wide association study. (NPY): Genetic Variation in the Human Promoter Molecular Vision. 2013. Vol 19 1238-1246. Alters Glucocorticoid Signaling, Yielding Increased Zubanov N, Webbink HD, Martin NGThe effect NPY Secretion and Stress Responses. Journal of schooling on problem drinking: evidence from You, H., Gobert, G.N., Duke, M.G., Zhang, W., of The American College of Cardiology. 2012. Vol Australian twins. Applied Economics. 2012. Vol Li, YS, Jones, M.K., McManus, D.P. The insulin 60(17):1678-1689. 45(12):1583-1599. receptor is a transmission blocking veterinary vaccine target for zoonotic Schistosoma japonicum. Zhang L, Morrison M, Nimmo GR, Sriprakash International Journal For Parasitology. 2012. Vol KS, Mondot S, Gowardman JR, George N, Marsh 42(9):801-807. N, Rickard CM.Molecular investigation of bacterial

Page 147 CHECKLIST

FA ACT Financial Accountability Act 2009 FPMS Financial and Performance Management Standard 2009 ARRs Annual Report Requirements for Queensland Government Agencies

Annual Summary of requirement Basis for requirement report reference Letter of A letter of compliance from the accountable ARRs – section 8 page 3 compliance officer or statutory body to the relevant Minister Accessibility Table of contents ARRs – section 10.1 page 1 Glossary page 150 Public availability ARRs – section 10.2 inside cover Interpreter service statement Queensland Government inside cover Language Services Policy ARRs – section 10.3 Copyright notice Copyright Act 1968 inside cover ARRs – section 10.4 Information licensing Queensland Government N/A Enterprise Architecture – Information licensing ARRs – section 10.5 General information Introductory Information ARRs – section 11.1 page 12 Agency role and main functions ARRs – section 11.2 page 12 Operating environment ARRs – section 11.3 page 13 Machinery of Government changes ARRs – section 11.4 N/A Non-financial Government objectives for the community ARRs – section 12.1 page 12 performance Other whole-of-government plans / specific ARRs – section 12.2 N/A initiatives Agency objectives and performance indicators ARRs – section 12.3 page 28 Agency service areas, service standards and ARRs – section 12.4 * other measures Financial Summary of financial performance ARRs – section 13.1 page 66 performance Chief Finance Officer (CFO) statement ARRs – section 13.2 page 72

Page 148 QIMR Annual Report 2012–2013 Annual Summary of requirement Basis for requirement report reference Governance – Organisational structure ARRs – section 14.1 page 26 management and Executive management ARRs – section 14.2 page 28 structure Related entities ARRs – section 14.3 N/A Boards and committees ARRs – section 14.4 page 18 Public Sector Ethics Act 1994 Public Sector Ethics Act page 14 1994 (section 23 and Schedule) ARRs – section 14.5 Governance – risk Risk management ARRs – section 15.1 page 24 management and External Scrutiny ARRs – section 15.2 page 24 accountability Audit committee ARRs – section 15.3 page 22 Internal Audit ARRs – section 15.4 page 24

Public Sector Renewal Program ARRs – section 15.5 N/A

Information systems and recordkeeping ARRs – section 15.7 page 17

Governance – Workforce planning, attraction and retention and ARRs – section 16.1 page 14 human resources performance Early retirement, redundancy and retrenchment Directive No.11/12 Early N/A Retirement, Redundancy and Retrenchment ARRs – section 16.2 Voluntary Separation Program ARRs – section 16.3 N/A

Open Data Open Data ARRs – section 17 page 24 Financial Certiﬁcation of ﬁnancial statements FAA – section 62 page 99 statements FPMS – sections 42, 43 and 50 ARRs – section 18.1 Independent Auditors Report FAA – section 62 page 100 FPMS – section 50 ARRs – section 18.2 Remuneration disclosures Financial Reporting page 92 Requirements for Queensland Government Agencies ARRs – section 18.3

* Please note QIMR has not reported on performance indicators in their service delivery statement, instead please refer to page 28 for performance indicators as relevant to QIMR’s strategic plan.

Page 149 ACRONYMS

Fellow of the Australian Academy MPN Myeloproliferative neoplasms (Hons) With Honours degree FAHA of the Humanities MSc Master of Science AAS Australian Academy of Science Fellow of the Australian Human FAHRI National Health and Medical Companion of the Order of Resources Institute NHMRC AC Research Council Australia Fellow of the Australian Institute FAICD NIH National Institutes of Health AEC Animal Ethics Committee of Company Directors

Fellow of the Australian Institute NPC Nasopharyngeal Carcinoma Australian Institute for FAIM AIBN Bioengineering and of Management OBE Order of the British Empire Nanotechnology Fellow of The Institute of Ofﬁce of Health and Medical Australian Infectious Diseases FCA Chartered Accountants in OHMR AID Research Research Centre Australia Ovarian Cancer Prognosis And Fellow of the Queensland OPAL ALF Australian Liver Foundation FQA Lifestyle Academy of Arts and Sciences AML Acute myeloid leukaemia Prostate Cancer Foundation PCFA FTE Full time equivalent Australia ANU Australian National University GMP Good manufacturing practice PhD Doctor of Philosophy APC Antigen presenting cells GVHD Graft versus host disease PNG Papua New Guinea ARC Australian Research Council GVL Graft versus leukaemia QIH Queensland Institute of Health Australian Society for Medical ASMR Research GWAS Genome wide association studies QSA Queensland Studies Authority

A-T Ataxia-telangiectasia HDC Higher Degree Committee Queensland Institute of Medical QIMR Research CCQ Cancer Council Queensland HIV Human Immunodeficiency Virus Queensland Tropical Health Consortium for Investigators of HKU Hong Kong University QTHA CIMBA Alliance Modifiers of BRCA1/2 HPV Human Papillomavirus Queensland University of CF Cystic fibrosis QUT Hon Honorary (degree) Technology CMV Cytomegalovirus HR Human Resources Royal Brisbane and Women’s RBWH Colon Hospital Colon cancer family registry International Agency for Research CFR IARC on Cancer RNA Ribonucleic acid Chronic obstructive pulmonary COPD IPO Initial Public Offering Roche Organ Transplantation disease ROTRF Research Foundation International Organisation for CPI Consumer price index ISO Standardization RSV Respitory syncytial virus CRC Cooperative Research Centre The International Union of TGA Therapeutic Goods Administration Commonwealth Scientific and IUBMB Biochemistry and Molecular CSIRO TLR Toll-like receptor Industrial Research Organisation Biology University of California, Los DC Dendritic cell LittD Doctorate of Literature UCLA Angeles DLitt Doctorate of Literature LLB Bachelor of Laws UNSW University of New South Wales DNA Deoxyribonucleic acid MA Master of Arts UQ University of Queensland DU Dean of University MAG Management advisory group University of Queensland Centre UQCCR Member of the Australian Institute for Clinical Research EBV Epstein-Barr virus MAICD of Company Directors EU European Union WHO World Health Organization MBus Master of Business EVC Emory Vaccine Center MDS Myelodysplastic syndrome Fellow of the Australian College of FACE Educators MPhil Master of Philosophy

Page 150 QIMR Annual Report 2012–2013

300 Herston Road T +61 7 3362 0222 Herston QLD 4006 Australia 1800 993 000 Locked Bag 2000 F +61 7 3362 0102 RBH QLD 4029 Australia E [email protected]

Better health through medical research | www.qimr.edu.au